Drug prescribing errors are a common cause of hospital admission, and adverse reactions can have devastating effects, none more so than the patient and family. Pocket Prescriber Emergency Medicine is a concise, up-to-date prescribing guide containing all the "must have" information on a vast range of drugs that staff from junior doctors to emergency nurses, nurse prescribers, paramedics and other pre-hospital providers may encounter in the emergency setting.

Key features:
- A full list of NICE of the most commonly prescribed drugs with each entry containing the key prescribing information
- Safety warnings, drug interactions and side effects
- Practical guidance on drug selection, dosage and prescriber guidelines
- Advice and reference information for complicated prescriptions
- Concise management summaries for common medical and surgical emergencies
- Essential advice for pain relief—from acute pain management to procedural sedation
- Clinically useful reminders of key facts from basic pharmacology
- Safety issues, warnings, drug errors and adverse effects

Pocket Prescriber Emergency Medicine supplies all your information needs concerning commonly prescribed drugs at a glance, enabling on-the-spot decision making to provide the highest standard of care whilst mitigating prescribing errors.
Pocket Prescriber
Emergency Medicine
Pocket Prescriber
Emergency Medicine

Anthony FT Brown MB ChB FRCP FRCSEd FACEM FCEM
Professor of Emergency Medicine, Discipline of Anaesthesiology and Critical Care, School of Medicine, University of Queensland, Brisbane, Australia
Senior Staff Specialist, Department of Emergency Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Australia

Timothy RJ Nicholson MBBS BSc MSc PhD MRCP MRCPsych
Academic Clinical Lecturer, Section of Cognitive Neuropsychiatry, Institute of Psychiatry, London, UK

Donald RJ Singer BMedBiol MD FRCP
Professor of Clinical Pharmacology and Therapeutics, Clinical Sciences Research, Warwick Medical School, University of Warwick and University Hospitals Coventry and Warwickshire, Coventry, UK
DEDICATION

To my Mum and Dad for their inspiration and zest for life, and to my sister Alison for being so supportive and kind.

Tony Brown
July 2013
## CONTENTS

**Contributors** ix  
**Foreword** xi  
**Preface** xiii  
**Acknowledgements** xiv  
**How to use this book** xv  
**List of abbreviations** xvii  
**How to prescribe safely in the ED** xxvii

### Common/useful drugs

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug selection</td>
<td>177</td>
</tr>
<tr>
<td>Analgesia in the ED</td>
<td>178</td>
</tr>
<tr>
<td>Antiemetics in the ED</td>
<td>179</td>
</tr>
<tr>
<td>Local anaesthesia</td>
<td>181</td>
</tr>
<tr>
<td>Procedural sedation and analgesia</td>
<td>182</td>
</tr>
<tr>
<td>Rapid sequence induction</td>
<td>184</td>
</tr>
<tr>
<td>Drug infusion guideline</td>
<td>186</td>
</tr>
<tr>
<td>How to prescribe</td>
<td>195</td>
</tr>
<tr>
<td>Intravenous fluids</td>
<td>196</td>
</tr>
<tr>
<td>Insulin</td>
<td>204</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>209</td>
</tr>
<tr>
<td>Steroids</td>
<td>217</td>
</tr>
<tr>
<td>Sedation in the ED</td>
<td>219</td>
</tr>
<tr>
<td>Controlled drugs</td>
<td>221</td>
</tr>
<tr>
<td>Medical emergencies</td>
<td>223</td>
</tr>
<tr>
<td>Cardiopulmonary resuscitation (CPR)</td>
<td>225</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>225</td>
</tr>
<tr>
<td>Acute coronary syndrome (ACS)</td>
<td>226</td>
</tr>
<tr>
<td>Acute LVF</td>
<td>234</td>
</tr>
<tr>
<td>Hypertension and accelerated hypertension</td>
<td>235</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>240</td>
</tr>
<tr>
<td>Acute severe asthma</td>
<td>242</td>
</tr>
</tbody>
</table>
Pneumonia 244
COPD exacerbation 247
Pulmonary embolism 248
Acute upper GI haemorrhage 249
Hypoglycaemia 251
DKA 252
HHS (HONK) 255
Addisonian crisis 256
Myxoedema coma/crisis 257
Thyrotoxic crisis/thyroid storm 257
Meningitis 258
Seizures 260
TIA and stroke 261
Severe sepsis or septic shock 264
Febrile neutropenia 265
Urinary tract infections 265
GI infections 266
TB pneumonia 267
Malaria 267
Electrolyte disturbances 269
Alcohol withdrawal 271
Acute poisoning 274

Surgical emergencies 285
Acute abdomen 286
Orthopaedic infections 287
ENT infections 288
Eye infections 288

Reference information 291
Glasgow coma scale 292
Mental state examination 293
Acid-base nomogram 294
Useful formulae 295
Common laboratory reference values 297

Index 301
CONTRIBUTORS

Adam MC Archibald BSc(Hons) MBChB
FY2 Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh

Peter J Barnes DM DSc FRCP FMedSci FRS
Professor and Consultant in Respiratory Medicine, National Heart and Lung Institute, Imperial College London

Alison Bedlow BSc MBBS FRCP
Consultant Dermatologist, South Warwickshire NHS Foundation Trust

Aodhan Breathnach MD FRCPath
Consultant Medical Microbiologist, Department of Medical Microbiology St George’s Hospital, London

Emma C Derrett-Smith BSc MBBS MRCP
Clinical Research Fellow, Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London

Timothy WR Doulton BSc MBBS MRCP MD
Consultant Nephrologist, Kent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust

Thomas M Galliford MBBS BSc(Hons) MRCP
SpR Department of Diabetes and Endocrinology, Imperial College NHS Healthcare Trust, London

Beth D Harrison MA BM BCh DM FRCP FRCPath
Consultant Haematologist, University Hospital Coventry and Warwickshire NHS Trust

Steven Harsum MBBS BSc PhD FRCOphth
Consultant Ophthalmologist, Sutton Eye Unit, Epsom and St Helier NHS Trust

Robin DC Kumar MBBS BSc FRCA
Clinical Fellow in Neuroanaesthesia, National Hospital for Neurology and Neurosurgery, Queen Square, London
Simon J Little  BA(Cantab) MBBS MRCP
SpR St Georges Hospital, London; and Wellcome Trust Research
Fellow, Functional Neurosurgery and Experimental Neurology,
Oxford University

Ramsay Singer  MA(Oxon) MBBS MRCP
Registrar in General Medicine and Paediatrics, Kivunge
Hospital, Zanzibar.

Allison C Morton  BMedSci MBChB MRCP PhD
Consultant Cardiologist, Sheffield Teaching Hospitals NHS Foundation
Trust; and Clinical Research Manager, NIHR Cardiovascular
Biomedical Research Unit, Northern General Hospital, Sheffield

Victor Pace  FRCP
Consultant in Palliative Medicine, St Christopher’s Hospice,
Sydenham, London

Stephen D Quinn  MB BS BSc MRCOG
Clinical Research Fellow, Imperial College London; and Honorary
Specialist Registrar, Imperial College Healthcare NHS Trust, London

Ricardo Sainz-Fuertes  LMS MSc MRCPsych
MRC Clinical Research Training Fellow, Institute of Psychiatry,
King’s College London and Honorary Specialist Registrar in
Psychiatry, South London and Maudsley NHS Foundation Trust

Biba Stanton  BMedSci MBBS MRCP PhD
Specialist Registrar, National Hospital for Neurology and
Neurosurgery, Queen Square, London

Rudolf Uher  MD PhD MRCPsych
Clinical Lecturer, Social, Genetic and Developmental Psychiatry
Centre, Institute of Psychiatry, King’s College London

Esther Unitt  BMedSci MBBS MRCP DM
Consultant Gastroenterologist and Hepatologist at the University
Hospital, Coventry and Warwickshire Hospitals NHS Trust

W Stephen Waring  PhD FRCP(Edin)
Consultant in Acute Medicine and Toxicology, Acute Medical Unit,
York Teaching Hospital NHS Foundation Trust
FOREWORD

Busy clinicians in every specialty must, in an age when all are overwhelmed by instant data at the touch of a button, be able to access straightforward didactic information that is reliable, consistent and useful at the bedside. Sometimes a small, *vade mecum* style pocket book fulfils the task perfectly and can be easier and quicker to use than any digital equivalent.

Arguably the most important part of clinical practice demanding this type of book is clinical pharmacology and drug prescribing. Drug errors continue to be a major barrier to the delivery of safe health care. Systematic attempts to reduce unnecessary patient morbidity and mortality are underway; any practical and simple aid that will help is welcomed.

This book does its job admirably. It is the first member of a new suite of books with the generic title *Pocket Prescriber*, but each is targeted at a specific audience, in this case emergency medicine care. The main section on over 500 common/useful drugs remains identical in each volume, with other sections adapted to the needs of the target group.

The structure of this new book is easy to follow and logical; all relevant information for a specific drug can be readily absorbed and digested, making the translation to safer prescribing smooth and more consistent. This volume includes important content on drugs, fluids and algorithms used in the emergency department, vastly expanded sections on medical and surgical emergencies, as well as a wealth of practical information around the use and delivery of medications.

This excellent book will prove itself an invaluable prescribing guide for all front line clinical staff who work in an emergency
department, whether they are permanent or in-training members of the team.

Geoff Hughes, Associate Professor
MBBS FRCP FCEM FACEM DRCOG
Editor-in-Chief, Emergency Medicine Journal, BMJ Group UK
Executive Director, Critical Care Services
Central Adelaide Local Health Network,
South Australia
This specialty edition of the hugely popular *Pocket Prescriber* series retains the same distinct format with the *Common/Useful Drugs* section essentially unchanged and content from the other sections rearranged and reformatted to best align with emergency department practice.

New content has been added including CPR, anaphylaxis, procedural sedation, local anaesthesia and rapid sequence induction, as well as vastly expanded medical and surgical emergencies sections. Finally all content has been updated to include the latest evidence-based guidelines to bring you the essence of emergency medicine prescribing in one compact source.

Tony Brown
July 2013
ACKNOWLEDGEMENTS

Particular thanks to Caroline Makepeace, head of Postgraduate and Professional Publishing, Health Sciences, and Stephen Clausard, senior project editor of Hodder Education, for their efficiency, enthusiasm and advice – both are an absolute delight to work with.

Also to Tim and Donald for so generously sharing their intellectual property to expand their concept into new specialty areas – again a pure pleasure to work with.

The information in this book has been collated from many sources, including manufacturer’s information sheets (‘SPCs’ – Summary of Product Characteristics sheets), the British National Formulary (BNF), national and international guidelines, as well as numerous pharmacology and general medical books, journals and papers. Where information is not consistent between these sources, that from the SPCs has generally been taken as definitive.

Tony Brown
July 2013
HOW TO USE THIS BOOK

STANDARD LAYOUT OF DRUGS

DRUG/TRADE NAME

Class/action: More information is given for generic forms, especially for the original and most commonly used drug(s) of each class.

Use: use (correlating to dose as below).

CI: contraindications; L (liver failure), R (renal failure), H (heart failure), P (pregnancy), B (breastfeeding). Allergy to active drug, or any excipients (other substances in the preparation) assumed too obvious to mention.

Caution: L (liver failure), R (renal failure), H (heart failure), P (pregnancy), B (breastfeeding), E (elderly patients). If a contraindication is given for a drug it is assumed too obvious to mention that a caution is also inherently implied.

SE: side effects; listed in order of frequency encountered. Common/important side effects set in bold.

Warn: information to give to patients before starting drug.

Monitor: parameters that need to be monitored during treatment.

Interactions: included only if very common or potentially serious; / (induces/inhibits cytochrome P450 metabolism), W+ (increases effect of warfarin), W– (decreases effect of warfarin).

Dose: dose (for Use as above). NB Doses are for adults only.

Use/dose: National Institute of Health and Clinical Excellence guidelines exist for the drug (basics often in BNF – see www.nice.org.uk for full details).

Dose: BNF/SPC: dose regimen complicated; please refer to BNF and/or SPC (Summary of Product Characteristics sheet; the manufacturer’s information sheet enclosed with drug packaging – can also be viewed at or downloaded from www.emc.medicines.org.uk).

Asterisks (*) and daggers (†) denote links between information within local text.
Only relevant sections are included for each drug. Trade names (in OUTLINE font) are given only if found regularly on drug charts or if non-proprietary (generic, non-trade-name) drug does not exist yet.

KEY

✿ Potential dangers highlighted with skull and crossbones
❖ New drug or new indication under intense surveillance by Committee on Safety of Medicines (CSM): important to report all suspected drug reactions via Yellow Card scheme (accurate as going to press: from June 2013 CSM list)
😊 Good for: reasons to give a certain drug when choice exists
😊 Bad for: reasons to not give a certain drug when choice exists
⇒ Causes/goes to
∶ Therefore
Δ Change/disturbance
Ψ Psychiatric
↑ Increase/high
↓ Decrease/low

 электроlytes refers to serum levels, unless stated otherwise.

DOSES

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>od</td>
<td>once daily</td>
</tr>
<tr>
<td>bd</td>
<td>twice daily</td>
</tr>
<tr>
<td>tds</td>
<td>three times daily</td>
</tr>
<tr>
<td>qds</td>
<td>four times daily</td>
</tr>
<tr>
<td>nocte</td>
<td>at night</td>
</tr>
<tr>
<td>mane</td>
<td>in the morning</td>
</tr>
<tr>
<td>prn</td>
<td>as required</td>
</tr>
<tr>
<td>stat</td>
<td>at once</td>
</tr>
</tbody>
</table>

Routes are presumed po, unless stated otherwise.

ROUTES

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>im</td>
<td>intramuscular</td>
</tr>
<tr>
<td>inh</td>
<td>inhaled</td>
</tr>
<tr>
<td>iv</td>
<td>intravenous</td>
</tr>
<tr>
<td>ivi</td>
<td>intravenous infusion</td>
</tr>
<tr>
<td>neb</td>
<td>via nebuliser</td>
</tr>
<tr>
<td>po</td>
<td>oral</td>
</tr>
<tr>
<td>pr</td>
<td>rectal</td>
</tr>
<tr>
<td>sc</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>top</td>
<td>topical</td>
</tr>
<tr>
<td>sl</td>
<td>sublingual</td>
</tr>
</tbody>
</table>
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-ASA</td>
<td>5-aminosalicylic acid</td>
</tr>
<tr>
<td>5HT</td>
<td>5-hydroxytryptamine (= serotonin)</td>
</tr>
<tr>
<td>AAA</td>
<td>abdominal aortic aneurysm</td>
</tr>
<tr>
<td>AAC</td>
<td>antibiotic-associated colitis</td>
</tr>
<tr>
<td>Ab</td>
<td>antibody</td>
</tr>
<tr>
<td>ABPM</td>
<td>ambulatory blood pressure monitoring</td>
</tr>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
</tr>
<tr>
<td>ACCP</td>
<td>American College of Chest Physicians</td>
</tr>
<tr>
<td>ACE-i</td>
<td>ACE inhibitor</td>
</tr>
<tr>
<td>ACh</td>
<td>acetylcholine</td>
</tr>
<tr>
<td>ACS</td>
<td>acute coronary syndrome</td>
</tr>
<tr>
<td>ADP</td>
<td>adenosine diphosphate</td>
</tr>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>Ag</td>
<td>antigen</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>AKI</td>
<td>acute kidney injury</td>
</tr>
<tr>
<td>ALL</td>
<td>acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>ALS</td>
<td>advanced life support (algorithm of European Resuscitation Council)</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine(-amino) transferase</td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
</tr>
<tr>
<td>AMTS</td>
<td>abbreviated mental test score (same as MTS)</td>
</tr>
<tr>
<td>ANA</td>
<td>anti-nuclear antigens</td>
</tr>
<tr>
<td>APTT</td>
<td>activate partial thromboplastin time</td>
</tr>
<tr>
<td>ARB(s)</td>
<td>angiotensin receptor blocker(s)</td>
</tr>
<tr>
<td>ARDS</td>
<td>adult respiratory distress syndrome</td>
</tr>
<tr>
<td>AS</td>
<td>aortic stenosis</td>
</tr>
<tr>
<td>ASAP</td>
<td>as soon as possible</td>
</tr>
<tr>
<td>assoc</td>
<td>associated</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate transaminase</td>
</tr>
<tr>
<td>AV</td>
<td>arteriovenous</td>
</tr>
<tr>
<td>AVM</td>
<td>arteriovenous malformation</td>
</tr>
<tr>
<td>AVN</td>
<td>atrioventricular node</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>AZT</td>
<td>zidovudine</td>
</tr>
<tr>
<td>BBB</td>
<td>bundle branch block</td>
</tr>
<tr>
<td>BCSH</td>
<td>British Committee for Standards in Haematology</td>
</tr>
<tr>
<td>BCT</td>
<td>broad complex tachycardia</td>
</tr>
<tr>
<td>BF</td>
<td>blood flow</td>
</tr>
<tr>
<td>BG</td>
<td>serum blood glucose in mmol/l; see also CBG</td>
</tr>
<tr>
<td>BCSH</td>
<td>British Committee for Standards in Haematology</td>
</tr>
<tr>
<td>BCT</td>
<td>broad complex tachycardia</td>
</tr>
<tr>
<td>BF</td>
<td>blood flow</td>
</tr>
<tr>
<td>BG</td>
<td>serum blood glucose in mmol/l; see also CBG</td>
</tr>
<tr>
<td>BCSH</td>
<td>British Committee for Standards in Haematology</td>
</tr>
<tr>
<td>BCT</td>
<td>broad complex tachycardia</td>
</tr>
<tr>
<td>BF</td>
<td>blood flow</td>
</tr>
<tr>
<td>BG</td>
<td>serum blood glucose in mmol/l; see also CBG</td>
</tr>
<tr>
<td>BIH</td>
<td>benign intracranial hypertension</td>
</tr>
<tr>
<td>BIPAP</td>
<td>bilevel/biphasic positive airway pressure</td>
</tr>
<tr>
<td>BLS</td>
<td>basic life support (algorithm of European Resuscitation Council)</td>
</tr>
<tr>
<td>BM</td>
<td>bone marrow (NB: BM is often used, confusingly, to signify finger-prick glucose; CBG - capillary blood glucose - is used instead in this book)</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BNF</td>
<td>British National Formulary</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>BPH</td>
<td>benign prostatic hypertrophy</td>
</tr>
<tr>
<td>BTS</td>
<td>British Thoracic Society</td>
</tr>
<tr>
<td>Bx</td>
<td>biopsy</td>
</tr>
<tr>
<td>C</td>
<td>constipation</td>
</tr>
<tr>
<td>CA$^{2+}$</td>
<td>calcium</td>
</tr>
<tr>
<td>Ca</td>
<td>cancer (NB: note calcium is written as CA$^{2+}$)</td>
</tr>
<tr>
<td>CAH</td>
<td>congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>cAMP</td>
<td>cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CAP</td>
<td>community-acquired pneumonia</td>
</tr>
<tr>
<td>CBF</td>
<td>cerebral blood flow</td>
</tr>
<tr>
<td>CBG</td>
<td>capillary blood glucose in mmol/l on finger-prick testing. (NB: BM is often used to denote this, but is confusing and less accurate, thus not used in this book)</td>
</tr>
<tr>
<td>CCF</td>
<td>congestive cardiac failure</td>
</tr>
<tr>
<td>cf</td>
<td>compared with</td>
</tr>
<tr>
<td>CI</td>
<td>contraindicated</td>
</tr>
<tr>
<td>CK</td>
<td>creatine kinase</td>
</tr>
<tr>
<td>CKD</td>
<td>chronic kidney disease</td>
</tr>
<tr>
<td>CLL</td>
<td>chronic lymphocytic leukaemia</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>CML</td>
<td>chronic myelogenous leukaemia</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CO</td>
<td>cardiac output</td>
</tr>
<tr>
<td>CO₂</td>
<td>carbon dioxide</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>COX</td>
<td>cyclo-oxygenase</td>
</tr>
<tr>
<td>CPR</td>
<td>cardiopulmonary resuscitation</td>
</tr>
<tr>
<td>CRF</td>
<td>chronic renal failure</td>
</tr>
<tr>
<td>CRP</td>
<td>C reactive protein</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CSM</td>
<td>Committee on Safety of Medicines</td>
</tr>
<tr>
<td>CT</td>
<td>computerised tomography</td>
</tr>
<tr>
<td>CVA</td>
<td>cerebrovascular accident</td>
</tr>
<tr>
<td>CVP</td>
<td>central venous pressure</td>
</tr>
<tr>
<td>CXR</td>
<td>chest X-ray</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>D</td>
<td>diarrhoea</td>
</tr>
<tr>
<td>D&amp;V</td>
<td>diarrhoea and vomiting</td>
</tr>
<tr>
<td>D₁/₂/₃ ...</td>
<td>dopamine receptor subtype 1/2/3...</td>
</tr>
<tr>
<td>DA</td>
<td>dopamine</td>
</tr>
<tr>
<td>DCT</td>
<td>distal convoluted tubule</td>
</tr>
<tr>
<td>dfx</td>
<td>defects</td>
</tr>
<tr>
<td>DI</td>
<td>diabetes insipidus</td>
</tr>
<tr>
<td>DIC</td>
<td>disseminated intravascular coagulation</td>
</tr>
<tr>
<td>DIGAMI</td>
<td>glucose, insulin and potassium intravenous infusion used in acute myocardial infarction</td>
</tr>
<tr>
<td>DKA</td>
<td>diabetic ketoacidosis</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DMARD</td>
<td>disease-modifying anti-rheumatoid arthritis drug</td>
</tr>
<tr>
<td>dt</td>
<td>due to</td>
</tr>
<tr>
<td>DWI</td>
<td>diffusion weighted imaging (specialist MRI mostly used for stroke/TIA)</td>
</tr>
<tr>
<td>Dx</td>
<td>diagnosis</td>
</tr>
<tr>
<td>EØ</td>
<td>eosinophils</td>
</tr>
<tr>
<td>e’lyte</td>
<td>electrolyte</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>EBV</td>
<td>Epstein-Barr virus</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECT</td>
<td>electroconvulsive therapy</td>
</tr>
<tr>
<td>ED</td>
<td>emergency department</td>
</tr>
<tr>
<td>EF</td>
<td>ejection fraction</td>
</tr>
<tr>
<td>ENT</td>
<td>ear, nose and throat</td>
</tr>
<tr>
<td>EPSE</td>
<td>extrapyramidal side effects</td>
</tr>
<tr>
<td>ERC</td>
<td>European Resuscitation Council</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>esp</td>
<td>especially</td>
</tr>
<tr>
<td>ESR</td>
<td>erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>EST</td>
<td>exercise stress test</td>
</tr>
<tr>
<td>ETT</td>
<td>endotracheal tube</td>
</tr>
<tr>
<td>exac</td>
<td>exacerbates</td>
</tr>
<tr>
<td>FBC</td>
<td>full blood count</td>
</tr>
<tr>
<td>Fe</td>
<td>iron</td>
</tr>
<tr>
<td>FFP</td>
<td>fresh frozen plasma</td>
</tr>
<tr>
<td>FHx</td>
<td>family history</td>
</tr>
<tr>
<td>FiO₂</td>
<td>inspired O₂ concentration</td>
</tr>
<tr>
<td>FMF</td>
<td>familial Mediterranean fever</td>
</tr>
<tr>
<td>fx</td>
<td>effects</td>
</tr>
<tr>
<td>G6PD</td>
<td>glucose-6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>GABA</td>
<td>gamma aminobutyric acid</td>
</tr>
<tr>
<td>GBS</td>
<td>Guillain-Barré syndrome</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow Coma Scale</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GIFTASUP</td>
<td>Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients</td>
</tr>
<tr>
<td>GIK</td>
<td>glucose, insulin and K⁺ infusion</td>
</tr>
<tr>
<td>GMC</td>
<td>General Medical Council (of UK)</td>
</tr>
<tr>
<td>GTN</td>
<td>glyceryl trinitrate</td>
</tr>
<tr>
<td>GU</td>
<td>genitourinary</td>
</tr>
<tr>
<td>h</td>
<td>hour(s)</td>
</tr>
<tr>
<td>H(O)CM</td>
<td>hypertrophic (obstructive) cardiomyopathy</td>
</tr>
<tr>
<td>Hb</td>
<td>haemoglobin</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HB</td>
<td>heart block</td>
</tr>
<tr>
<td>HBPM</td>
<td>home blood pressure monitoring</td>
</tr>
<tr>
<td>HCM</td>
<td>hypertrophic cardiomyopathy (formerly known as HOCM)</td>
</tr>
<tr>
<td>Hct</td>
<td>haematocrit</td>
</tr>
<tr>
<td>HDL</td>
<td>high density lipoprotein</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>HHS</td>
<td>hyperosmolar, hyperlycaemic state (formerly known as HONK)</td>
</tr>
<tr>
<td>Hib</td>
<td><em>H. influenzae</em>, type b</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HLA</td>
<td>human leucocyte antigen</td>
</tr>
<tr>
<td>HMG-CoA</td>
<td>3-hydroxy-3-methyl-glutaryl coenzyme A</td>
</tr>
<tr>
<td>HONK</td>
<td>hyperosmolar non-ketotic state (see HHS above)</td>
</tr>
<tr>
<td>hrly</td>
<td>hourly</td>
</tr>
<tr>
<td>HSV</td>
<td>herpes simplex virus</td>
</tr>
<tr>
<td>HTN</td>
<td>hypertension</td>
</tr>
<tr>
<td>HUS</td>
<td>haemolytic uraemic syndrome</td>
</tr>
<tr>
<td>Hx</td>
<td>history</td>
</tr>
<tr>
<td>IBD</td>
<td>inflammatory bowel disease</td>
</tr>
<tr>
<td>IBS</td>
<td>irritable bowel syndrome</td>
</tr>
<tr>
<td>IBW</td>
<td>ideal body weight</td>
</tr>
<tr>
<td>ICH</td>
<td>intracranial haemorrhage</td>
</tr>
<tr>
<td>ICP</td>
<td>intracranial pressure</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>IHD</td>
<td>ischaemic heart disease</td>
</tr>
<tr>
<td>IL-2</td>
<td>interleukin 2</td>
</tr>
<tr>
<td>im</td>
<td>intramuscular</td>
</tr>
<tr>
<td>inc</td>
<td>including</td>
</tr>
<tr>
<td>inh</td>
<td>inhaled</td>
</tr>
<tr>
<td>INR</td>
<td>international normalised ratio (prothrombin ratio)</td>
</tr>
<tr>
<td>IOP</td>
<td>intraocular pressure</td>
</tr>
<tr>
<td>ITP</td>
<td>immune/idiopathic thrombocytopenic purpura</td>
</tr>
<tr>
<td>ITU</td>
<td>intensive therapy unit</td>
</tr>
<tr>
<td>iv</td>
<td>intravenous</td>
</tr>
<tr>
<td>IVDU</td>
<td>intravenous drug user</td>
</tr>
</tbody>
</table>
ivi intravenous infusion
Ix investigation
K⁺ potassium (serum levels unless stated otherwise)
LØ lymphocytes
LA long-acting
LBBB left bundle branch block
LDL low density lipoprotein
LF liver failure
LFTs liver function tests
LMWH low-molecular-weight heparin
LP lumbar puncture
LVF left ventricular failure
MØ macrophages
mane in the morning
MAOI monoamine oxidase inhibitor
MAP mean arterial pressure
MCA middle cerebral artery
MCV mean corpuscular volume
metab metabolised
Mg²⁺ magnesium
MG myasthenia gravis
MHRA Medicines and Healthcare Products Regulatory Authority (UK)
MI myocardial infarction
MMF mycophenolate mofetil
MMSE Mini-Mental State Examination (scored out of 30*)
MR modified-release (drug preparation)†
MRI magnetic resonance imaging
MRSA methicillin-resistant Staphylococcus aureus
MS multiple sclerosis
MSU mid-stream urine
MTS (abbreviated) Mental Test Score (scored out of 10*)
MUST malnutrition universal screening tool
Mx management
N nausea
N&V nausea and vomiting
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NØ</td>
<td>neutrophils</td>
</tr>
<tr>
<td>NA</td>
<td>noradrenaline (norepinephrine)</td>
</tr>
<tr>
<td>Na⁺</td>
<td>sodium (serum levels unless stated otherwise)</td>
</tr>
<tr>
<td>NBM</td>
<td>nil by mouth</td>
</tr>
<tr>
<td>NCT</td>
<td>narrow complex tachycardia</td>
</tr>
<tr>
<td>NDRI</td>
<td>noradrenaline and dopamine reuptake inhibitor</td>
</tr>
<tr>
<td>neb</td>
<td>via nebuliser</td>
</tr>
<tr>
<td>NGT</td>
<td>nasogastric tube</td>
</tr>
<tr>
<td>NH</td>
<td>non-Hodgkin’s (lymphoma)</td>
</tr>
<tr>
<td>NIHSS</td>
<td>National (US) Institute of Health Stroke Scale</td>
</tr>
<tr>
<td>NIV</td>
<td>non-invasive ventilation</td>
</tr>
<tr>
<td>NMJ</td>
<td>neuromuscular junction</td>
</tr>
<tr>
<td>NMS</td>
<td>neuroleptic malignant syndrome</td>
</tr>
<tr>
<td>NPIS</td>
<td>National Poisons Information Service</td>
</tr>
<tr>
<td>NSAID</td>
<td>nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>non-ST elevation myocardial infarction</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>OCD</td>
<td>obsessive compulsive disorder</td>
</tr>
<tr>
<td>OCP</td>
<td>oral contraceptive pill</td>
</tr>
<tr>
<td>OD</td>
<td>overdose (NB: od = once daily!)</td>
</tr>
<tr>
<td>OGD</td>
<td>oesophagastroduodenoscopy</td>
</tr>
<tr>
<td>p’way(s)</td>
<td>pathway(s)</td>
</tr>
<tr>
<td>PAN</td>
<td>polyarteritis nodosa</td>
</tr>
<tr>
<td>PBC</td>
<td>primary biliary cirrhosis</td>
</tr>
<tr>
<td>PCI</td>
<td>percutaneous coronary intervention (preferred term for percutaneous transluminal coronary angioplasty (PTCA), which is a type of PCI)</td>
</tr>
<tr>
<td>PCOS</td>
<td>polycystic ovary syndrome</td>
</tr>
<tr>
<td>PCP</td>
<td><em>Pneumocystis carinii</em> pneumonia</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PCV</td>
<td>packed cell volume</td>
</tr>
<tr>
<td>PDA</td>
<td>patent ductus arteriosus</td>
</tr>
<tr>
<td>PE</td>
<td>pulmonary embolism</td>
</tr>
<tr>
<td>PEA</td>
<td>pulseless electrical activity</td>
</tr>
<tr>
<td>PEG</td>
<td>percutaneous endoscopic gastrostomy</td>
</tr>
<tr>
<td>PG(x)</td>
<td>prostaglandin (receptor subtype x)</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>phaeo</td>
<td>phaeochromocytoma</td>
</tr>
<tr>
<td>PHx</td>
<td>past history (of)</td>
</tr>
<tr>
<td>PID</td>
<td>pelvic inflammatory disease</td>
</tr>
<tr>
<td>PML</td>
<td>progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>PMR</td>
<td>polymyalgia rheumatica</td>
</tr>
<tr>
<td>po</td>
<td>by mouth</td>
</tr>
<tr>
<td>PO_4</td>
<td>phosphate (serum levels, unless stated otherwise)</td>
</tr>
<tr>
<td>PPI</td>
<td>proton pump inhibitor</td>
</tr>
<tr>
<td>pr</td>
<td>rectal</td>
</tr>
<tr>
<td>PR</td>
<td>per rectal (digital examination)</td>
</tr>
<tr>
<td>prep(s)</td>
<td>preparation(s)</td>
</tr>
<tr>
<td>prn</td>
<td>as required</td>
</tr>
<tr>
<td>PSA</td>
<td>prostate specific antigen</td>
</tr>
<tr>
<td>Pt</td>
<td>platelet(s)</td>
</tr>
<tr>
<td>PT</td>
<td>prothrombin time</td>
</tr>
<tr>
<td>PTH</td>
<td>parathyroid hormone</td>
</tr>
<tr>
<td>PTSD</td>
<td>post-traumatic stress disorder</td>
</tr>
<tr>
<td>PU</td>
<td>peptic ulcer</td>
</tr>
<tr>
<td>PUO</td>
<td>pyrexia of unknown origin</td>
</tr>
<tr>
<td>PVD</td>
<td>peripheral vascular disease</td>
</tr>
<tr>
<td>Px</td>
<td>prophylaxis</td>
</tr>
<tr>
<td>QT(c)</td>
<td>QT interval (corrected for rate)</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>RAD</td>
<td>right axis deviation</td>
</tr>
<tr>
<td>RAS</td>
<td>renal artery stenosis</td>
</tr>
<tr>
<td>RBBB</td>
<td>right bundle branch block</td>
</tr>
<tr>
<td>RBF</td>
<td>renal blood flow</td>
</tr>
<tr>
<td>RF</td>
<td>renal failure</td>
</tr>
<tr>
<td>RLS</td>
<td>restless legs syndrome</td>
</tr>
<tr>
<td>ROSIER</td>
<td>Recognition Of Stroke In Emergency Room scale for diagnosis of stroke/TIA</td>
</tr>
<tr>
<td>RR</td>
<td>respiratory rate</td>
</tr>
<tr>
<td>RRT</td>
<td>renal replacement therapy</td>
</tr>
<tr>
<td>RSI</td>
<td>rapid sequence induction</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>RTI</td>
<td>respiratory tract infection</td>
</tr>
</tbody>
</table>
RV right ventricle
RVF right ventricular failure
Rx treatment
SAH subarachnoid haemorrhage
SAN sinoatrial node
SBE subacute bacterial endocarditis
sc subcutaneous
SE(s) side effect(s)
sec second(s)
SIADH syndrome of inappropriate antidiuretic hormone
SIGN Scottish Intercollegiate Guidelines Network
SJS Stevens-Johnson syndrome
sl sublingual
SLE systemic lupus erythematosus
SOA swelling of ankles
SOB (OE) shortness of breath (on exertion)
SPC Summary of Product Characteristics drug sheet
spp species
SR slow/sustained release (drug preparation)
SSRI selective serotonin reuptake inhibitor
SSS sick sinus syndrome
STEMI ST elevation myocardial infarction
supp suppository
SVT supraventricular tachycardia
\( t_{1/2} \) half-life
\( T_3 \) triiiodothyronine/lithyronine
\( T_4 \) thyroxine (↑↓\( T_4 \) = hyper/hypothyroid)
TBG thyroid binding globulin
TCA tricyclic antidepressant
TE thromboembolism
TEDS thromboembolism deterrent stockings
TEN toxic epidermal necrolysis
TFTs thyroid function tests
TG triglyceride
TIBC total iron binding capacity
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIMI score</td>
<td>risk score for UA/NSTEMI named after TIMI (thrombolysis in MI) trial</td>
</tr>
<tr>
<td>TNF</td>
<td>tumour necrosis factor</td>
</tr>
<tr>
<td>top</td>
<td>topical</td>
</tr>
<tr>
<td>TPMT</td>
<td>thiopurine methyltransferase</td>
</tr>
<tr>
<td>TPR</td>
<td>total peripheral resistance</td>
</tr>
<tr>
<td>TTA(s)</td>
<td>(drugs) to take away, i.e. prescriptions for inpatients on discharge/leave (aka TTO)</td>
</tr>
<tr>
<td>TTO(s)</td>
<td>see TTA</td>
</tr>
<tr>
<td>TTP</td>
<td>thrombotic thrombocytopenic purpura</td>
</tr>
<tr>
<td>U&amp;Es</td>
<td>urea and electrolytes</td>
</tr>
<tr>
<td>UA(P)</td>
<td>unstable angina (pectoris)</td>
</tr>
<tr>
<td>UC</td>
<td>ulcerative colitis</td>
</tr>
<tr>
<td>URTI</td>
<td>upper respiratory tract infection</td>
</tr>
<tr>
<td>USS</td>
<td>ultrasound scan</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>V</td>
<td>vomiting</td>
</tr>
<tr>
<td>VBG</td>
<td>venous blood gas</td>
</tr>
<tr>
<td>VE(s)</td>
<td>ventricular ectopic(s)</td>
</tr>
<tr>
<td>VF</td>
<td>ventricular fibrillation</td>
</tr>
<tr>
<td>vit</td>
<td>vitamin</td>
</tr>
<tr>
<td>VLDL</td>
<td>very low density lipoprotein</td>
</tr>
<tr>
<td>VT</td>
<td>ventricular tachycardia</td>
</tr>
<tr>
<td>VTE</td>
<td>venous thromboembolism</td>
</tr>
<tr>
<td>VZV</td>
<td>varicella zoster virus (chickenpox/shingles)</td>
</tr>
<tr>
<td>w</td>
<td>with</td>
</tr>
<tr>
<td>w/in</td>
<td>within</td>
</tr>
<tr>
<td>w/o</td>
<td>without</td>
</tr>
<tr>
<td>WCC</td>
<td>white cell count</td>
</tr>
<tr>
<td>WE</td>
<td>Wernicke’s encephalopathy</td>
</tr>
<tr>
<td>wk</td>
<td>week</td>
</tr>
<tr>
<td>WPW</td>
<td>Wolff–Parkinson–White syndrome</td>
</tr>
<tr>
<td>Wt</td>
<td>weight</td>
</tr>
<tr>
<td>xs</td>
<td>excess</td>
</tr>
<tr>
<td>ZE</td>
<td>Zollinger–Ellison syndrome</td>
</tr>
</tbody>
</table>
HOW TO PRESCRIBE SAFELY IN THE ED

Take time/care to ↓risk to patients (and to protect yourself).

Always check the following are correct for all prescriptions:

Patient, indication and drug, legible format (generic name, clarity, handwriting, identifiable signature, your contact number), dosage, frequency, time(s) of day, date, duration of treatment, route of administration.

Know where to find information, if you are uncertain:

Look up the drug dose, contraindication, caution, side effect or interaction, whenever you are unsure. Whether in a book (this one!), online, smart phone, app or even by asking a colleague, get into the habit of checking, then rechecking.

DO

- Make a clear, accurate record in the notes of all medicines prescribed, written at the time of prescription
- Complete allergy box and alert labels, where relevant
- Include on all drug charts and TTAs the patient’s surname and given name, date of birth, date of admission and consultant (if possible use a printed label for patient details)
- PRINT (i.e. use upper case) all drugs as approved (generic) names, e.g. ‘IBUPROFEN’ not ‘nurofen’
- State dose, route and frequency, giving strength of solutions/creams
- Write the word microgram in full; avoid abbreviations such as mcg or µ
- Shorten the word gram to ‘g’ (rather than ‘gm’ which is easily confused with mg)
- Write the word ‘units’ in full, preceded by a space; abbreviating to ‘U’ can be misread as zero (a 10-fold error)
- Document weight where dosing is weight-dependent
- Write quantities <1 g in mg (e.g. 400 mg not 0.4 g)
- Write quantities <1 mg in micrograms (e.g. 200 micrograms not 0.2 mg)
• Not use trailing zeroes (10 mg not 10.0 mg)
• Precede decimal points with another figure (e.g. 0.8 ml not .8 ml) and only use decimals where unavoidable
• Check and recheck calculations
• Provide clear additional instructions, e.g. for monitoring, review of antibiotic route and duration, maximum daily/24 h dose for PRN drugs
• Specify solution to be used and duration of any iv infusions/injections
• Avoid using abbreviated/non-standard drug names
• Avoid writing ‘T’ (tablet sign) for non-tablet formulations, e.g. sprays
• Amend a prescribed drug by drawing a line through it, date and initial this, then rewrite as new prescription
• Check and count number of drugs when rewriting a drug chart

IMPORTANT FURTHER ADVICE

1 Make sure choice of drug and dose is right for the patient, their condition and significant comorbidity, with particular attention to age*, gender, ethnicity, renal or liver dysfunction, risk of drug–drug and drug–disease interactions, and risks in pregnancy (and those of child-bearing age who may become pregnant) and during breastfeeding. Anticipate possible effects of over-the-counter and herbal medicines and lifestyle (e.g. dietary salt and alcohol intake).

*Although arbitrary, age of >65 yrs denotes ‘elderly’, but the fx of age can occur earlier/later and are continuous across age spectrum.

2 Common settings where drug problems occur are often predictable if you understand relevant pathology, routes of drug metabolism (liver, P450, renal, etc) and drug mechanisms of action. Take particular care with:
• Renal or liver disease
• Pregnancy/breastfeeding: use safest options (in the UK consider consulting the National Teratology Information Service; tel: 0191 232 1525)
• NSAIDs/bisphosphonates and peptic ulcer disease
• Asthma and β-blockers
• Conditions worsened by antimuscarinic drugs (see p. 276): urinary retention/BPH, glaucoma, paralytic ileus
• Rare conditions where drugs commonly pose risk, e.g. porphyria, myasthenia, G6PD deficiency, phaeo

3 Always obtain informed consent; agree proposed prescriptions with the patient (or carer if patient has authorised their involvement in their care or has lost capacity), explaining proposed benefits, nature and duration of treatment, clarifying concerns, warning of possible, especially severe, adverse effects, highlighting recommended monitoring and review arrangements and stating what the patient should do in the event of a suspected adverse reaction.

• Only in extreme emergencies is it justified to not do this. For drugs with common potentially fatal/severe side effects document that these risks have been explained to, and accepted by the patient, such as with thrombolysis (see p. 230).

4 Check that appropriate previous medicines are continued and over-the-counter and herbal medicine use is recorded.

5 Make sure that you are being objective. Prescribing should be for the benefit of the patient not the prescriber.

6 Keep up to date about medicines you are prescribing and the related conditions you are treating.

7 Follow CSM guidance on reporting suspected adverse reactions to medicines (see top right link at www.mhra.gov.uk for links to details of the Yellow Card reporting scheme and downloads of reported adverse drug reactions for specific medicines).

8 Ensure continuity of care by keeping the patient’s GP (or other preferred medical adviser) informed about prescribing, monitoring and follow-up arrangements and responsibilities. Write a letter/summary.

9 Assume a letter given to the patient will be opened and read, so email, fax or post any discharge letter that may contain sensitive information.

10 See legal advice on eligibility to prescribe and use of unlicensed medicines on the GMC website (www.gmc-uk.org).
Common/useful drugs
**ABCIXIMAB/REOPRO**

Antiplatelet agent – monoclonal Ab against platelet glycoprotein IIb/IIIa receptor (involved in Pt aggregation).

**Use:** Px of ischaemic complications of PCI and Px of MI in unstable angina unresponsive to conventional Rx awaiting PCI\textsuperscript{NICE} (see p. 233).

**CI:** active internal bleeding, CVA w/in 2 years, intracranial neoplasm, aneurysm or AVM. Major surgery, intracranial/intraspinal surgery or trauma w/in 2 months. Hypertensive retinopathy, vasculitis, ↓Pt, haemorrhagic diathesis, severe ↑BP. L (if severe)/R (if requiring haemodialysis)/B.

**Caution:** drugs that ↑bleeding risk, L/R/P/E.

**SE:** bleeding* /↓Pt*, N&V, ↓BP, ↓HR, pain (chest, back or pleuritic), headache, fever, oedema. Rarely, hypersensitivity, tamponade, ARDS.

**Monitor:** FBC* (baseline plus 2–4 h, 12 h and 24 h after giving) and clotting (baseline at least).

**Dose:** 250 microgram/kg iv over 1 min, then 0.125 microgram/kg/min (max 10 microgram/min) ivi; see BNF/product literature for dose timing. NB: use iv non-pyrogenic, low protein binding filter. Needs concurrent heparin. Specialist use only: get senior advice or contact on-call cardiology.

**ACAMPROSATE/CAMPRAL EC**

Modifies GABA transmission ⇒ ↓pleasurable fx of alcohol . ↓s craving and relapse rate.

**Use:** maintaining alcohol abstinence supported by counselling.

**CI:** L (only if severe), R/P/B.

**SE:** GI upset, pruritus, rash, Δ libido.

**Dose:** 666 mg tds po if age 18–65 years (avoid outside this age range) and >60 kg (if <60 kg give 666 mg mane then 333 mg noon and nocte). Start ASAP after alcohol stopped. Usually give for 1 year.

**ACARBOSE**

Oral hypoglycaemic: intestinal α-glucosidase inhibitor. Delays digestion and ↓s absorption of starch and sucrose.

**Use:** IDDM not controlled by other oral hypoglycaemics and/or diet.
**ACETYLCESTEINE**

- Cl: IBD, hernia, Hx of abdominal surgery or obstruction R (if severe)
- L/P/B.
- SE: flatulence, GI upset, rarely hepatitis and ileus.
- Monitor: LFTs.
- Interactions: may ↑ hypoglycaemic fx of sulphonylureas and insulin.
- Dose: initially 50 mg od po, ↑ up to 200 mg tds po.

**ACIDEX**

Alginate raft-forming oral suspension for acid reflux.

Dose: 10–20 ml after meals and at bedtime (NB: 3 mmol Na⁺/5 ml)

**ACETAZOLAMIDE/DIAMOX**

Carbonic anhydrase inhibitor (sulphonamide-like).

- Use: glaucoma (acute-angle closure, primary open-angle unresponsive to maximal topical Rx, or secondary), ↑ ICP. Rarely epilepsy or diuresis.
- Cl: ↓ K⁺, ↓ Na⁺, ↑ Cl⁻ acidosis, sulphonamide allergy, adrenocortical insufficiency. L/R
- Caution: acidosis, pulmonary obstruction R/P/E.
- SE: nausea/GI upset, paraesthesia, drowsiness, mood Δ, headache, Δ LFTs. If prolonged use acidosis (metabolic) and e’lyte Δs. Rarely blood disorders and skin reactions (inc SJS/TENS).
- Monitor: FBC, U&E if prolonged use.
- Interactions: Many e.g.: ↑ s levels of carbamazepine and phenytoin. Can ↑ cardiac toxicity (via ↓ K⁺) of disopyramide, flecainide, lidocaine and cardiac glycosides. ↓ s fx of methenamine and ↑ fx of quinidine.
- Dose: 0.25–1 g/day po or iv^{SPC} (divided doses above 250 mg).
  Also available as 250 mg MR preparation (as Diamox SR; max 2 capsules/day). Epilepsy: see BNF.

Extravasation at injection site can ⇒ necrosis.

**ACETYLCYSTEINE/PARVOLEX**

Precursor of glutathione, which detoxifies metabolites of paracetamol.

- Use: paracetamol OD.
- Caution: asthma* and atopy.
SE: allergy: rash, bronchospasm*, anaphylactoid reactions (esp if ivi too quick**).
Dose: initially 150 mg/kg in 200 ml 5% glucose as ivi over 60 min, then 50 mg/kg in 500 ml over 4 h, then 100 mg/kg in 1 litre over 16 h.
NB: use max weight of 110 kg for dose calculation, even if patient weighs more. Ensure not given too quickly**. See p. 279 for Mx of paracetamol OD and treatment line graph.

ACICLOVIR (previously ACYCLOVIR)
Antiviral. Inhibits DNA polymerase only in infected cells: needs activation by viral thymidine kinase (produced by herpes spp).
Use: iv: severe HSV or VZV infections, e.g. meningitis, encephalitis and in immunocompromised patients (esp HIV – also used for Px);
po/top: mucous membrane, genital, eye infections.
Caution: dehydration*, R/P/B.
SE: at ↑doses: AKI, encephalopathy (esp if dehydrated*). Also hypersensitivity, seizures, GI upset, blood disorders, skin reactions (including photosensitivity), headache, many non-specific neurological symptoms, ↓Pt, ↓WBC. Rarely Ψ reactions and hepatotoxicity.
Interactions: levels ↑d by probenecid and cimetidine.
Dose: 5 mg/kg tds ivi over 1 h (10 mg/kg if HSV encephalitis or VZV in immunocompromised patients); po/topSPC/BNF.

ACTIVATED CHARCOAL see Charcoal.

ACTRAPID Short-acting soluble insulin; see p. 204 for use.

ADENOSINE
Purine nucleoside. Slows AVN conduction time, dilates coronary arteries; acts on its own specific receptors.
Use: Rx of paroxysmal SVT (esp if accessory p’ways e.g. WPW) and Dx of SVT (NCT or BCT; ↓s rate to reveal underlying rhythm).
CI: ☢ asthma*, COPD (consider verapamil). ☢ H, ↓BP, ↑QTc, 2nd-/3rd-degree AV block or sick sinus syndrome (unless pacemaker fitted).
Caution: heart transplant (↓dose), AF/atrial flutter (↑s accessory pathway conduction).
SE: bronchospasm*, ↓BP. Rarely ↓HR/astyle/arrhythmias (mostly transient), angina (discontinue if occurs), flushing, respiratory failure.
Warn: can ⇒ transient unpleasant feelings: facial flushing, dyspnoea, choking feeling, nausea, chest pain and light-headedness.
Interactions: fx ≠ by dipyridamole: ↓initial adenosine dose to 0.5–1 mg and watch for ↑bleeding (anti-Pt fx of dipyridamole ↑d by adenosine). fx ↓d by theophyllines and caffeine. Use with digoxin may ↑risk of VF.
Dose: 6 mg iv over 2 sec; if needed 12 mg after 1-2 min, repeated after 1-2 min; stop if significant AV block (max 12 mg/dose); ↓quarter usual dose if dipyridamole essential. NB: attach cardiac monitor and give via central (or large peripheral) vein, then flush. t₁/₂ <10 sec: often needs readministration (esp if given for Rx cf Dx).

ADRENALINE (im/iv)
Sympathomimetic: powerful stimulation of α (vasoconstriction), β₁(↑HR, ↑contractility) and β₂ (vasodilation, bronchodilation, uterine relaxation). Also ↓s immediate mast cell cytokine release.
Use: CPR and anaphylaxis (see algorithms on inside and outside front cover, respectively). Rarely for other causes of bronchospasm or shock (e.g. 2° to spinal/epidural anaesthesia).
Caution: cerebrovascular* and heart disease (esp arrhythmias and HTN), DM, ↑T₄, glaucoma (angle closure), labour (esp 2nd stage), phaeo. H/E/R.
SE: ↑HR, ↑BP, anxiety, sweats, tremor, headache, peripheral vasoconstriction, arrhythmias, pulmonary oedema (at ↑doses), N&V, weakness, dizziness, Ψ disturbance, hyperglycaemia, urinary retention (esp if ↑prostate), local reactions. Rarely CVA* (2° to HTN: monitor BP).
Interactions: fx ↑d by dopexamine, TCAs, ergotamine and oxytocin. Risk of: 1. ↑↑BP and ↓HR with non-cardioselective...
β-blockers (can also ⇒ ↓HR), TCAs, MAOIs and moclobemide. 2. arrhythmias with digoxin, quinidine and volatile liquid anaesthetics (e.g. halothane) and TCAs. Avoid use with tolazine or rasagiline.  

**Dose:** CPR: 1 mg iv ⇒ 10 ml of 1 in 10 000 (100 microgram/ml) then flush with ⇒ 20 ml saline. If no or delayed iv access, try intraosseous route. Repeat as per ALS algorithm (see front cover). **Anaphylaxis:** 0.5 mg im (or sc) ⇒ 0.5 ml of 1 in 1000 (1 mg/ml); repeat after 5 min if no response. (If cardiac arrest seems imminent or concerns over im absorption, give 0.5 mg iv slowly ⇒ 5 ml of 1 in 10 000 (100 microgram/ml) at 1 ml/min until response – get senior help first if possible as iv route ⇒ ↑risk of arrhythmias.)

**ADVIL** see Ibuprofen.

**AGGRASTAT** see Tirofiban; IIb/IIIa inhibitor (anti-Pt drug) for IHD.

**AGOMELATINE/VALDOXAN**
Antidepressant: synthetic melatonin analogue; melatonin receptor (MT1/MT2) agonist (also 5HT2CB antagonist); no effect on monoamine reuptake; resynchronises circadian rhythms and ↑s NA/DA in frontal cortex via 5HT2C antagonism. **Use:** depression; esp if risk of inconsistent use (low risk of withdrawal syndrome on discontinuation) or if prominent insomnia/sleep reversal. **Cl:** dementia and see interactions below **L/B.**

**Caution:** elderly, history of mania (bipolar). **R/P/E.**

**SE:** nausea, diarrhoea, constipation, abdo pain, ΔLFTs (↑ transaminases in 5%; usually transient), drowsiness, headache, sweating, anxiety, suicidal behaviour.

**Monitor:** LFTs before and 3, 6, 12 and 24 wks after starting. **Interactions:** levels ↑↑ by strong CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin – avoid) and ↑ by moderate inhibitors (e.g. propranolol, enoxacin, oestrogens, smoking). ↑ risk of convulsions with atomoxetine. Avoid with artemether/lumefantrine.
Dose: 25 mg nocte (can ↑ to 50 mg nocte after 2 wks).

**ALENDRONATE (ALENDRONIC ACID)/FOSAMAX**
Bisphosphonate: ↓s osteoclastic bone resorption.
**Use:** osteoporosis Rx and Px (esp if on corticosteroids).
**Cl:** delayed GI emptying (esp achalasia and oesophageal stricture/other abnormalities), ↓Ca$^{2+}$, unable to sit/stand upright ≥30 min, R (if severe)/P/B.
**Caution:** upper GI disorders (inc gastritis/PU) R.
**SE:** oesophageal reactions*, GI upset/distension, ↓Ca$^{2+}$, ↓PO$_4^{2-}$ (transient), PU, hypersensitivity (esp skin reactions), myalgia. Rarely osteonecrosis and femoral stress fractures (discontinue drug and should receive no further bisphosphonates).
**Warn:** take upright with full glass of water on an empty stomach; stay upright ≥30 min until breakfast* or other oral medicine. Stop tablets and seek medical attention if symptoms of oesophageal irritation.
**Dose:** 10 mg mane$^{SPC/BNF}$ (10 mg od dosing can be given as once-wkly 70-mg tablet if for post-menopausal osteoporosis).

**ALFACALCIDOL**
1-α-hydroxycholecalciferol: partially activated vitamin D (1α hydroxy group normally added by kidney), but still requires hepatic (25)-hydroxylation for full activation.
**Use:** severe vitamin D deficiency 2° to CRF.
**Cl/SE:** ↑Ca$^{2+}$
**Caution:** nephrolithiasis, breast-feeding E.
**Monitor:** Ca$^{2+}$: monitor levels wkly, watch for symptoms (esp N&V), rash, nephrocalcinosis.
**Interactions:** fx ↓d by barbiturates, anticonvulsants; ↑d by thiazides.
**Dose:** initially 1 microgram (=1000 nanograms) od po; maintenance 250–1000 nanograms od po. NB: ↓dose in elderly (initial dose 500 nanograms).

▼ **ALISKIREN**
Direct renin inhibitor (↓s angiotensinogen ⇒ angiotensin I).
**Use:** essential HTN *(for advice on stepped HTN Mx see p. 235).*
CI: potent P-glycoprotein inhibitors (*ciclosporin, itraconazole, verapamil, quinidine) P/B.

Caution: not recommended with ACE-i, ARBs, dehydration (risk of ↓BP), RAS, diuretics, ↓Na⁺ diet, **↑K⁺, moderate potent P-glycoprotein inhibitors (*ketoconazole, clari-/teli-/ery-thromycin, verapamil, amiodarone), DM**, R(if GFR <30 ml/min)/H/P/B/E.

SE: diarrhoea, dizziness, ↓BP, ↑K⁺, ↓GFR. Rarely rash, angioedema, ↓Hb.

Monitor: U&Es esp **↑K⁺ if taking ACE-i, ARBs, K⁺ sparing diuretics, K⁺ salts (inc dietary salt substitutes) or heparin. Check BG/HbA₁C regularly**.

Interactions: metab by/Ø/P450 : many; ↓s furosemide levels. Levels ↓ by irbesartan; levels ↑ by keto-/itra-conazole. fx ↓ by ↓Na⁺ diet and NSAIDs. fx ↑ by P-glycoprotein inhibitors (see *CI/Caution).

Dose: initially 150 mg od, ↑ing to 300 mg od if required.

**ALLOPURINOL**

Xanthine oxidase inhibitor: ↓s uric acid synthesis.

Use: Px of gout, renal stones (urate or Ca²⁺ oxalate) and other ↑urate states (esp 2° to chemotherapy).

CI: acute gout: can worsen – don’t start drug during attack (but don’t stop drug if acute attack occurs during Rx).

Caution: R (↓dose), L (↓dose and monitor LFTs), P/B.

SE: GI upset, severe skin reactions (stop drug if rash develops and allopurinol is implicated – can reintroduce cautiously if mild reaction and no recurrence). Rarely, neuropathy (and many non-specific neurological symptoms), blood disorders, RF, hepatotoxicity, gynaecomastia, vasculitis.

Warn: report rashes, maintain good hydration.

Interactions: Include ↑s fx/toxicity of azathioprine (and possibly other cytotoxics, esp ciclosporin), chlorpropamide and theophyllines. Level ↓d by salicylates and probenecid. ↑rash with ampicillin and amoxicillin. W+.

Dose: initially 100 mg od po (↑if required to max of 900 mg/day in divided doses of up to 300 mg) after food. Usual dose 300 mg/day.
NB: ↓dose if ↑fx other drugs or LF or RF. Initial Rx can ↑gout: give colchicine or NSAID (e.g. indometacin or diclofenac – *not aspirin*) Px until >1 month after urate normalised.

**ALPHAGAN** see Brimonidine; α-agonist eye drops for glaucoma.

**ALTEPLASE** ((recombinant) tissue-type plasminogen activator, rt-PA, TPA). Recombinant fibrinolytic.  
**Use:** acute MI, acute massive PE (with haemodynamic instability). Acute ischaemic CVA w/in 4.5 h of onset (specialist use only).  
**CI/Caution/SE:** See p. 230 for use in MI (for use in PE/CVA, see SPC). **L** (avoid if severe).  
**Dose:** MI: total dose of 100 mg – regimen depends on time since onset of pain: 0–6 h: 15 mg iv bolus, then 50 mg ivi over 30 min, then 35 mg ivi over 60 min; 6–12 h: 10 mg iv bolus, then 50 mg ivi over 60 min, then four further 10 mg ivis, each over 30 min.  
PE: 10 mg iv over 1–2 min then 90 mg ivi over 2 h.  
Ο ↓doses if patient <65 kg; see SPC ϑ. If MI concurrent unfractionated iv heparin needed for ≥24 h; see p. 232. Heparin also needed if giving for PE; see SPC.

**ALUMINIUM HYDROXIDE**  
Antacid, PO$_4$-binding agent (↓s GI absorption).  
**Use:** dyspepsia, ↑PO$_4$ (which can ↑risk of bone disease; esp good if secondary to RF, when ↑Ca$^{2+}$ can occur dt ↑PTH, as other PO$_4$ binders often contain Ca$^{2+}$).  
**CI:** ↓PO$_4$, porphyria.  
**SE:** constipation*. Aluminium can accumulate in RF (esp on dialysis) ⇒ ↑risk of encephalopathy, dementia, osteomalacia.  
**Interactions:** can ↓absorption of oral antibiotics (e.g. tetracyclines).  
**Dose:** 1–2 (500-mg) tablets or 5–10 ml of 4% suspension prn (qds often sufficient). ↑doses to individual requirements, esp if for ↑PO$_4$. Also available as 475 mg capsules as **Alucaps** (contains ↓Na$^+`). Most effective taken with meals and at bedtime. Consider laxative Px*.
AMANTADINE
Weak DA agonist; ↑s release and ↓s reuptake of DA. Also antiviral properties; ↓s release of viral nucleic acid.
**Use:** Parkinson’s disease and dyskinesias. Also used for Px of influenza A (if immunocompromised, vaccine CI or in exposed health workers).
**CI:** gastric ulcer (inc Hx of), epilepsy, R (if creatinine clearance <15 ml/min), P/B.
**Caution:** confused or hallucinatory states L/H/E.
**SE:** confusion, hallucinations, leg oedema.
**Warn:** Can ↓skilled task performance (esp driving). Stop drug slowly*.
**Interactions:** memantine ↑risk of CNS toxicity, anticholinergics.
**Dose:** 100–400 mg daily^[SPC/BNF]. NB: ↓dose in RF, E. ≥ 65 yrs NB: stop slowly*: risk of withdrawal syndrome.

AMFEBUTAMONE see Bupropion; aid to smoking cessation.

AMILORIDE
K⁺-sparking diuretic (weak): inhibits DCT Na⁺ reabsorption and K⁺ excretion.
**Use:** oedema (2° to HF, cirrhosis or ↑aldosterone), HTN (esp in conjunction with ↑K⁺-wasting diuretics as combination preparations; see Co-amilofruse and Co-amilozide). *For advice on stepped HTN Mx see p. 235.*
**CI:** ↑K⁺, Addison’s, anuria R.
**Caution:** DM (as risk of RF; monitor U&E), ↑risk of acidosis, ↓Na⁺, drugs causing low Na⁺, high K⁺ P/B/E.
**SE:** ↑K⁺, GI upset, headache, dry mouth, ↓BP (esp postural), ↓Na⁺, rash, confusion. Rarely encephalopathy, hepatic/renal dysfunction.
**Interactions:** ↑s lithium levels. Can ↑nephrotoxicity of NSAIDs.
**Dose:** 2.5–20 mg od (or divide into bd doses).

Beware if on other drugs that ↑K⁺, e.g. spironolactone, triamterene, ACE-i, ARBs and ciclosporin. Don’t give oral K⁺ supplements inc dietary salt-substitute tablets. 🚫
AMINOPHYLLINE
Methylxanthine bronchodilator: as theophylline but $\uparrow$H$_2$O solubility (is mixed w ethylenediamine) and $\downarrow$hypersensitivity.

**Use/CI/Caution/SE/Interactions:** see Theophylline; also available iv for use in acute severe bronchospasm; see p. 243. ☭ NB: has many important interactions (dose adjustment may be needed) and can $\Rightarrow$ arrhythmias (use cardiac monitor if giving iv).

**Monitor:** serum levels at 6, 18 and 24 h after starting iv. Also do levels initially if taking po.

**Dose:** po: MR preparation (Phyllocontin continus) $\Rightarrow$ $\downarrow$SEs, has different doses at 225–450 mg bd (or 350–700 mg bd if Forte tablets – for smokers and others with short $t_{1/2}$). *If on a particular brand, ensure this is prescribed as they have different pharmacokinetics.* iv: load* with 5 mg/kg (usually $\approx 250–500$ mg) over $\geq 20$ min, then 0.5 mg/kg/h ivi, then adjusted to keep plasma levels at 10–20 mg/l (= 55–110 micromol/l). If possible, contact pharmacy for dosing advice to consider interactions, obesity and liver/heart function.

If already taking maintenance po aminophylline/theophylline, omit loading dose* and check levels ASAP to guide dosing ☭.

AMIODARONE
Class III antiarrhythmic: $\uparrow$s refractory period of conducting system; useful as has $\downarrow$negative inotropic fx than other drugs and can give when others ineffective/CI.

**Use:** tachyarrhythmias: esp paroxysmal SVT, AF, atrial flutter, nodal tachycardias, VT and VF. Also in CPR/periarrest arrhythmias.

**CI:** $\downarrow$HR (sinus), sinoatrial HB, SAN disease or severe conduction disturbance w/o pacemaker, Hx of thyroid disease/iodine sensitivity, P/B.

**Caution:** porphyria, $\downarrow$K$^+$ (risk of torsades), L/R/H/E.

**SE:** Acute: N&V (dose-dependent), $\downarrow$HR/BP. Chronic: rarely but seriously $\uparrow$or $\downarrow$T4, interstitial lung disease (e.g. fibrosis, but reversible if caught early), hepatotoxicity, conduction disturbances
(esp ↓HR). Common: malaise, fatigue, photosensitive skin (rarely ‘grey-slate’), corneal deposits ± ‘night glare’ (reversible), tremor, sleep disorders. Less commonly: optic neuritis (rare but can ↓vision), peripheral neuropathy, blood disorders, hypersensitivity.

Monitor: TFTs and LFTs (baseline then 6-monthly). Also baseline K⁺ and CXR (watch for ↑SOB/alveolitis).

Warn: avoid sunlight/use sunscreen (inc several months after stopping).

Interactions: ↑s fx of phenytoin and digoxin. Other class III and many class Ia antiarrhythmics, antipsychotics, TCAs, lithium, erythromycin, co-trimoxazole, antimalarials, nelfinavir, ritonavir ⇒↑risk of ventricular arrhythmias. Verapamil, diltiazem and β-blockers ⇒↑risk of ↓HR and HB; CYP 3A4 dpt statins ↑myopathy W+.

Dose: po: load with 200 mg tds in 1st wk, 200 mg bd in 2nd wk, then (usually od) maintenance dose according to response (long t½: months before steady plasma concentration) NB: initiate in hospital or specialist outpatient service; iv: (extreme emergencies only) 150–300 mg in 10–20 ml 5% glucose over ≥3 min (don’t repeat for at least 15 min); ivi: 5 mg/kg over 20–120 min (max 1.2 g/day). For use in cardiac arrest/periarrest arrhythmias see ALS and tachycardia algorithms in the front and back cover flaps of this book respectively.

AMITRIPTYLINE
Tricyclic antidepressant (TCA): blocks reuptake of NA (and 5HT).

Use: depression¹ (esp if insomnia, ↓appetite, psychomotor slowing or agitation prominent. NB: ↑danger in OD cf other antidepressants), neuropathic pain², migraine prophylaxis.

Cl: recent MI (w/in 3 months), arrhythmias (esp HB), mania, L (if severe).

Caution: cardiac/thyroid disease, epilepsy*, glaucoma (angle closure), ↑prostate, phaeo, porphyria, anaesthesia. Also Hx of mania, psychosis or urinary retention, L/H/P/B/E.
**SE:** antimuscarinic fx (see p. 276), cardiac fx (arrhythmias, HB, HR, postural ↓BP, dizziness, syncope: dangerous in OD), ↑Wt, sedation** (often ⇒ ‘hangover’), seizures*. Rarely mania, fever, blood disorders, hypersensitivity, ΔLFTs, ↓Na⁺ (esp in elderly), neuroleptic malignant syndrome.

**Warn:** may impair driving**.

**Interactions:** MAOIs ⇒ HTN and CNS excitation. Never give with, or <2 wks after, MAOI 🛑. Levels ↑d by SSRIs, phenothiazines and cimetidine. ↑Risk of arrhythmias with amiodarone, pimozide (is CI), thioridazine and some class I antiarrhythmics. ↑risk of paralytic ileus with antimuscarinics. ↑s sedative fx of alcohol. ↑CNS toxicity with sibutramine (is CI).

**Dose:** initially 75 mg (30–75 mg in elderly) nocte or in divided doses (↑if required to max 200 mg/day)¹; initially 10 mg nocte ↑ing if required to 75 mg nocte².

**AMLODIPINE/ISTIN**

Ca²⁺ channel blocker (dihydropyridine): as nifedipine, but ⇒ no ↓contractility or ↑HF.

**Use:** HTN (for advice on stepped HTN Mx see p. 229), angina (esp ‘Prinzmetal’s’ = coronary vasospasm).

**CI:** ACS, cardiogenic shock, significant aortic stenosis, P/B.

**Caution:** BPH (poly-/nocturia), acute porphyria, L.

**SE:** as nifedipine but ↑ankle swelling and possibly ↓vasodilator fx (headache, flushing and dizziness).

**Interactions:** may ↑fx of theophyllines; care with inducers of cytochrome 3A4; ↓simvastatin dose max. 20 mg od.

**Dose:** initially 5 mg od po (↑if required to 10 mg). NB: consider ↓dose in LF.

**AMOXICILLIN**

Broad-spectrum penicillin; good GI absorption (can give po and iv).

**Use:** mild pneumonias¹ (esp community-acquired), UTI, Listeria meningitis, endocarditis Px and many ENT/dental/other infections.

*Often used with clavulanic acid as co-amoxiclav.*

**CI/Caution/SE/Interactions:** see Ampicillin.
**Dose:** 500–1000 mg tds po/iv; for other severe infections see SPC/BNF (mild/moderate infections usually 250–500 mg tds po). NB: ↓dose in RF.

**AMPICILLIN**
Broad-spectrum penicillin for iv use: has ↓GI absorption cf amoxicillin, which is preferred po.

**Use:** Meningitis (esp *Listeria*; see p. 258)\(^1\), Px pre-operative or for endocarditis during invasive procedures if valve lesions/prostheses, respiratory tract/ENT infections (esp community-acquired pneumonia dt *Haemophilus influenzae* or *Streptococcus pneumoniae*), UTIs (not for blind Rx, as *Escherichia coli* often resistant).

**CI:** penicillin hypersensitivity (NB: cross-reactivity with cephalosporins).

**Caution:** EBV/CMV infections, ALL, CLL (all ↑risk of rash), R.

**SE:** rash (erythematous, maculopapular: often does not reflect true allergy) commoner in RF or crystal nephropathy N&V&D (rarely AAC), hypersensitivity, CNS/blood disorders.

**Interactions:** levels ↑by probenecid. ↑effects of warfarin. ↑risk of rash with allopurinol. Can ↓fx of OCP (warn patient); ↑levels of methotrexate.

**Dose:** Most indications 0.25–1 g qds po, 500 mg qds im/iv\(^{SPC/BNF}\) (meningitis 2 g 4-hrly ivi\(^1\)). NB: ↓dose in RF.

**ANTABUSE** see Disulfiram; adjunct to alcohol withdrawal.

**ANTACIDS** see Alginates (e.g. Acidex, Gastrocote, Gaviscon or Peptac) or Co-magaldrox.

**AQUEOUS CREAM** Emulsifying ointment (phenoxyethanol in purified water). Topical cream used as emollient in dry skin conditions and as a soap-substitute.

**▼ ARIPIPRAZOLE/ABILIFY**
Atypical (third generation) antipsychotic; partial D\(_2\) (and 5HT\(_{1A}\)) agonist ⇒ ↓dopaminergic neuronal activity. Also potent 5HT\(_{2A}\) antagonist.
**Use:** schizophrenia, mania (Px and acute Rx).

**CI:** Coma, CNS depression, phaeo B.

**Caution:** cerebrovascular disease, Hx or ↑risk of seizures, family Hx of ↑QT L/P/E.

**SE:** EPSE (esp akathisia/restlessness, although generally ⇒ ↓EPSE than other antipsychotics), dizziness, sedation (or insomnia), blurred vision, fatigue, headache, gastrointestinal upset, anxiety and ↑salivation. Rarely ↑HR, depression, orthostatic ↓BP. Very rarely skin/blood disorders, ↑QTc, DM, NMS, tardive dyskinesia, seizures and CVA.

**Interactions:** metab by P450 .: many; most importantly levels ↑by itra-conazole, HIV protease/itra-conazole, HIV protease inhibitors and levels ↓by carbamazepine, rifampicin, rifabutin, phenytoin, primodone, efavirenz, nevirapine and St John’s wort.

**Dose:** 10–15 mg po od (max 30 mg/od); 5.25–15 (usually 9.75) mg im as single dose repeated after ≥2 h if required (max 3 injections/day or combined im/po dose of 30 mg/day). NB: ↓dose in elderly.

**ARTHROTEC**

Combination tablets of diclofenac with misoprostol (200 microgram/tablet) to ↓GI SEs (esp PU/bleeds).

**CI/Caution/SE/Interactions:** see Diclofenac and Misoprostol.

**Dose:** 50 mg bd/tds po or 75 mg bd (prescribed as dose of diclofenac).

**ASACOL** see Mesalazine: ‘new’ aminosalicylate for UC with ↓SEs.

Available po (3–6 tablets of 400 mg per day in divided doses), as suppositories (0.75–1.5 g daily in divided doses) or as foam enemas (1–2 g daily).

**ASPIRIN**

NSAID. Inhibits COX-1 and COX-2 ⇒ ↓PG synthesis (: anti-inflammatory and antipyrexial) and ↓thromboxane A2 (: anti-Pt aggregation).

**Use:** mild to moderate pain/pyrexia¹, IHD and thromboembolic CVA Px² and acute Rx³.
**Cl:** <16 years old, unless specifically indicated (can ⇒ Reye’s syndrome), PU (active or PHx of), hypersensitivity to any NSAID, haemophilia, **R** (GFR<10 ml/min)/**L** (if severe)/**B**.

**Caution:** asthma, any allergic disease*, dehydration, uncontrolled HTN, gout, G6PD deficiency, **L/R** (avoid if either severe)/**P/E**.

**SE:** GI irritation, bleeding (esp GI: ↑↑risk if also anticoagulated)**. Rarely hypersensitivity* (anaphylaxis, bronchospasm, skin reactions), AKI, hepatotoxicity, ototoxic in OD.

**Interactions:** ↑GI bleeding with anticoagulants**, other NSAIDs (avoid), SSRIs & venlafaxine. **W +** Can ⇒ ↑levels of methotrexate, ↑fx anticonvulsants & ↓fx spironolactone.

**Dose:** 300–900 mg 4–6-hrly (max 4 g/day)**, 75 mg od**², 300 mg stat³.

Stop 7 days before surgery if significant bleeding is expected. If cardiac surgery or patient has ACS, consider continuing.

**ATENOLOL**

- **β-blocker:** (mildly) cardioselective* (β₁ > β₂), ↑H₂O solubility :.
- ↓central fx** and ↑renal excretion***.

**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235), angina², MI (w/in 12 h as early intervention)³, arrhythmias⁴.

**Cl/Caution/SE/Interactions:** see Propranolol ⇒ ↓bronchospasm* (but avoid in all asthma/only use in COPD if no other choice) and ↓sleep disturbance/nightmares**.

**Dose:** 25–50 mg od po¹; 100 mg od po²; 5 mg iv over 5 min, 50 mg po 15 min later, 50 mg po after 12 h, then 100 mg od po ³; 50–100 mg od po⁴ (for iv doses see SPC/BNF). NB: consider ↓dose in RF***.

**ATORVASTATIN/LIPITOR**

- **H MG-CoA reductase inhibitor.**

**Use/Cl/Caution/SE:** see Simvastatin.

**Interactions:** ↑risk of myopathy includes with ☠️ fibrates ☠️, daptomycin, ciclosporin, nicotinic acid, itra-/posa-conazole. Levels ↑by clari-/teli-thromycins.
**ATROPINE**

**Dose:** initially 10 mg nocte (↑if necessary, at intervals ≥4 wks, to max 80 mg). Post ACS dose 80 mg daily.

**ATRACURIUM**


**Use:** neuromuscular blockade for surgery¹ or during intensive care (esp in LF or RF)²

**Cl:** anaesthetist not confident of airway maintenance.

**Caution:** neuromuscular disease (MG, Eaton-Lambert syndrome, old polio), hypersensitivity to other neuromuscular blockers (allergic cross-reactivity), burns (resistance can develop).

**SE:** histamine release (skin flushing, ↓BP, ↑HR, bronchospasm, anaphylactoid reactions), seizures.

**Monitor:** cardiac and respiratory function.

**Interactions:** fx ↑by aminoglycosides, clindamycin and polymyxins. Can ⇒ haemolysis if given with blood transfusion.

**Dose:** initially 300–600 micrograms/kg iv then 100–200 micrograms/kg iv as required or initially 200–600 micrograms/kg iv then 300–600 micrograms/kg/hr ivi¹; initially 300–600 micrograms/kg iv (optional) then 270–1770 micrograms/kg/hr ivi (usually 650–780 micrograms/kg/hr)². **NB:** if obese (weight 30% above ideal body weight (IBW; see p.296)) use IBW for dose calculation.

**ATROPINE (SULPHATE) iv**

Muscarinic antagonist: blocks vagal SAN and AVN stimulation, bronchodilates and ↓s oropharyngeal secretions.

**Use:** severe ↓HR (see algorithm on inside front cover) or HB¹, CPR [atropine NOT recommended for asystole], organophosphate/anticholinesterase* OD/poisoning² and specialist anaesthetic uses.
**Cl:** (don’t apply if life-threatening condition/CPR!): glaucoma (angle closure), MG (unless anticholinesterase overdosage, when atropine is indicated*), paralytic ileus, pyloric stenosis, bladder neck obstruction (e.g. ↑prostate).

**Caution:** Down’s syndrome, gastro-oesophageal reflux, diarrhoea, UC, acute MI, HTN, ↑HR (esp 2° to ↑T4, cardiac insufficiency or surgery), pyrexia, P/B/E.

**SE:** transient ↓HR (followed by ↑HR, palpitations, arrhythmias), antimuscarinic fx (see p. 276), N&V, confusion (esp in elderly), dizziness.

**Dose:** 0.3–0.6 mg iv1; 1–2 mg im/iv every 10–30 min2 (every 5 min in severe cases) up to max 100 mg in 1st 24 h, until symptomatic response (skin flushes and dries, pupils dilate, HR↑s).

**ATROVENT** see Ipratropium; bronchodilator for COPD/asthma.

**AUGMENTIN** see Co-amoxiclav (amoxicillin + clavulanic acid) 375 or 625 mg tds po (1.2 g tds iv).

**AZATHIOPRINE**

Antiproliferative immunosuppressant: inhibits purine-salvage p’ways; prodrug for 6-mercaptopurine.

**Use:** prevention of transplant rejection, autoimmune disease (esp as steroid-sparing agent, but also maintenance Rx for SLE/vasculitis).

**Cl:** hypersensitivity (to azathioprine or mercaptopurine), P/B.

**Caution:** L/R/E.

**SE:** myelosuppression (dose-dependent, ⇒ ↑infections, esp HZV), hepatotoxicity, hypersensitivity reactions (inc interstitial nephritis: stop drug!), N&V&D (esp initially), pancreatitis. Rarely cholestasis, alopecia, pneumonitis, risk of neoplasia, hepatic veno-occlusion.

**Warn:** immediately report infections or unexpected bruising/bleeding.

**Monitor:** FBC (initially ≥wkly ↓ing to ≥3-monthly), LFTs, U&Es.

**Interactions:** fx ↑ by allopurinol, ACE-i, ARBs, trimethoprim (and septrin). fx ↓ by rifampicin. W–.
**Dose:** Initially 1–3 mg/kg daily for ≤12 wks\(^{SPC/BNF}\) (preferably po as iv very irritant). **NB:** ↓dose in RF.

⚠️ Before starting Rx, screen for common gene defect that ↓s TPMT enzyme (which metabolises azathioprine) activity: if homozygote for defect avoid thiopurine drugs; if heterozygote, ↓dose (esp if taking aminosalicylate derivatives, e.g. olsalazine, mesalazine or sulfasalazine).⚠️

---

**AZITHROMYCIN**

Macrolide antibiotic: see Erythromycin.  
**Use:** see Erythromycin (but with ↑activity against Gram –ve and ↓activity against Gram +ve organisms). Also genital chlamydia and non-severe typhoid.  
**CI:** as erythromycin, plus **L** (if severe).  
**Caution/SE/Interactions:** as erythromycin (NB: ↑\(\text{P}450\) ↓: many interactions) but ⇒ ↓GI SEs.  
**Dose:** 500 mg od po for 3 days only (continue for 7 days for typhoid); for GU infections 1 g od po as single dose.

**AZOPT** see Brinzolamide; eye drops for glaucoma.

**AZT** see Zidovudine; antiretroviral for HIV.

---

**BACLOFEN**  
Skeletal muscle relaxant: ↓s spinal reflexes, general CNS inhibition at ↑doses.  
**Use:** spasticity, if chronic/severe, (esp 2° to MS or cord pathology).  
**CI:** PU, porphyria, hereditary galactose intolerance.  
**Caution:** Ψ disorders, epilepsy, Hx of PU, Parkinson’s, porphyria, DM, hypertonic bladder sphincter, respiratory/cerebrovascular disease, **L/R/P/E.**  
**SE:** sedation, ↓muscle tone, nausea, urinary dysfunction, GI upset, ↓BP. Others rare: ↑spasticity (stop drug!), multiple neurological/Ψ symptoms, cardiac/hepatic/respiratory dysfunction.  
**Warn:** may ↓skilled tasks (esp driving), ↑s fx of alcohol.
**Interactions:** fx ↑by TCAs. May ↑fx of antihypertensives.

**Dose:** 5 mg tds po (after food) ↑ing, if required, to max of 100 mg/day. NB ↓dose in RF. In severe cases, can give by intrathecal pump (see SPC/BNF).

Stop gradually over ≥1–2 wks to avoid withdrawal symptoms: confusion, ↑spasticity, ψ reactions, fits, ↑HR.

**BACTROBAN** see Mupirocin; topical antibiotic (esp for nasal MRSA). See local policy for infection control.

**BECLOMETASONE**

Inh corticosteroid: ↓s airway oedema and mucous secretions.

**Use:** chronic asthma not controlled by short-acting β_2_ agonists alone.

**Caution:** TB (inc quiescent).

**SE:** oral candidiasis (2° to immunosuppression: ↓d by rinsing mouth with H_2_O after use), hoarse voice. Rarely glaucoma, hypersensitivity. ↑Doses may ⇒ adrenal suppression, Cushing’s, ↓bone density, lower RTI, ↓growth (controversial).

**Dose:** 200–2000 microgram daily inh (normally start at 200 microgram bd). Use high-dose inhaler if daily requirements are >800 microgram^{SPC/BNF}. Specify named product for CFC metered disc inhalers as dose ranges from 50 to 400 microgram/delivery. CFC-free pressurized metered dose inhalers are not interchangeable.

Rarely ⇒ paradoxical bronchospasm: can be prevented by switching from aerosol to dry powder forms or by using inh β_2_ agonists.

**BECOTIDE** see Beclometasone.

**BENDROFLUMETHIAZIDE**

Thiazide diuretic: ↓s Na^+ (and Cl) reabsorption from DCT ⇒ Na^+ and H_2_O loss and stimulates K^+ excretion.

**Use:** oedema^1_ (2° to HF or low-protein states), HTN^2_ (in short term by ↓ing fluid volume and CO; in long term by ↓ing TPR; for advice on stepped HTN Mx see p. 235), Px against renal stones in hypercalciuria^3_.

__L/R/H = Liver, Renal and Heart failure (full key see p. xv)
**Cl**: $\downarrow$K$^+$ (refractory to Rx), $\downarrow$Na$^+$, $\uparrow$Ca$^{2+}$, Addison’s disease, $\uparrow$urate (if symptoms), L/R (if either severe, otherwise caution).

**Caution**: porphyria, and can worsen gout, DM or SLE, P/B/E.

**SE**: dehydration (esp in elderly), $\downarrow$BP (esp postural), $\downarrow$K$^+$, GI upset, impotence, $\downarrow$Na$^+$, alkalosis (with $\downarrow$Cl), $\downarrow$Mg$^{2+}$, $\uparrow$Ca$^{2+}$, $\uparrow$urate/gout, $\uparrow$glucose, lipid metabolism (esp $\uparrow$cholesterol), rash, photosensitivity, blood disorders (inc $\downarrow$Pt, $\downarrow$NØ), pancreatitis, intrahepatic cholestasis, hypersensitivity reactions (inc severe respiratory and skin reactions), arrhythmias.

**Interactions**: $\uparrow$s lithium levels. fx $\downarrow$by NSAIDs and oestrogens. If $\downarrow$K$^+$ can $\uparrow$toxic fx of many drugs (esp digoxin, NSAIDs, corticosteroids and many antiarrhythmics). $\uparrow$risk of $\downarrow$Na$^+$ with carbamazepine $\uparrow$risk of $\downarrow$K$^+$ with amphotericin.

**Dose**: initially 5–10 mg mane po$^1$, then $\downarrow$dose frequency (i.e. omit days) if possible; 2.5 mg od po$^{2,3}$ (little benefit from $\uparrow$doses).

**BENZYPENICILLIN (= PENICILLIN G)**

Penicillin with poor po absorption : only given im/iv: used mostly against streptococcal (esp *S. pneumoniae*) and neisserial (esp *N. gonorrhoeae, N. meningitidis*) infections.

**Use**: (usually in conjunction with other agents) severe skin infections (esp cellulitis, wound infections, gas gangrene) (see p. 287), meningitis, endocarditis, ENT infections, pneumococcal pneumonia.

**Cl**: penicillin hypersensitivity (NB: cross-reactivity with cephalosporins common).

**Caution**: Hx of allergy, false +ve glycosuria, R$^*$. 

**SE**: hypersensitivity (inc fever, arthralgia, rashes, urticaria, angioedema, anaphylaxis, serum sickness-like reactions, haemolytic $\downarrow$Hb, interstitial nephritis), diarrhoea (rarely AAC). Rarely blood disorders ($\downarrow$Pt, $\downarrow$NØ, coagulation disorders), CNS toxicity (inc convulsions, esp at $\uparrow$doses or if RF$^*$). $\uparrow$doses can $\Rightarrow$$\downarrow$K$^+$ (and $\downarrow$Na$^+$).

**Interactions**: levels $\uparrow$d by probenecid. $\uparrow$risk of rash with allopurinol. Can $\downarrow$fx of OCP.

**Dose**: 0.6–1.2 g qds iv (or im/ivi). If very severe, give 2.4 g every 4 h (only as iv/ivi). NB: $\downarrow$dose in RF.
BETAHISTINE/SERC
Histamine analogue (H1 antagonism and H3 antagonism): ↑s middle-ear microcirculation ⇒ ↓endolymphatic pressure.
**Use:** Ménière’s disease (if tinnitus, vertigo or hearing loss).
**CI:** phaeo.
**Caution:** asthma, Hx of PU, P/B.
**SE:** GI upset. Rarely headache, rash, pruritus.
**Dose:** 16 mg tds po (maintenance usually 24–48 mg/day).

BETAMETHASONE CREAM (0.1%)/OINTMENT
‘Potent’ strength topical corticosteroid (rarely used as weaker 0.05% or 0.025% preparations).
**Use:** inflammatory skin conditions, in particular eczema.
**CI:** untreated infection, rosacea, acne.
**SE:** skin atrophy, worsening of infections, acne.
**Dose:** apply thinly 1–2 times per day. Use ‘ointment’ in dry skin conditions.

BETNOVATE see Betamethasone cream 0.1% (potent strength). Available as Betnovate RD (moderate strength) 0.025%.

BEZAFIBRATE
Fibrate (lipid-lowering): ⇒ ↓TG, ↓LDL, ↑HDL by stimulating lipoprotein lipase (⇒ ↓conversion of VLDL/TG to LDL and ⇒ ↑LDL clearance from circulation). Also ⇒ (mild) ↓cholesterol.
**Use:** hyperlipidaemias (esp if ↑TG: types IIa/b, III, IV, V).
**CI:** gallbladder disease, PBC, ↓albumin (esp nephrotic syndrome), R */ L (if either severe; otherwise caution), P/B.
**Caution:** ↓T₄ (needs to be corrected).
**SE:** GI upset, ↓appetite, ↑gallstones, myositis (rarer but important: ↑risk if RF*). Also impotence, rash (inc pruritus, urticaria), headache. Rarer: dizziness, vertigo, fatigue, hair loss, blood disorders (↓Hb, ↓WCC, ↓Pt).
**Interactions:** ♀ ‘statins’ ⇒ ↑risk of myositis♀. ↑s fx of anti-diabetics. ↑risk of hepatotoxicity with MAOIs. Can ↑renal toxicity of ciclosporin. W +.
**BOSENTAN/Tracleer**

Endothelin receptor antagonist: relaxes vascular smooth muscle.

**Use:** pulmonary arterial HTN\(^1\), Rx of digital ulcers in systemic sclerosis.\(^2\)

**CI:** SBP <85 mmHg, acute porphyria, P/B.

**Caution:** ↓BP, L (avoid if severe).

**SE:** Δ LFTs, ↓BP, palpitations, oedema, headache, flushing, bleeding/↓Hb, ↓NO (O needs forward diagonal strike-through symbol for neutrophils), ↓Pt, hypersensitivity reactions, dyspepsia, D.

**Warn:** avoid sudden withdrawal and report symptoms of LF.

**Monitor:** LFTs monthly (and 2 wks after dose ↑) and Hb monthly for 1st 4 wks then 3-monthly. INR at start or change in dose.

**Interactions:** metab by and ↑P450. Levels ↑by ciclosporin, keto-/flu-/itraconazole. Levels ↓by rifampicin. ↓s fx of OCP and simvastatin. ↑risk of hepatotoxicity with glibenclamide.
**Dose:** specialist use only: initially 62.5 mg po bd for 4 wks then ↑to 125 mg bd\(^1,2\) (can ↑to 250 mg bd\(^1\))\(^{SPC/BNF}\).

**BOWEL PREPARATIONS**

Bowel-cleansing solutions for preparation for GI surgery/Ix.

**Cl:** GI obstruction/ulceration/perforation, ileus, gastric retention, toxic megacolon/colitis, H.

**Caution:** UC, DM, heart disease, reflux oesophagitis, ↑risk of regurgitation/aspiration (e.g. ↓swallow/gag reflex/GCS), R/P.

**SE:** nausea, bloating, abdominal pains, vomiting.

**Dose:** see Citramag, Fleet (Phospho-soda), Klean-prep, Picolax.

**BRICANYL** see Terbutaline (inh β\(_2\) agonist for asthma). Various delivery devices available\(^{SPC/BNF}\).

**BRIMONIDINE EYE DROPS/ALPHAGAN**

Topical α\(_2\) agonist: ↓s aqueous humour production ↓↓s IOP.

**Use:** open-angle glaucoma, ocular HTN (esp if β-blocker or PG analogue Cl or fails to ↓IOP).

**Caution:** postural ↓BP/HR, Raynaud’s, cardiovascular disease (esp IHD), cerebral insufficiency, depression*, P/B R/L.

**SE:** sedation, headache, dry mouth, HTN, blurred vision, local reactions (esp discomfort, pruritus, hyperaemia, follicular conjunctivitis). Rarely, palpitations, depression*, hypersensitivity.

**Interactions:** ☠ MAOIs, TCAs, mianserin (or other antidepressants affecting NA transmission) are CI ☠.

**Dose:** 1 drop bd of 0.2% solution. Also available as od combination drop with timolol 0.5% (Combigan).

**BRINZOLAMIDE/ AZOPT**

Topical carbonic anhydrase inhibitor for glaucoma. Similar to dorzolamide (↓s aqueous humour production).

**Cl:** Hyperchloraemic acidosis, R (GFR <30 ml/min)

**Caution:** P/B
**Dose:** 1 drop bd<tds. Also available as od combination drop with timolol 0.5% (Azarga).

**BROMOCRIPTINE**
DA agonist; ↓s pituitary release of prolactin and growth hormone.

**Use:** endocrine disorders¹ (e.g. prolactinoma, galactorrhoea, acromegaly) and NMS. Rarely used for Parkinsonism if L-dopa insufficient/not tolerated.

**CI:** cardiac valvulopathy, hypersensitivity to ergot alkaloids, uncontrolled HTN. Also HTN/IHD postpartum or in puerperium.

**Caution:** cardiovascular disease, PU, porphyria, Raynaud’s disease, serious Ψ disorders (esp psychosis), P/B.

**SE:** GI upset, postural ↓BP (esp initially and if ↑alcohol intake), behavioural Δs (confusional states, Ψ disorders), ↑sleep (sudden onset/daytime). Rarely but seriously fibrosis*: pulmonary**, cardiac, retroperitoneal*** (can ⇒ AKI).

**Warn:** of ↑sleep. Report persistent cough** or chest/abdo pain.

**Monitor:** BP, ESR*, U&Es***, CXR**; pituitary size and visual fields (pregnancy and ¹)**.

**Interactions:** levels ↑by ery/-clari-thromycin and octreotide.

**Dose:** 1–30 mg/daySPC/BNF. NB: consider ↓dose in LF.

**BUCCASTEM** Prochlorperazine (antiemetic) buccal tablets: absorbed rapidly from under top lip .: don’t need to be swallowed and retained in stomach for absorption if N&V.

**Caution:** See Prochlorperazine L.

**Dose:** 3–6 mg bd.

▼ **BUDESONIDE**
Inh corticosteroid for asthma¹; similar to beclometasone but stronger (approximately double the strength per microgram). Also available po or as enemas for IBD² (see BNF).

**Caution:** L.
**Dose:** 200–800 microgram bd inh (aerosol or powder) or 1–2 mg bd neb¹.

**BUMETANIDE**
Loop diuretic: inhibits \( \text{Na}^+ / \text{K}^+ \) pump in ascending loop of Henle.

**Use/Ci/Caution/SE/Monitor/Interactions:** as furosemide; also headaches, gynaecomastia and at \( \uparrow \) doses can \( \Rightarrow \) myalgia.

**Dose:** 1 mg mane po (500 microgram may suffice in elderly), \( \uparrow \)ing if required (5 mg/24 h usually sufficient; \( \uparrow \) by adding a lunchtime dose, then \( \uparrow \) ing each dose). 1–2 mg im/iv (repeat after 20 min if required). 2–5 mg ivi over 30–60 min.

**NB:** give iv in severe oedema; bowel oedema \( \Rightarrow \) po absorption.

**BUPROPION (= AMFEBUTAMONE)/ZYBAN**
NA and to lesser extent DA reuptake inhibitor (NDRI) developed as antidepressant, but also \( \uparrow \) s success of giving up smoking.

**Use:** (adjunct to) smoking cessation⁷ NICe.

**Ci:** CNS tumour, acute alcohol/benzodiazepine withdrawal, Hx of seizures*, eating disorders, bipolar disorder, L (if severe cirrhosis)/P/B.

**Caution:** if \( \uparrow \) risk of seizures* : alcohol abuse, Hx of head trauma and DM, R/E.

**SE:** seizures*, insomnia (and other CNS reactions, e.g. anxiety, agitation, depression, fever, headaches, tremor, dizziness). Also \( \uparrow \)HR, AV block, \( \uparrow \) or \( \downarrow \)BP**, chest pain, hypersensitivity (inc severe skin reactions), GI upset, \( \uparrow \) Wt, mild antimuscarinic fx (esp dry mouth; see p. 276 for others).

**Monitor:** BP**.

**Interactions:** \( \downarrow \)P450 : many interactions, but importantly CNS drugs, esp if \( \downarrow \) seizure threshold*, e.g. antidepressants ( MAOIs; avoid together, including <2 wks after MAOI ), antimalarials, antipsychotics (esp risperidone), quinolones, sedating antihistamines, systemic corticosteroids, theophyllines, tramadol. Ritonavir \( \Rightarrow \) \( \downarrow \) plasma level of bupropion. \( \downarrow \) dose of CYP2B6 mod antiarrhythmics.
**Dose:** 150 mg od for 6 days then 150 mg bd for max 9 wks (↓dose if elderly or ↑seizure risk\(^{SPC/BNF}\)). Start 1–2 wks before target date of stopping smoking. **NB:** max 150 mg/day in LF or RF.

**BURINEX** Bumetanide 1-mg tablets.

**BUSCOPAN** see Hyoscine butylbromide; GI antispasmodic.

**CACIT** see Calcium carbonate.

**CACIT D3** Calcium carbonate + low dose vitamin D\(_3\).
**Use:** Px of vitamin D deficiency.
**Caution:** L.
**Dose:** 1 tablet od (= 12.5 mmol Ca\(^{2+}\) + 11 microgram cholecalciferol).

**CALCICHew** see Calcium carbonate.

**CALCICHew D3** Calcium carbonate + low dose vitamin D\(_3\).
**Use:** Px of vitamin D deficiency.
**Dose:** 1 tablet od. Each tablet = 12.5 mmol Ca\(^{2+}\) + 5 microgram vit D\(_3\) (cholecalciferol) or 10 microgram vit D\(_3\) in ‘forte’ preparations.

**CALCIPOTRIOL OINTMENT AND CREAM**
Vitamin D analogue for plaque psoriasis.
**SE:** local skin reactions (itching, redness).
**Caution:** Avoid excessive sunlight exposure use <100 g/wk, E.
**CI:** patients with disorders of Ca\(^{2+}\) metabolism.
**Use:** apply od or bd. Also used as ointment or gel combined with betamethasone (Dovobet) od ≤4 wks.

**CALCITONIN**
Synthetic hormone (normally produced by C cells of thyroid): binds to specific osteoclast receptors ⇒ ↓resorption of bone and ↓Ca\(^{2+}\). Its fx are specific to abnormal (high-turnover) bone.
**Use:** \( \uparrow \text{Ca}^{2+} \) (esp dt malignancy; also \( \downarrow \)s bone metastases pain), Paget’s disease (\( \downarrow \)s pain and neurological symptoms, e.g. deafness). Rarely for Px/Rx of postmenopausal osteoporosis.

**Cl:** \( \downarrow \text{Ca}^{2+} \) **P/B**.

**Caution:** Hx of any allergy, **R/H**.

**SE:** GI upset (esp N&V), **flushing**, \( \uparrow \)urinary frequency, taste, vision/sensory \( \Delta \), hypersensitivity (inc anaphylaxis), myalgia, local inflammation, oedema, rash, malignancy (long term use), tremor.

**Dose:** see BNF/SPC.

### Calcium Carbonate

**Use:** osteoporosis, \( \downarrow \text{Ca}^{2+} \), \( \uparrow \text{PO}_4 \) (esp 2° to RF; binds \( \text{PO}_4 \) in gut ⇒ \( \downarrow \)absorption).

**Cl:** conditions assoc with \( \uparrow \text{Ca}^{2+} \) (in serum or urine).

**Caution:** sarcoid, Hx of kidney stones, phenylketonuria, **R**.

**SE:** GI upset, \( \uparrow \text{Ca}^{2+} \) (serum or urine), \( \downarrow \)HR, arrhythmias.

**Interactions:** fx \( \uparrow \)by thiazides, fx \( \downarrow \)by corticosteroids, \( \downarrow \)s absorption of tetracyclines (give \( \geq 2 \) h before or 6 h after) and bisphosphonates.

**Dose:** as required up to 40 mmol/day in osteoporosis if \( \downarrow \)dietary intake, e.g. **Calcichew** (standard 12.5-mmol or ‘forte’ 25-mmol tablets), **Cacit** (12.5-mmol tablets), **Calcium 500** (12.5-mmol tablets) or **Adcal** (15-mmol tablets).

### Calcium Chloride

\( \text{Ca}^{2+} \) for emergency iv

**Use:** mostly CPR as ⇒ \( \uparrow \)venous irritation cf calcium gluconate. Can also use for severe \( \downarrow \text{Ca}^{2+} \) or \( \uparrow \text{K}^{+} \).

**Cl:** **VF**, conditions assoc with \( \uparrow \text{Ca}^{2+} \) (in serum or urine).

**SE:** GI upset, \( \uparrow \text{Ca}^{2+} \), \( \downarrow \)HR, \( \downarrow \)BP, arrhythmias.

**Dose:** available as syringes of 10 ml of 10% solution (= total of 6.8 mmol \( \text{Ca}^{2+} \)). Give iv no quicker than 1 ml/min (otherwise can ⇒ arrhythmias) as per indication and clinical/e’lyte response.

**E.g.** **Min-i-jet**: often in crash trolleys if iv \( \text{Ca}^{2+} \) needed urgently.

### Calcium + Ergocalciferol

Tablets of 2.4 mmol \( \text{Ca}^{2+} \) low-dose (10 microgram) ergocalciferol (= calciferol = vitamin D$_2$).
**Calci**um glu**co**nate

*Use:* Px of vitamin D deficiency.
**Cl/Caution/SE:** see Ergocalciferol.
**Dose:** 1 tablet od

**Calci**um glu**co**nate

*Use:* iv preparation of Ca^2+ (also available po, but used rarely).
*Use:* ↓Ca^2+ (if severe)^1, ↑K^+ (↓s arrhythmias: ‘cardioprotective’, see p. 269)^2, ↑mg^2+.
**Cl/SE:** as calcium chloride.
**Dose:** 10 ml of 10% iv over 3 min (= total of 2.2 mmol Ca^2+)^1,2, repeating if necessary according to clinical and electrolyte response; consider following with ivi

**Calci**um resonium

Polystyrene sulphonate ion-exchange resin.
*Use:* chronic ↑K^+ with oligo-anuria (not for *initial* Mx of acute ↑K^+).
**Cl:** obstructive bowel disease, diseases likely to ↑Ca^2+ (↑PTH, multiple myeloma, sarcoid, metastatic cancer), K^+<5 mmol/l.
**Caution:** Use sodium resin if HTN, oedema or H/P/B.
**SE:** GI upset (inc ulceration, GI necrosis, severe constipation; often need Px of 10–20 ml lactulose), ↓K^+, ↓Mg^2+, ↑Ca^2+.
**Interactions:** ↑risk GI obstruction with aluminium hydroxide, ↑risk of alkalosis with aluminium carbonate and magnesium hydroxide. May ↓lithium and levothyroxine levels. Avoid sorbitol (GI necrosis).
**Dose:** 15 g tds/qds po. NB: takes 24–48 h to work.* Also available as 30-g enemas (rarely ⇒ rectal ulceration and colonic necrosis: needs cleansing enema first and washout afterwards; see SPC).

**Calci**um Sandoz

Ca^2+ supplement syrup; 108.3 mg (2.7 mmol) Ca^2+/5 ml.

**Calpol** Paracetamol (paediatric) suspension.
**Dose:** according to age; all doses up to 4-hrly, max qds < 3 mths

3–6 months 60 mg, 6–24 months 120 mg, 2–4 yrs 180 mg, 6–8 yrs 250 mg, 8–10 yrs 375 mg, 10–12 yrs 500 mg, 12–16 yrs 480–750 mg
NB: Two strengths available: ‘standard’ INFANT (120 mg/5 ml) and stronger SIX Plus (250 mg/5 ml).

CANDESARTAN/AMIAS
Angiotensin II antagonist.
**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235) or HF² (when ACE-i not tolerated).
**CI:** cholestasis, L (if severe)/P/B.
**Caution/SE/Interactions:** see Losartan.
**Dose:** initially 8 mg od¹ (4 mg if LF, 4 mg if RF/intravascular volume depletion) ing at 4-wk intervals if necessary to max of 32 mg od; initially 4 mg od² ing at intervals ≥2 wks to ‘target dose’ of 32 mg od (or max tolerated). NB: ↓dose in LF.

CANESTEN
Clotrimazole 1% cream: antifungal, esp for vaginal candida infections (thrush). Also available as powder, solution and spray for hairy areas.
**Dose:** apply bd/tds.

CAPTOPRIL
ACE-i: short-acting; largely replaced by longer-acting drugs.
**Use:** HTN (for advice on stepped HTN Mx see p. 235), HF, post-MI, and diabetic nephropathy (i.e. consistent proteinuria).
**CI:** renovascular disease* (known or suspected bilateral RAS), angioedema/other hypersensitivity ² to ACE-i, porphyria, P.
**Caution:** symptomatic aortic stenosis, Hx of idiopathic or hereditary angioedema, if taking drugs that ↑K**, L/R/B/E.
**SE:** ↓BP (esp with 1st dose, if HF, dehydrated or on diuretics, dialysis or ↓Na⁺ diet : take at night), RF*, dry cough, ↑K⁺, acidosis, hypersensitivity (esp rashes and angioedema), photosensitivity, Δ taste, upper respiratory tract symptoms (inc sore throat/sinusitis/rhinitis), GI upset, Δ LFTs (rarely cholestatic jaundice/hepatitis), pancreatitis, blood disorders, many non-specific neuro symptoms.
**Monitor:** U&Es, esp baseline and 2 wks after starting*.
Interactions: fx ↓d by NSAIDs (also ⇒ ↑risk RF*). Diuretics, TCAs and antipsychotics ⇒ risk of ↓↓BP. ↑s fx of lithium (and antidiabetics). Dose: 6.25–75 mg bd po^{SPC/BNF}. NB: ↓dose in RF. **Beware if on other drugs that ↑K+, e.g. amiloride, spironolactone, triamterene, ARBs and ciclosporin. Don’t give with oral K+ supplements – inc dietary salt substitutes.

CARBAMAZEPINE/TEGRETOL
Antiepileptic, mood stabiliser, analgesic; ↓s synaptic transmission. Use: epilepsy¹ (generalised tonic-clonic and partial seizures, but may exacerbate absence/myoclonic seizures), Px bipolar disorder² (if unresponsive to lithium), neuralgia³ (esp post-herpetic, trigeminal and DM-related).
CI: unpaced AV conduction dfx, Hx of BM suppression, acute porphyria.
Caution: cardiac disease, Hx skin disorders (HLA-B*1502 in Han Chinese or Thai origin have ↑risk of SE – esp SJS), Hx haematological drug reactions, glaucoma, L/R, P (⇒ neural tube dfx*: ⇒ folate Px and screen for dfx), B.
Dose-related SEs: N&V, headache, drowsiness, dizziness, vertigo, ataxia, visual Δ (esp double vision): control by ↓ing dose, Δ dose times/spacing or use of MR preparations**.
Other SEs: skin reactions (transient erythema common), blood disorders (esp ↓WCC*** – often transient, ↓Pt, aplastic anaemia), ↑gamma-GT (usually not clinically relevant), oedema, ↓Na+ (inc SIADH), HF, arrhythmias. Many rarer SEs^{SPC/BNF}, including suicidal thoughts/behaviour.
Monitor: U&Es, LFTs, FBC*** ± serum levels (optimum therapeutic range = 4–12 mg/l). Vit D level.
Warn: driving may be impaired, and watch for signs of liver/skin/haematological disease.
Interactions: ↑P450*: many (see^{SPC/BNF}) – may cause failure of OCP; fx are ↑d by ery-/clari-thromycin, isoniazid, verapamil and diltiazem; and fx are ↓d by phenytoin, phenobarbitone. CI with MAOIs. W–.
**Dose:** initially 100–200 mg od/bd (↑slowly to max of 1.6 g/day\(^2,3\) or 2 g/day\(^1\)). (MR forms** available\(^{SPC/BNF}\))

**CARBIMAZOLE**
Thionamide antithyroid: peroxidase inhibitor; stops I\(^-\) ⇒ I\(_2\) and ↓s T\(_3\)/T\(_4\) production. Possibly also immunosuppressive fx.

**Use:** ↑T\(_4\).

**Cl:** severe blood disorders. Severe L.

**Caution:** L, P/B (can cause fetal/neonatal goitre/↓T\(_4\) ↓: use min dose to control symptoms and monitor neonatal development closely – ‘block-and-replace’ regimen ↓: not suitable).

**SE:** hypersensitivity: rash and pruritus (if symptoms not tolerated or not eased by antihistamines, switch to propylthiouracil), fever, arthralgia. Also GI disturbance (esp nausea), headache. Rarely hepatic dysfunction, alopecia, blood disorders – esp agranulocytosis\(^*\) (0.5%) and ↓ WCC (often transient and benign).

**Warn/monitor:** see box below.

**Dose:** 15–60 mg/day in 2–3 divided doses (↓dose once euthyroid; maintenance dose usually 5–15 mg od, unless on ‘block-and-replace’ regimen, where ↑d doses are maintained). Normally give for only 12–18 months. Remission often occurs; if not, other Rx (e.g. surgery/radioiodine) may be needed.

\[\text{Agranulocytosis: warn patient to report immediately signs/symptoms of infection (esp sore throat, but also fever, malaise, mouth ulcers, bruising and non-specific illness). If suspect infection, do FBC (routine screening unhelpful as can occur rapidly). Stop drug if clinical or laboratory evidence of ↓NO\(^*\).}\]

**CARVEDILOL**
β-blocker: non-selective but also blocks α\(_1\) ↓: arterial vasodilation.

**Use:** HF\(^1\) (added to stable treatment). Less commonly for angina\(^2\) and HTN\(^3\) (for advice on stepped HTN Mx see p. 235).

**Cl/ Caution:** as propranolol, plus L. Also H if severe and chronic HF (caution in severe and non-chronic HF, and avoid if acute or decompensated HF needing iv inotropes).
SE: as propranolol, but worse postural ↓BP.  
Interactions: as propranolol, but can ↑levels of ciclosporin.  
Dose: initially 3.125 mg bd¹ (∩at intervals ≥2 wks to max of 25–50 mg bd); initially 12.5 mg bd²/od³ (can ↑to 50 mg/day).  
Before ↑ing dose, check HF and renal function not worsening.

CEFACLOR  
Oral 2nd-generation cephalosporin.  
Use: mild respiratory infections, UTIs, external infections (skin/soft tissue infections, sinusitis, otitis media), esp in pregnancy* (is one of the safest antibiotics) or dt H. influenzae.  
CI: cephalosporin hypersensitivity.  
Caution: if at ↑risk of AAC (e.g. recent other antibiotic use, ↑age, severe underlying disease, ↑hospital/nursing home stay, GI surgery, conditions/drugs that ↓gastric acidity (esp PPIs)), penicillin hypersensitivity (10% also allergic to cephalosporins), R/P/B (but appropriate to use*).  
SE: GI upset (esp N&D, but also AAC), allergy (anaphylaxis, fever, arthralgia, skin reactions (inc severe)), AKI, interstitial nephritis (reversible), hepatic dysfunction, blood disorders, CNS disturbance (inc headache).  
Interactions: levels ↑by probenecid, mild W +.  
Dose: 250 mg tds po (500 mg tds in severe infections; max 4 g/day).  
NB: ↓dose in RF.  
Cephalosporins can ⇒ false-positive Coombs’ and urine glucose tests.

CEFALEXIN  
Oral 1st-generation cephalosporin.  
Use/CI/Caution/SE/Interactions: see Cefaclor and AAC warning.  
Dose: 250 mg qds or 500 mg bd/tds po (↑in severe infections to max 1.5 g qds). For Px of UTI, give 125 mg po nocte. NB: ↓dose in RF.

CEFOTAXIME  
Use: severe infections, esp meningitis and typhoid, UTI, pyelonephritis, soft-tissue infections, gonorrhoea.

Cl/Caution/SE/Interactions: see Cefaclor and AAC warning, but can also rarely ⇒ arrhythmias if given as rapid iv injection.

Dose: 1 g bd im/iv/ivi (↑ing to max of 3 g qds if needed). NB: ↓dose in RF.

CEFRADINE
Oral or parenteral 1st-generation cephalosporin.

Use: as cefaclor.

Cl/Caution/SE/Interactions: see Cefaclor and AAC warning.

Dose: po: 250–500 mg qds or 0.5–1 g bd (max 1 g qds). NB: ↓dose in RF.

CEFTAZIDIME
Parenteral 3rd-generation cephalosporin: good against *Pseudomonas*.

Use: see Cefotaxime (often reserved for ITU setting).

Cl/Caution/SE/Interactions: see Cefaclor and AAC warning.

Dose: 1 g tds im/iv/ivi, ↑ing (with care in elderly) to 2 g tds or 3 g bd iv (not im, where max single dose is 1 g) if life-threatening, e.g. meningitis, immunocompromised. NB: ↓dose in RF.

CEFTRIAXONE
Parenteral 3rd-generation cephalosporin.

Use: as cefotaxime, plus pre-operative Px.

Cl/Caution/SE/Interactions: as Cefaclor and AAC warning, plus L (if coexistent RF), R (if severe), caution if dehydrated, young or immobile (can precipitate in urine or gallbladder). Rarely ⇒ pancreatitis and ↑PT.

Dose: 1 g od im/iv/ivi (max 4 g/day); 1–2 g im/iv/ivi at induction.

NB: ↓dose in RF.

Max im dose = 1 g per site; if total >1 g, give at divided sites.

CEFUROXIME
Parenteral and oral 2nd-generation cephalosporin: good for some Gram-negative infections (*H. influenzae*, *N. gonorrhoeae*) and better
than 3rd-generation cephalosporins for Gram-positive infections (esp *S. aureus*).

**Use:** po: respiratory infections¹, UTIs², pyelonephritis³; iv: severe infections⁴, pre-operative Px⁵.

**Cl/Caution/SE/Interactions:** see Cefaclor and AAC warning.

**Dose:** 250–500 mg bd po¹; 125 mg bd po²; 250 mg bd po³; 750 mg tds/qds iv/im⁴ (1.5 g tds/qds iv in very severe infections and 3 g tds if meningitis); 1.5 g iv at induction (+750 mg iv/im tds for 24 h if high-risk procedure)⁵. NB: ↓dose in RF.

**CELECOXIB/CELEBREX**

NSAID which selectively inhibits COX-2. ↓GI SEs (COX-1 mediated).

**Use:** osteoarthritis/RA², ankylosing spondylitis. Beneficial GI fx (↓bleeding) lost if on aspirin: don’t use together.

**Cl:** IHD, cerebrovascular disease, active bleeding/PU, PVD, hypersensitivity to aspirin or any other NSAID (inc asthma, angioedema, urticaria, rhinitis), *sulphonamide* hypersensitivity, IBD, L (if severe)/R (GFR<30)/H (moderate-severe)/P/B.

**Caution:** Hx of PU/GI bleeding, left ventricular dysfunction, HTN (monitor BP), ↑cardiovascular risk (e.g. DM, ↑lipids, smokers), oedema H (mild), asthma. R²/L (if either mild-moderate)/E.

**SE/Interactions:** as ibuprofen, but ⇒ ↓PU/GI bleeding (but only if not in combination with aspirin) & ⇒ ↑risk of MI/CVA. Very rarely ⇒ seizures. Also, fluconazole ⇒ ↑serum levels & rifampicin ⇒ ↓serum levels. Mild W +.

**Dose:** 100–200 mg bd po. ↓dose in RF*. Consider gastroprotective Rx.

---

**COX-2 inhibitors and ↑risk of cardiovascular complications:** CSM advises assessment of cardiovascular risk and use in preference to other NSAIDs only if at ↑↑risk of GI ulcer, perforation or bleeding. Use lowest effective dose and duration.

**CEPH-** see CEF-
CETIRIZINE/ZIRTEK
Non-sedating antihistamine: selective peripheral H<sub>1</sub> antagonist; antimuscarinic.
**Use:** symptomatic relief from allergy (esp hay fever, urticaria).
**CI:** acute porphyria, P/B.
**Caution:** epilepsy, ↑prostate/urinary retention, glaucoma, pyloroduodenal obstruction, R/L.
**SE:** mild antimuscarinic fx (see p. 276), very mild sedation, headache.
**Warn:** may impair driving.
**Dose:** 10 mg od (or 5 mg bd) po. ↓dose in severe RF.

CHARCOAL
Binds and ↓s absorption of tablets/poisons.
**Use:** ODs (up to 1 h post-ingestion; longer if MR/SR preparations or antimuscarinic drugs. See p. 276).
**Caution:** corrosive poisons, ↓GI motility (can ⇒ obstruction), ↓GCS (risk of aspiration, unless endotracheal tube in situ).
**Dose:** 50 g po. Give once for paracetamol and most drugs apart from alcohols or metal ions. Repeated doses (every 4 h) often needed for barbiturates, carbamazepine, phenytoin, digoxin, dapsone, paraquat, quinine, salicylates, theophylline and MR/SR preparations.

CHLORAMPHENICOL iv (and po)
Broad-spectrum antibiotic: inhibits bacterial protein synthesis; very potent action, but SEs limit use.
**Use:** severe infections inc *H. influenzae* and typhoid, esp where other drugs CI, e.g. due to allergy.
**CI:** porphyria, L (avoid if possible)/P/B.
**Caution:** avoid repeated courses R/E.
**SE:** blood disorders (inc aplastic ↓Hb), neuritis (peripheral, optic), GI upset, hepatotoxicity, hypersensitivity, stomatitis, glossitis.
**Monitor:** FBC, serum drug levels* pre-dose (trough) and 1-h post-dose (peak).
**CHLORAMPHENICOL EYE DROPS**
Topical antibiotic, with no significant systemic fx, for superficial bacterial eye infections (e.g. conjunctivitis), or as prophylaxis, e.g. postoperatively or for corneal abrasions. Can rarely ⇒ aplastic anaemia.
**Dose:** 1 drop of 0.5% qds. Can give as 1% ointment qds (or nocte only if using drops in daytime as well).

**CHLORDIAZEPOXIDE**
Benzodiazepine, long-acting.
**Use:** anxiety - short term use (esp in alcohol withdrawal).
**Cl/Caution/SE/Interactions:** see Diazepam.
**Dose:** 10 mg tds po, ↑ing if required to max of 100 mg/day. NB: ↓dose in RF, LF and elderly. ↑dose if benzodiazepine-resistant or in initial Rx of alcohol withdrawal (see p. 272 for reducing regimen).

**CHLORHEXIDINE**
Disinfectant mouthwash or solution for skin cleansing before invasive procedures and bladder washout.
**Cl:** avoid contact with eye, middle ear, brain, meninges, body cavities.

**CHLOROQUINE**
Antimalarial: inhibits protein synthesis and DNA/RNA polymerases.
**Use:** malaria Px¹ (only as Rx² if ‘benign’ spp (i.e. P. ovale/vivax/ malariae); P. falciparum often resistant. Rarely for RA, SLE.
**Caution:** G6PD deficiency, severe GI disorders, can worsen psoriasis and MG, neurological disorders (esp epilepsy*), L (avoid other hepatotoxic drugs), R/P.
**SE:** GI upset, headache (mild, transient), visual Δ (rarely retinopathy**), seizures*, hypersensitivity/skin reactions (inc pigment Δs), hair loss. Rarely BM suppression, cardiomyopathy. Arrhythmias common in OD.

**Monitor:** FBC, vision** (ophthalmology review if long-term Rx).

**Interactions:** absorption ↓by antacids. ↑risk of arrhythmias with amiodarone and moxifloxacin. ↑risk of convulsions with mefloquine. ↑s levels of digoxin and ciclosporin. ↓s levels of praziquantel.

**Dose:** Px¹: 300 mg once wkly as base (specify on prescription: don’t confuse with salt doses). Used mostly in conjunction with other drugs, depending on local resistance patternsSpC/BnF. Rx²: see p. 268.

**NB:** ↓dose in RF.

---

**CHLORPHEN(IR)AMINE/Piriton**

Antihistamine: H₁ antagonist (peripheral and central ∴ sedating).

**Use:** allergies¹ (esp drug reactions, hay fever, urticaria), anaphylaxis² (inc blood transfusion reaction³).

**Cl:** hypersensitivity to any antihistamine.

**Caution:** pyloroduodenal obstruction, urinary retention/↑prostate, thyrotoxicosis, asthma, bronch-itis/-iectasis, severe HTN/cardiovascular disease, glaucoma, epilepsy, R/L/P/B.

**SE:** drowsiness (rarely paradoxical stimulation), antimuscarinic fx (esp dry mouth; see p. 276), GI upset, arrhythmias, ↓BP, skin and hypersensitivity reactions (inc bronchospasm, photosensitivity). If given iv can cause transient CNS stimulation.

**Warn:** driving may be impaired.

**Interactions:** can ↑phenytoin levels. MAOIs can ⇒ ↑↑antimuscarinic fx (SpC says chlorphenamine Cl if MAOI given w/ in 2 wks but evidence unclear) 🤔.

**Dose:** 4 mg 4–6-hrly po¹(max 24 mg/24 h)↓E; 10 mg iv over 1 min² (can ↑to 20 mg, max 40 mg/24 h); 10–20 mg sc³ (max 40 mg/24 h).

---

**CHLORPROMAZINE**

Phenothiazine (‘typical’) antipsychotic: dopamine antagonist (D₁ and 3 > D₂ and 4). Also blocks serotonin (5HT₂A), histamine (H₁), adrenergic (α₁>2) and muscarinic receptors, causing many SEs.
**Use:** schizophrenia, acute sedation (inc mania, severe anxiety, violent behaviour), resistant migraine headache\(^1\), intractable hiccups.

**Ci:** CNS depression (inc coma), elderly patients with dementia, Hx of blood dyscrasias, severe cardiovascular disease.

**Caution:** Parkinson’s, drugs that ↑QTc, epilepsy, MG, phaeo, glaucoma (angle-closure), ↑prostate, severe respiratory disease, jaundice, blood disorders, predisposition to postural ↓BP, ↑or ↓temperature. Avoid direct sunlight (⇒ photosensitivity), L/R/H/P/B/E.

**Class SE:** sedation, extrapyramidal fx (see p. 278), antimuscarinic fx (see p. 276), seizures, ↑Wt, ↓BP (esp postural), ECG Δs (↑QTc), arrhythmias, endocrine fx (menstrual Δs, galactorrhoea, gynaecomastia, sexual dysfunction), ΔLFTs/jaundice, blood disorders (inc agranulocytosis, ↓WCC), ↓or ↑temperature (esp in elderly), rash/↑pigmentation, neuroleptic malignant syndrome.

Don’t crush tablets (contact hypersensitivity; also possible from iv solution).

**Warn:** avoid alcohol/direct sunlight, ↓s skilled tasks (e.g. driving).

**Monitor:** FBC, BP.

**Interactions:** May ↑sedation caused by alcohol and sedative medications. May ↑hypotension caused by other medications, fx ↑d by TCAs (esp antimuscarinic fx), lithium (esp extrapyramidal fx ± neurotoxicity), ritonavir, cimetidine and β-blockers (esp arrhythmias with sotalol; propranolol fx also ↑d by chlorpromazine). ↑risk of CNS toxicity with sibutramine. Avoid artemether/lumefantrine and drugs that ↑QTc or risk of ventricular arrhythmias (e.g. disopyramide, moxifloxacin).

**Dose:** 25–300 mg tds po\(^{SPC/BNF}\); 25–50 mg tds/qds im (painful, and may ⇒ ↓BP/↑HR); 0.2 mg/kg iv\(^1\). **NB:** ↓dose in elderly (approx 1/3–1/2 adult dose but 10 mg od po may suffice) or if severe RF.

**CICLESONIDE/ALVESCO**

Inh corticosteroid for asthma Px, similar to beclomethasone but od.

**Caution:** L.

**Dose:** 80–160 microgram od inh (aerosol).
CICLOSPORIN
Calcineurin inhibitor: \( \downarrow \)IL-2-mediated LØ proliferation.

**Use:** immunosuppression (esp nephrotic syndrome and post-transplant), atopic dermatitis, psoriasis, RA.

**Cl:** *only apply if given for nephrotic syndrome:* uncontrolled infection or HTN, malignancy. Avoid co-treatment with sirolimus.

**Caution:** HTN, ↑urate, porphyria, drugs that ↑K⁺, L/R/P/B/E.

**SE:** nephrotoxicity and tremor (both dose-related), ↑BP, hepatotoxicity, GI upset, biochemical Δs (↑K⁺, ↑urate/gout, ↓Mg²⁺, ↑cholesterol, ↑glucose), pancreatitis. Rarely neuromuscular symptoms, HUS, neoplasms (esp lymphoma), BIH, encephalopathy, demyelination (esp if liver transplant).

**Warn:** hypertrichosis, gingival hypertrophy, avoid XS sun exposure (photosensitivity); burning sensation in hands and feet.

**Monitor:** levels, LFTs, U&Es, Mg²⁺, lipids, BP.

**Interactions:** metab by P450, ∴ many, particularly antibacterials and antifungals\(^{\text{SPC/BNF}}\) (cephalosporins and penicillins OK). Levels esp ↓by phenytoin, carbamazepine, phenobarbital, St John’s wort, rifampicin, orlistat, ticlopidine and octreotide. Levels esp ↑by ery-/clari-thromycin, keto-/flu-/itra-conazole, protease inhibitors, diltiazem, nicardipine, verapamil, metoclopramide, amiodarone, allopurinol, danazol, ursodeoxycholic acid, corticosteroids and OCP. Can ↑levels of digoxin and diclofenac. Nephrotoxic and myotoxic drugs can become more so.

**Dose:** specialist use\(^{\text{SPC/BNF}}\). Must prescribe by brand name (Neoral, Sandimmun or SangCya) as have different bioavailabilities and changing brands can ∴. ↓immunosuppression or ↑toxicity. NB: dose adjustment needed if LF or RF.

CIMETIDINE
As ranitidine, but ↑↑interactions (↓P450 and \( W + \)) and ↑gynaecomastia ∴ prescribed rarely. **Dose:** 400 mg bd (can ↑to 4-hrly\(^{\text{SPC/BNF}}\)).

NB: ↓dose if LF or RF.
CIPROFLOXACIN
(Fluoro)quinolone antibiotic: inhibits DNA gyrase; ‘cidal’ with broad spectrum, but particularly good for Gram-negative infections.

Use: GI infections¹ (esp salmonella, shigella, campylobacter), respiratory infections (non-pneumococcal pneumonias², esp Pseudomonas). Also GU infections (esp UTIs³, acute uncomplicated cystitis in women⁴, gonorrhoea⁵), 1st-line initial Rx of anthrax.

CI: hypersensitivity to any quinolone, P/B.

Caution: seizures (inc Hx of, or predisposition to), MG (can worsen), G6PD deficiency, children/adolescents (theoretical risk of arthropathy), avoid ↑urine pH or dehydration*, R.

SE: GI upset (esp N&D, sometimes AAC), pancreatitis, neuro-Ψ fx (esp confusion, seizures; also headache, dizziness, hallucinations, sleep and mood Δs), tendinitis ± rupture (esp if elderly or taking steroids), chest pain, oedema, hypersensitivity (rash, pruritis, fever). Rarely hepatotoxicity, RF/interstitial nephritis, crystalluria*, blood disorders, ↑glucose, skin reactions (inc photosensitivity**, SJS, TEN).

Warn: avoid UV light**, avoid ingesting Fe- and Zn-containing products (e.g. antacids***). May impair skilled tasks/driving.

Interactions: ↑s levels of theophyllines; NSAIDs ⇒ ↑risk of seizures; ↑s nephrotoxicity of ciclosporin; FeSO₄ and antacids*** ⇒ ↓ciprofloxacin absorption (give 2 h before or 6 h after ciprofloxacin), W +.

Dose: 250–750 mg bd po, 100–400 mg bd ivi (each dose over 1 h) according to indicationSPC/BNF (100 mg bd po for 3 days for cystitis); 500 mg po single dose⁴; 100 mg iv single dose⁵. NB: ↓dose if severe RF.

 sax Stop if tendinitis, severe neuro-Ψ fx or hypersensitivity ⚠️.

CITALOPRAM/CIPRAMIL
SSRI antidepressant.

Use: depression¹ (and panic disorder). Useful if polypharmacy, as ↓interactions and ↓cardio-/hepato-toxicity cf other SSRIs.
**Cl/Caution/SE/Warn:** as fluoxetine, but ↑risk of withdrawal syndrome if stopped abruptly. Can also ↑QTc (dose dependent); Cl if ↑QTc (or congenital ↑QTc syndrome or taking other drugs that can ↑QTc) and caution if ↑risk torsades de pointes (e.g. congestive HF, recent MI, bradyarrhythmias, predisposition to ↓K⁺ or ↓Mg²⁺ dt concomitant illness or medicines), epilepsy.

**Interaction:** ☮️ Never give with, or <2 wks after, MAOIs ☮️.  
**Dose:** 20 mg od¹ ↑ing if necessary to max 40 mg (max 20 mg if elderly or LF).

**CITRAMAG** see Bowel preparations  
**Cl:** GI obstruction or perforation. **R** (if severe).  
**Caution:** risk of ↑Mg²⁺ in RF.  
**Dose:** 1 sachet at 8 am and 3 pm the day before GI surgery or Ix.

**CLARITHROMYCIN**  
Macrolide antibiotic: binds 50S ribosome.  
**Use:** as erythromycin; (see p. 65), part of triple therapy for *H. pylori*.  
**Cl/Caution/SE/Interactions:** as erythromycin, but ⇒ ↓GI SEs.  
**Dose:** 250–500 mg bd po or 500 mg bd iv. **NB:** ↓dose if RF.

**CLEXANE** see Enoxaparin; low-molecular-weight heparin.

**CLINDAMYCIN**  
Antibiotic; same action (but different structure and ↓: class) as clarithromycin; good against staphylococci, streptococci and anaerobes (esp bacteroides); penetrates bone well.  
**Use:** cellulitis, osteomyelitis, intra-abdominal sepsis, endocarditis Px, falciparum malaria. Alternative to penicillin in case of allergy.  
**Use limited due to SEs (esp AAC).**  
**Cl:** diarrhoea.  
**Caution:** GI disease, porphyria, atopy, **L/R/P/B.**  
**SE:** GI upset (often ⇒ AAC), hepatotoxicity, blood disorders, local reactions at injection site, arthralgia, myalgia, hypersensitivity.  
**Monitor:** U&Es, LFTs.
**Interactions:** ↑s fx of neuromuscular blocking agents.
**Dose:** 150–450 mg qds po; 0.6–4.8 g daily in divided doses im/ivi (doses >600 mg must be as ivi), max single dose iv is 1.2 g.

⚠️ Stop drug if diarrhoea develops: AAC common and potentially very severe.

**CLOBETASOL PROPIONATE 0.05% CREAM OR OINTMENT/DERMOVATE**
Very-potent-strength topical corticosteroid.
**Use:** short-term Rx of severe inflammatory skin conditions (esp discoid lupus, lichen simplex and palmar plantar psoriasis).
**CI:** untreated infection including H. zoster, rosacea, acne.
**SE:** skin atrophy, worsening of infections, acne (↑SEs cf less potent topical steroids).
**Dose:** apply thinly od/bd, usually under specialist supervision.

**CLOBETASONE BUTYRATE 0.05% CREAM OR OINTMENT/EUMOVATE**
Moderately-potent-strength topical corticosteroid.
**Use:** inflammatory skin conditions, esp eczema, dermatitis.
**CI:** untreated infection, rosacea, acne.
**SE:** skin atrophy, worsening of infections, acne.
**Dose:** apply thinly od/bd.

**CLONAZEPAM**
Benzodiazepine; long-acting
**Use:** epilepsy (all forms¹ inc status epilepticus²). Not licensed, but often used, for Ψ disorders³ (esp psychosis and mania).
**CI/Caution/SE/Warn/Interactions:** see Diazepam.
**Dose:** 0.5–1 mg ↑ing according to response to max 20 mg/day¹⁄³ in divided doses; 1 mg iv (over ≥2 min) or as ivi².

**CLOPIDOGREL/PLAVIX**
Antiplatelet agent: ADP receptor antagonist. ↑antiplatelet fx cf aspirin (but also ↑SEs).
**Use:** Px of atherothrombotic events if STEMI or NSTEMI (for 12 months in combination with aspirin, aspirin continued indefinitely), MI (within ‘a few’ to 35 days), ischaemic CVA (within 7 days to 6 months) or peripheral arterial disease. For use in ACS (see p. 226).

**CI:** active bleeding, L (if severe – otherwise caution), B.

**Caution:** ↑bleeding risk; trauma, surgery, drugs that ↑bleeding risk (avoid with warfarin), ↓fx by omeprazole, esomeprazole. R/P.

**SE:** haemorrhage (esp GI or intracranial), GI upset, PU, pancreatitis, headache, fatigue, dizziness, paraesthesia, rash/pruritus, hepatobiliary/respiratory/blood disorders (↓NØ, ↑EØ, very rarely, TTP).

**Monitor:** FBC and for signs of occult bleeding (esp after invasive procedures).

**Dose:** 75 mg od. If not already on clopidogrel, usually load with 300 mg for ACS then 75 mg od starting next day. If pre-PCI, load with 300–600 mg usually on morning of procedure.

Stop 7 days before operations if antiplatelet fx not wanted (e.g. major surgery); discuss with surgeons doing operation.

**CLOTRIMAZOLE/CANESTEN**
Imidazole antifungal (topical).

**Use:** external candida infections (esp vaginal thrush).

**Caution:** can damage condoms and diaphragms.

**Dose:** 2–3 applications/day of 1% cream, continuing for 14 days after lesion healed. Also available as powder/solution/spray for hairy areas, as pessary, and in 2% strength. See more^BNF/SPC

**CLOZAPINE**
Atypical antipsychotic: blocks dopamine (D³ > D₁ > D₂ and 3) and SHT₂A receptors. Also mild blockade of muscarinic and adrenergic receptors.

**Use:** schizophrenia, but only if resistant or intolerant (e.g. severe extrapyramidal fx) to other antipsychotics^NICE.

**CI:** severe cardiac disorders (inc Hx of circulatory collapse, myocarditis, cardiomyopathy), coma/severe CNS depression, alcoholic/toxic psychosis, drug intoxication, Hx of agranulocytosis or ↓NØ,
bone marrow disorders, paralytic ileus, uncontrolled epilepsy, R/H (if severe, otherwise caution), L (inc active liver disease), B.

**Caution:** Hx of epilepsy, cardiovascular disease, ↑prostate, glaucoma (angle-closure), P/E.

**SE:** as olanzapine, but also can ⇒ ↓NØ* (3% of patients) and ☠ agranulocytosis ☠ (1%). Also commonly ⇒ ↑salivation (Rx with hyoscine hydrobromide), ↓BP (esp during initial titration), constipation (can ⇒ ileus/obstruction: have low threshold for giving laxatives), ↑Wt, sedation. Less commonly seizures, urinary incontinence, priapism, myocarditis/ cardiomyopathy (stop immediately!), ↑HR, arrhythmias, hyperglycaemia, N&V, ↑BP, delirium, RF, ↓Pt. Rarely hepatic dysfunction (stop immediately!), ↑TG, neuroleptic malignant syndrome.

**Monitor:** FBC*, BP (esp during start of Rx), serum levels (pre-dose) and cardiac function (get baseline ECG/watch for persistent ↑HR).

**Warn:** to report symptoms of infection, e.g. fever, sore throat.

**Interactions:** as chlorpromazine, plus care with all drugs that constipate, ↑QT threshold or ↓leucopoiesis (e.g. cytotoxics, sulphonamides/co-trimoxazole, chloramphenicol, penicillamine, carbamazepine, phenothiazines, esp depots). Caffeine, risperidone, SSRIs, cimetidine and erythromycin ↑clozapine levels. Smoking, carbamazepine and phenytoin ↓clozapine levels.

**Dose:** initially 12.5 mg nocte, ↑ing to 200–450 mg/day SPC/BNF usually given bd (max 900 mg/day). ↓doses if elderly.

If >2 days’ doses missed, restart at 12.5 mg od and ↑gradually.

Monitoring: primarily to avoid fatal agranulocytosis, is done by the manufacturers: in the UK Clozaril Patient Monitoring Service (tel: 0845 7698269), Denzapine Monitoring Service (tel: 01635 568500) or Zaponex Treatment Access System (tel: 0207 3655842). Register and then authorise/monitor baseline and subsequent FBCs* and serum levels*. These are very useful resources for all clozapine questions.
CO-AMILOFRUSE
Diuretic combination preparation for oedema that keeps K+ stable: amiloride (K+ sparing) + furosemide (K+ wasting) in 3 strengths of tablet as 2.5/20, 5/40 and 10/80 (reflecting amiloride mg/furosemide mg).
**Monitor:** BP, U&Es.
**Dose:** 1 tablet mane (NB: specify strength!).

CO-AMILOZIDE
Diuretic combination preparation for HTN (for advice on stepped HTN Mx see p. 235), CCF and oedema. Keeps K+ stable: amiloride (K+ sparing) + hydrochlorothiazide (K+ wasting) in 2 strengths of tablet as 2.5/25 and 5/50 (reflecting amiloride mg/hydrochlorothiazide mg).
**Caution:** crystalluria esp if ↑dose or RF.
**Monitor:** BP, U&Es.
**Dose:** 1/2–4 tablets daily, according to tablet strength and indication

CO-AMOXICLAV/AUGMENTIN
Combination of amoxicillin + clavulanic acid (β-lactamase inhibitor) to overcome resistance.
**Use:** UTIs, respiratory/skin/soft-tissue (plus many other) infections. Reserve for when β-lactamase-producing strains known/strongly suspected or other Rx has failed.
**CI/Caution/SE/Interactions:** as ampicillin, plus caution if anticoagulated, L (↑risk of cholestasis), P.
**Dose:** as amoxicillin Dose: 250 mg tds po (500 mg tds po if severe); 1 g tds/qds iv/ivi. Non-proprietary and as Augmentin. NB: ↓dose if LF.

CO-BENELDOPA/MADOPAR
L-dopa + benserazide (peripheral dopa-decarboxylase inhibitor).
**Use:** Parkinsonism.
**CI/Caution/SE/Warn/Interactions:** see Levodopa.
**Dose:** (expressed as levodopa only) initially 50 mg tds/qds, ↑ing total dose and number of doses, according to response, to usual maintenance of 400–800 mg/day (↓ in elderly)\textsuperscript{BNF/SPC}. Available in dispersible form.

**CO-CARELDOPA/SINEMET**
L-dopa + carbidopa (peripheral dopa-decarboxylase inhibitor).

**Use:** Parkinsonism.

**Cl/Caution/SE/Warn/Interactions:** see Levodopa.

**Dose:** (expressed as levodopa only) initially 100 mg tds, ↑ing total dose and number of doses, according to response, to usual maintenance of 400–800 mg/day (↓ in elderly)\textsuperscript{BNF/SPC}. Available in dispersible form.

**CO-CODAMOL** (30/500) = codeine 30 mg + paracetamol 500 mg per tablet.

**Use/Cl/Caution/SE/Interactions:** see Paracetamol and Codeine.

**Warning:** prescribe by dose as also available as 8/500 and 15/500.

**Dose:** 2 tablets qds prn. NB: ↓dose if LF, RF or elderly.

**CO-DANTHRAMER** see Dantron; stimulant laxative - palliative care.

**Dose:** 1–2 capsules or 5–10 ml suspension nocte (available in regular and strong formulations).

**CO-DANTHRUSATE** see Dantron; stimulant laxative - palliative care.

**Dose:** 1–3 capsules or 5–15 ml suspension nocte.

**CODEINE (PHOSPHATE)**
Weak opiate analgesic. Mainly metabolised to morphine.

**Use:** mild/moderate pain, diarrhoea, anti-tussive.

**Cl:** acute respiratory depression, risk of ileus, ↑ICP/head injury/coma.

**Caution:** all other conditions where morphine is either contraindicated or cautioned.

**SE:** as morphine, but milder. Constipation is the major problem: dose and length of Rx-dependent; anticipate this and give laxative Px as appropriate, esp in elderly. Also sedation, esp if LF.
**Interactions:** MAOIs: don’t give within 2 weeks of. As morphine, but does not interact with baclofen, gabapentin and ritonavir.

**Dose:** 30–60 mg up to 4-hrly po/im (max 240 mg/24 h). Genetic ultrarapid metabolisers (3% of Europeans, 8% of Americans, 40% of North Africans) risk serious toxicity & poor metabolisers obtain little analgesia. Watch closely when initiating & adjust dose/change drug accordingly. **NB:** ↓dose if LF, RF or elderly.

**CO-DYDRAMOL** Dihydrocodeine 10/20/30 mg + paracetamol 500 mg per tablet (10/500, 20/500, 30/500).

**Dose:** 1–2 tablets 4–6 hrly, max qds po. Usually prescribed 2 tablets qds (prn). **NB:** ↓dose if LF, RF or elderly.

**COLCHICINE**

Anti-gout: binds to tubulin of leucocytes and stops their migration to uric acid deposits : ⇒ ↓inflammation. **NB:** slow action (needs >6 h to work).

**Use:** gout: Rx of acute attacks or Px when starting allopurinol* (which can initially ↑symptoms) or awaiting other drugs to work.

**CI:** blood dyscrasias, P-glycoprotein and strong CYP3A4 inhibitors. **P Caution:** GI diseases, **L/H/R/B/E.**

**SE:** GI upset (N&V&D and abdominal pain – all common and dose-related). Rarely GI haemorrhage, hypersensitivity, renal/hepatic impairment, peripheral neuritis, myopathy, alopecia, ↓spermatogenesis (reversible), blood disorders (if prolonged Rx).

**Interactions:** ↑s nephro-/myo-toxicity of ciclosporin and myopathy of simvastatin. fx ↓by thiazide diuretics. Toxicity ↑by erythromycin and tolbutamide.

**Dose:** 0.5 mg bd/qds until relief (start ASAP after symptom onset). Max. 6 mg. More aggressive regimens exist but ⇒ ↓GI upset w/o significant ↑in response. Continue 0.5 mg bd when starting allopurinol*. Do not repeat course within 3 days. **NB:** ↓dose if RF.

**COLESTYRAMINE**

Anion exchange resin. Binds bile acids in gut preventing reabsorption; ⇒ hepatic cholesterol ⇒ bile acids; ⇒ hepatic LDL receptors ⇒ ↑LDL cholesterol plasma clearance.
**Use:** pruritus (2° to PBC or partial biliary obstruction)\(^1\), diarrhoeal disorders\(^2\). *If diet and other measures insufficient:* hyperlipidaemia\(^3\) (esp type IIa), Px of IHD\(^4\), 1° hypercholesterolaemia\(^5\).

**Cl:** ineffective in complete biliary obstruction.

**Caution:** Risk of ↓ fat soluble vitamins. Sachets contain sucrose or aspartame. DM. **P/B.**

**SE:** ↓ Vits A/D/K, ↑ bleeding risk, taste Δ, GI upset/obstruction, ↑ Cl⁻ acidosis.

**Warn:** take other drugs >1 h before or > 4–6 h after colestyramine*.

**Monitor:** for vitamin deficiency (and INR if on warfarin).

**Interactions:** delay or ↓ drug absorption* inc digoxin, tetracycline, chlorothiazide, thyroxine. **W + or W–.**

**Dose:** initially 4 g od, ↑ ing if required by 4 g/wk to 8 g/day\(^1\) (max 36 g/day\(^2,3,4,5\))

NB: take with ≥150 ml suitable liquid/4 g sachet.

**CO-MAGALDROX antacid** (AlOH + MgOH).

**Dose:** 10–20 ml 20–60 min after meals, and at bedtime or prn.

**COMBIVENT** Compound bronchodilator (salbutamol + ipratropium bromide).

**Dose:** 2.5 ml (one vial: ipratropium 500 microgram + salbutamol 2.5 mg) tds/qds neb\(^\text{SPC/BNF}\).

**CORSODYL** Chlorhexidine mouthwash for Rx/Px of mouth infections (inc MRSA eradication); see local infection protocol.

**CO-TRIAMTERZIDE**

Diuretic for HTN\(^1\) (*for advice on stepped HTN Mx see p. 235*), or oedema\(^2\): triamterene (↑s K⁺) combined with hydrochlorothiazide (↓s K⁺) to keep K⁺ stable.

**Monitor:** BP, U&E s.

**Dose:** initially 1 tablet\(^1\) (or 2 tablets\(^2\)) mane of 50/25 strength (= 50 mg triamterene + 25 mg hydrochlorothiazide), ↑ ing if necessary to max of 4 tablets/day.
CO-TRIMOXAZOLE/SEPTRIN
Antibiotic combination preparation: 5 to 1 mixture of sulfamethoxazole (a sulphonamide) + trimethoprim ⇒ synergistic action.
Use: PCP; other uses limited due to SEs (also rarely used for toxoplasmosis and nocardiosis).
Cl: porphyria, L/R (if either severe, otherwise caution).
Caution: blood disorders, asthma, G6PD deficiency, risk factors for ↓folate P/B/E.
SE: skin reactions (inc SJS, TEN), blood disorders (↓NØ, ↓Pt, ↓Glucose, BM suppression, agranulocytosis) relatively common, esp in elderly. Also N&V&D (inc AAC), nephrotoxicity, hepatotoxicity, hypersensitivity, anorexia, abdo pain, glossitis, stomatitis, pancreatitis, arthralgia, myalgia, SLE, pulmonary infiltrates, seizures, ataxia, myocarditis.
Interactions: ↑s phenytoin levels. ↑s risk of arrhythmias with amiodarone, crystalluria with methenamine, antifolate fx with pyrimethamine, agranulocytosis with clozapine and toxicity with ciclosporin, azathioprine, mercaptopurine and methotrexate. W +.
Dose: PCP Rx: 120 mg/kg/day po/ivi in 2–4 divided doses (PCP Px 480–960 mg od po). PCP PxBNF/SPC. NB: ↓dose if RF.

CYCLIZINE
Antihistamine antiemetic.
Use: N&V Rx/Px (esp 2° to iv/im opioids, but not 1st choice in angina/MI/LVF*), vertigo, motion sickness, labyrinthine disorders.
Cl/Caution/SE/Warn: as chlorphenamine, but also avoid in severe HF* (may undo haemodynamic benefits of opioids). Antimuscarinic fx (see p. 276) are most prominent SEs.
Dose: 50 mg po/im/iv tds.

CYCLOPENTOLATE 0.5%/1% EYE DROPS/MYDRILATE
For pupil dilation (for pain relief and prevention of complications in uveitis). Also cycloplegic (paralyses accommodation); useful for refracting children.
**SE:** blurred vision.
**Dose:** 1 drop (tds for prolonged use). 30 min to work, lasts several hours.

**CYCLOPHOSPHAMIDE**
Cytotoxic¹ and immunosuppressant²: alkylating agent (cross-links DNA bases, ing replication).

**Use:** cancer¹, autoimmune diseases²: esp vasculitis (inc rheumatoid arthritis, ANCA-associated vasculitis and SLE (esp if renal/cerebral involvement)), systemic sclerosis, Wegener’s, nephrotic syndrome in children.

**CI:** haemorrhagic cystitis, P/B.

**Caution:** BM suppression, severe infections, L/R.

**SE:** GI upset, alopecia (reversible). Others rare but important: hepatotoxicity, blood disorders, malignancy (esp acute myeloid leukaemia), ↓fertility (can be permanent), cardiac toxicity, pulmonary fibrosis (at high doses), haemorrhagic cystitis (only if given iv: ensure good hydration, give ‘mesna’ as Px; can occur months after Rx).

**Warn:** ↓fertility may be permanent (bank sperm if possible) – need to counsel and obtain consent regarding this before giving.

**Monitor:** FBC.

**Interactions:** can ↑fx of oral hypoglycaemics. ↑risk of agranulocytosis with clozapine and toxicity with pentostatin.

**Dose:** specialist use only. NB: ↓dose if LF or RF.

Stop immediately if rash or blood disorder occurs ☢.

**CYCLOSPORIN** see Ciclosporin

**CYPROTERONE ACETATE**
Anti-androgen; blocks androgen receptors. Also ↑s progestogens.

**Use:** Ca prostate¹ (as adjunct), acne² (esp 2° to PCOS, where often used with ethinylestradiol as co-cyprindiol), rarely for hypersexuality/sexual deviation³ (males only!).

**CI:** (none apply if for Ca prostate) advanced DM (if vascular disease), sickle cell, malignancy/wasting diseases, Hx of TE, age
<18 years (can ⇒ ↓bone/testicular development), severe depression, L/P/B.

SE: fatigue, gynaecomastia, ↑or ↓Wt, hepatotoxicity, blood disorders, hypersensitivity, osteoporosis, ↓spermatogenesis (reversible), TE, depression, carbohydrate metabolism and hair Δs. 

Monitor: FBC, LFTs, adrenocortical function. 

Warn: driving and other skilled tasks may be impaired. 

Dose: 200–300 mg po daily in divided doses¹, 50 mg bd po³. 

▼ DABIGATRAN (ETEXILATE)/PRADAXA

Oral anticoagulant; direct thrombin inhibitor. Rapid onset and doesn’t require therapeutic monitoring (unlike warfarin). 

Use: Px of VTE (after THR/TKR)¹; and non-valve AF embolism². 

CI: active bleeding, impaired haemostasis, L (if severe) P/B. 

Caution: bleeding disorders, active GI ulceration, recent surgery, bacterial endocarditis, anaesthesia with postoperative indwelling epidural catheter (risk of paralysis; give initial dose ≥2 h after catheter removal and monitor for neurological signs), weight <50 kg, R (avoid if creatinine clearance <30 ml/min) H/E. 

SE: haemorrhage, hepatobiliary disorders. 

Monitor: for ↓Hb or signs of bleeding (stop drug if severe). 

Interactions: NSAIDs ↑risk of bleeding. Levels ↑by amiodarone*. 

Dose: 110 mg (75 mg if >75 years old) 1–4 h after surgery then 220 mg od (150 mg if >75 years old) for 9 days after knee replacement or 27–34 days after hip replacement¹; 150 mg po bd². 

NB: ↓dose in RF, elderly or if taking amiodarone*. 

▼ DALTEPARIN/FRAGMIN 

Low-molecular-weight heparin (LMWH). 

Use: DVT/PE Rx¹ and Px² (inc pre-operative), ACS (with aspirin)³. 

CI/Caution/SE/Monitor/Interactions: see Heparin. 

Dose: all sc: 200 units/kg (max 18000 units) od¹; 2500–5000 units od² (according to risk³ for ≥5 days; 120 units/kg bd³ for ≥5 days (max 10 000 units bd) reviewing dose if >8 days needed³. 

L/R/H = Liver, Renal and Heart failure (full key see p. xv)
Consider monitoring anti Xa (3–4 h post dose) ± ↓dose if RF (i.e. creatinine >150), pregnancy, Wt >100 kg or <45 kg; see p. 209.

DANTRON
Stimulant laxative; theoretical risk of carcinogenicity*.
**Use:** constipation (often limited to the terminally ill*).
**Caution/SE:** see Senna; possible carcinogenic risk. (CI if GI obstruction, P/B)
**Dose:** see Co-danthramer and Co-danthrusate.

DARBEPOETIN see Erythropoietin (recombinant form for ↓Hb).

DERMOVATE see Clobetasol propionate (steroid) cream 0.05%.

DESFERRIOXAMINE
Chelating agent; binds Fe (and Al) in gut ↓ing absorption/↑ing clearance.
**Use:** ↑Fe: acute (OD/poisoning\(^1\)), chronic (e.g. xs transfusions for blood disorders, haemochromatosis when venesection CI). Also for ↑Al (e.g. 2° to dialysis).
**Caution:** Al-induced encephalopathy (may worsen), ↑risk of Yersinia/mucormycosis infection R/P/B.
**SE:** ↓BP (related to rate of ivi), lens opacities, retinopathy, GI upset, blood disorders, hypersensitivity. Also neurological/respiratory/renal dysfunction. ↑doses can ⇒ ↓growth and bone Δs.
**Monitor:** vision and hearing during chronic Rx.
**Dose:** acutely up to 15 mg/kg/h ivi (max 80 mg/kg/day\(^1\)). Otherwise according to degree of Fe or Al overload\(^{SPC/BNF}\).

DEXAMETHASONE 0.1% EYE DROPS/MAXIDEX
Topical corticosteroid.
**Use:** uveitis, Px of post-eye surgery anterior segment inflammation.
**CI:** ocular infection.
**SE:** ocular infection (aggravation of existing or ↑susceptibility) or ocular HTN. If prolonged use, glaucoma and cataract possible.
**Dose:** 1 drop qds (max 1-hrly); specialist use only.
DEXAMETHASONE PHOSPHATE
Glucocorticoid; minimal mineralocorticoid activity, long duration of action (see p. 217).
Use: cerebral oedema (from malignancy), spinal cord compression, Dx of Cushing’s, N&V (2° to chemotherapy or surgery), allergy/inflammation (esp if unresponsive shock), congenital adrenal hyperplasia, rheumatic disease.
CI/Caution/SE/Warn/Interactions: see Prednisolone and steroids section (p. 217).
Dose: cerebral oedema: acutely 10 mg iv, then 4 mg im qds 2–4 days (if not life-threatening, some go straight to 4 mg qds iv then switch to po a few days later, stopped gradually over 5–7 days). For other indications, see SPC/BNF.

Doses given here are for dexamethasone phosphate and must be prescribed as such: other forms have different doses!

DF118 (suffix FORTE often omitted) Dihydrocodeine 40 mg.
Dose: 40–80 mg tds po.
NB: tablets are different dose to non-proprietary dihydrocodeine.

DIAMORPHINE (HEROIN HYDROCHLORIDE)
Strong opiate (1.5 × strength of morphine if both given iv).
Use: severe pain (acute and chronic)¹, AMI², acute LVF³.
CI/Caution/SE/Interactions: as morphine, but less nausea/ØBP, and does not interact with baclofen, gabapentin and ritonavir.
Respiratory depression (esp elderly)
Dose: 5–10 mg sc/im (or 1/4–1/2 this dose iv) up to 4-hrly¹; 5 mg iv (at 1–2 mg/min) followed by further 2.5–5 mg if necessary²; 0.5–1 mg iv (at 0.5 mg/min)³. Can give via sc pump in chronic pain/palliative care. NB: Ødose if elderly, LF or RFBNF/SPC.

DIAZEMULS iv diazepam emulsion: ⇒ Øvenous irritation.
**DIAZEPAM**
Benzodiazepine, long-acting.

**Use:** seizures (esp status epilepticus\(^1\), febrile convulsions), short-term Rx of acute alcohol withdrawal\(^2\), anxiety\(^3\), insomnia\(^4\) (if also anxiety; if not, then shorter-acting forms preferred as ⇒ ↓hangover sedation). Also used for muscle spasm\(^5\).

**CI:** respiratory depression, marked neuromuscular respiratory weakness inc unstable myasthenia gravis, sleep apnoea, acute pulmonary insufficiency, chronic psychosis, depression (don’t give diazepam alone), L (if severe).

**Caution:** respiratory disease, muscle weakness (inc MG), Hx of drug/alcohol abuse, personality disorder, porphyria, R/P/B/E.

**SE:** respiratory depression (rarely apnoea), drowsiness, dependence. Also ataxia, amnesia, headache, vertigo, GI upset, jaundice, ↓BP, ↓HR, visual/libido/urinary disturbances, blood disorders, paradoxical disinhibition in \(\Psi\) disorder.

**Warn:** sedation ↑by alcohol and ⇒ ↓driving/skilled task ability.

**Interactions:** metab by P450 .: many: ery-/clari-/teli-thromycin, quinu-/dalfo-pristin and flu-/itra-/keto-/posa-conazole can ↑levels. Sedative fx ↑by antipsychotics, antidepressants, antiepileptics and antiretrovirals. Can ↑fx of zidovudine and sodium oxybate. ↑risk of ↓HR/BP and respiratory depression with im olanzapine.

**Dose:** for status epilepticus\(^1\) and alcohol withdrawal\(^2\), see p. 260 and p. 271, respectively; 2 mg tds po (↑up to 30 mg/day)\(^3,5\); 5–15 mg nocte po\(^4\). NB: ↓dose if elderly, LF or RF. If chronic exposure to benzodiazepines, ↑doses may be needed; don’t stop suddenly, as can ⇒ withdrawal.

\(\Psi\) **Respiratory depression:** if ↑doses used (esp iv/im), monitor \(O_2\) sats and have \(O_2\) (± intubation equipment) at hand, caution with flumazenil – see p. 284 for Mx \(\Psi\).

**DICLOFENAC**
Medium-strength NSAID; non-selective COX inhibitor.

**Use:** pain/inflammation, esp musculoskeletal; RA, osteoarthritis, acute gout, migraine, post-op and dental pain.
**Cl/Caution/SE/Interactions:** as ibuprofen, but somewhat ↑risk PU/GI bleeds & thrombotic events (↓risk PU/GI bleeds if given with misoprostol as Arthrotec). Doses ≥ 150 mg daily associated with ↑thrombotic risk. Avoid in acute porphyria. Ciclosporin ⇒ ↑serum levels. No known interaction with baclofen. Mild W +.

**Dose:** 25–50 mg tds po or 75 mg bd po (or im, but for max of 2 days); 75–150 mg/day pr (divided doses). Rarely used ivBNF/SPC.

MR and top preparations availableBNF/SPC. NB: Avoid/↓dose in RF & consider gastroprotective Rx.

**DIFFLAM** Benzydamine: topical NSAID for painful inflammatory conditions of oropharynx (e.g. mouth ulcers, radio-/chemo-therapy-induced mucositis). Available as spray (4–8 sprays 1.5–3-hrly) or oral rinse (15 ml 1.5–3-hrly, diluting in 15 ml water if stinging). Rarely fi hypersensitivity reactions.

**DIGIBIND** Anti-digoxin Ab for digoxin toxicity/OD unresponsive to supportive Rx. See SPC for dose.

**DIGOXIN** Cardiac glycoside: ↓s HR by slowing AVN conduction and ↑ing vagal tone. Also weak inotrope.

**Use:** AF (and other SVTs), HF.

**Cl:** HB (intermittent complete), 2nd-degree AV block, VF, VT, HCM (can use with care if also AF and HF), SVTs 2° to WPW.

**Caution:** recent MI, ↓K+/↓T4 (both ⇒ ↑digoxin sensitivity*), SSS, rhythms resembling AF (e.g. atrial tachycardia with variable AV block), R/E (↓dose), P.

**SE:** generally mild unless rapid ivi, xs Rx or OD: GI upset (esp nausea), arrhythmias/HB, neuro-Ψ disturbances (inc visual Δs, esp blurred vision and yellow/green halos), fatigue, weakness, confusion, hallucinations, mood Δs. Also gynaecomastia (if chronic Rx), rarely ↓Pt, rash, ↑EØ.

**Monitor:** U&Es, digoxin levels (ideally take 6 h post-dose: therapeutic range = 1–2 microgram/l).
**Interactions:** digoxin fx/toxicity ↑d by Ca\(^{2+}\) antagonists (esp verapamil), amiodarone, propafenone, quinidine, antimalarials, itraconazole, amphotericin, ciclosporin, St John’s wort and diuretics (mostly via ↓K\(^{+}\)), but also ACE-i/ARBs and spironolactone (despite potential ↑K\(^{+}\)). Cholestyramine and antacids can ↓digoxin absorption.

**Dose:** non-acute AF/SVTs: load with 125–250 microgram bd po (maintenance dose 62.5–250 microgram od). For HF: 62.5–125 microgram od. NB: ↓dose if RF, elderly or digoxin given <2 wks ago.

Digoxin loading for acute AF/SVTs: *either* 0.75–1 mg as ivi over 2 h or 500 microgram po repeated 12 h later. Then follow non-acute schedule.

**DIHYDROCODEINE** see Codeine: similar-strength opioid.

**Dose:** 30 mg 4–6 hourly po (or up to 50 mg 4–6 hourly im/sc) with or after food. ↑doses can be given under close supervision. ↓dose if RF.

**DILATING EYE DROPS** (for funduscop). Generally safe but rarely ⇒ angle closure glaucoma (suspect if develops red painful eye with ↓vision and nausea; *ophthalmic emergency*). Dilation blurs vision. Driving unsafe for at least 4 hours when both eyes dilated. Apply 1 drop and allow 15 mins for effect.

1. **Tropicamide** 1% Most common; CI in children <1 yr old (use 0.5%).
2. **Phenylephrine** 2.5% or 10% Frequently used in combination with tropicamide. 2.5% most common. 10% ↑s systemic SEs. CI if cardiac disease, HTN, ↑HR, aneurysms, ↑T\(_4\).

Consider cycloplegic forms (e.g. cyclopentolate 1%) for refraction in children or if analgesia required, e.g. corneal abrasions & uveitis (↓s ciliary spasm).

**DILTIAZEM**

Rate-limiting benzothiazepine Ca\(^{2+}\) channel blocker: ↓s HR and contractility* (but < verapamil) and ↓s BP. Also dilates peripheral/ coronary arteries.

**Use:** Rx/Px of angina\(^1\) (esp if β-blockers CI) and HTN\(^2\) (*for advice on stepped HTN Mx see p. 235*).
**CI:** LVF* with pulmonary congestion, ↓↓HR, 2nd/3rd-degree AV block (without pacemaker), SSS, acute porphyria P/B.  
**Caution:** 1st-degree AV block, ↓HR, ↑PR interval, L/R/H.  
**SE:** headache, flushing, GI upset (esp N&C), oedema (esp ankle), ↓HR, ↓BP, gum hyperplasia. Rarely SAN/AVN block, arrhythmias, rash, hepatotoxicity, gynaecomastia.  
**Interactions:** β-blockers and verapamil (can ⇒ asystole, AV block, ↓↓HR, HF). ↑s fx of digoxin, ciclosporin, theophyllines, carbamazepine and phenytoin. 🍁↑risk of VF with iv dandrolene 🍁.  
**Dose:** 60 mg tds (↑ing to max of 360 mg/day)¹; 180–480 mg/day in 1 or 2 doses² (suitable for HTN only as MR preparation: no non-proprietary forms exist and brands vary in clinical fx .specify which is requiredSPC/BNF). NB: Consider ↓ing doses if LF or RF.  

**DIPROBASE** Paraffin-based emollient cream/ointment for dry skin conditions (e.g. eczema, psoriasis).  

**DIPYRIDAMOLE/PERSANTIN**  
Antiplatelet agent: inhibits Pt aggregation, adhesion and survival (also ⇒ arterial dilation: inc coronaries).  
**Use:** 2° prevention of ischaemic TIA/CVA¹, Px of TE from prosthetic valves (as adjunct to warfarin)².  
**Caution:** recent MI, angina (if unstable), aortic stenosis, coagulation disorders, ↓BP, MG*, migraine (may worsen), H/B.  
**SE:** GI upset, dizziness, myalgia, headache, ↓BP, ↑HR, hot flushes, rarely worsening of IHD, hypersensitivity (rash, urticaria, bronchospasm, angioedema), ↑postoperative bleeding, ↓Pt.  
**Interactions:** ↓s fx (but ↑s hypotensive fx) of cholinesterase inhibitors*, ↑s fx of adenosine. W +.  
**Dose:** 200 mg bd po as MR preparation (Persantin Retard)¹,²; 100–200 mg tds po². All doses to be taken with food.  

**DISODIUM ETIDRONATE** see Pamidronate.
DISODIUM PAMIDRONATE  see Pamidronate.

DISULFIRAM/ANTABUSE
Alcohol dehydrogenase inhibitor: \( \Rightarrow \) systemic acetaldehyde \( \Rightarrow \) unpleasant SE when alcohol ingested (inc small amounts \( : \) care with alcohol-containing medications, foods, toiletries).

**Use:** alcohol withdrawal (maintenance of).

**CI:** Hx of IHD or CVA, HTN, psychosis, \( \uparrow \) suicide risk, severe personality disorder, H/P/B.

**Caution:** DM, epilepsy, respiratory disease, L/R.

**SE:** only if alcohol ingested – N&V, flushing, headache, \( \uparrow \) HR, \( \downarrow \) BP (\( \pm \) collapse if xs alcohol intake).

**Interactions:** \( \uparrow \)s fx of phenytoin, \( \uparrow \) toxicity with paraldehyde W +.

**Dose:** initially 200 mg od, \( \uparrow \) dose if needed: max. 500 mg po od Review if >6 months.

**NB:** Must have consumed no alcohol within at least 24 h of 1st dose. Prescribe under specialist supervision.

DOBUTAMINE
Inotropic sympathomimetic: mostly \( \beta_1 \) fx \( \Rightarrow \) contractility. \( \downarrow \) fx on HR compared with dopamine.

**Use:** shock (cardiogenic, septic).

**Caution:** Avoid in phaeo. severe \( \downarrow \) BP, arrhythmias, AMI.

**SE:** \( \uparrow \) HR, \( \uparrow \) BP (if xs Rx), phlebitis, \( \downarrow \) Pt.

**Interactions:** risk of \( \uparrow \) BP crisis with \( \beta \)-blockers (esp if ‘non-selective’).

**Dose:** 2.5–10 microgram/kg/min ivi, titrating to response (via central line, preferably with invasive cardiac monitoring). Often given with dopamine; seek expert help.

DOCUSATE SODIUM
Stimulant laxative: \( \Rightarrow \) GI motility (also a softening agent).

**Use/Caution/SE:** see Senna (CI if GI obstruction).

**Dose:** 50–100 mg up to tds po (max 500 mg/day). Also available as enemas \( \text{SPC/BNF} \).
DOMPERIDONE
Antiemetic: D₂ antagonist – inhibits central nausea chemoreceptor trigger zone. Poor BBB penetration. ↓central SEs (extrapyramidal fx, sedation) cf other dopamine antagonists.

**Use:** N&V, esp 2° to chemotherapy or ‘morning-after pill’, and in Parkinson’s disease or migraine. Rarely for gastro-oesophageal reflux and dyspepsia.

**Cl:** prolactinoma, when GI obstruction harmful, drugs that ↑QTc L.

**Caution:** GI obstruction R/P/B.

**SE:** ↑QTc, rash, allergy, ↑prolactin (can ⇒ gynaecomastia, galactorrhoea and hyperprolactinoma). Rarely ↓libido, dystonia and extrapyramidal fx.

**Dose:** 10 mg tds po (can ↑to max 20 mg qds); 60 mg bd pr. Not available im/iv. NB: ↓dose if RF.

DONEPEZIL/ARICEPT
Acetylcholinesterase inhibitor (reversible); see Rivastigmine.

**Use:** Alzheimer’s disease: mild or moderate NICE.

**Cl:** P/B.

**Caution:** supraventricular conduction dfx (esp SSS), ↑risk of PU (e.g. Hx of PU or NSAID), COPD/asthma, extrapyramidal symptoms can worsen, L.

**SE:** cholinergic fx (see p. 276), GI upset (esp initially), insomnia (if occurs, change dose to mane), headache, fatigue, dizziness, syncope, rash, Ψ disturbances. Rarely ↓ or ↑BP, seizures, PU/GI bleeds, SAN/AVN block, hepatotoxicity.

**Interactions:** metab by P450. inhibitors and inducers on p. 279 could ↑ or ↓ levels, respectively; check BNF/SPC.

**Dose:** 5 mg nocte (↑to 10 mg after 1 month if necessary); specialist use only – need review for clinical response and tolerance. Continue only if MMSE remains 10–20 NICE.

DOPAMINE
Inotropic sympathomimetic: dose-dependent fx on receptors: low doses (2–3 microgram/kg/min) stimulate peripheral DA receptors but little else. ⇒ ↑renal perfusion*; higher doses (>5 microgram/kg/min)
also have β₁ fx (⇒ ↑contractility); even higher doses have α fx (⇒ vasoconstriction, but can worsen HF).

**Use:** shock, esp if AKI* or cardiogenic (e.g. post-MI or cardiac surgery).

**CI:** tachyarrhythmias, phaeo, ↑T₄.

**Caution:** correct hypovolaemia before giving.

**SE:** N&V, ↓ or ↑BP, ↑HR, peripheral vasoconstriction.

**Interactions:** fx ↑by cyclopropane and halogen hydrocarbon anaesthetics (are CI) or MAOIs (can ⇒ ↑↑BP; consider ↓↓dose of dopamine).

**Dose:** initially 2–5 microgram/kg/min ivi (via central line, preferably with invasive cardiac monitoring), then adjust to response; seek specialist help.

---

**DORZOLAMIDE/TRUSOPT**

Topical carbonic anhydrase inhibitor: as acetazolamide (oral preparation, which is more potent but has ↑SEs*).

**Use:** glaucoma (esp if β-blocker or PG analogue CI or fails to ↓IOP).

**CI:** ↑Cl⁻ acidosis, R (severe only), P/B.

**Caution:** Hx of renal stones†, L.

**SE:** local irritation & allergic reactions, blurred vision, bitter taste, rash. Rarely* systemic SEs (esp urolithiasis†) and interactions; see Acetazolamide.

**Dose:** apply 2% drop tds (bd with topical β-blocker). Available as combination drop with timolol 0.5% (*Cosopt*).

---

**DOXAPRAM**

Respiratory stimulant: ↑s activity of respiratory and vasomotor centres in medulla ⇒ ↑depth (and, to lesser extent, rate) of breathing. Also indirect fx by stimulation of chemoreceptors in aorta and carotid artery.

**Use:** hypoventilation, life-threatening respiratory failure – usually only if dt transient/reversible cause, e.g. post-operative/-general anaesthetic or acute deterioration with known precipitant. Mostly used in preventing respiratory depression ²° to ↑FiO₂ used in severe respiratory acidosis (can be harmful if CO₂ ↓ or normal).
**Cl:** severe asthma or HTN, IHD, ↑T₄, epilepsy, physical obstruction of respiratory tract.

**Caution:** if taking MAOIs, phenelzine L/H/P.

**SE:** headache, flushing, chest pains, arrhythmias, vasoconstriction, ↑BP, ↑HR, laryngo-/broncho-spasm, cough, salivation, GI upset, dizziness, seizures.

**Dose:** specialist use only (mostly in ITU).

▼ **DOXAZOSIN/CARDURA**

α₁-Blocker ⇒ systemic vasodilation and relaxation of internal urethral sphincter . ⇒ ↓TPR¹ and ↑bladder outflow².

**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235), BPH².

**Cl:** postural ↓BP, anuria B.

**Caution:** postural ↓BP, micturition syncope, L/H/P/E.

**SE:** postural ↓BP (esp after 1st dose*), dizziness, headache, urinary incontinence (esp women), GI upset (esp N&V), drowsiness/fatigue, syncope, mood Δs, dry mouth, oedema, somnolence, blurred vision, rhinitis. Rarely erectile dysfunction, ↑HR, arrhythmias, hypersensitivity/rash. Chronic Rx ⇒ beneficial lipid Δs (↑HDL, ↓LDL, ↓VLDL, ↓TG, ↓Pt, ↓NØ).

**Interactions:** ↑s hypotensive fx of diuretics, β-blockers, Ca²⁺ antagonists, silden-/tadal-/vardenafil, general anaesthetics, moxisylyte and antidepressants.

**Dose:** initially 1 mg od (give 1st dose before bed*), then slowly ↑according to response (max 16 mg/day¹ or 8 mg/day²). 4 mg or 8 mg od if MR preparation, as Cardura XL.

**DOXYCYCLINE**

Tetracycline antibiotic: inhibits ribosomal (30S) subunit. Has longest t₁/₂ of all tetracyclines . od dosing.

**Use:** genital infections, esp syphilis, chlamydia, PID, salpingitis, urethritis (non-gonococcal). Also *Rickettsia* (inc Q fever), *Brucella*, Lyme disease (*Borrelia burgdorferi*), malaria (Px/Rx, not 1st-line), mycoplasma (genital/respiratory), COPD infective exac (*H. influenzae*), MRSA infection (if mild, sensitive strain).
**Cl/Caution/SE/Interactions:** as tetracycline, but can give with caution if RF, although is also CI in SLE and achlorhydria. Can ⇒ anorexia, flushing, tinnitus and can ↑ciclosporin levels.

**Warn:** avoid UV light and Zn-/Fe-containing products (e.g. antacids).

**Dose:** 100–200 mg od/bd

**▼ DULOXETINE/CYMBALTA**¹,²,³ or **YENTREVE**⁴
SHT and noradrenaline reuptake inhibitor.

**Use:** depression¹, generalised anxiety disorder², diabetic neuropathy³ (review need ≤3 monthly and stop if inadequate response after 2 months), stress urinary incontinence⁴ (assess benefit/tolerability after 2–4 wks).

**Cl:** R (avoid if creatinine clearance <30 ml/min) L/P/B.

**Caution:** cardiac disease, Hx of mania or seizures, ↑IOP, susceptibility to angle closure glaucoma, bleeding disorders/on drugs ↑ing bleeding risk, H/P/B/E.

**SE:** N&V&C, abdominal pain, dyspepsia, WtΔ, ↓appetite, palpitations, hot flushes, insomnia, sexual dysfunction, suicidal behaviour.

**Interactions:** metabolism ↓by ciprofloxacin, fluvoxamine. ↑5HT fx with St John’s wort and antidepressants (esp moclobemide and MAOIs; avoid concomitant use and don’t start for 1 wk after stopping duloxetine). Avoid with artemether/lumefantrine. ↑risk CNS toxicity with sibutramine.

**Warn:** patient not to stop suddenly*.

**Dose:** 60 mg od¹; initially 30 mg od (↑to max 120 mg/day if required)²; 60 mg od (↑to bd if required)³; 40 mg bd⁴.

**EDROPHONIUM**
Short-acting cholinesterase antagonist, given iv during Tensilon test for Dx of MG: look for ↓signs (e.g. ↑power, ↓ptosis).

**ENALAPRIL/INNOVACE**
ACE-i.

**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235), LVF².
**Cl/ Caution/ SE/ Interactions:** as Captopril, plus L.

**Dose:** initially 5 mg od1 (2.5 mg od2) ↑ing according to response max 40 mg/day. NB: ↓dose elderly, taking diuretics or RF.

### ENOXAPARIN/CLEXANE
Low-molecular-weight heparin (LMWH).

**Use:** DVT/PE Rx1 and Px2 (inc pre-operative), ACS (with aspirin)3.

**Cl/ Caution/ SE/ Monitor/ Interactions:** as Heparin, plus B.

**Dose:** (all sc; 1 mg = 100 units) 1.5 mg/kg od1, 40 mg od (20 mg od if not high risk)2, 1 mg/kg bd3.

Consider monitoring anti-Xa (3–4 h post dose) and ↓dose if RF (i.e. creatinine >150), pregnancy, Wt >100 kg or <45 kg; see p. 209.

**ENSURE** Protein and calorie supplement drinks.

**EPADERM** Paraffin-based emollient ointment for very dry skin (and as soap substitute).

**EPILIM** see Valproate.

**EPINEPHRINE** see Adrenaline.

**EPOETIN** see Erythropoietin (recombinant form for ↓Hb).

**EPROSARTAN/TEVETEN**
Angiotensin II antagonist; see Losartan.

**Use:** HTN (for advice on stepped HTN Mx see p. 235)

**Cl:** L (if severe), P/B.

**Caution/ SE/ Interactions:** see Losartan.

**Dose:** 600 mg od (max 800 mg od). Start at 300 mg and then ↑as required if elderly, RF or LF.

**EPTIFIBATIDE/INTEGRILIN**
Antiplatelet agent: glycoprotein IIb/IIIa receptor inhibitor – stops binding of fibrinogen and inhibits platelet aggregation.

**Use:** Px of MI in unstable angina or NSTEMI (if last episode of chest pain w/in 24 h), esp if high risk and awaiting PCI NICE (see p. 233).
ERYTHROMYCIN
Macrolide antibiotic: binds 50S ribosome.
Use: atypical pneumonias (with other agents; see p. 244), rarely Chlamydia/other GU infections, Campylobacter enteritis. Often used if allergy to penicillin.

ERGOCALCIFEROL (= CALCIFEROL)
Vit D₂: needs renal (1) and hepatic (25) hydroxylation for activation.
Use: vitamin D deficiency.
Cl: ↑Ca²⁺, metastatic calcification.
Caution: R (if high ‘pharmacological’* doses used), B.
SE: ↑Ca²⁺. If over-Rx: GI upset, weakness, headache, polydipsia/polyuria, anorexia, RF, arrhythmias.
Monitor: Ca²⁺ (esp if N&V develops or ↑doses in RF*).
Interactions: fx ↓by anticonvulsants and ↑by thiazides.
Dose: 10–20 microgram (400–800 units) od as part of multivitamin preparations or combined with calcium lactate or phosphate as ‘calcium + ergocalciferol’: non-proprietary preparations available but is often prescribed by trade name (e.g. Cacit D₃, or Calcichew D₃). ↑doses of 0.25–1.0 mg od (of ‘pharmacological strength’ preparations*) used for GI malabsorption and chronic liver disease (up to 5 mg daily for ↓PTH or renal osteodystrophy).

*Specify strength of tablet required to avoid confusionSPC/BNF.
**Cl**: macrolide hypersensitivity or if taking terfenadine, pimozide, ergotamine or dihydroergotamine.

**Caution**: ↑QTc (inc drugs that predispose to), porphyria, L/R/P/B.

**SE**: GI upset (rarely AAC), dry itchy skin, hypersensitivity (inc SJS, TEN), arrhythmias (esp VT), chest pain, reversible hearing loss (dose-related, esp if RF), cholestatic jaundice.

**Interactions**: ↓P450 ∴ many; most importantly ↑s levels of ciclosporin, digoxin, theophyllines and carbamazepine, W +.

**Dose**: 500 mg qds po (250 mg qds if mild infection, 1 g qds if severe); 50 mg/kg daily iv in 4 divided doses.

**NB**: venous irritant ∴ give po if possible.

**ERYTHROPOIETIN**

Recombinant erythropoietin.

**Use**: ↓Hb 2° to CRF or chemotherapy (AZT or platinum-containing). Also unlicensed use for myeloma, lymphoma and certain myelodysplasias. 3 types: α (Eprex), β (NeoRecormon) and longer-acting darbepoetin (Aranesp).

**SE**: ↑BP, ↑K⁺, headache, arthralgia, oedema, TE. Rarely ⇒ red cell aplasia (esp subcutaneous Eprex if RF, which is now CI) 🤔.

**CI/Caution/Dose**: specialist use only SPC/BNF; given subcutaneously (self-administered) or iv (as inpatient). ↓Fe/folate (monitor), ↑Al, infections and inflammatory disease can ↓response. NB: transfusion is 1st-line Rx for ↓Hb 2° to cancer chemotherapy.

**ESCITALOPRAM/CIPRALEX**

SSRI (active enantiomer of citalopram).

**Use**: Depression, OCD, anxiety disorders.

**CI/Caution/SE/Warn/Interactions**: as citalopram.

**Dose**: initially 10 mg od, ↑ing if necessary to 20 mg od. NB: max dose 10 mg in elderly and halve doses in LF and for most anxiety disorders.

**ESMOLOL**

β-blocker: cardioselective (β₁ > β₂) and short-acting*.

**Use**: SVTs (inc AF, atrial flutter, sinus ↑HR), HTN (esp peri-operatively), acute MI (*safer than long-acting preparations).

**CI/Caution/SE/Interactions**: see Propranolol.
**Ethambutol**

Anti-TB antibiotic: inhibits cell-wall synthesis (‘static’).

**Use:** TB initial Rx phase (1st 2 months) *if isoniazid resistance known or suspected* (see pp. 267) as part of combination drugs.

**Cl/Caution/Interactions:** optic neuritis, ↓vision.

**Caution:** R (monitor levels* and ↓dose if creatinine clearance <30 ml/min), P/E.

**SE:** neuritis; peripheral and optic (can ⇒ ↓visual acuity**, colour-blindness, ↓visual fields : ⇒ baseline and regular ophthalmology review). Rarely GI upset, skin reactions, ↓Pt.

**Warn:** patient to report immediately any visual symptoms – use alternative drug if unable to do this (e.g. very young, ↓IQ).

**Monitor:** visual acuity** (inc baseline before Rx), plasma levels*.

**Dose:** 15 mg/kg od (30 mg/kg 3 times a week if ‘supervised’ Rx)\(^{SPC/BNF}\).

NB: ↓dose if RF.
ETOMIDATE
Intravenous anaesthetic.

Use: induction of anaesthesia.

CI: anaesthetist not confident of airway maintenance

Caution: acute porphyria, produces fx in one arm-brain circulation, hypovolaemia cardiovascular disease. Can cause apnoea & ↓BP.

SE: N&V, apnoea, ↓BP (esp on induction), hyperventilation, stridor, rash, dyskinesia, extraneous muscle movements (minimised with opioid or benzodiazepine just before induction), pain on injection, ↓s adrenocortical function (not for maintenance anaesthesia or in sepsis), seizure, cardiac arrest.

Warn: injection painful, don’t drive for 24h.

Monitor: cardiac and respiratory function.

Interactions: ↑s hypotensive effect with adrenergic neurone blockers, α-blockers, antipsychotics, verapamil. Alfentanil ↑s levels.

Dose: titrated to effect except during ‘rapid sequence induction’;

PREPARATION DEPENDENT: Etomidate-Lipuro:
150–300 micrograms/kg iv (slow).

Hypnomidate: 300 micrograms/kg (max. total dose 60 mg) iv slow. ↓ Dose if elderly (150–200 micrograms/kg) or LF.

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

ETORICOXIB/ARCOXIA
NSAID which selectively inhibits COX-2. ↓GI SEs (COX-1 mediated). Provides no Px against IHD/CVA (unlike aspirin).

Use: osteo/rheumatoid arthritis NICE, ankylosing spondylitis, acute gout.

CI/Caution/SE/Interactions: as celecoxib (except fluconazole interaction), plus CI in uncontrolled HTN (persistently >140/90 mmHg) – monitor BP w/in 2 wks of starting & regularly thereafter. Also ↑s ethinylestradiol levels. Not CI in sulphonamide hyper-sensitivity. Mild [W +].
**Dose:** 30–60 mg od\(^1\); 90 mg od\(^2\); 120 mg od\(^3\) for max 8 days. 
**NB:** ↓dose if LF.

**EUMOVATE** see Clobetasone butyrate 0.05%; steroid cream.

**FANSIDAR**
Antimalarial: combination tablet of pyrimethamine (25 mg) + sulfadoxine (500 mg).
**Use:** Rx of falciparum malaria (with or following quinine).
**Cl:** sulphonamide or pyrimethamine allergy, porphyria.
**Caution:** blood disorders, asthma, G6PD deficiency, \(L/R/P/B/E\).
**SE:** blood disorders, skin reactions\(^*\), pulmonary infiltrates, insomnia, GI upset, nephrotoxicity, hepatotoxicity, hypersensitivity.
**Monitor:** FBC (if chronic Rx) and for rash\(^*\) or cough/SOB (stop drug).
**Dose:** see BNF/SPC.

**FELODIPINE/PLENDIL**
Ca\(^{2+}\) channel blocker (dihydropyridine): as amlodipine but \(\Rightarrow \) HF/–ve inotropic fx.
**Use:** HTN\(^1\) (for advice on stepped Mx see p. 235), angina Px\(^2\).
**Cl:** IHD (if unstable angina or w/in 1 month of MI), significant aortic stenosis, acute porphyria, \(H\) (if uncontrolled)/\(P\).
**Caution:** stop drug if angina/HF worsen, \(L/B\).
**SE:** as nifedipine but \(\uparrow\)ankle swelling and possibly \(\downarrow\)vasodilator fx (headache, flushing and dizziness).
**Interactions:** metab by \(P450\). levels \(\uparrow\)by cimetidine, erythromycin, ketoconazole and grapefruit juice. Hypotensive fx \(\uparrow\)by \(\alpha\)-blockers. Levels \(\downarrow\)by primidone. \(\uparrow\)s fx of tacrolimus.
**Dose:** initially 5 mg od, \(\uparrow\)if required to 10 mg (max 20 mg\(^1\)).
**NB:** ↓dose if LF or elderly.

**FENTANYL**
Strong opioid; used in severe chronic/palliative pain (top/sl/buccal/nasal spray) and in anaesthesia (iv).
CI: acute respiratory depression, risk of ileus, ↑ICP/head injury/coma.
Caution: all other conditions where morphine is CI or cautioned, but better tolerated in RF. Also DM, cerebral tumour.
SE: as morphine but generally ↓N&V/constipation.
Interactions: as morphine but levels ↑(not ↓) by ritonavir, levels ↑by itra-/flu-conazole & no known interaction with gabapentin. May ↑levels of midazolam.
Warn: patients/carers of signs/symptoms of opiate toxicity.
Dose: Patches: last 72 h and come in 5 strengths: 12, 25, 50, 75 and 100, which denote release of microgram/h (to calculate initial dose, these are approx equivalent to daily oral morphine requirement of 45, 90, 180, 270 and 360 mg, respectively).
Lozenges (buccal) for ‘breakthrough’ pain as Actiq: initially 200 microgram over 15 min, repeating after 15 min if needed and adjusting dose to give max 4 lozenges daily (available as 200, 400, 600, 800, 1200 or 1600 microgram).
Tablets: for ‘breakthrough’ pain as ▼ Effentora (buccal) or ▼ Abstral(sl) 100, 200, 400, 600 and 800 microgramSPC/BNF.
Only use if taking regular opioids (fatalities reported otherwise).
If >4 doses/day needed, adjust background analgesia.
Nasal spray: for ‘breakthrough’ pain as ▼ Instanyl or ▼ PecFent SPC/BNF.
NB: ↓dose if LF or elderly. No initial ↓dose needed in RF, but may accumulate over time. Unless given iv has prolonged onset/offset; use only when opioid requirements stable & cover 1st 12 hrs after initial Rx with prn short acting opioid. Only for use if have previously tolerated opioids. If serious adverse reactions remove patch immediately and monitor for up to 24 h. Fever/external heat can ⇒ ↑absorption (: ↑fx) from patches.

FERROUS FUMARATE
As ferrous sulphate, but ↓GI upset; available in UK as Fersaday (322-mg tablet od as Px or bd as Rx), Fersamal (1–2 tablets of 210 mg tds) or Galfer (305 mg capsule od/bd).
FERROUS GLUCONATE
As ferrous sulphate, but ↓GI upset. Px: 600 mg od; Rx: 1.2–1.8 g/day in 2–3 divided doses.

FERROUS SULPHATE
Oral Fe preparation.
**Use:** Fe-deficient ↓Hb Rx/Px.
**Caution:** P.
**SE:** dark stools (can confuse with melaena, which smells worse (!) and is always unformed), GI upset (esp nausea; consider switching to ferrous gluconate/fumarate or take with food, but latter can ⇒ ↓absorption), Δ bowel habit (dose-dependent).
**Dose:** Rx: 200 mg bd/tds. Px: 200 mg od.

FINASTERIDE
Antiandrogen: 5-α-reductase inhibitor; ↓s testosterone conversion to more potent dihydrotestosterone.
**Use:** BPH¹ (↓s prostate size and symptoms), male-pattern baldness².
**Caution:** Ca prostate (can ⇒ ↓PSA and ↓ mask), obstructive uropathy, P (teratogenic; although not taken by women, partners of those on the drug can absorb it from handling crushed tablets and from semen, in which it is excreted ↓. females must avoid handling tablets, and sexual partners of those on the drug must use condoms if, or likely to become, pregnant).
**SE:** sexual dysfunction, testicular pain, gynaecomastia, hypersensitivity (inc swelling of lips/face).
**Dose:** 5 mg od¹ (Proscar), 1 mg od² (Propecia).

FLAGYL see Metronidazole; antibiotic for anaerobes

FLECAINIDE
Class Ic antiarrhythmic; local anaesthetic; ↓s conduction.
**Use:** VT¹ (if serious and symptomatic), SVT² (esp junctional re-entry tachyarrhythmias and paroxysmal AF).
**CI:** SAN dysfunction, atrial conduction dfx, HB (not 1st-degree), BBB, AF post-cardiac surgery, chronic AF (with no attempts at
Common/useful drugs

Caution: pacemakers, ensure e’lytes normalised before use,

SE: GI upset, syncope, dyspnoea, oedema, vision/mood disturbances. Rarely arrhythmias.

Monitor: pre-dose plasma levels in LF or RF (keep at 0.2–1 mg/l), ECG if giving iv.

Interactions: levels ↑d by amiodarone, ritonavir, fluoxetine and quinine. ↑s digoxin levels. Myocardial depression may occur with β-blockers/verapamil. ↑risk of arrhythmias with antipsychotics, TCAs, artemether/lumefantrine and dolasetron.

Dose: initially 100 mg bd po, ↓ing after 3–5 days if possible (max 400 mg/day)¹; 50 mg bd po, ↑ing if necessary to 300 mg/day². Acutely, 2 mg/kg iv over 10–30 min (max 150 mg), then (if required) 1.5 mg/kg/hi for 1 h, then ↓ing to 100–250 microgram/kg/h for up to 24 h, then give po (max cumulative dose in 1st 24 h = 600 mg). With ECG monitoring. NB: ↓dose if LF/RF. Drug initiated under consultant supervision.

Fleet (Phospho-Soda) see Bowel preparations.

Dose: 45 ml (mixed with 120 ml water, then followed by 240 ml water) taken twice: for morning procedures, at 7 am and 7 pm the day before; for afternoon procedures, at 7 pm the day before and at 7 am on the day of procedure.

Flixotide see Fluticasone (inh steroid). 50, 100, 250 or 500 microgram/puff as powder. 50, 125 or 250 microgram/puff as aerosol.

Dose: 100–2000 microgram/day⁶⁵⁶⁷⁸⁹ (aerosol doses ?<powder doses).

Flomaxtra XL see Tamsulosin; α₁-blocker for ↑prostate.

Flucloxacillin

Penicillin (penicillinase-resistant).

Use: penicillin-resistant (β-lactamase-producing) staphylococcal infections, esp skin¹ (surgical wounds, iv sites, cellulitis, impetigo,
otitis externa), rarely as adjunct in pneumonia\(^1\). Also osteomyelitis\(^2\), endocarditis\(^3\).

**CI/Caution/SE/Interactions:** as benzylpenicillin, plus CI if Hx of flucloxacillin-associated jaundice/hepatic dysfunction and caution if LF, as rarely ⇒ hepatitis or **cholestatic jaundice** (may develop up to 2 months after Rx stopped).

**Dose:** 250–500 mg qds po/im (or up to 2 g qds iv\(^1\); up to 2 g qds iv\(^2\); 2 g qds (4-hrly if Wt > 85 kg) iv\(^3\).

**NB:** ↓dose in severe RF.

### FLUCONAZOLE

Triazole antifungal: good po absorption and CSF penetration.

**Use:** fungal meningitis (esp cryptococcal), candidiasis (mucosal, vaginal, systemic), other fungal infections (esp tinea, pityriasis).

**Caution:** susceptibility to \(\uparrow\)\(\text{QTc}\), \(L/R/P/B\).

**SE:** GI upset, hypersensitivity (can ⇒ angioedema, TEN, SJS, anaphylaxis: if develops rash, stop drug or monitor closely), hepatotoxicity, headache. Rarely blood/metabolic (\(\uparrow\)lipids, \(\downarrow\)\(\text{K}^+\)) disorders, dizziness, seizures, alopecia.

**Monitor:** LFTs; stop drug if features of liver disease develop.

**Interactions:** \(\downarrow\)\(\text{P450}\) \(\downarrow\)many; most importantly, \(\uparrow\)\(\text{s fx of theophyllines, ciclosporin, phenytoin and tacrolimus. Also \(\downarrow\) clopidogrel fx. W +}.

**Dose:** 50–400 mg/day po or iv according to indication\(\text{SPC/BNF}\).

**NB:** ↓dose in RF.

### FLUDROCORTISONE

Mineralocorticoid (also has glucocorticoid actions).

**Use:** adrenocortical deficiency, esp Addison’s disease\(^1\).

**CI/Caution/Interactions:** See Prednisolone.

**SE:** \(\text{H}_2\text{O/Na}^+\) retention, \(\downarrow\)\(\text{K}^+\) (monitor U&Es). Also can ⇒ immunosuppression (and other SEs of corticosteroids; see p. 217).

**Dose:** 50–300 microgram/day po\(^1\).
FLUMAZENIL
Benzodiazepine antagonist (competitive).

**Use:** benzodiazepine OD/toxicity (only if respiratory depression and ventilatory support not immediately available).

**CI:** life-threatening conditions controlled by benzodiazepines (e.g. ↑ICP, status epilepticus).

**Caution:** mixed ODs (esp TCAs), benzodiazepine dependence (may ⇒ withdrawal fx), Hx of panic disorder (can ⇒ relapse), head injury, epileptics on long-term benzodiazepine Rx (may ⇒ fits), L/P/B/E.

**SE:** N&V, dizziness, flushing, rebound anxiety/agitation, transient ↑BP/HR. Very rarely anaphylaxis.

**Dose:** initially 200 microgram iv over 15 sec, then, if required, further doses of 100 microgram at 1 min intervals. *Max total dose 1 mg (2 mg in ITU).* Can also give as ivi at 100–400 microgram/h adjusting to response. NB: see p. 284 for Rx of acute OD.

**NB:** short t½ (40–80 min); observe closely after Rx and consider further doses or ivi (at 0.1–0.4 mg/h adjusted to response).

---

Flumazenil is not recommended as a diagnostic test and should not be given routinely in overdoses as risk of inducing:

- fits (esp if epileptic, or if co-ingested drugs that predispose to fits)
- withdrawal syndrome (if habituated to benzodiazepines)
- arrhythmias (esp if co-ingested TCA or amphetamine-like drug).

If in any doubt get senior opinion and exclude habituation to benzodiazepines and get ECG before giving unless life-threatening respiratory depression and benzodiazepine known to be cause 🙄.

---

FLUOXETINE/PROZAC
SSRI antidepressant: long t½ compared with others*.

**Use:** depression¹, other Ψ disorders (inc bulimia², OCD³).

**CI:** active mania.
Caution: epilepsy, receiving ECT, Hx of mania or bleeding disorder (esp GI), heart disease, DM†, glaucoma (angle closure), ↑risk of bleeding, age <18 yrs L/R/H/P/B/E.

Class SEs: GI upset, ↓Wt, insomnia**, agitation**, headache, hypersensitivity. Can ⇒ withdrawal fx when stopped (see p. 277) ∴ stop slowly; more important for SSRIs with ↓t1/2*. Rarely extrapyramidal (see p. 278) and antimuscarinic fx (see p. 276), sexual dysfunction, convulsions, ↓Na+ (inc SIADH), blood disorders, GI bleed, serotonin syndrome (see p. 277) and suicidal thoughts/behaviour.

Specific SEs: rarely hypoglycaemia†, vasculitis (rash may be 1st sign). Warn: can ↓performance at skilled tasks (inc driving). Don’t stop suddenly (not as important as for other SSRIs).

Interactions: ↓P450 : many, but most importantly ↑s levels of TCAs, benzodiazepines, clozapine and haloperidol. ↑s lithium toxicity and ⇒ HTN and ↑CNS fx with sele-/rasa-giline (and other dopaminergics). ↑risk of CNS toxicity with drugs that ↑5HT (e.g. tramadol, sibutramine, sumatriptan, St John’s wort). ↑risk of bleeding with aspirin and NSAIDs. Levels ↑by ritonavir. Antagonises antiepileptics (but ↑s levels of carbamazepine and phenytoin). Avoid with artemether/lumefantrine and tamoxifen. ☠ Never give with, or ≤2 wks after, MAOIs ☠. (Mild W +.)

Dose: initially 20 mg1,3 (↑to max 60 mg) od; 60 mg od2 – give mane as can ↓sleep**.

NB: ↓dose in LF.

FLUTICASONE/FLIXOTIDE (various delivery devices availableBNF)
Inhaled corticosteroid for asthma: see Beclometasone.

Dose: 100–2000 microgram/day inh (or 0.5–2 mg bd as nebs).

1 microgram equivalent to 2 microgram of beclometasone or budesonide.

FOLIC ACID (= FOLATE)
Vitamin: building block of nucleic acids. Essential co-factor for DNA synthesis ⇒ normal erythropoiesis.
**Use:** megaloblastic ↓Hb Rx/Px if haemolysis/dialysis\(^1\) (or GI malabsorption where ↑doses may be needed), Px against neural-tube dfx in pregnancy\(^2\) (esp if on antiepileptics), Px of mucositis and GI upset if on methotrexate\(^3\).

**CI:** malignancy (unless megaloblastic ↓Hb due to ↓folate is an important complication).

**Caution:** undiagnosed megaloblastic ↓Hb (i.e. ↓B\(_{12}\), as found in pernicious anaemia) – never give alone if B\(_{12}\) deficiency as can precipitate subacute combined degeneration of spinal cord.

**SE:** GI disturbance (rare).

**Dose:** 5 mg od\(^1\) (in maintenance, ↓frequency of dose, often to wkly); 400 microgram od from before conception until wk 12 of pregnancy\(^2\) (unless mother has neural-tube defect herself or has previously had a child with a neural-tube defect, when 5 mg od needed); 5 mg once wkly\(^3\).

**FOMEPIZOLE** Antidote for toxic alcohols.

\[\text{**▼ FONDAPARINUX/ARIXTA**}\]

Anticoagulant; activated factor X inhibitor.

**Use:** ACS (UA, NSTEMI or STEMI), Px of VTE, Rx of DVT/PE.

**CI:** active bleeding, bacterial endocarditis.

**Caution:** bleeding disorders, active PU, other drugs that ↑risk of bleeding, recent intracranial haemorrhage, recent brain/ophthalmic/spinal surgery, spinal/epidural anaesthesia (avoid Rx doses), Wt <50 kg. **R** (avoid or ↓dose according to indication and creatinine clearance\(^\text{SPC/BNF}\), **L/P/B/E**).

**SE:** bleeding, ↓Hb, ↓(or ↑)Pt, coagulopathy, purpura, oedema, LFT Δs, GI upset. Rarely ↓K\(^+\), ↓BP, hypersensitivity.

**Dose:** UA/NSTEMI/Px of VTE 2.5 mg sc od (start 6-h post-op); STEMI 2.5 mg iv/ivi od for 1st day then sc; Rx of PE/DVT by Wt (<50 kg = 5 mg sc od, 50–100 kg = 7.5 mg sc od, >100 kg = 10 mg sc od). NB: Length of Rx depends on indication\(^\text{SPC/BNF}\), timing of doses post-op critical if Wt <50 kg or elderly. **Consider** ↓dose in RF.

Specialist use only: get senior advice or contact on-call cardiology/haematology.
FORMOTEROL (= EFORMOTEROL)/FORADIL, OXIS
Long-acting β2 agonist ‘LABA’; as Salmeterol plus L.
**Dose:** 6–48 microgram daily (mostly bd regime)\textsuperscript{SPC/BNF} inh (min/max doses vary with preparations\textsuperscript{SPC/BNF}).

FOSPHENYTOIN
Antiepileptic: prodrug of phenytoin; allows safer rapid loading.
**Use:** epilepsy (esp ‘status’ & seizures assoc with neurosurgery/head injury).
**CI/Caution/SE/Monitor/Warn/Interactions:** as phenytoin, but ↓SEs (esp ↓arrhythmias and ‘purple glove syndrome’).
**Dose:** as phenytoin, but prescribe as ‘phenytoin sodium equivalent’ and note \( \times \) fosphenytoin 1.5 mg = phenytoin 1 mg \( \times \).
**NB:** consider ↓dose in LF or RF.

FOSTAIR
Combination asthma inhaler: each puff contains 100 microgram beclomethasone (steroid) + 6 microgram formoterol (long-acting β2-agonist) in a metered dose inhaler.
**Dose:** 1–2 puffs bd inh.

\( \nabla \) FRAGMIN see \( \nabla \) Dalteparin; low-molecular-weight heparin.

FRUMIL see Co-amilofruse; tablets are 5/40 (5 mg amiloride + 40 mg furosemide) unless stated as LS (2.5/20) or generic (10/80).

FRUSEMIDE now called Furosemide.

FUROSEMIDE (previously Frusemide).
Loop diuretic: inhibits Na\(^+\)/K\(^+\) pump in ascending loop of Henle ⇒ ↓resorption and ∴ ↑loss of Na\(^+\)/K\(^+\)/Cl/H\(_2\)O.
**Use:** LVF (esp in acute pulmonary oedema, but also in chronic LVF/CCF or as Px during blood transfusion), resistant HTN (for advice on stepped HTN Mx see p. 235), oliguria secondary to AKI (after correcting hypovolaemia first).
**CI:** ↓↓K\(^+\), ↓Na\(^+\), Addison’s, cirrhosis (if precomatose), R (if anuria).
**Caution:** ↓BP, ↑prostate, porphyria, diabetes, L/P/B.
**SE:** ↓BP (inc postural), ↓K⁺, ↓Na⁺, ↓Ca²⁺, ↓Mg²⁺, ↓Cl alkalosis. Also ↑urate/gout, GI upset, ↑glucose/impaired glucose tolerance, ↑cholesterol/TGs (temporary). Rarely BM suppression (stop drug), RF, skin reactions, pancreatitis, tinnitus/deafness (if ↑doses or RF: reversible).

**Interactions:** ↑s toxicity of digoxin, flecainide, sotalol, NSAIDs, vancomycin, gentamicin and lithium. ↓fx of antidiabetics. NSAIDs may ↓diuretic response.

**Monitor:** U&Es; if ↓K⁺, add po K⁺ supplements/K⁺-spaving diuretic or change to combination tablet (e.g. co-amilo fruse).

**Dose:** usually 20–80 mg po/im/iv daily in divided doses. ↑doses used in acute LVF (see p. 234) and oliguria. If HF or RF, ivi (max 4 mg/min) can ⇒ smoother control of fluid balanceSPC/BNF. For blood transfusions, a rough guide is to give 20 mg with every unit if existing LVF, and with every 2nd unit if at risk of LVF. NB: may need ↑dose in RF.

Give iv if severe oedema: as bowel oedema ⇒ ↓po absorption.

---

**FUSIDIC ACID/FUCIDIN**

Antibiotic; good bone penetration and activity against *S. aureus*.

**Use:** osteomyelitis, endocarditis (2° to penicillin-resistant staphylococci) – needs 2nd antibiotic to prevent resistance.

**Caution:** biliary disease or obstruction (⇒ ↓elimination), L/P/B.

**SE:** GI upset, hepatitis*. Rarely: skin/blood disorders, AKI.

**Monitor:** LFTs* (esp if chronic Rx, ↑doses or LF).

**Dose:** 500 mg tds po (equivalent to 750 mg tds if using suspension) – in severe infection to ↑1 g tds po; 500 mg tds iv (6–7 mg/kg tds if Wt <50 kg). NB: ↓dose in LF.

---

**FUSIDIC ACID 1% EYE DROPS/FUCITHALMIC**

Topical antibiotic (esp vs. *Staphylococcus*); commonly used for blepharitis.

**Dose:** 1 drop bd.

---

**FYBOGEL**

Laxative: bulking agent (ispaghula husk) for constipation (inc IBS).

**CI:** ↓swallow, GI obstruction, faecal impaction, colonic atony.

**Dose:** 1 sachet or 10 ml bd after meals with water.
GABAPENTIN
Antiepileptic: similar structure to GABA but mechanism of action is different from drugs affecting GABA receptors.
**Use:** neuropathic pain, epilepsy (adjunctive Rx of partial seizures ± 2° generalisation).
**Caution:** Hx of psychosis or DM, R/P/B/E.
**SE:** fatigue/somnolence, dizziness, cerebellar fx (esp ataxia; see p. 278), dipl-/ambly-opia, headache, rhinitis. Rarely ↓WCC, GI upset, arthra-/my-algia, skin reactions, suicidal ideation.
**Interactions:** fx ↓by antidepressants and antimalarials (esp mefloquine). Antipsychotics reduce seizure threshold.
**Dose:** initially 300 mg od, ↑ing by 300 mg/day to max 3.6 g daily in 3 divided doses (NB: stop drug over ≥1 wk). NB: ↓dose in RF.

Can give false-positive urinary dipstick results for proteinuria.

GASTROCOTE Compound alginate for acid reflux.
**Dose:** 5–15 ml or 1–2 tablets after meals and at bedtime (NB: 2.13 mmol Na\(^+\)/5 ml and 1 mmol Na\(^+\)/tablet).

GAVISCON (ADVANCE) Alginate raft-forming oral suspension for acid reflux.
**Dose:** 5–10 ml or 1–2 tablets after meals and at bedtime (NB: 2.3 mmol Na\(^+\) and 1 mmol K\(^+\)/5 ml and 2.25 mmol Na\(^+\) and 1 mmol K\(^+\)/tablet).

Ensure good hydration, esp if elderly, GI narrowing or ↓GI motility.

GELOFUSINE
Colloid plasma substitute (gelatin-based) for iv fluid resuscitation (see p. 201). 1 l contains 154 mmol Na\(^+\) (but no K\(^+\)).

GENTAMICIN
Aminoglycoside: broad-spectrum ‘cidal’ antibiotic; inhibs ribosomal 30S subunit. Good Gram-negative aerobe/staphylococci cover; other organisms often need concurrent penicillin ± metronidazole.
**Use:** severe infections, esp sepsis, meningitis, endocarditis. Also pyelonephritis/prostatitis, biliary tract infections, pneumonia.
**Cl:** MG*.
**Caution:** obesity, R/P/B/E.
**SE:** ototoxic, nephrotoxic (dose- and Rx length-dependent), hypersensitivity, rash. Rarely AAC, N&V, seizures, encephalopathy, blood disorders, myasthenia-like syndrome* (at ↑doses; reversible), ↓ Mg²⁺ (if prolonged Rx).
**Monitor:** serum levels** after 3 or 4 doses (earlier if RF).
**Interactions:** fx (esp toxicity) ↑by loop diuretics (esp furosemide), cephalosporins, vancomycin, amphotericin, ciclosporin, tacrolimus and cytotoxics; if these drugs must be given, space doses as far from time of gentamicin dose as possible. ↑s fx of muscle relaxants and anticholinesterases. W +.

**Dose:** once daily regimen: initially 5–7 mg/kg ivi adjusting to levels (NB: consult local protocol; od regimen not suitable if endocarditis, >20% total body surface burns or creatinine clearance <20 ml/min).
**Multiple daily regimen:** 3–5 mg/kg/day in 3 divided doses im/iv/ivi (if endocarditis give 1 mg/kg tds iv).

NB: ↓doses if RF (and consider if elderly or ↑↑BMI), otherwise adjust according to serum levels*: call microbiology department if unsure.

**Gentamicin levels:** Measure peak at 1 h post-dose (ideally = 5–10 mg/l) and trough immediately predose (ideally ≤2 mg/l). Halve ideal peak levels if for endocarditis. If levels high, can ↑spacing of doses (as well as ↓ing amount of dose); as ⇒↑risk of ototoxicity, monitor auditory/vestibular function. **NB: od regimens usually only require pre-dose level.**

**GLIBENCLAMIDE**
Oral antidiabetic (long-acting sulphonylurea): ↑s pancreatic insulin release – stimulates β islet cell receptors (and inhibits gluconeogenesis).

**Use:** type 2 DM; requires endogenous insulin to work. Not recommended for obese* (use metformin) or elderly** (use short-acting preparations, e.g. gliclazide).

**Cl:** ketoacidosis, acute porphyria, L/R (if either severe, otherwise caution), P/B.
Caution: may need to replace with insulin during intercurrent illness/surgery, porphyria, E.
SE: hypoglycaemia (esp in elderly**), GI upset, Wt*. Rarely hypersensitivity (inc skin) reactions, blood disorders, hepatotoxicity and transient visual Ds (esp initially).
Interactions: fx ↑d by chloramphenicol, sulphonamides (inc co-trimoxazole), sulfinpyrazone, antifungals (esp flu-/mic-onazole), warfarin, fibrates and NSAIDs. Levels ↓by rifampicin/rifabutin. ↑Risk of hepatotoxicity with bosentan.
Dose: initially 5 mg mane (with food), ing as necessary (max 15 mg/day).
NB: ↓dose in severe LF.

GLICLAZIDE
Oral antidiabetic (short-acting sulphonylurea).
Use/CI/Caution/SE/Interactions: as glibenclamide, but shorter action* and hepatic metabolism** mean ↓d risk of hypoglycaemia (esp in elderly* and RF**).
Dose: initially 40–80 mg mane (with food), ing as necessary (max 320 mg/day). MR tablets available (Diamicron MR) of which 30 mg has equivalent effect to 80 mg of normal release (dose initially is 30 mg od, ing if necessary to max 120 mg od). NB: ↓dose in RF or severe LF.

GLIMEPIRIDE
Oral antidiabetic (short-acting sulphonylurea).
Use/CI/Caution/SE/Interactions: as gliclazide, plus manufacturer recommends monitoring of FBC and LFTs. CI in severe LF. May need to substitute with insulin; seek specialist advice.
Dose: initially 1 mg mane (with food), ing as necessary (max 6 mg/day).

GLIPIZIDE
Oral antidiabetic (short-acting sulphonylurea).
**Use/CI/Caution/SE/Interactions:** as gliclazide, plus avoid if both L and R.

**Dose:** initially 2.5–5.0 mg mane (with food), ↑ing as necessary (max single dose 15 mg; max daily dose 20 mg).

**NB:** ↓dose in severe LF and RF.

---

**GLUCAGON**

Polypeptide hormone: ↑s hepatic glycogen conversion to glucose.

**Use:** hypoglycaemia: if acute and severe, esp if no iv access or if 2° to xs insulin (see p. 251).

**CI:** phaeo.

**Caution:** glucagonomas/insulinomas. Will not work if hypoglycaemia is chronic (inc starvation) or 2° to adrenal insufficiency.

**SE:** N&V&D, ↓BP, ↓K⁺, rarely hypersensitivity, W +.

**Dose:** 1 mg (= 1 unit) im (or sc/iv)⁴PC/BNF.

Often stocked in cardiac arrest (‘crash’) trolleys.

---

**GLYCEROL (= GLYCERIN) SUPPOSITORIES**

Rectal irritant bowel stimulant.

**Use:** constipation: 1st-line suppository if oral methods such as lactulose and senna fail.

**Dose:** 1–2 pr prn.

---

**GLYCERYL TRINITRATE** see GTN.

---

**GRANISETRON**

Antiemetic: 5HT₃ antagonist.

**Use:** N&V; see Ondansetron.

**Caution:** GI obstruction (inc subacute), ↑QTc, P/B.

**SE:** constipation (or diarrhoea), headache, sedation, fatigue, dizziness. Rarely seizures, chest pain, ↓BP, Δ LFTs, rash, hypersensitivity.

**Dose:** 1 mg bd or 2 mg od po/iv/ivi for non-specialist use. 2–3 mg loading doses often given before chemotherapy⁴PC/BNF (max 9 mg/24 h).
**GTN (≡ GLYCERYL TRINITRATE)**

Nitrate: ⇒ coronary artery + systemic vein dilation ⇒ ↑O₂ supply to myocardium and ↓preload, ↓↓O₂ demand of myocardium.

**Use:** Angina, LVF.

**Cl:** ↓BP, ↓↓Hb, aortic/mitral stenosis, constrictive pericarditis, tamponade, HCM, glaucoma (closed-angle), hypovolaemia, ↑ICP.

**Caution:** recent MI, ↓T₄, hypothermia, head trauma, cerebral haemorrhage, malnutrition, L/R (if either severe).

**Se:** ↓BP (inc postural), headache, dizziness, flushing, ↑HR.

**Interactions:** 😱 sildenafil, tadalafil and vardenafil (are CI as ⇒ ↓↓BP) 😱. ↓s fx of heparins (if given iv).

**Warn:** may develop tolerance with ↓therapeutic effect (esp if long-term transdermal patch use) and don’t stop abruptly.

**Dose:** 2 sprays or tablets sl prn (also available as transdermal SR patches). For acute MI/LVF: 10–200 microgram/min iv, titrating to clinical response and BP (see p. 234).

---

**HALOPERIDOL**

Butyrophenone (‘typical’) antipsychotic: dopamine antagonist (D₂ and 3 > D₁ and 4). Also blocks serotonin (5HT₂A), histamine (H₁), adrenergic (α₁ > 2) and muscarinic receptors, causing many SEs.

**Use:** acute sedation (e.g. agitation and behavioural disturbance), schizophrenia/bipolar disorder, N&V.

**Cl/Caution/Se:** as chlorpromazine, but ⇒ ↑incidence of extrapyramidal fx (see p. 278), although ⇒ ↓sedation, ↓skin reactions, ↓antimuscarinic fx, ↓BP fx, but can ⇒ hypoglycaemia and SIADH. Also risk of CNS toxicity with lithium.

**Interactions:** metab by P450 [many, but most importantly: levels ↑by fluoxetine, venlafaxine, quinidine, buspirone and ritonavir]. Levels ↓by carbamazepine, phenytoin, rifampicin. ↑risk of arrhythmias with amiodarone and ↓s fx of anticonvulsants.

**Dose:** 1.5–5.0 mg bd/tds po (max 30 mg/day); 2–10 mg im/iv 4–8-hrly (max 18 mg/day); 0.5–2.0 mg tds im/sc/iv. Also used im as a 4-wkly ‘depot’ if concerns over compliance. **NB:** ↓dose in severe RF or elderly.
Start at bottom of dose range if naive to antipsychotics, esp if elderly. See p. 219 for advice on acute sedation.

**HARTMANN’S SOLUTION**
Compound sodium lactate iv fluid. GIFTASUP guidelines recommend this over 0.9% NaCl in surgical patients for resuscitation or fluid replacement unless vomiting/gastric losses. 1 l contains 5 mmol K⁺, 2 mmol Ca²⁺, 29 mmol HCO₃, 131 mmol Na⁺, 111 mmol Cl⁻.

**HEPARIN**, standard/unfractionated (NB: ≠ LMWHs).
iv (and rarely sc) anticoagulant: potentiates protease inhibitor antithrombin III, which inactivates thrombin. Also inhibits factors IXa/Xa/XIa/XIIa.

**Use:** anticoagulation if needs to be immediate or quickly reversible (only as inpatient); DVT/PE Rx/Px (inc preoperative), MI/unstable angina Rx/Px, extracorporeal circuits (esp haemodialysis, cardiopulmonary bypass).

**Cl:** haemorrhagic disorders (inc haemophilia), ↓Pt (inc Hx of HIT*), severe HTN, PU, acute bacterial endocarditis, recent cerebral haemorrhage or major surgery/trauma to eye/brain/spinal cord, epidural/spinal anaesthesia (but can give Px doses), L (if severe, esp if oesophageal varices).

**Caution:** ↑K**, **R/P/E.

**SE:** haemorrhage, ↓Pt* (HIT*), hypersensitivity (inc anaphylaxis, urticaria, angioedema), ↑K** (inhibits aldosterone: ↑risk if DM, CRF, acidosis or on K⁺-sparing drugs), osteoporosis (if prolonged Rx).

**Monitor:** FBC* if >5 days Rx, U&E** if > 7 days Rx.

**Interactions:** fx may ↓by GTN ivi. NSAIDs ⇒ ↑bleeding risk.

**Dose:** see p. 210 (inc dose-adjustment advice).

**HIT** Heparin Induced Thrombocytopenia: immune mediated ↓delayed onset – ↑risk if Rx for >5 days (see p. 209).

**HUMALOG** see Insulin lispro; short-acting recombinant insulin. Also available as biphasic preparations (Mix 25, Mix 50), are combined with longer-acting isophane suspension.
HUMULIN  Recombinant insulin available in various forms:
1  **HUMULIN S** soluble, short-acting for iv/acute use.
2  **HUMULIN I** isophane (combined with protamine), long-acting.
3  **HUMULIN M** ‘biphasic’ preparations, combination of short-acting (S) and long-acting (I) forms to give smoother control throughout the day. Numbers denote 1/10% of soluble insulin (i.e. M3 = 30% soluble insulin).

HYDRALAZINE  
Antihypertensive: vasodilates smooth muscle (arteries > veins).
**Use:** HTN¹ (inc severe², esp if RF or pregnancy), HF³. *For advice on HTN Mx see p. 235.*
**CI:** severe ↑HR, myocardial insufficiency (2° to mechanical obstruction, e.g. aortic/mitral stenosis or constrictive pericarditis), cor pulmonale, dissecting aortic aneurysm, SLE*, porphyria, H (if ‘high output’, e.g. ↑T₄).
**Caution:** IHD, cerebrovascular disease, L/R/P/B.
**SE:** (all SEs ↓if dose 100 mg/day) ↑HR, GI upset, headache, lupus-like syndrome* (watch for unexplained ↓Wt, arthritis, ill health – measure ANA* and dipstick urine for protein if on high doses/clinical suspicion). Also fluid retention (↓d if used with diuretics), palpitations, dizziness, flushing, ↓BP (even at low doses), blood disorders, arthr-/my-algia, rash and can worsen IHD.
**Dose:** 25–50 mg bd po¹; 5–10 mg iv² (can be repeated after 20–30 min) or 50–300 microgram/min iv³; 25–75 mg tds/qds po³. 
**NB:** ↓dose if LF or RF.

HYDROCORTISONE BUTYRATE CREAM (0.1%) 
Potent-strength topical corticosteroid. NB: much stronger than ‘standard’ (i.e. non-butyrate) hydrocortisone cream; see below!

HYDROCORTISONE CREAM/OINTMENT (1%) 
Mild-strength topical corticosteroid (rarely used as weaker 0.5%, 0.25% and 0.1% preparations).
**Use:** inflammatory skin conditions, in particular eczema.
**CI:** untreated infection, rosacea, acne.
SE: rare compared to more potent steroids: skin atrophy, worsening of infections, acne.
Dose: apply thinly 1 or 2 times per day.

HYDROCORTISONE iv/po
Glucocorticoid (with significant mineralocorticoid activity).
Use: acute hypersensitivity (esp anaphylaxis, angioedema), Addisonian crisis, asthma, COPD, $T_4$ (and $\uparrow T_4$), IBD. Also used po in chronic adrenocortical deficiency.
Cl/Caution/SE/Interactions: see p. 217.
Dose: acutely: 100–500 mg im or slowly iv up to qds if required. Exact dose recommendations vary: consult local protocol if unsure (see Medical emergencies section of this book for rational starting dose for some specific indications). Chronic replacement: usually 20–30 mg po daily in divided doses (usually 2/3 in morning and 1/3 nocte), often together with fludrocortisone.

▼ HYDROXOCOBALAMIN
Vitamin B$_{12}$ replacement.
Use: pernicious anaemia (also macrocytic anaemias with neurological involvement, tobacco amblyopia, Leber’s optic atrophy).
SE: skin reactions, nausea, 'flu-like symptoms, $\downarrow K^+$ (initially), rarely anaphylaxis.
Interactions: fx $\downarrow$ by OCP and chloramphenicol.
Dose: 1 mg im injection: frequently at first for Rx (3–7/wks: exact number depends on indication$^{SPC/BNF}$) until no further improvement, then $\downarrow$ frequency (to once every 1–3 months) for maintenance.

HYDROXYCARBAMIDE (= HYDROXYUREA)
Antineoplastic agent for primary polycythaemia and essential thrombocythaemia (1st line Rx) and CML (initial Rx only). Also (unlicensed) use for severe psoriasis.
Cl/Caution: see SPC.
SE: Nausea, blood disorders (esp myelosuppression), skin reactions.
Dose: 20–30 mg/kg daily titrated against full blood count. Specialist use only.
HYDROXYCHLOROQUINE/PLAQUENIL
DMARD (↓s activation of dendritic cells/inflammatory response) and antimalarial (action as chloroquine).

**Use:** RA, SLE, dermatological disorders aggravated/cause by sunlight.

**Cl/Caution/SE/Interactions/Monitor:** see Chloroquine.

**Dose:** 200–400 mg/day.

Seek expert advice before commencing treatment.

HYOSCINE BUTYLBROMIDE/BUSCOPAN
Antimuscarinic: ↓s GI motility. Does not cross BBB (unlike hyoscine hydrobromide): less sedative.

**Use:** GI (or GU) smooth-muscle spasm; esp biliary colic, diverticulitis and IBS. Rarely used for dysmenorrhoea.

**Cl:** glaucoma (closed-angle), MG, megacolon, ↑prostate.

**Caution:** GI obstruction, ↑prostate/urinary retention, ↑HR (inc ↑T₄) H/P/B/E.

**SE:** antimuscarinic fx (see p. 276), drowsiness, confusion.

**Interactions:** ↓s fx of metoclopramide (and vice versa) and sublingual nitrates. ↑s tachycardic fx of β-agonists.

**Dose:** 20 mg qds po (for IBS, start at 10 mg tds) or 20 mg im/iv (repeating once after 30 min, if necessary; max 100 mg/day).

Don’t confuse with hyoscine hydrobromide: different fx and doses!

HYOSCINE HYDROBROMIDE (= SCOPOLAMINE)
Antimuscarinic: predominant fx on CNS (↓s vestibular activity¹).
Also ↓s respiratory/oral secretions²,³.

**Use:** motion sickness¹, terminal care/chronic ↓swallow² (e.g. CVA), hypersalivation 2° to antipsychotics³ (unlicensed use).

**Cl:** glaucoma (closed-angle).

**Caution:** GI obstruction, ↑prostate/urinary retention, cardiovascular disease, porphyria, Down’s, MG, L/R/P/B/E.

**SE:** antimuscarinic fx (see p. 276), generally sedative (although rarely ⇒ paradoxical agitation when given as sc infusion).

**Warn:** driving may be impaired, ↑s fx of alcohol.
**Interactions:** ↓s fx of sublingual nitrates (e.g. GTN).

**Dose:** 300 microgram 6-hrly po (max 3 doses/24 h)\(^1\) (or as transdermal patches; release 1 mg over 72 h); 0.6–2.4 mg/24 h as sc infusion\(^2\); 300 microgram bd po\(^3\) (can ↑to tds).

Don’t confuse with hyoscine *butylbromide*: different fx and doses!

---

**HYPROMELLOSE 0.3% EYE DROPS**

Artificial tears for treatment of dry eyes.

**Dose:** 1 drop prn, max 4–6 times/day unless preservative free drops.

---

**IBUGEL** Ibuprofen topical gel, for musculoskeletal pain.

---

**IBUPROFEN**

Mild-moderate strength NSAID. Non-selective COX inhibitor; analgesic, anti-inflammatory and antipyrexial\(^{†}\) properties.

**Use:** mild/moderate pain\(^1\) (inc musculoskeletal, headache, migraine, dysmenorrhoea, dental, post-op; not 1st choice for gout/RA as ↓anti-inflammatory fx compared to other NSAIDs), mild local inflammation\(^2\).

**CI:** Hx of hypersensitivity to aspirin or any other NSAID (inc asthma/angioedema/urticaria/rhinitis). Active/Hx of PU/GI bleeding/perforation, L/R/H (if any of these 3 are severe)/P (3rd trimester).

**Caution:** Asthma, allergic disorders, uncontrolled HTN, IHD, PVD, cerebrovascular disease, cardiovascular risk factors, connective tissue disorders, coagulopathy, IBD. *Can mask signs of infection*\(^{†}\).

**L/R/H/P** (1st/2nd trimester: preferably avoid)/B/E.

**SE:** GI upset/bleeding/PU (less than other NSAIDs). AKI, hypersensitivity reactions (esp bronchospasm and skin reactions, inc, very rarely, SJS/TEN), fluid retention/oedema, headache, dizziness, nervousness, depression, drowsiness, insomina, tinnitus, photosensitivity, haematuria. >1.2 g/day ⇒ small ↑risk thrombotic events. Reversible ↓female fertility if long-term use. Very rarely, blood disorders, ↑BP, ↑K\(^+\).

**Interactions:** ↑risk GI bleeding with aspirin, clopidogrel, anticoagulants, corticosteroids, SSRIs, venlafaxine and erlotinib. ↑s
*Indometacin* (toxic) fx of digoxin, quinolones, lithium, phenytoin, baclofen, methotrexate, AZT and sulphnylureas. ↑risk of RF with ACE-i, ARB, diuretics, tacrolimus and ciclosporin. ↑risk ↑K⁺ with K-sparing diuretics and aldosterone antagonists. ↓s fx of antihypertensives and diuretics. ↑levels with ritonavir and triazoles. Mild W +.

**Dose:** initially 300–400 mg tds po¹ (max 2.4 g/day); topically as gel².

NB: Avoid/↓dose in RF & consider gastroprotective Rx.

**INDAPAMIDE**

Thiazide derivative diuretic; see Bendroflumethiazide.

**Use:** HTN *(for advice on stepped HTN Mx see p. 235).*

**Cl:** Hx of sulphonamide derivative allergy, ↓K⁺, ↓Na⁺, ↑Ca²⁺, L/R (if either severe).

**Caution:** ↑PTH (stop if ↑Ca²⁺), ↑aldosterone, gout, porphyria, R/P/B/E.

**SE:** as bendroflumethiazide, but reportedly fewer metabolic disturbances (esp less hyperglycaemia).

**Monitor:** U&Es, urate.

**Interactions:** ↑s lithium levels and toxicity of digoxin (if ⇒ ↓K⁺).

**Dose:** 2.5 mg od mane (or 1.5 mg od of SR preparation).

**INDOMETACIN**

High-strength NSAID; non-selective COX inhibitor.

**Use:** musculoskeletal pain¹, esp RA, ankylosing spondylitis, OA; acute gout²; dysmenorrhoea³. Use limited by SEs*. Specialist uses: PDA closure, premature labourSPC/BNF.

**Cl/Caution/SE/Interactions:** as ibuprofen, but ↑incidence of SEs*, inc PU/GI bleeds, thrombotic events, GI upset and headache. Light-headedness (impairing driving) is common. Rarely: Ψ disturbances, convulsions, syncope, blood disorders, ↑CBG, peripheral neuropathy, optic neuritis, intestinal strictures; pr doses may ⇒ rectal irritation/bleeding. Caution in epilepsy, Parkinsonism & Ψ disturbance. Probenecid ⇒ ↑serum levels. ↑risk of AKI with triamterene: avoid. Possible severe drowsiness with haloperidol. No known interaction with baclofen or triazoles. Mild W +.
**Dose:** 25–50 mg max qds po or 100 mg max bd pr\(^1\). 150–200 mg/day in divided doses, ↓ing dose once pain under control\(^2\). 75 mg/day in divided doses\(^3\). MR preparations available\(^{SPC/BNF}\).

NB: Avoid/↓dose in RF & consider gastroprotective Rx.

**INFLIXIMAB/REMICAPEDE**
Monoclonal Ab against TNF-α (inflammatory cytokine).
**Use:** Crohn’s/UC\(^{NICE}\), RA\(^{NICE}\), psoriasis (for skin or arthritis)\(^{NICE}\) or ankylosing spondylitis\(^{NICE}\).
**Cl:** TB or other severe infections, H (unless mild when only caution), P/B.
**Caution:** infections, demyelinating CNS disorders, L/R.
**SE:** severe infections, TB (inc extrapulmonary), CCF (exac of), CNS demyelination. Also GI upset, ‘flu-like symptoms, cough, fatigue, headache. ↑incidence of hypersensitivity (esp transfusion) reactions.
**Dose:** specialist use only. Often prescribed concurrently with methotrexate.

**INSULATARD** Long-acting (isophane) insulin, either recombinant human or porcine/bovine.

**INSULIN** see p. 204 for different types and prescribing advice.

**INTEGRILIN** see Eptifibatide; anti-Pt agent for IHD.

**IODINE and IODIDE** see Lugol’s solution; used for ↑↑T\(_4\).

**IPOCOL** see Mesalazine; ‘new’ aminosalicylate for UC, with ↓SEs.

**IPRATROPIUM**
Inh muscarinic antagonist; bronchodilator and ↓s bronchial secretions.
**Use:** chronic\(^1\) and acute\(^2\) bronchospasm (COPD > asthma). Rarely used topically for rhinitis.
**SE:** antimuscarinic fx (see p. 276), usually minimal.
**Caution:** glaucoma (angle closure only; protect patient’s eyes from drug, esp if giving nebs: use tight-fitting mask), bladder outflow obstruction (e.g. ↑prostate), P/B.
**Dose:** 20–40 microgram tds/qds inh\(^1\) (max 80 microgram qds); 250–500 microgram qds neb\(^2\) (↑ing up to 4-hrly if severe).
IRBESARTAN/APROVEL
Angiotensin II antagonist.
Use: HTN (for advice on stepped HTN Mx see p. 235), type 2 DM nephropathy.
Ci: P/B.
Caution/SE/Interactions: see Losartan.
Dose: initially 150 mg od, ing to 300 mg od if required (halve initial dose if age >75 years or on haemodialysis).

IRON TABLETS see Ferrous sulphate/fumarate/gluconate.
ISMN see Isosorbide mononitrate.
ISMO see Isosorbide mononitrate.

ISONIAZID
Antituberculous antibiotic; ‘static’.
Use: TB (see p. 267).
Cl: drug-induced liver disease.
Caution: Hx of psychosis/epilepsy/po phyria or if d risk of neuropathy† (e.g. DM, alcohol abuse, CRF, malnutrition, HIV: give pyridoxine 10–20 mg od as Px), po phyria, L/R/P/B.
SE: optic neuritis, peripheral neuropathy†, hepatitis*, rash, gynaecomastia, GI upset. Rarely lupus, blood disorders (inc rarely agranulocytosis**), hypersensitivity, convulsions, psychosis.
Warn: patient of symptoms of liver disease and to seek medical help if they occur.
Monitor: LFTs*, FBC**.
Interactions: ↓ P450 . many, but most importantly ↑s levels of carbamazepine, phenytoin, ethosuximide and benzodiazepines W +. Dose: by weightSPC/BNF or as combination preparation (see p. 267).
Take on empty stomach (≥30 min before or ≥2 h after meal).
Acetylator-dependent metabolism: if slow acetylator ⇒ ↑risk of SEs.

ISOSORBIDE MONONITRATE (ISMN)
Nitrate; as GTN, but po rather than sl delivery.
Use/Ci/Caution/SE/Interactions: as GTN, but ⇒ ↓headache.
**Dose:** 10–40 mg bd/tds po (od MR preparations available\(^\text{SPC/BNF}\)).

**ISTIN** see Amlodipine; \(\text{Ca}^{2+}\) channel blocker for HTN/IHD.

**ITRACONAZOLE/SPORANOX**
Triazole antifungal: needs acidic pH for good po absorption*.

**Use:** fungal infections (candida, tinea, cryptococcus, aspergillosis, histoplasmosis, onychomycosis, pityriasis versicolor).

**Caution:** risk of HF: Hx of cardiac disease or if on negative inotropic drugs (risk \(\uparrow\)s with dose, length of Rx and age), L/R/P/B.

**SE:** HF, hepatotoxicity**, GI upset, headache, dizziness, peripheral neuropathy (if occurs, stop drug), cholestasis, menstrual \(\Delta\)s, skin reactions (inc angioedema, SJS). With prolonged Rx can \(\Rightarrow\) \(\downarrow\)K\(^+\), oedema, hair loss.

**Monitor:** LFTs** if Rx \(\geq 1\) month or Hx of (or develop clinical features of) liver disease: stop drug if become abnormal.

**Interactions:** \(\downarrow\) P450 :. many; most importantly \(\uparrow\)s risk of myopathy with statins (avoid together) and \(\uparrow\)s risk of HF with negative inotropes (esp \(\text{Ca}^{2+}\) blockers). \(\uparrow\)s fx of \(\text{\&}\) midazolam, quinidine, pimozide \(\text{\&}\), ciclosporin, digoxin, indinavir and siro-/tacro-limus. \(\downarrow\)d by rifampicin, phenytoin and antacids\(^*\), W +.

**Dose:** dependent on indication\(^\text{SPC/BNF}\). *Take capsules with food (or liquid on empty stomach).* NB: consider \(\downarrow\)dose in LF.

**IVABRADINE/PROCORALAN**
\(\downarrow\)s HR by selective cardiac pacemaker \(I_f\) channel current blockade \(\Rightarrow\) \(\downarrow\)SAN myocyte Na\(^+\) and K\(^+\) entry.

**Use:** angina (if sinus rhythm and \(\beta\)-blockers CI/not tolerated).

**CI:** severe \(\downarrow\)HR (\(< 60\) bpm) or \(\downarrow\)BP, cardiogenic shock, ACS (inc acute MI), acute CVA, 2nd or 3rd degree HB, SSS, pacemaker dependent, SAN block congenital \(\uparrow\)QT syndrome, strong P450 3A4 inhibitors**, L (if severe)/H (if moderate/severe)/P/B.

**Caution:** retinitis pigmentosa, galactose intolerance*/Lapp lactase deficiency*/glucose-galactose malabsorption*, R/E.

**SE:** visual \(\Delta\)s (esp luminous phenomena*), \(\downarrow\)HR, HB, ectopics, VF, headaches, dizziness. Less commonly GI upset, cramps, dyspnoea, \(\uparrow\)EØ, \(\uparrow\)uric acid, \(\downarrow\)GFR.
**Warn:** tablets contain lactose*, may ↓ vision if night driving/using machinery with rapid light intensity Δs.

**Monitor:** HR (maintain resting ventricular rate >50 bpm) and rhythm, BP.

**Interactions:** 🎯 **metab by P450 3A4**; inhibitors ↑ levels and strong inhibitors** (clari-/ery-/josa-/tei-thromycin, itra-/keto-conazole, nelfi-/rito-navir, nefazodone) are CI but ↓ doses can be given with fluconazole. Inducers ↓ levels (inc rifampicin, barbiturates, phenytoin, St John’s wort). Levels also ↑ by diltiazem and verapamil. ↑ risk of VF with drugs that ↑ QTc (inc amiodarone, disopyramide, mefloquine, pentamidine, pimozide, sertindole, sotalol) 🎯.

**Dose:** initially 5 mg bd po; ↑ ing if required after 3–4 wks to max 7.5 mg bd po.

NB: consider ↓ dose if not tolerated, elderly or severe RFSPC/BNF.

---

**KAY-CEE-L**

KCl syrup (1 mmol/ml) for ↓ K⁺; see Sando-K.

**Dose:** according to serum K⁺: average 25–50 ml/day in divided doses if diet normal. Caution if taking other drugs that ↑ K⁺.

NB: ↓ dose if RF.

---

**KETAMINE/KETALAR**

IV anaesthetic (but can also be given im). NMDA receptor antagonist & inhibitor of nitric oxide synthase.

**Use:** induction and maintenance of anaesthesia (mainly paediatric use; esp if repeated administration required).

**CI:** anaesthetist not confident of airway maintenance, HTN, pre-eclampsia / eclampsia, severe coronary or myocardial disease, CVA, ↑ ICP, head trauma, acute porphyria.

**Caution:** hypovolaemia / dehydration, cardiovascular disease, patients in whom ↑ BP would constitute a serious hazard, respiratory tract infection (⇒ laryngospasm), ↑ IOP, head injury / intracranial mass lesions, ↑ CSF pressure, ↑ seizure risk, Ψ disorders (esp psychosis), thyroid dysfunction, EtOH xs (acute or chronic). L / H / P (may ↓ neonatal respiration if used during delivery) / B (avoid for ≥ 12 hrs after last dose); E (↓ dose & rate of administration);
SE: nightmares, psychosis (can ↓ with benzodiazepines), N&V, ↑RR, ↑HR/BP, diplopia, nystagmus, rash, hypertonia, extraneous muscle movements. Can ⇒ delirium during recovery period.

Warn: don’t drive or use hazardous machinery for 24 hrs.

Monitor: Cardiac, respiratory and motor function (recovery is relatively slow).

Interactions: memantine (⇒ CNS toxicity). ↑s fx of atracurium and tubocurarine (respiratory depression and apnoea). Theophylline ⇒ convulsions. ↓BP with adrenergic neurone blockers, α-blockers, antipsychotics, verapamil (also ⇒ AV delay). Thyroid hormones (⇒ HTN and ↑HR).

Dose: titrate to effect, except during ‘rapid sequence induction’. IM:
For short procedures; initially 6.5–13 mg/kg adjusting to response (10 mg/kg usually ⇒ 12–25 mins anaesthesia). For diagnostic manoeuvres / procedures not involving intense pain, initially 4 mg/kg. IV (over ≥60 secs): short procedures, initially 1 – 4.5 mg/kg (2 mg/kg usually ⇒ 5–10 mins anaesthesia). IVI (1 mg/mL solution):
For longer procedures; induction total dose of 0.5–2 mg/kg then maintenance 10–45 micrograms/kg/min adjusting to response.

KETOCONAZOLE/NIZORAL
Imidazole antifungal: good po absorption.

Use: fungal infection Rx (if systemic, severe or resistant to topical Rx) and Px if immunosuppression; use limited (due to hepatotoxicity) to dermatophytosis, Malassezia folliculitis and cutaneous or oropharyngeal candidosis and only when topical and oral agents can’t be used.

CI: L/P/B.

Caution: porphyria.

SE: hepatitis*, GI upset, skin reactions (rash, urticaria, pruritus, photosensitivity, rarely angioedema), gynaecomastia, blood disorders, paraesthesia, dizziness, photophobia.
**Monitor:** LFTs*, esp if Rx >14 days.

**Warn:** seek urgent medical attention if signs of LF (explain symptoms to patient).

**Interactions:** ↓ P450 : . many; most importantly, ↑s risk of myopathy with statins (avoid together). ↑s fx of ☠ midazolam, quinidine, pimozide ☠, vardenafil, eplerenone, cilostazol, reboxetine, aripiprazole, sertindole, felodipine, ergot alkaloids, antidiabetics, buprenorphine, artemether/lumefantrine, indi-/rino-navir and ciclosporin (and possibly theophyllines). ↓s fx of rifampicin (rifampicin can also ↓fx of ketoconazole, as can phenytoin and clopidogrel), W +.

**Dose:** 200 mg od po with food (400 mg od in severe/resistant cases).

**KLEAN-PREP** see Bowel preparations.

**Dose:** up to 2 powder sachets the evening before and repeated on the morning of GI surgery or Ix.

**LABETALOL**

β-blocker with arteriolar vasodilatory properties : . also ⇒ ↓TPR.

**Use:** uncontrolled/severe HTN (inc during pregnancy1 or post-MI2 or with angina). For advice on HTN Mx see p. 235.

**CI/Caution/SE/Interactions:** as propranolol, plus can ⇒ ☠ severe/postural ↓BP ☠ and hepatotoxicity* (L).

**Monitor:** LFTs* (if deteriorate stop drug).

**Dose:** initially 100 mg bd po (halve dose in elderly), ↑ing every fortnight if necessary to max of 600 mg qds po; if essential to ↓BP rapidly give 50 mg iv over ≥1 min repeating after 5 min if necessary (or can give 2 mg/min ivi), up to max total dose 200 mg; 20 mg/h ivi1, doubling every 30 min to max of 160 mg/h; 15 mg/h ivi2, ↑ing slowly to max of 120 mg/h. NB: consider ↓dose in RF.

**LACRI-LUBE**

Artificial tears for dry eyes.

**SE:** blurred vision : . usually used at bedtime (or if vision secondary consideration, e.g. Bell’s palsy or blind eye).

**Dose:** 1 application prn.
**LACTULOSE**  
Osmotic laxative: bulking agent. Also ↓s growth of NH₄-producing bacteria.  
**Use:** constipation, hepatic encephalopathy.  
**CI:** GI obstruction, galactosaemia.  
**Caution:** lactose intolerance.  
**SE:** flatulence, distension, abdominal pains.  
**Dose:** 15 ml od/bd (↑dose according to response; NB: *can take 2 days to work*); 30–50 ml tds. *Take with plenty of water.*

**LAMISIL** see Terbinafine.

▼ **LAMOTRIGINE/LAMICTAL**  
Antiepileptic: ↓s release of excitatory amino acids (esp glutamate) via action on voltage-sensitive Na⁺ channels.  
**Use:** epilepsy (esp partial and 1° or 2° generalised tonic–clonic), Px depressive episode in bipolar disorder.  
**Caution:** avoid abrupt withdrawal† (rebound seizure risk; taper off over ≥2 wks unless stopping due to serious skin reaction*), L/R/P/B/E.  
**SE:** cerebellar symptoms (see p. 278), skin reactions* (often severe, e.g. SJS, TEN, lupus, esp in children, if on valproate, or high initial doses), blood disorders** (↓Hb, ↓WCC, ↓Pt), N&V. Rarely, ↓memory, sedation, ψ disorders, sleep Δ, acne, pretibial ulcers, alopecia, worsening of seizures, poly-/an-uria, hepatotoxicity.  
**Monitor:** U&Es, FBC, LFTs, clotting.  
**Warn:** report rash* plus any ’flu-like symptoms, signs of infection/↓Hb or bruising**. Don’t stop tablets suddenly†. Risk of suicidal ideation.  
**Interactions:** fx are ↓d by OCP, phenytoin, carbamazepine, mefloquine, TCAs and SSRIs. fx ↑d by valproate.  
**Dose:** 25–700 mg daily SPC/BNF; ↑dose slowly to ↓risk of skin reactions* (also need to restart at low dose). NB: ↓dose in LF.

**LANSOPRAZOLE/ZOTON**  
PPI. As omeprazole, but ↓interactions.  
**Dose:** 15–30 mg od po (↓to 15 mg od for maintenance).
**LARIAM** see Mefloquine; antimalarial (Px and Rx).

**LASIX** see Furosemide; loop diuretic.

▼ **LATANOPROST 0.01%/XALATAN**  
Topical PG analogue: ↑s uveoscleral outflow.  
**Use:** ↑IOP in glaucoma and ocular HTN (1st line agent).  
**Caution:** asthma (if severe), aphakia, pseudophakia, uveitis, macular oedema P/B.  
**SE:** iris colour Δ* (can ⇒ permanent ↑brown pigmentation, esp if unocular use), blurred vision, local reactions (e.g. conjunctival hyperaemia in up to 30% initially). Also darkening of periorcular skin and ↑eyelash length (both reversible). Rarely cystoid macular oedema (if aphakia), uveitis, angina.  
**Warn:** can Δ iris colour*.  
**Dose:** 1 drop od.

**LEFLUNOMIDE/ARAVA**  
DMARD; inhibits pyrimidine synthesis (also anti-inflammatory fx).  
**Use:** active rheumatoid or psoriatic arthritis if standard DMARDs (e.g. methotrexate or sulfasalazine) CI or not tolerated.  
**CI:** severe immunodeficiency, BM suppression, severe hypoproteinaemia, serious infection, L/R/P/B.  
**Caution:** blood disorders, recent hepato-/myelo-toxic drugs, TB (inc Hx of).  
**SE:** BM toxicity, ↑risk of infection/malignancy, hepatotoxicity (potentially life-threatening in 1st 6 months), SJS, HTN.  
**Warn:** teratogenic: must exclude pregnancy before starting Rx and use contraception during Rx (and until drug no longer active*).  
**Monitor:** LFTs, FBC, BP.  
**Dose:** specialist use only.

Long $t_{1/2}$*: if serious SE discontinue treatment and needs prolonged washout period or active measures (e.g. cholestyramine 8 g tds or activated charcoal 50 g qds) to ↑elimination if wishing to conceive.
LEVOBUNOLOL
β-blocker eye drops: similar to timolol ⇒ ↓ aqueous humour production. Significant systemic absorption can occur.
Use: chronic simple (wide-/open-angle) glaucoma.
CI/Caution/Interactions: as propranolol; interactions less likely.
SE: local reactions. Rarely anterior uveitis and anaphylaxis. Can ⇒ systemic fx, esp bronchoconstriction/cardiac fx; see Propranolol.
Dose: 1 drop of 0.5% solution od/bd.

LEVODOPA (= L-DOPA)
Precursor of dopamine: needs concomitant peripheral dopa decarboxylase inhibitor such as benzerazide (see Co-beneldopa) or carbidopa (see Co-careldopa) to limit SEs.
Use: Parkinsonism.
CI: glaucoma (closed-angle), taking MAO-A inhibitors*, melanoma†, P/B.
Caution: pulmonary/cardiovascular/P disease, endocrine disorder, glaucoma (open angle), osteomalacia, Hx of PU or convulsions, ventricular arrhythmias, L/R.
SE: dyskinesias, abdominal upset, postural ↓BP/arrythmias, drowsiness, aggression, Ψ disorders (confusion, depression, suicide, hallucinations, psychosis, hypomania), seizures, dizziness, headache, flushing, sweating, peripheral neuropathy, taste Δs, rash/pruritus, can reactivate melanoma†, Δ LFTs, GI bleeding, blood disorders, dark body fluids (inc sweat).
Warn: can ⇒ daytime sleepiness (inc sudden-onset sleep) and ↓ability to drive/operate machinery.
Interactions: fx ↓d by neuroleptics, SEs ↑d by bupropion, risk of ↑BP crisis with MAOls* (but can give with MAO-B inhibitors), risk of arrhythmias with halothane.
Dose: 125–500 mg daily, after food, ↑ing according to response.
Abrupt withdrawal can ⇒ neuroleptic malignant-like syndrome.
LEVOMEPROMAZINE (= METHOTRIMEPRAZINE)
Phenothiazine antipsychotic; as chlorpromazine, but used in palliative care as has good antiemetic\(^1\) and sedative\(^2\) fx, but little respiratory depression.

**Use:** refractory N\&V\(^1\) or restlessness/distress\(^2\) in the terminally ill.

**CI/Caution/SE/Interactions:** as chlorpromazine, but ↑risk of postural ↓BP (esp in elderly: don’t give if age >50 years and ambulant) and ↑risk of seizures (caution if epilepsy/brain tumour).

**Dose:** 6.25–25 mg po/sc/im/iv od/bd (can ↑to tds/qds), or 25–200 mg/24 h sc infusion. **Parenteral dose is half equivalent oral dose.**

**NB:** for N\&V low doses may be effective and ⇒ ↓sedation. Doses >25 mg sc/24 hrs rarely needed except as major sedation.

**NB:** ↓dose in RF and elderly.

LEVOTHYROXINE see Thyroxine.

LIBRIUM see Chlordiazepoxide; long-acting benzodiazepine.

LIDOCAINE (previously Lignocaine)
Class Ib antiarrhythmic (↓s conduction in Purkinje and ventricular muscle fibres), local anaesthetic (blocks axonal Na\(^+\) channels).

**Use:** ventricular arrhythmias (esp post-MI), local anaesthesia.

**CI:** myocardial depression (if severe), SAN disorders, atrioventricular block (all grades), porphyria.

**Caution:** epilepsy, severe hypoxia/hypovolaemia/↓HR, L/H/P/B/E.

**SE:** dizziness, drowsiness, confusion, tinnitus, blurred vision, paraesthesia, GI upset, arrhythmias, ↓BP, ↓HR. Rarely respiratory depression, seizures, anaphylaxis.

**Monitor:** ECG during iv administration.

**Interactions:** ↑risk of arrhythmias with antipsychotics, dolasetron and quinu-/dalf-pristin. ↑myocardial depression with other antiarrhythmics and \(\beta\)-blockers. Levels ↑by propranolol, ataza-/lopinavir and cimetidine. Prolongs action of suxamethonium.

**Dose (for ventricular arrhythmias):** 50–100 mg iv at rate of 25–30 mg/min followed immediately by ivi at 4 mg/min for
30 min then 2 mg/min for 2 h and 1 mg/min thereafter (↓dose further if drug needed for >24 h). NB: short t₁/₂. . . . if 15 min delay in setting up ivi, can give max 2 further doses of 50–100 mg iv ≥10 min apart. In emergencies, can often be found stocked in crash trolleys as Minijet syringes of 1% (10 mg/ml) or 2% (20 mg/ml) solutions.

Local anaesthetic preparations must never be injected into veins or inflamed tissue, as can ⇒ systemic fx (esp arrhythmias) ☠.

**LIGNOCAINE** see Lidocaine.

**LIOTHYRONINE (= L-TRI-IODOTHYRONINE) SODIUM**

Synthetic T₃: quicker and more potent action than thyroxine (T₄).

**Use:** severe hypothyroidism (e.g. myxoedema coma*: see page 257).

**CI/Caution/SE/Interactions:** see Thyroxine.

**Dose:** 5–20 microgram iv slowly. Repeat every 4–12 h as necessary; seek expert help. Also available po, but thyroxine (T₄) often preferred. NB: 20 microgram liothyronine = 100 microgram (levo) thyroxine.

Concurrent hydrocortisone iv is often also needed*.

**LISINOPRIL**

ACE-i; see Captopril.

**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235), HF², Px of IHD post-MI³, DM nephropathy⁴.

**CI/Caution/SE/Interactions:** as Captopril.

**Dose:** initially 10 mg od¹ (2.5–5.0 mg if RF or used with diuretic) ↑ing if necessary to max 80 mg/day; initially 2.5–5 mg od²-⁴ adjusted to response to usual maintenance of 5–20 mg/day. Doses post-MI³ depend on BP⁰¹²⁴⁰

NB: ↓dose in LF or RF.

**LITHIUM**

Mood stabiliser: modulates intracellular signalling; blocks neuronal Ca²⁺ channels and changes GABA pathways.
Use: mania Rx/Px, bipolar disorder Px. Rarely for recurrent depression Px and aggressive/self-mutilating behaviour Rx.

CI: ↓T₄ (if untreated), Addison’s, SSS, cardiovascular disease, P (⇒ Ebstein’s anomaly: esp in 1st trimester), R/H/B. (NB: manufacturers don’t agree on definitive list and all CI are relative – decisions should be made in clinical context and expert help sought if unsure.)

Caution: thyroid disease, MG, E.

SE: thirst, polyuria, GI upset (↑Wt, N&V&D), fine tremor* (NB: in toxicity ⇒ coarse tremor), tardive dyskinesia, muscular weakness, acne, psoriasis exacerbation, ↑WCC, ↑Pt. Rarer but serious: ↓(or ↑) T₄ ± goitre (esp in females), renal impairment (diabetes insipidus, interstitial nephritis), arrhythmias. Very rarely can ⇒ neuroleptic malignant syndrome.

Monitor: serum levels 12 h post-dose: keep at 0.6–1 mmol/l (>1.5 mmol/l may ⇒ toxicity, esp if elderly), U&Es, TFTs.

Warn: report symptoms of ↓T₄, avoid dehydration.

Interactions: toxicity (± levels) ↑d by NSAIDs, diuretics** (esp thiazides), SSRIs, ACE-i, ARBs, amiodarone, methyldopa, carbamazepine and haloperidol. Theophyllines, caffeine and antacids may ↓lithium levels.

Dose: see SPC/BNF: 2 types (salts) available with different doses (‘carbonate’ 200 mg = ‘citrate’ 509 mg) and bioavailabilities of particular brands vary. must specify salt and brand required. For ‘carbonate’ starting dose usually 200 mg nocte, adjusting to plasma levels (maintenance usually 600 mg – 1 g nocte).

NB: ↓dose in LF.

Consider stopping 24 h before major surgery or ECT; restart once e’lytes return to normal. Discuss with anaesthetist ± psychiatrist.

Lithium toxicity

Features: D&V, coarse tremor*, cerebellar signs (see p. 278), renal impairment/oliguria, ↓BP, ↑reflexes, convulsions, drowsiness ⇒ coma, arrhythmia. Rx: stop drug, control seizures, correct electrolytes (normally need saline ivi; high risk if ↓Na+: avoid low-salt diets and diuretics**). Consider haemodialysis if RF.
**LOCIOID** see Hydrocortisone butyrate 0.1% (potent steroid) cream.

**LOFEPRAMINE**
2nd generation TCA.
**Use:** depression
**CI/Caution/SE/Warn/Monitor/Interactions:** as amitriptyline but also R (if severe). Also ⇒ ↓sedation (sometimes alerting – don’t give nocte if occurs) and ↓anticholinergic and cardiac SEs :. ↓danger in OD.
**Dose:** 140–210 mg daily in divided (bd/tds) doses.

**LOPERAMIDE/IMODIUM**
Antimotility agent: synthetic opioid analogue; binds to receptors in GI muscle ⇒ ↓peristalsis, ↑transit time, ↑H₂O/electrolyte resorption, ↓gut secretions, ↑sphincter tone. Extensive 1st-pass metabolism ⇒ minimal systemic opioid fx.
**Use:** diarrhoea.
**CI:** constipation, ileus, megacolon, bacterial enterocolitis 2° to invasive organisms (e.g. salmonella, *Shigella, Campylobacter*), abdominal distension, active UC/AAC, pseudomembranous colitis.
**Caution:** in young (can ⇒ fluid + electrolyte depletion), L/P.
**SE:** constipation, abdominal cramps, bloating, dizziness, drowsiness, fatigue. Rarely hypersensitivity (esp skin reactions), paralytic ileus.
**Dose:** initially 4 mg, then 2 mg after each loose stool (max 16 mg/day for 5 days). NB: can mask serious GI conditions.

**LORATADINE**
Non-sedating antihistamine: see Cetirizine.
**Dose:** 10 mg od. Non-proprietary or as Clarityn.

**LORAZEPAM**
Benzodiazepine, short-acting.
**Use:** sedation¹ (esp acute behavioural disturbance/Ψ disorders, e.g. acute psychosis), status epilepticus².
**CI/Caution/SE/Interactions:** see Diazepam.
**Dose:** 0.5–2 mg po/im/iv prn (bottom of this range if elderly/respiratory disease/naive to benzodiazepines; top of range if young/recent exposure to benzodiazepines; max 4 mg/day)\(^1\); 0.1 mg/kg ivi at 2 mg/min (max 4 mg repeated once after 10 mins if necessary)\(^2\).

NB: ↓dose in RF.

 Bettai respiratory depression: have \(O_2\) (± resuscitation trolley) at hand, esp if respiratory disease or giving high doses im/iv.

**\(\bigtriangledown\) LOSARTAN/COZAAR**

Angiotensin II receptor antagonist: specifically blocks renin–angiotensin system. does not inhibit bradykinin and ⇒ dry cough.

**Use:** HTN *(for advice on stepped HTN Mx see p. 235)*, Px of type 2 DM nephropathy (if ACE-i not tolerated*).

**CI:** P/B.

**Caution:** RAS, HCM, mitral/aortic stenosis, if taking drugs that ↑K**⁺**, L/R/E.

**SE/Interactions:** as captopril, but ↓dry cough (major reason for ACE-i intolerance*). As with ACE-i, can ⇒ ↑K**⁺**(esp if taking ↑K**⁺** sparing diuretics/salt substitutes or if RF).

**Dose:** initially 25–50 mg od (↑ing to max 100 mg od). NB: ↓dose in LF or RF.

**\(\bigtriangledown\)** Beware if on other drugs that ↑K**⁺**, e.g. amiloride, spironolactone, triamterene, ACE-i and ciclosporin. Don’t give with oral K**⁺** supplements (inc dietary salt substitutes).

**LOSEC** see Omeprazole; PPI (ulcer-healing drug).

**LUGOL’S SOLUTION**

Oral I\(_2\) solution (containing iodine and K**⁺** iodide).

**Use:** ↑T\(_4\) if severe (‘thyroid storm’) or pre-operatively.

**CI:** B.

**Caution:** not for long-term Rx, P.

**SE:** hypersensitivity.

**Dose:** 0.1–0.3 ml tds (of solution containing 130 mg iodine/ml).
LYMECYCLINE
Tetracycline, broad-spectrum antibiotic (see Tetracycline).
Use: acne vulgaris, rosacea.
CI/Caution/SE/Interactions: as tetracycline.
Dose: 408 mg od for ≥8 wks (can ↑to bd for other indications).

MADOPAR see Co-beneldopa; L-dopa for Parkinson's.

MAGNESIUM SULPHATE (iv)
Mg$^{2+}$ replacement.
Use: life-threatening asthma\(^1\) (unlicensed indication), serious arrhythmias\(^2\) (esp if torsades or if ↓K\(^+\); often caused by ↓Mg\(^{2+}\)), MI\(^3\) (equivocal evidence of ↓mortality), eclampsia/pre-eclampsia\(^4\) (↓s seizures), symptomatic ↓Mg\(^{2+}\) \(^5\) (mostly 2° to GI loss).
Caution: monitor BP, respiratory rate and urine output, L/R.
SE: flushing, ↓BP, GI upset, thirst, ↓reflexes, weakness, confusion/ drowsiness. Rarely arrhythmias, respiratory depression, coma.
Interactions: ↑risk of ↓BP with Ca\(^{2+}\) channel blockers.
Dose: 4–8 mmol ivi over 20 min\(^1\); 8 mmol iv over 10–15 min\(^2\) (repeating once if required); 8 mmol ivi over 20 min then ivi of 65–72 mmol over 24 h\(^3\); 4 mg ivi over 5–10 min then ivi at 1 mg/h until 24 hr after the last seizure\(^4\); up to 160 mmol ivi/im according to need\(^5\) (over up to 5 days). For iv injection, use concentrations of ≦20%; if using 50% solution dilute 1 part with ≧1.5 parts water for injection.

MANNITOL
Osmotic diuretic.
Use: cerebral oedema\(^1\) (and glaucoma).
CI: pulmonary oedema, H.
SE: GI upset, fever/chills, oedema. Rarely seizures, HF.
Dose: 0.25–2 g/kg (2.5–20 ml/kg 10% solution) as rapid ivi over 30–60 min\(^1\).

MAXOLON see Metoclopramide; antiemetic (DA antagonist).
MEBEVERINE
Antispasmodic: direct action on GI muscle.
**Use:** GI smooth-muscle cramps (esp IBS, diverticulitis).
**CI:** ileus (paralytic).
**Caution:** porphyria, P.
**SE:** hypersensitivity/skin reactions.
**Dose:** 135–150 mg tds (20 min before food) or 200 mg bd of SR preparation (Colofac MR).

MEFENAMIC ACID/PONSTAN
Mild NSAID; non-selective COX inhibitor.
**Use:** musculoskeletal pain, dysmenorrhoea, menorrhagia.
**CI/Caution/SE/Interactions:** as ibuprofen, but also CI if IBD, caution if epilepsy or acute porphyria. Can ⇒ severe diarrhoea, skin reactions, stomatitis, paraesthesia, fatigue, haemolytic/aplastic ↓Hb, ↓Pt. No known interaction with baclofen or triazoles. Mild W +.
**Dose:** 500 mg tds.

MEFLOQUINE/LARIAM
Antimalarial; kills asexual forms of *Plasmodium*.
**Use:** malaria Px¹ (in areas of chloroquine-resistant falciparum spp) and rarely as Rx if not taking the drug as Px.
**CI:** hypersensitivity to mefloquine or quinine, Hx of neuro-Ψ disorders (inc depression, convulsions).
**Caution:** epilepsy, cardiac conduction disorders, L/P/B.
**SE:** GI upset, neuro-Ψ reactions (dizziness, ↓balance, headache, convulsions, sleep disorders, neuropathies, tremor, anxiety, depression, psychosis, hallucinations, panic attacks, agitation). Also cardiac fx (AV block, other conduction disorders, ↑or ↓HR, ↑or ↓BP), hypersensitivity reactions.
**Warn:** can ↓driving/other skilled tasks and ⇒ neuro-Ψ reactions.
**Interactions:** ↑risk of seizures with quinine, chloroquine and hydroxychloroquine. ↓s fx of anticonvulsants (esp valproate and carbamazepine). ↑risk of arrhythmias with amiodarone, quinidine, moxifloxacin and pimozide. Avoid artemether/lumefantrine.
Dose: 250 mg once-wkly¹ (↓dose if Wt < 45 kg)SPC/BNF.

Need to start Px 2 1/2 wks before entering endemic area (to identify neuro-Ψ reactions; 75% of reactions occur by 3rd dose) and continue for 4 wks after leaving endemic area.

MEROPENEM
Carbapenem broad-spectrum antibiotic (β-lactam, but non-penicillin/non-cephalosporin).
Use: severe Gram +ve and −ve aerobic and anaerobic infections. Hospital acquired septicaemia.
Caution: β-lactam sensitivity (avoid if immediate hypersensitivity reaction) L/R/P/B.
SE: GI upset (N&V&D – inc AAC), ΔLFTs, headache, blood/skin disorders. Rarely seizures, SJS/TENS.
Monitor: LFTs.
Dose: 500 mg tds iv/ivi (↑to 1 g tds if severe infection or 2 g tds if meningitis or exacerbation of lower RTI in CF).
NB: ↑interval ± ↓dose if RFSPC/BNF.

MESALAZINE
‘New’ aminosalicylate: as sulfasalazine, but with ↓sulphonamide SEs.
Use: UC (Rx/maintenance of remission).
CI: hypersensitivity to any salicylates, coagulopathies, R (caution only if mild), L (caution only if not severe).
Caution: P/B/E.
SE: GI upset, blood disorders, hypersensitivity (inc lupus), RF, headache.
Warn: report unexplained bleeding, bruising, fever, sore throat or malaise.
Monitor: U&E, FBC (stop drug if blood disorder suspected).
Interactions: fx ↓by lactulose. NSAIDs and azathioprine may ↑nephrotoxicity.
Dose: as Asacol (or Ipocoll, Mezavant, Mesren, Pentasa and Salofalk). Preparations not interchangeable as delivery characteristics may vary.
MESNA
Binds to metabolite (acrolein) of thiol-containing chemotherapy agents (cyclophosphamide, ifosfamide), which are toxic to urothelium and can ⇒ severe haemorrhagic cystitis. Give as Px before chemotherapy; see BNF for details.

METFORMIN
Oral antidiabetic (biguanide): ⇒ ↑insulin sensitivity w/o affecting levels (⇒ ↓gluconeogenesis and ↓GI absorption of glucose and ↑peripheral use of glucose). Only active in presence of endogenous insulin (i.e. functional islet cells).

Use: type 2 DM: usually 1st-line if diet control unsuccessful (esp if obese, as ⇒ less ↑Wt than sulphonylureas). Also used in PCOS (unlicensed; specialist use).

Cl: DKA, ↑risk of lactic acidosis (e.g. RF, severe dehydration/infection/peripheral vascular disease, shock, major trauma, respiratory failure, alcohol dependence, recent MI*, general anaesthetic** or iodine-containing radiology contrast media*), L/R/P/B.

Se: GI upset (esp initially or if ↑doses), taste disturbance. Rarely ↓vit B₁₂ absorption, lactic acidosis† (stop drug).

Dose: Standard release tablets – initially 500 mg mane, ↑ing as required to max 2 g/day in divided doses. Modified release tablets – initially 500 mg daily, ↑ing as required to max 2 g daily in 1. Take with meals. NB: ↓dose in mild RF, avoid in severe RF.

METHADONE
Opioid agonist: ↓euphoria and long t₁/₂ (⇒ ↓withdrawal symptoms) compared with other opioids.

Use: opioid dependence as aid to withdrawal.

Cl/Caution/Se/Interactions: as morphine but levels ↓by ritonavir, but are ↑by voriconazole and cimetidine and ↑risk of
ventricular arrhythmias with atomoxetine and amisulpride. Can ↑QTc (caution if family history of sudden death).

**Dose:** individual requirements vary widely according to level of previous abuse: sensible starting dose is 10–20 mg/day po, ↑ing by 10–20 mg every day until no signs or symptoms of withdrawal – which usually stop at 60–120 mg/day. Then aim to wean off gradually. Available as non-proprietary solutions (1 mg/ml) or as Methadose (10 mg/ml or 20 mg/ml). Can give sc/imSPC/BNF. NB: ↓dose if LF, RF or elderly.

⚠️ Don’t confuse solutions of different strengths ⚠️.

**METHIONINE**
Sulphur-containing amino acid: binds toxic metabolites of paracetamol.

**Use:** paracetamol OD <12 h post-ingestion (ineffective after this) and not vomiting, mostly when acetylcysteine ivi cannot be given (e.g. outside hospital).

**Cl:** metabolic acidosis.

**Caution:** schizophrenia (can worsen), L.

**Se:** N&V, irritability, drowsiness.

**Interactions:** can ↓fx of L-dopa.

**Dose:** 2.5 g po 4-hrly (for 4 doses only: total dose = 10 g).

**METHOTREXATE**
Immunosuppressant, antimetabolite: dihydrofolate reductase inhibitor (↓s nucleic acid synthesis).

**Use:** rheumatoid arthritis ¹ (1st-line DMARD) and other inflammatory joint and muscle disorders, psoriasis (if severe/resistant), Ca (ALL, non-Hodgkin’s lymphoma, choriocarcinoma, various solid tumours), rarely in Crohn’s disease.

**Cl:** severe blood disorders, active infections, immunodeficiency, R/L (if either significant, otherwise caution), P (females and males must avoid conception for ≥3 months after stopping treatment), B.
**Caution:** effusions (esp ascites and pleural effusions: drain before starting treatment as risk of ↑toxicity), ↑rheumatoid nodules, blood disorders, UC, PU, ↓immunity, porphyria, E.

**SE:** mucositis/GI upset, myelosuppression, skin reactions. Rarely pulmonary fibrosis/pneumonitis (esp in RA), liver toxicity/hepatic fibrosis (esp in psoriasis), neurotoxicity (incl necrotising demyelinating leukoencephalopathy), seizures, RF (esp tubular necrosis).

**Monitor:** U&Es, FBC, LFTs ± procollagen 3 protein (to monitor for hepatic fibrosis).

**Interactions:** NSAIDs (e.g. concomitant use in RA), trimethoprim, co-trimoxazole, corticosteroids (e.g concomitant use in RA), probenecid, nitrous oxide, pyrimethamine, clozapine, cisplatin, acitretin, ciclosporin all ⇒ ↑toxicity ± levels.

**Warn:** avoid over-the-counter NSAIDs*, report any clinical features of infection (esp sore throat).

**Dose:** Oral: start 7.5 mg once weekly (max oral weekly dose 20 mg)¹. For other indications and routes see BNF/SPC. NB: ↓dose in RF. *Usually needs concomitant folic acid (range 5 mg once/wk–5 days/wk (omitted day of and day after, methotrexate)).

**METHOTRIMEPRAZINE** see Levomepromazine; DA antagonist.

**METHYLDOPA**

Centrally acting α₂ agonist.

**Use:** HTN; esp pregnancy-induced and 1° HTN during pregnancy.

**CI:** depression, phaeo, porphyria, L (if active liver disease).

**Caution:** Hx of depression/L, R.

**SE:** (minimal if dose <1 g/day) dry mouth, sedation, dizziness, weakness, headache, GI upset, postural ↓BP, ↓HR. Rarely blood disorders, hepatotoxicity, pancreatitis, Ψ disorders, Parkinsonism, lupus-like syndrome, false +ve direct Coombs’ test.

**Monitor:** FBC, LFTs.
**Interactions:** ↑s neurotoxicity of lithium. Hypotensive fx ↑d by antidepressants, anaesthetics and salbutamol ivi. 🚫 Avoid with, or within 2 wks of, MAOIs 🚫.  
**Dose:** initially 250 mg bd/tds (125 mg bd in elderly), ↑ing gradually at intervals ≥2 days (max 2 g/day in elderly) to max of 3 g/day. NB: ↓dose in RF.

---

**METHYLPREDNISOLONE**

Glucocorticoid (mild mineralocorticoid activity).  
**Use:** acute flares of inflammatory diseases\(^1\) (esp rheumatoid arthritis, MS), cerebral oedema, Rx of graft rejection.  
**CI/Caution/SE/Interactions:** see Steroids section (p. 217).  
**Dose:** acutely, 10–500 mg ivi\(^1\); up to 1 g ivi od for up to 3 days\(^2\). Also available po and as im depot\(^\text{BNF}\).

---

**METOCLOPRAMIDE/MAXOLON**

Antiemetic: D\(_2\) antagonist: acts on central chemoreceptor trigger zone and directly stimulates GI tract (⇒ ↑motility).  
**Use:** N&V, esp GI (gastroduodenal, biliary, hepatic) or opiate-/chemotherapy-induced.  
**CI:** GI obstruction/perforation/haemorrhage (inc 3–4 days post-GI surgery), phaeo, B.  
**Caution:** epilepsy, porphyria, L/R/P/E.  
**SE:** extrapyramidal fx (see p. 278 – esp in elderly and young females: reversible if drug stopped w/in 24 h or with procyclidine), drowsiness, restlessness (akathisia), GI upset, behavioural/mood Δs, ↑prolactin. Rarely skin reactions, neuroleptic malignant syndrome.  
**Interactions:** ↑s fx of NSAIDs and ciclosporin levels. ↑s risk of extrapyramidal fx of antipsychotics, SSRIs and TCAs.  
**Dose:** 10 mg tds po/im/iv. NB: ↓dose if RF, LF, 15–19 yrs old or weight <60 kg.

---

**METOLAZONE**

Potent thiazide-like diuretic: as bendroflumethiazide, plus has additive diuretic fx with loop diuretics.  
**Use:** oedema\(^1\), HTN\(^2\) (for advice on stepped HTN Mx see p. 235).
**METRONIDAZOLE** / FLAGYL

Antibiotic, 'cidal': binds DNA of anaerobic (and microaerophilic) bacteria/protozoa.

**Use:** anaerobic and protozoal infections, abdominal sepsis (esp Bacteroides), aspiration pneumonia, C. difficile (AAC), H. pylori eradication, Giardia/Entamoeba infections, Px during GI surgery. Also dental/gynaecological infections, bacterial vaginosis (Gardnerella), PID.

**Caution:** avoid with alcohol: drug metabolised to acetaldehyde and other toxins ⇒ flushing, abdominal pain, ↓BP (‘disulfiram-like’ reaction), acute porphyria, L/P/B.

**SE:** GI upset (esp N&V), taste disturbed, skin reactions. Rarely, drowsiness, headache, dizziness, dark urine, hepatotoxicity, blood disorders, myalgia, arthralgia, seizures (transient), ataxia, peripheral neuropathy (if prolonged Rx).

**Interactions:** can ↑busulfan, lithium, ciclosporin and phenytoin levels, W +.

**Dose:** 500 mg tds ivi/400 mg tds po for severe infections. Lower doses can be given po or higher doses pr (1 g bd/tds) according to indication. NB: ↓dose in LF.
MICONAZOLE
Imidazole antifungal (topical) but *systemic absorption can occur*.
**Use:** oral fungal infections (give po), cutaneous fungal infections (give topically).
**Cl:** L. Oral gel – in infants: impaired swallowing reflex, and up to 5–6 months if born pre-term.
**Caution:** acute porphyria, P/B.
**SE:** GI upset. Rarely hypersensitivity, hepatotoxicity.
**Interactions:** as ketoconazole, but less commonly significant. W +.
**Dose:** po: oral gel (Daktarin) 5–10 ml qds (after food); 2.5 ml bd (4 months–2 yrs), 5 ml bd (2–6 yrs), 5 ml qds (6 yrs+) or buccal tablets (Loramyc) 50 mg od mane. NB: with oral gel treat for 48 h after lesions healed. **top:** apply 1–2 times/day.

MIDAZOLAM
Benzodiazepine, very short-acting.
**Use:** sedation for stressful/painful procedures (esp if amnesia desirable) and for agitation/distress in palliative care.
**Cl/Caution/SE/Warn/Interactions:** see Diazepam.
**Dose:** 1.0–7.5 mg iv; initially 2 mg (0.5–1 mg if elderly) over 60 sec, then titrate up slowly until desired sedation achieved using 0.5–1.0-mg boluses over 30 sec (can also give im); 2.5–5 mg sc prn (or via sc pump). Also available as buccal liquid (with 2.5, 5 or 10 mg/ml, ‘special order’ preparations) – unlicensed use.
**NB:** ↓dose in RF or elderly.

**MINOCYCLINE**
Tetracycline antibiotic: inhibits ribosomal (30S subunit) protein synthesis; broadest spectrum of tetracyclines.
**Use:** acne, rosacea.
**Cl/Caution/SE/Interactions:** as tetracycline, but ↓bacterial resistance, although ↑risk of SLE and irreversible skin/body fluid
discoloration. Can also use (with caution) in RF. Check hepatic toxicity every 3 months – discontinue if develops.  
**Dose:** 100 mg od po¹ (can ↑to bd for other indications). Use for ≥ 6 weeks in acne.

**MINOXIDIL**  
Peripheral vasodilator (arterioles >> veins): also ⇒ ↑CO, ↑HR, fluid retention .: *always needs concurrent* β-blocker and diuretic.  
**Use:** HTN (if severe/Rx-resistant); *for HTN Mx advice see p. 235*.  
**CI:** phaeo.  
**Caution:** IHD, acute porphyria, **R/P/B**.  
**SE:** hypertrichosis, coarsening of facial features (reversible, but makes it less suitable for women), ↑Wt, peripheral oedema, pericardial effusions, angina (dt ↑HR). Rarely, GI upset, gynaecomastia/breast tenderness, renal impairment, skin reactions.  
**Dose:** initially 2.5–5 mg/day in 1 or 2 divided doses, ↑ing by 5–10 mg at an interval of at least 3 days if needed up to usual max of 50 mg/day. **NB:** ↓dose in elderly and dialysis patients. Also used topically for male-pattern baldness.

**MIRTAZAPINE/ZISPIN**  
Antidepressant: Noradrenaline And Specific Serotonin Agonist (NASSA); specifically stimulates 5HT₁ receptors (antagonises 5HT₂C/5HT₃), antagonises central presynaptic α₂ receptors.  
**Use:** depression, esp in elderly* or if insomnia†.  
**CI/Caution/SE:** as fluoxetine, but ⇒ ↓sexual dysfunction/GI upset, ↑sedation† (esp during titration) and ↑appetite/Wt (can be beneficial in elderly*). Rarely, blood disorders (inc agranulocytosis**), Δ LFTs, convulsions, myoclonus, oedema.  
**Warn:** of initial sedation, to not stop suddenly (risk of withdrawal) and to report signs of infection** (esp sore throat, fever): stop drug and check FBC if concerned.  
**Interactions:** avoid with other sedatives (inc alcohol), artemether/lumefantrine. ♦ Never give with, or ≤2 wks after, MAOIs ♦.  
**Dose:** initially 15 mg nocte, ↑ing to 30 mg after 1–2 wks (max 45 mg/day). **Note lower doses more sedating than higher doses.**
MISOPROSTOL
Synthetic PGE$_1$ analogue: ↓s gastric acid secretion.
**Use:** Px/Rx of PU (esp NSAID-induced). Unlicensed uses: po or topically to cervix for induction of labour, to induce medical abortion and to ripen cervix for surgical abortion; also pr in postpartum haemorrhage.

**CI:** 🍼 pregnancy 🍼 (actual or planned; only give to women of childbearing age if high risk of PU and contraceptives prescribed), P/B.

**Caution:** cardiovascular/cerebrovascular disease (can ⇒ ↓BP), IBD.

**SE:** diarrhoea. Rarely, other GI upset, rash, light-headedness, menstrual Δs, vaginal bleeding.

**Warn:** women of child-bearing age of risks to pregnancy and need for adequate contraception when taking.

**Dose:** most often used with diclofenac as Arthrotec. Also available with naproxen as Napratec. Both these preparations contain 200 microgram misoprostol per tablet, i.e. total daily dose < the ideal 800 microgram.

**MMF** see Mycophenolate mofetil; immunosuppressant.

**MOMETASONE (FUROATE) CREAM OR OINTMENT/ ELOCON**
Potent topical corticosteroid.

**Use:** inflammatory skin conditions, esp eczema.

**CI:** untreated infection, rosacea, acne.

**SE:** skin atrophy, worsening of infections, acne.

**Dose:** apply thinly od top (use ‘ointment’ in dry skin conditions).

**MONTELUKAST/SINGULAIR**
Leukotriene receptor antagonist: ↓s Ag-induced bronchoconstriction.

**Use:** non-acute asthma, esp if large exercise-induced component or associated seasonal allergic rhinitis.

**Caution:** acute asthma, Churg–Strauss syndrome P/B.

**SE:** headache, GI upset, myalgia, dry mouth/thirst. Rarely Churg–Strauss syndrome: asthma (± rhin-/sinus-itis) with systemic vasculitis and ↑EO*.
Monitor: FBC* and for development of vasculitic (purpuric/non-blanching) rash, peripheral neuropathy, \( \uparrow \) respiratory/cardiac symptoms: all signs of possible Churg–Strauss syndrome.  
Dose: 10 mg nocte (↓ doses if <15 years old\textsuperscript{SPC/BNF}).

MORPHGESIC SR Morphine (sulphate) SR (10, 30, 60 or 100 mg). Given bd. NB: ↓ dose if LF, RF or elderly.

MORPHINE (SULPHATE)  
Opiate analgesic.  
Use: severe pain (inc post-op), AMI and acute LVF.  
CI: acute respiratory depression, acute severe obstructive airways disease, \( \uparrow \) risk of paralytic ileus, delayed gastric emptying, biliary colic, acute alcoholism, \( \uparrow \) ICP/head injury (respiratory depression \( \Rightarrow \) CO\(_2\) retention and cerebral vasodilation \( \Rightarrow \) \( \uparrow \) ICP), phaeo. H (if 2° to chronic lung disease).  
Caution: ↓ respiratory reserve, obstructive airways disease, ↓ BP/shock, acute abdomen, biliary tract disorders (NB: biliary colic is CI), pancreatitis, bowel obstruction, IBD, \( \uparrow \) prostate/urethral stricture, arrhythmias, ↓ T\(_4\), adrenocorticoid insufficiency, MG, L (can ⇒ coma), R/P/B/E.  
SE: N&V (and other GI disturbance) constipation* (can ⇒ ileus), respiratory depression, ↓ BP (inc orthostatic. NB: rarely \( \Rightarrow \) \( \uparrow \) BP), ↓\( \uparrow \) HR, pulmonary oedema, oedema, bronchospasm, ↓ cough reflex, sedation, urinary retention, RF, biliary tract spasm, \( \uparrow \) pancreatitis, \( \uparrow \) LFTs, hypothermia, muscle rigidity/fasciculation/myoclonus, \( \uparrow \) ICP, dry mouth, vertigo, syncope, headache, miosis, sensory disturbance, pruritis, anorexia, allodynia, mood \( \Delta \)(\( \uparrow \) or ↓), delirium, hallucinations, restlessness, seizures (at ↑ doses), rhabdomyolysis, amenorrhoea, ↓ libido, dependence. Rarely, skin reactions.  
Interactions: \( \uparrow \) MAOIs (don’t give within 2 wks of) \( \uparrow \). Levels ↓ by ritonavir. ↓ s levels of ciprofloxacin. \( \uparrow \) sedative fx with antihistamines, baclofen, alcohol (also \( \Rightarrow \) ↓ BP), TCAs, antipsychotics (also ↓ BP), anxiolytics/hypnotics, barbiturates and
moclobemide (also ⇒ ↑CNS and ↑/↓BP). ↑s fx of sodium oxybate, gabapentin.

**Dose:** **Acute pain:** 5–20 mg sc/im 4-hrly; 2.5–15 mg iv up to 4-hrly (2 mg/min). NB: iv doses are generally 1/4–1/2 im doses. **AMI:** 5–10 mg iv (1–2 mg/min), repeated if necessary. **Acute LVF:** 1–2.5 mg iv (1 mg/min). **Chronic pain:** use po as Oramorph solution or as MST Continus, Morphgesic, MXL, Sevredol or Zomorph tablets; dose adjustment may be required when switching brands. Also available pr as suppositories of 10, 15, 20 and 30 mg giving 15–30 mg up to 4-hrly. **Unless short-term Rx, always consider laxative Px*. Can ↑doses and frequency with expert supervision. Always adjust dose to response. NB: ↓dose if LF, RF or elderly.

If ↓BMI or elderly, titrate dose up slowly, monitor O₂ sats and have naloxone ± resuscitation trolley at hand ☭.

**MST CONTINUS** Oral morphine (sulphate), equivalent in efficacy to Oramorph but SR: dose every 12 hrs. Need to specify if tablets (5, 10, 15, 30, 60, 100 or 200 mg) or suspension (sachets of 20, 30, 60, 100 or 200 mg to be mixed with water).

**MUPIROCIN/BACTROBAN**
Topical antibiotic for bacterial infections (esp eradication of nasal MRSA carriage); available as nasal ointment, applied bd/tds.

Local MRSA eradication protocols often exist; if not, then a sensible regimen is to give for 5 days and then swab 2 days later, repeating regimen if culture still positive.

**MXL CAPSULES** Morphine (sulphate) capsules (30, 60, 90, 120, 150 or 200 mg), equivalent in efficacy to Oramorph but SR: dose od. NB: ↓dose if LF, RF or elderly.

**MYCOPHENOLATE MOFETIL (MMF)**
Immunosuppressant: ↓s B-/T-cell lymphocytes (and ↓s Ab production by B-cells).

**Use:** transplant rejection Px, autoimmune diseases, vasculitis.

**Cl:** P/B
Caution: active serious GI diseases†, E.
Monitor: FBC and LFTs (wkly for 1st 4 weeks, 2-wkly for 2 months, then monthly for 1st year).
Warn: patient to report unexplained bruises/bleeding/signs of infection. Avoid strong sunlight*.
SE: GI upset, blood disorders (esp ↓NØ, ↓Pt), weakness, tremor, taste Δ, headache, ↑cholesterol, ↑or ↓K+. Rarely GI ulceration/bleeding/perforation†, hepatotoxicity, skin neoplasms*.
Interactions: Levels Ø by rifampicin.
Dose: Specialist use onlySPC/BNF.

N-ACETYLCYSTEINE see Acetylcysteine; paracetamol antidote.

NALOXONE
Opioid receptor antagonist for opiate reversal if OD or over-Rx.
Caution: cardiovascular disease, if taking cardiotoxic drugs, physical dependence on opioids, H.
Dose: 0.4–2 mg iv (or sc/im), much larger doses may be needed for certain opioids (e.g. tramadol), repeating after 2 min if no response (or ↑ing if severe poisoning). NB: Short-acting: may need repeating every 2–3 min (to total 10 mg) then review and consider ivi (10 mg made up to 50 ml with 5% dextrose; useful start rate is 60% of initial dose over 1 h, then adjusted to response).

NALTREXONE
Opioid antagonist: ↓s euphoria of opioids if dependence and ↓s craving and relapse rate in alcoholic withdrawal (opioids thought to mediate alcohol addiction; not licensed for this in UK yet).
Use: Opioid and alcohol withdrawal; start >1 wk after stopping*. CI: if still taking opioids (can precipitate withdrawal*), L (inc acute hepatitis), severe R.
Caution: P/B.
SE: GI upset, hepatotoxicity, sleep and Ψ disorders.
Monitor: LFTs.
Warn: patient that trying to overcome opiate blockade OD can ⇒ acute intoxication.
**Dose:** initial dose 25 mg od po, thereafter 50 mg od (or 350 mg per week split into 2 × 100 mg and 1 × 150 mg doses); specialist use only.

**NB:** also ↓s fx of opioid analgesics.

**NAPROXEN**
Moderate-strength NSAID; non-selective COX inhibitor.

**Use:** rheumatic disease¹; acute musculoskeletal pain and dysmenorrhoea²; acute gout³.

**Cl/Caution/SE/Interactions:** as ibuprofen, but somewhat ↑SEs, notably, ↑risk PU/GI bleeds. Lowest thrombotic risk of any NSAID. Probenecid ⇒ ↑serum levels. No known interaction with baclofen or triazoles. Mild W +.

**Dose:** 500 mg–1 g daily in 1–2 divided doses¹; 500 mg initially then 250 mg 6–8-hrly (max 1.25 g/day)²; 750 mg initially then 250 mg 8-hrly³. Also available with misoprostol as Px against PU (as Napratec). **NB:** Avoid or ↓dose in RF & consider gastroprotective Rx.

**NARATRIPTAN/NARAMIG**
5HT₁B/₁D agonist for acute migraine.

**Cl/Caution/SE/Interactions:** see Sumatriptan. Not recommended if >65 yrs.

**Dose:** 2.5 mg po (can repeat after ≥4 h if responded then recurs). Max 5 mg/24 h (2.5 mg if LF or RF, avoid if severe).

**NARCAN** see Naloxone; opiate antidote.

**NICORANDIL**
K⁺-channel activator (⇒ arterial dilation ⇒ ↓afterload) with nitrate component (⇒ venous dilation ⇒ ↓preload).

**Use:** angina Px/Rx (unresponsive to other Rx).

**Cl:** ↓BP (esp cardiogenic shock), LVF with ↓filling pressures, B.

**Caution:** hypovolaemia, acute pulmonary oedema, ACS with LVF and ↓filling pressures, P.
**SE:** headache (often only initially*), flushing, dizziness, weakness, N&V, ↓BP, ↑HR (dose-dependent). Rarely GI/perianal ulcers (consider stopping drug), myalgia, angioedema, hepatotoxicity. **Interactions:** ✅ risk of ↓↓BP with sildenafil-/tadalafil-/vardenafil ✅. **Dose:** 5–30 mg bd (start low, esp if susceptible to headaches*).

**NICOTINIC ACID/NIASPAN**
Water-soluble B-complex vitamin; ↓s synthesis of cholesterol/TGs and ↑s HDL-cholesterol. **Use:** dyslipidaemia (↑cholesterol, ↑TG, ↓HDL-cholesterol) added to statin or if statin not tolerated. **CI:** active bleeding, active PU disease. L(if severe)/B. **Caution:** ACS, gout, history of PU, ↑alcohol intake, DM. R/P. **SE:** GI upset, dyspepsia, flushing, itch, rash, headache ↑HR, ↓BP, syncope, SOB, oedema, ↑uric acid, ↑INR, ↓Pt, ↓phosphate, DM, muscle disorders. Rarely rhabdomyolysis, anorexia. **Warn:** avoid alcohol or hot drink around time of tablet (↑flushing and itch); false +ve urine G result. Flushing prostaglandin mediated; can be avoided if ↓ initial dose taken with meals, or if taking aspirin give 30 mins before nicotinic acid. **Monitor:** BG, CK (if ↑risk myopathy) and LFTs (if mild-moderate LF). **Interactions:** ↑risk of myopathy with statins. **Dose:** 375 mg (MR tablets) od nocte after low fat snack; ↑dose weekly for 4 wks then monthly if needed. Maintenance dose 1–2 g od nocte.

**NIFEDIPINE**
Ca\(^{2+}\) channel blocker (dihydropyridine): dilates smooth muscle, esp arteries (inc coronaries). Reflex sympathetic drive ⇒ ↑HR and ↑contractility : ⇒ ↓HF cf other Ca\(^{2+}\) channel blockers (e.g. verapamil, and to a lesser degree diltiazem), which ⇒ ↓HR + ↓contractility. Also diuretic fx. **Use:** angina Px\(^1\), HTN\(^2\) (for advice on stepped HTN Mx see p. 235), Raynaud’s\(^3\).
**Cl:** cardiogenic shock, clinically significant aortic stenosis, ACS (inc w/in 1 month of MI).

**Caution:** angina or LVF can worsen (consider stopping drug), ↓BP, DM, BPH, acute porphyria L/R/H/P/B.

**SE:** flushing, headache, ankle oedema, dizziness, ↓BP, palpitations, poly-/nocturia, rash/pruritus, GI upset, weakness, myalgia, arthralgia, gum hyperplasia, rhinitis. Rarely, PU, hepatotoxicity.

**Interactions:** metab by P450. ↑s fx of digoxin, theophylline and tacrolimus. ↓s fx of quinidine. Quinu-/dalfo-pristin, ritonavir and grapefruit juice ↑fx of nifedipine. Rifampicin, phenytoin and carbamazepine ↓fx of nifedipine. Risk of ↓↓BP with α-blockers, β-blockers or Mg$^{2+}$ iv/im.

**Dose:** 5–20 mg tds po; use long-acting preparations for HTN/angina, as normal-release preparations ⇒ erratic BP control and reflex ↑HR, which can worsen IHD (e.g. Adalat LA or Retard and many others with differing fx and doses$^{SPC/BNF}$). **NB:** ↓dose if severe LF.

**NITROFURANTOIN**

Antibiotic: only active in urine (no systemic antibacterial fx).

**Use:** UTIs (but not pyelonephritis).

**Cl:** G6PD deficiency, acute porphyria, R (also ⇒ ↓activity of drug: it needs to be concentrated in urine), infants <3 yrs old, P/B.

**Caution:** DM, lung disease, ↓Hb, ↓vitamin B, ↓folate, electrolyte imbalance, susceptibility to peripheral neuropathy, L/E.

**SE:** GI upset, pulmonary reactions (inc effusions, fibrosis), peripheral neuropathy, hypersensitivity. Rarely, hepatotoxicity, cholestasis, pancreatitis, arthralgia, alopecia (transient), skin reactions (esp exfoliative dermatitis), blood disorders, BIH.

**Dose:** 50 mg qds po (↑to 100 mg if severe chronic recurrent infection); od nocte if for Px. Take with food. Not available iv or im.

**NB:** can ⇒ false-positive urine dipstick for glucose and discolour urine.
NORADRENALINE (= NOREPINEPHRINE)
Vasoconstrictor sympathomimetic: stimulates α-receptors ⇒ vasoconstriction.
**Use:** ↓BP (unresponsive to other Rx).
**CI:** ↑BP, P.
**Caution:** thrombosis (coronary/mesenteric/peripheral), Prinzmetal’s angina, post-MI, ↑T₄, DM, ↓O₂, ↑CO₂, hypovolaemia (uncorrected), E.
**SE:** can ↓BF to vital organs (esp kidney). Also headache, ↓HR, arrhythmias, peripheral ischaemia. ↑BP if over-Rx.
**Interactions:** risk of arrhythmias with halothane and cyclopropane. Risk of ↑BP with clonidine, MAOIs and TCAs.
**Dose:** 80 microgram/ml iv at 0.16–0.33 ml/min (adjust according to response). (NB: doses given here are for noradrenaline acid tartrate, not base.)

NORETHISTERONE
Progestogen (testosterone analogue).
**Use:** endometriosis¹, dysfunctional uterine bleeding and menorrhagia², dysmenorrhoea³, postponement of menstruation⁴.
**CI:** liver/genital/breast cancers (unless progestogens being used for these conditions), atherosclerosis, undiagnosed vaginal bleeding, acute porphyria, Hx of idiopathic jaundice, severe pruritis, pemphigoid during pregnancy.
**Caution:** risk of fluid retention, TE disease, DM, depression. L/H/R.
**SE:** ↑weight, nausea, headache, dizziness, insomnia, drowsiness, breast tenderness, acne, depression, Δ libido, skin reactions, hirsuitism & alopecia.
**Dose:** 5 mg bd-tds po for ≥4–6 months, commencing on day 5 of cycle (can ↑ to 10 mg bd-tds (max 25 mg / day) if spotting occurs, ↓ing when stops)¹; 5 mg tds po for 10 days for Rx (for Px give 5 mg bd po from day 19–26 of cycle)²; 5 mg tds po from day 5–24 for 3–4 cycles³; 5 mg tds po starting 3 days prior to expected menstruation onset (bleeding will commence 2–3 days after stopping)⁴.
NUROFEN see Ibuprofen; NB: ‘over-the-counter’ use can ⇒ poor response to HTN and HF Rx.

NYSTATIN
Polyene antifungal.
**Use:** *Candida* infections: topically for skin/mucous membranes (esp mouth/vagina); po for GI infections (not absorbed).
**SE:** GI upset (at ↑doses), skin reactions.
**Dose:** po suspension: 100,000 units qds, usually for 1 wk, for Rx after food.

OFLOXACIN 0.3% EYE DROPS/EXOCIN
Topical antibiotic; mostly used for corneal ulcers\(^1\) (only start if corneal Gram stain/cultures taken and specialist not available).
**Caution:** P/B.
**SE:** local irritation. Rarely dizziness, headache, numbness, nausea.
**Dose:** 1 drop 2–4 hourly for 1st 2 days then qds (max 10 days)\(^1\). See SPC for other uses.

OLANZAPINE/ZYPREXA
‘Atypical’ antipsychotic: D\(_1\), D\(_2\), D\(_4\) and 5HT\(_2\) (+ mild muscarinic) antagonist.
**Use:** schizophrenia\(^{\text{NICE}}\), mania, bipolar Px, acute sedation.
**CI:** B. If giving im also acute MI/ACS, ↓↓BP/HR, SSS or recent heart surgery. See also Chlorpromazine.
**Caution:** drugs that ↑QTc, dementia, cardiovascular disease (esp if Hx of or ↑risk of CVA/TIA), DM*, ↑prostate, glaucoma (angle closure), Parkinson’s, Hx of epilepsy, blood disorders, paralytic ileus. ↑s fx of alcohol, L/R/H/P/E.
**SE:** sedation, ↑Wt, ankle oedema, Δ LFTs, postural ↓BP (esp initially ↓↑titrate up dose slowly). ↑glucose* (rarely diabetic DM/DKA). Also extrapyramidal/anticholinergic fx (see p. 278; often transient) and rarely neuroleptic malignant syndrome and hepatotoxicity.
**Monitor:** BG* (± HbA\(_1\)C), LFTs, U&Es, FBC, prolactin, Wt, lipids (and CK if neuroleptic malignant syndrome suspected). If giving im closely monitor cardiorespiratory function for ≥4 h post-dose, esp if given other antipsychotic or benzodiazepine.
**Interactions:** metab by P450. many, but most importantly, levels ↓ by carbamazepine and smoking. ↑ risk of ↓ NO with valproate. Levels may be ↑ by ciprofloxacin. ↑ risk of CNS toxicity with sibutramine. ↑ risk of arrhythmias with drugs that ↑ QTc and atomoxetine. ↑ risk of ↓ BP with general anaesthetics. ↓ s fx of anticonvulsants.

**Dose:** 5–20 mg po daily (preferably nocte to avoid daytime sedation). Available in ‘melt’ form if ↓ compliance/swallowing (as Velotab). Available in quick-acting im form (▼) for acute sedation; give 5–10 mg (2.5–5 mg in elderly) repeating 2 h later if necessary to max total daily dose, inc po doses, of 20 mg (max 3 injections/day for 3 days).

NB: im doses not recommended with im/iv benzodiazepines (↑ risk of respiratory depression) which should be given ≥ 1 h later; if benzodiazepines already given, use with caution and closely monitor cardiorespiratory function.

**OLMESARTAN/OLMETEC**
Angiotensin II antagonist: see Losartan.

**Use:** HTN; for advice on stepped HTN Mx see p. 235.

**CI:** biliary obstruction, P/B.

**Caution/SE/Interactions:** see Losartan.

**Dose:** initially 10 mg od, ↑ ing to max 40 mg (20 mg in LF, RF or elderly).

**OMEGA-3-ACID ETHYL ESTERS 90/OMACOR**
Essential fatty acid combination: 1 g capsule = eicosapentaenoic acid 460 mg and decosahexaenoic acid 380 mg.

**Use:** Adjunct to diet in type IIb and III ↑ TG1 (with statin) or type IV. Added for 2° prevention w/in 3 months of acute MI2.

**CI:** B.

**Caution:** bleeding disorders, anticoagulants, DM L/P.

**SE:** GI; rarer: taste disorder, dry nose, dizziness, hypersensitivity, hepatotoxicity, headache, rash, ↓ BP, DM, ↑ WBC.

**Monitor:** LFTs, INR.

**Dose:** Capsules: 2–4 g od1; 1 g od2. Take with food.
OMEPRAZOLE/LOSEC
PPI: inhibits H⁺/K⁺ ATPase of parietal cells ⇒ ↓ acid secretion.
Use: PU Rx/Px (esp if on NSAIDs), gastro-oesophageal reflux disease (if symptoms severe or complicated by haemorrhage/ulcers/stricture)\textsuperscript{NICE}. Also used for \textit{H. pylori} eradication and ZE syndrome.
Caution: can mask symptoms of gastric Ca, L/P/B.
SE: GI upset, headache, dizziness, arthralgia, weakness, skin reactions. Rarely, hepatotoxicity, blood disorders, hypersensitivity.
Interactions: ↓ (and ↑) \textbf{P450} \textbf{\&} many, most importantly ↑s phenoxytoin, cilostazol, diazepam, raltegravir and digoxin levels. ↓s fx of ataza-/nelfi-/tipra-navir, mild W +.
Dose: 20 mg od po, ↑ing to 40 mg in severe/resistant cases and ↓ing to 10 mg od for maintenance if symptoms stable; 20 mg bd for \textit{H. pylori} eradication regimens. If unable to take po (e.g. perioperatively, ↓GCS, on ITU), give 40 mg iv od either over 5 min or as ivi over 20–30 min. NB: max dose 20 mg if LF.

ND: also specialist use iv for acute bleeds. Usually as 8 mg/h ivi for 72 h if endoscopic evidence of PU (prescribed as divided infusions, as drug is unstable). Contact pharmacy ± GI team for advice on indications and exact dosing regimens.

ONDANSETRON
Antiemetic: 5HT\textsubscript{3} antagonist: acts on central and GI receptors.
Use: N&V, esp if resistant to other Rx or severe postoperative/chemotherapy-induced.
Caution: GI obstruction (inc subacute), ↑QTc*, L (unless mild), P/B.
SE: constipation (or diarrhoea), headache, sedation, fatigue, dizziness. Rarely seizures, chest pain, ↓BP, \Delta LFTs, rash, hypersensitivity.
Interactions: metab by \textbf{P450}. Levels ↓by rifampicin, carbamazepine and phenoxytoin. ↓s fx of tramadol. Avoid with drugs that ↑QTc*.
Dose: 8 mg bd po; 16 mg od pr; 8 mg 2–8-hrly iv/im. Max 24 mg/day usually (8 mg/day if LF). Can also give as ivi at 1 mg/h for max of 24 h. Exact dose and route depends on indication\textsuperscript{SPC/BNF}. 
**ORAMORPH** Oral morphine solution for severe pain, esp useful for prn or breakthrough pain.  
**Dose:** Multiply sc/im morphine dose by 2 to obtain approx equivalent* Oramorph dose. NB: ↓dose if LF or RF.  
Solution mostly commonly used is 10 mg/5 ml, but can be 100 mg/5 ml ↓. *specify strength if prescribing in ml (rather than mg).*

**OTOSPORIN** Ear drops for otitis externa (esp if bacterial infection suspected): contains antibacterials (neomycin, polymyxin B) and hydrocortisone 1%.  
**Dose:** 3 drops tds/qds.

**OXYBUTYNIN**  
Anticholinergic (selective M$_3$ antagonist); antispasmodic (↓s bladder muscle contractions).  
**Use:** detrusor instability (also neurogenic bladder instability, nocturnal enuresis).  
**Cl:** bladder outflow or GI obstruction, urinary retention, severe UC/toxic megacolon, glaucoma (narrow angle), MG, B.  
**Caution:** ↑prostate, autonomic neuropathy, hiatus hernia (if reflux), ↑T$_4$, IHD, arrhythmias, porphyria, L/R/H/P/E.  
**Se:** antimuscarinic fx (see p. 276), GI upset, palpitations/↑HR, skin reactions – mostly dose-related and reportedly less severe in MR preparations*.  
**Dose:** initially 5 mg bd/tds po (2.5 mg bd if elderly) ↑ing if required to max of 5 mg qds (bd if elderly). Also available as MR tablet (Lyrinel XL* 5–20 mg od) and transdermal patch (Kentera 36 mg; releases 3.9 mg/day and lasts 3–4 days).

**OXYCODONE (HYDROCHLORIDE)/OXYNORM**  
Opioid for moderate/severe pain (esp in palliative care.)  
**Cl:** as fentanyl, plus acute abdomen, delayed gastric emptying, chronic constipation, cor pulmonale, acute porphyria. L (if moderate/severe)/R (if severe), P/B.  
**Caution:** all other conditions where morphine is Cl/cautioned.
SE/Interactions: as morphine, but does not interact with baclofen, gabapentin and ritonavir.

**Dose:** 4–6-hrly po/sc/iv or as sc infusion. NB: 2.5 mg sc/iv = 5 mg po = approx 10 mg morphine po. Available in MR form as OxyContin (12-hrly). Available with naloxone (works locally to ↓GI SEs) as ▼ Targinact (12-hrly). NB: ↓dose if LF, RF or elderly.

### OXYTETRACYCLINE
Tetracycline antibiotic: inhibits ribosomal protein synthesis.

**Use:** acne vulgaris (and rosacea).

**CI/Caution/SE/Interactions:** as tetracycline, plus caution in porphyria.

**Dose:** 500 mg bd po (1 h before food or on empty stomach) for ≥16 wks.

### PABRINEX
Parenteral (iv or im) vitamins that come as a pair of vials. Vial 1 contains B₁ (thiamine*), B₂ (riboflavin) and B₆ (pyridoxine). Vial 2 contains C (ascorbic acid), nicotinamide and glucose.

**Use:** Acute vitamin deficiencies (esp thiamine*).

**Caution:** Rarely ⇒ anaphylaxis (esp if given iv too quickly; should be given over ≥ 30 mins). Ensure access to resuscitation facilities.

*See p. 273 for Wernicke’s encephalopathy Px/Rx in alcohol withdrawal.

### (DISODIUM) PAMIDRONATE
Bisphosphonate: ↓s osteoclastic bone resorption.

**Use:** ↑Ca²⁺ (esp metastatic: also ↓s pain), Paget’s disease, myeloma.

**CI:** P/B.

**Caution:** Hx of thyroid surgery, cardiac disease, L/R/H.

**SE:** ‘flu-like symptoms (inc fever, transient pyrexia), GI upset (inc haemorrhage), dizziness/somnolence (common post-dose*), ↑ (or ↓) BP, seizures, musculoskeletal pain, osteonecrosis of jaw
(esp in cancer patients; consider dental examination or preventative Rx – MHRA advice), e’lyte Δs (↓PO₄, ↓or ↑K⁺, ↑Na⁺, ↓Mg²⁺), RF, blood disorders.

**Monitor:** e’lytes (inc U&E before each dose), Ca²⁺, PO₄⁻, before starting biphosphonate consider dental check as risk of osteonecrosis of the jaw.

**Warn:** not to drive/operate machinery immediately after Rx*.

**Dose:** 15–90 mg ivi according to indication (±Ca²⁺ levels¹). NB: if RF max rate of ivi 20 mg/h (unless for life-threatening ↑Ca²⁺). *Never given regularly for sustained periods.*

---

**PANCURONIUM**

Neuromuscular blocker; as vecuronium but ↑duration of action (60–120 mins).

**Use:** neuromuscular blockade for surgery¹ or during intensive care².

**CI:** anaesthetist not confident of airway maintenance.

**Caution:** hypersensitivity to other neuromuscular blockers (allergic cross-reactivity), neuromuscular disease (MG/Eaton-Lambert syndrome, old polio), ↑BP, fluid/e’lyte Δ (unpredictable response). L (slower onset, ↑dose requirement, ↑recovery time) / R (↑duration of block).

**SE:** ↑HR, ↑BP, myopathy.

**Warn:** Don’t drive for 24h after full recovery. Injection painful.

**Monitor:** Cardiac, respiratory & motor function.

**Interactions:** fx ↑ by aminoglycosides, clindamycin and polymyxins. Only administer after full recovery from neuromuscular blockade from suxamethonium. Corticosteroids can ↑ risk of myopathy. Tricyclic antidepressants can ⇒ arrhythmia.

**Dose:** initially 100 micrograms/kg then 20 micrograms/kg iv as required¹; initially 100 micrograms/kg (optional) then 60 micrograms/kg iv every 60–90 mins². **NB:** if obese (weight 30% above ideal body weight (IBW; see p.296)) use IBW for dose calculation.

*Specialist use only; respiration needs assistance / control until drug inactivated or antagonised and anaesthetic / sedative to prevent awareness.*
PANTOPRAZOLE
PPI; as omeprazole, but ↓interactions and can ⇒ ↑TGs.
**Dose:** 20–80 mg mane po (↓ing to 20 mg maintenance if symptoms allow). If unable to take po (e.g. perioperatively, ↓GCS, on ITU), can give 40 mg iv over ≥2 min (or as ivi) od. ↑doses if ZE syndrome. NB: ↓dose if RF or LF.

PARACETAMOL
Antipyretic & mild analgesic. Unlike NSAIDs, *has no anti-inflammatory fx*.
**Use:** mild pain (or moderate/severe in combination with other Rx), pyrexia.
**Caution:** alcohol dependence, L (CI if severe liver disease), R.
**SE:** all rare: rash, blood disorders, hepatic (rarely renal) failure – esp if over-Rx/OD (for Mx, see p. 279).
**Interactions:** may W + if prolonged regular use.
**Dose:** 0.5–1 g po/pr; 1 g (or 15 mg/kg if <50 kg) iv. All doses 4–6 hourly, max 4 g/day. Max 3 g/day iv (▼) in LF, dehydration, chronic alcoholism or chronic malnutrition. Minimum iv dosing interval in RF: 6-hrly. (For children, see Calpol.)

PAROXETINE/SEROXAT
SSRI antidepressant; as fluoxetine, but ↓t₁/₂ *.
**Use:** depression¹, other Ψ disorders (social/generalised anxiety disorder¹, PTSD¹, panic disorder², OCD³).
**CI/Caution/SE/Interactions:** as fluoxetine, but ↓frequency of agitation/insomnia, although ↑frequency of antimuscarinic fx (see p. 276), extrapyramidal fx (see p. 278) and withdrawal fx* (see p. 277). Avoid if <18 yrs old as may ↑suicide risk & hostility. Also does not ↑carbamazepine levels (but its levels are ↓by carbamazepine) but ↑s galantamine levels. Risk of CNS toxicity if given with tramadol. Avoid if patient enters manic stage. P.
**Dose:** initially 20 mg¹,³ (10 mg²) mane, ↑ing if required to max 50 mg¹ or 60 mg²,³.
NB: ↓dose if RF, LF or elderly.
Stop slowly over at least a few weeks, as short $t_{1/2} \Rightarrow \uparrow$ risk of withdrawal syndrome.

**PARVOLEX** see Acetylcysteine; antidote for paracetamol poisoning.

**PENICILLAMINE**
Chelates copper/lead $\Rightarrow \uparrow$ elimination (also acts as DMARD): slow onset of action (6–12 wks).

**Use:** Wilson’s disease*, copper/lead poisoning, rarely for rheumatoid arthritis (also autoimmune hepatitis, cystinuria).

**CI:** SLE, R (unless mild when only caution).

**Caution:** penicillin allergy (can also be penicillamine allergic), taking other nephrotoxic drugs, P.

**SE:** RF (esp immune nephritis $\Rightarrow$ proteinuria*: stop drug if severe), blood disorders ($\downarrow$Pt, $\downarrow$NØ, agranulocytosis, aplastic $\downarrow$Hb), rashes (inc SJS, pemphigus), taste $\Delta$s, GI upset (esp nausea, but $\downarrow$s if taken with food). Can $\uparrow$ neurological symptoms in Wilson’s. Rarely hepatotoxicity, pancreatitis, autoimmune phenomena: poly-/dermatomyositis, Goodpasture’s syndrome, lupus-/myasthenia-like syndromes.

**Warn:** immediately report sore throat, fever, infection, non-specific illness, unexpected bleeding/bruising, purpura, mouth ulcers or rash.

**Monitor:** FBC, U&Es, urine dipstick ± 24-h collection*.

**Interactions:** $\uparrow$ risk of agranulocytosis with clozapine. Absorption $\downarrow$ by antacids and FeSO$_4$. Can $\downarrow$ levels of digoxin.

**Dose:** 125–2000 mg daily$^{SPCBNF}$ depending on indication.

**NB:** consider $\downarrow$ dose if RF or elderly.

Can $\Rightarrow \downarrow$ pyridoxine which often needs supplementing. Consider stopping if fever, lymphaedemopathy, $\downarrow$Pt/NØ, proteinuria or worsening neuro symptoms. Sensitivity occurs in 10%; can restart with prednisolone – get senior advice.

**PENICILLIN G** see Benzylpenicillin.

**PENICILLIN V** see Phenoxymerthylpenicillin.
PENTASA see Mesalazine; aminosalicylate for UC, with ↓SEs.

PEPPERMINT OIL
Antispasmodic: direct relaxant of GI smooth muscle.
**Use:** GI muscle spasm, distension (esp IBS).
**SE:** perianal irritation, indigestion. Rarely rash or other allergy.
**Dose:** 1–2 capsules tds, before meals and with water.

PEPTAC Alginate raft-forming oral suspension for acid reflux.
**Dose:** 10–20 ml after meals and at bedtime (NB: 3 mmol Na⁺/5 ml).

PERINDOPRIL/COVERSYL
ACE-i; see Captopril.
**Use:** HTN (for advice on stepped HTN Mx see p. 235), HF, Px of IHD.
**Cl/Caution/SE/Monitor/Interactions:** as Captopril, plus can ⇒ mood/sleep Δs.
**Dose:** 2–8 mg od³⁵⁸ SPC/BNF, starting at 2–4 mg od. NB: consider ↓dose if RF, elderly, taking a diuretic, cardiac decompensation or volume depletion.

PETHIDINE
Opioid; less potent than morphine but quicker action ⇒ ↑euphoria + ↑abuse/dependence potential . not for chronic use e.g. in palliative care.
**Use:** moderate/severe pain, obstetric and peri-op analgesia.
**Cl:** acute respiratory depression, risk of ileus, ↑ICP/head injury/coma, phaeo.
**Caution:** any other condition where morphine Cl/cautioned.
**SE:** as morphine, but ↓constipation. Toxic metabolites can accumulate.
**Interactions:** as morphine but 🐞 ↑risk of hyperpyrexia/CNS toxicity with MAOIs 🐞. Ritonavir ⇒ ↓levels and ↑s toxic metabolites. May ↑serotonergic effects of duloxetine. No known interaction with gabapentin or baclofen.
**Dose:** 25–100 mg up to 4-hrly im/sc (can give 2-hrly post-op or 1–3-hrly in labour with max 400 mg/24 hrs); 25–50 mg up to 4-hrly
slow iv. Rarely used po: 50–150 mg up to 4-hrly. NB: ↓dose if LF, RF or elderly.

**PHENOBARBITAL (≡ PHENOBARBITONE)**
Barbiturate antiepileptic: potentiates GABA (inhibitory neurotransmitter), antagonises fx of glutamate (excitatory neurotransmitter).

**Use:** status epilepticus (SEs and interactions limit other uses).

**Caution:** respiratory depression, acute porphyria, L/R/P/B/E.

**SE:** hepatitis, cholestasis, respiratory depression, sedation, ↓BP, ↓HR, ataxia, skin reactions. Rarely, paradoxical excitement (esp in elderly), blood disorders.

**Interactions:** ↑P450. ↓s levels/ fx of aripiprazole, antivirals, carbamazepine, Ca²⁺ antagonists, chloramphenicol, corticosteroids, ciclosporin, eplerenone, mianserin, tacrolimus, telithromycin, posa-/vori-conazole and OCP. Anticonvulsant fx ↓by antipsychotics, TCAs and SSRIs. Avoid with St John’s wort. ↑s fx of sodium oxybate. Caution with other sedative drugs (esp benzodiazepines), W–.

**Dose:** total of 10 mg/kg as ivi at 50–100 mg/min (max total 1 g).

**PHENOXYMETHYLPENICILLIN (≡ PENICILLIN V)**
As benzylpenicillin (penicillin G) but active orally: used for ENT/skin infections (esp erysipelas), Px of rheumatic fever/S. pneumoniae infections (esp post-splenectomy).

**Dose:** 0.5–1.0 g qds po (take on empty stomach; ≥ 1 hr before food or ≥ 2 hrs after food).

**PHENTOLAMINE**
α-Blocker, short-acting.

**Use:** HTN 2ᵉ to phaeo (esp during surgery).

**Cl:** ↓BP, IHD (inc Hx of MI).

**Caution:** PU/gastritis, asthma, R/P/B/E.

**SE:** ↓BP, ↑HR, dizziness, weakness, flushing, GI upset, nasal congestion. Rarely, coronary/cerebrovascular occlusion, arrhythmias.
**Interactions:** see Doxazosin.
**Dose:** 2–5 mg iv (repeat if necessary).

**PHENYLEPHRINE EYE DROPS**
Topical sympathomimetic for pupil dilation (commonly used in combination with cyclopentolate or tropicamide).
**Caution:** cardiovascular disease, ↑HR, ↑T₄, children E.
**SE:** blurred vision, local irritation, ↑BP, ↑HR, arrhythmias, coronary artery spasm.
**Dose:** 1 drop. 2.5% drops most common (10% available but ↑risk of ↑BP).

**PHENYTOIN**
Antiepileptic: blocks Na⁺ channels (stabilises neuronal membranes).
**Use:** all forms of epilepsy¹ (except absence seizures) inc status epilepticus².
**Cl:** if giving iv (do not apply if po); sinus ↓HR, Stokes–Adams syndrome, SAN block, 2nd-/3rd-degree HB, acute porphyria.
**Caution:** DM, porphyria ↓BP, L/H/P (⇒ cleft lip/palate, congenital heart disease), B.
**SE (acute):** dose-dependent: drowsiness (also confusion/dizziness), cerebellar fx (see p. 278), rash (common cause of intolerance and rarely ⇒ SJS/TEN), N&V, diplopia, dyskinesia (esp orofacial). If iv, risk of ↓BP (from propylene glycol diluent), arrhythmias* (esp ↑QRS), ‘purple glove syndrome’ (hand damage distal to injection site), CNS/respiratory depression.
**SE (chronic):** gum hypertrophy, coarse facies, hirsutism, acne, ↓folate (⇒ megaloblastic ↓Hb), Dupuytren’s, peripheral neuropathy, rickets, osteomalacia. Rarely, blood disorders, hepatotoxicity, suicidal thoughts/behaviour.
**Monitor:** FBC**, keep serum levels at 10–20 mg/l (narrow therapeutic index). ☠ If iv, closely monitor BP and ECG* (esp QRS) ☠.
**Warn:** report immediately any rash, mouth ulcers, sore throat, fever, bruising, bleeding.
**Interactions:** metab by and ↑s P450 :. many; most importantly ↓s fx of OCP, doxycycline, Ca²⁺ antagonists (esp nifedipine), imatinib,
lapatinib, ciclosporin, keto-/itra-/posa-conazole, indinavir, quinidine, theophyllines, eplerenone, telithromycin, aripiprazole, mianserin, mirtazapine, paroxetine, TCAs and corticosteroids. Fx ↓ by rifampicin, rifabutin, theophyllines, mefloquine, pyrimethamine, sucralfate, antipsychotics, TCAs and St John’s wort. Levels ↑ by NSAIDs (esp azapropropazone), fluoxetine, mi-/flu-/vori-conazole, diltiazem, disulfiram, trimethoprim, cimetidine, esomeprazole, amiodarone, metronidazole, chloramphenicol, clarithromycin, isoniazid, sulphonamides, sulfinpyrazone, topiramate (levels of which are ↓) and ethosuximide. Complex interactions with other antiepileptics\textsuperscript{SPC/BNF}. \textbf{W–} (or rarely \textbf{W +}).

**Dose:** po \textsuperscript{1}: 150–500 mg/day in 1–2 divided doses\textsuperscript{SPC/BNF}. iv \textsuperscript{2}: load with 18 mg/kg ivi at max rate of 25–50 mg/min, then maintenance iv doses of approximately 100 mg tds/qds, adjusting to weight, serum levels and clinical response. If available give iv as pro-drug fosphenytoin (NB: doses differ).

NB: ↓ dose if LF.

\begin{itemize}
  \item \textbf{Stop drug if ↓ WCC** is severe, worsening or symptomatic.}
\end{itemize}

**PHOSPHATE ENEMA**

Laxative enemas; ⇒ osmotic H\textsubscript{2}O retention ⇒ ↑ evacuation.

**Use:** severe constipation (unresponsive to other Rx).

**CI:** acute GI disorders.

**Caution:** if debilitated or neurological disorder, \textbf{E}.

**SE:** local irritation.

**Dose:** 1 prn.

**PHYLLOCONTIN CONTINUS** see Aminophylline (MR).

**Dose:** initially 1 tablet (225 mg) bd po, then ↑ to 2 tablets bd after 1 wk according to serum levels. (Forte tablets of 350 mg used if smoker/other cause of ↓ \text{t}_{1/2}, e.g. interactions with other drugs; see Theophylline.) NB: ↓ dose if LF.

**PHYTOMENADIONE**

Intravenous vit K\textsubscript{1} for warfarin overdose/poisoning; see p. 216.

**Caution:** give iv injections slowly. NB: not compatible with NaCl \textbf{P}. 

\textbf{NB:}
**Picolax** see Bowel preparations.

**Dose:** 1 sachet at 8 am and 3 pm the day before GI surgery or Ix.

**Pioglitazone/Actos**

Thiazolidinedione (glitazone) antidiabetic; ↓s peripheral insulin resistance (and, to lesser extent, hepatic gluconeogenesis).

**Use:** type 2 DM in combination with a sulphonylurea (if metformin not tolerated) or metformin (if risk of ↓glucose with sulphonylurea unacceptable) or sulphonylurea + metformin (if obese, metabolic syndrome or human insulin unacceptable due to lifestyle/personal issues)\(^NICE\).

**CI:** ACS (inc Hx of), previous or active bladder cancer, H (inc Hx of), L/P/B

**Caution:** peri-operatively cardiovascular disease. Omit pioglitazone peri-operatively as insulin needed. R.

**SE:** oedema (esp if HTN/CCF), ↓Hb, ↑Wt, GI upset (esp diarrhoea), headache, hypoglycaemia (if also taking sulphonylureas), ↑risk of distal fractures, rarely hepatotoxicity.

**Monitor:** LFTs. ![Discontinue if jaundice develops](image)

**Interactions:** levels ↓by rifampicin and ↑by gemfibrozil.

**Dose:** initially 15–30 mg od (max 45 mg od)

**Piperacillin**

Ureidopenicillin: antipseudomonal.

**Use:** only available with tazobactam* (β-lactamase inhibitor) as Tazocin, reserved for severe infections.

**CI/Caution/SE/Interactions:** see Benzylpenicillin.

**Dose:** see Tazocin*.

**Piriton** see Chlorphenamine; antihistamine for allergies.

**Plavix** see Clopidogrel; anti-Pt agent for Px of IHD (and CVA).

**Potassium Tablets** see Kay-cee-L (syrup 1 mmol/ml), Sando-K (effervescent 12 mmol/tablet) and Slow-K (MR non-
effervescent 8 mmol/tablet, reserved for when syrup/effervescent preparations are inappropriate; avoid if ↓swallow).

PRAMIPEXOLE/MIRAPEXIN
Dopamine agonist (non-ergot derived); use in early Parkinson’s ⇒ ↓motor complications (e.g. dyskinesias) but ↓motor performance cf L-dopa.

**Use:** Parkinson’s¹, moderate-severe restless legs syndrome (RLS)².

**CI:** B.

**Caution:** psychotic disorders, severe cardiovascular disease R/H/P.

**SE:** GI upset, sleepiness (inc sudden onset sleep), ↓BP (inc postural, esp initially), Ψ disorders (esp psychosis and impulse control disorders e.g. gambling and ↑sexuality), amnesia, headache, oedema.

**Warn:** sleepiness and ↓BP may impair skilled tasks (inc driving).

Avoid abrupt withdrawal.

**Monitor:** ophthalmological testing if visual Δs occur.

**Dose:** initially 88 microgram tds¹ (or 88 microgram nocte for RLS²) ↑ing if tolerated/required to max 1.1 mg tds¹ (or 540 microgram nocte²). NB: doses given for BASE (not SALT) & ↓dose if RF.

PRAVASTATIN/LIPOSTAT
HMG-CoA reductase inhibitor: ‘statin’; ↓s cholesterol/LDL (and TG).

**Use/CI/Caution/SE/Monitor:** see Simvastatin.

**Interactions:** ↑risk of myositis (± ↑levels) with ☠/fibrates ☠, nicotinic acid, daptomycin, ciclosporin and ery-/clari-thromycin.

**Dose:** 10–40 mg nocte. NB: ↓dose if RF (10 mg if moderate to severe RF).

PREDNISOLONE
Glucocorticoid (and mild mineralocorticoid activity).

**Use:** anti-inflammatory (e.g. rheumatoid arthritis, IBD, asthma, eczema), immunosuppression (e.g. transplant rejection Px, acute leukaemias), glucocorticoid replacement (e.g. Addison’s disease, hypopituitarism).

**CI:** systemic infections (w/o antibiotic cover).
Caution/SE/Interactions: see p. 217.
Warn: carry steroid card (and avoid close contact with people who have chickenpox/shingles if patient has never had chickenpox).
Dose: usually 2.5–15 mg od po for maintenance. In acute/initial stages, 20–60 mg od often needed (depends on cause and often physician preference), e.g. acute asthma (40–50 mg od), acute COPD (30 mg od), temporal arteritis (40–60 mg daily). Take with food (↓Na⁺, ↑K⁺ diet recommended if on long-term Rx). For other causes, consult SPC/BNF, pharmacy or local specialist relevant to the disease. Also available as once or twice weekly im injection.

Warn patient not to stop tablets suddenly (can ⇒ Addisonian crisis). Requirements may ↑ if intercurrent illness/surgery. Consider Ca/vit D supplements/bisphosphonate to ↓risk of osteoporosis and PPI to ↓risk of GI ulcer.

PREGABALIN/LYRICA
Antiepileptic; GABA analogue.
Use: epilepsy (partial seizures w or w/o 2° generalisation), neuropathic pain, generalised anxiety disorder.
CI: B.
Caution: avoid abrupt withdrawal, H (if severe) R/P/E.
SE: neuro-Ψ disturbance; esp somnolence/dizziness (⇒ falls in elderly), confusion, visual Δ (esp blurred vision), mood ↑ or ↓ (and possibly suicidal ideation/behaviour†), ↓libido, sexual dysfunction and vertigo. Also GI upset, ↑appetite/Wt, oedema and dry mouth. Rarely HF (esp if elderly and/or CVS disease).
Warn: seek medical advice if ↑suicidality or mood ↓§†. Don’t stop abruptly as can ⇒ withdrawal fx* (insomnia, headache, N&öD, ’flu-like symptoms, pain, sweating, dizziness, pain).
Dose: 50–600 mg/day po in 2–3 divided doses SPC/BNF. NB: stop over ≥1wk* and ↓dose if RF.

PROCHLORPERAZINE/STEMETIL
Antiemetic: DA antagonist (phenothiazine :: also antipsychotic, but now rarely used for this).
**Use:** N&V (inc labyrinthine disorders).
**Cl/Caution/SE/Monitor/Warn/Interactions:** as chlorpromazine, but CI are relative and ⇒ ↓sedation. NB: can ⇒ extrapyramidal fx (esp if elderly/debilitated) inc restlessness (akathisia); see p. 278.
**Dose:** po: acutely 20 mg, then 10 mg 2 h later (5–10 mg bd/tds for Px and labyrinthine disorders); im: 12.5 mg, then po doses 6 h later; pr: 25 mg then po doses 6 h later (5 mg tds pr for migraine). Available as quick-dissolving 3-mg tablets to be placed under lip (Buccastem); give 1–2 bd. NB: ↓dose if RF.

**PROCYCLIDINE**
Antimuscarinic: ↓s cholinergic to dopaminergic ratio in extrapyramidal syndromes ⇒ ↓tremor/rigidity. No fx on bradykinesia (or tardive dyskinesia; may even worsen).
**Use:** extrapyramidal symptoms (e.g. Parkinsonism), esp if drug-induced (e.g. antipsychotics; see p. 278).
**Cl:** urinary retention (if untreated), glaucoma* (angle-closure), GI obstruction, MG.
**Caution:** cardiovascular disease, ↑prostate, tardive dyskinesia, L/R/H/P/B/E.
**SE:** antimuscarinic fx (see p. 276), Ψ disturbances, euphoria (can be drug of abuse), glaucoma*.
**Warn:** can ↓ability at driving/skilled tasks.
**Dose:** 2.5 mg tds po prn (↑if necessary to max of 10 mg tds); 5–10 mg im/iv if acute dystonia or oculogyric crisis.
NB: do not stop suddenly: can ⇒ rebound muscarinic fx.

**PROMETHAZINE**
Sedating antihistamine.
**Use:** insomnia. Also used iv/im for anaphylaxis and po for symptom relief in chronic allergies.
**Cl:** CNS depression/coma, MAOI w/in 14 days.
**Caution:** urinary retention, ↑prostate, glaucoma, epilepsy, IHD, asthma, porphyria, pyloroduodenal obstruction, R (↓dose), L (avoid if severe)/P/B/E.
SE: antimuscarinic fx (see p. 276), hangover sedation, headache.  
Warn: can ↓ability at driving/skilled tasks.  
Interactions: ↑s fx of anticholinergics, TCAs and sedatives/hypnotics.  
Dose: 25 mg nocte¹ (can ↑dose to 50 mg).

PROPOFOL  
Anaesthetic (iv).  
Use: induction or maintenance of anaesthesia. Also for sedation during intensive care (if >16 years old*) or diagnostic procedures.  
CI: anaesthetist not confident of airway maintenance, ICU sedation in children <16*, peanut or soya allergy.  
Caution: hypovolaemia, ↓BP, cardiovascular disease, respiratory impairment, epilepsy, ↑ICP, L/R/P/B (for 24h)/E  
SE: local pain, headache, N&V in recovery, anaphylaxis, extraneous muscle movements, convulsions (inc delayed onset), ↓HR (occasionally profound- treat with IV antimuscarinic), ↓BP, flushing, transient apnoea, hyperventilation, coughing, hiccup during induction, propofol infusion syndrome* if <16 yrs old in sedation in intensive care- potentially fatal, metabolic acidosis, HF, rhabdomyolysis, hyperlipidaemia, hepatomegaly) arrhythmia (↑/↓HR, asystole).  
Warn: injection painful (can ↓ by giving into large vein or with iv lidocaine); don’t drive/operate machinery for ≥12h (or longer depending on age, and patient condition); avoid alcohol before and for at least 8 hrs after.  
Monitor: Cardiac / respiratory function. Have resus equipment readily available.  
Interactions: other CNS depressants ↑ sedation & cardiorespiratory depression. Suxamethonium (↑risk of myocardial depression & ↓HR), ↑ hypotensive fx with adrenergic neurone blockers, α-blockers, antipsychotics, verapamil.  
Dose: age, weight and drug concentration dependent⁷ BNF/SPC; titrated to effect, except when using ‘rapid sequence induction’.
PROPRANOLOL

β-Blocker (non-selective): $\beta_1 \Rightarrow \downarrow HR$ and $\downarrow$ contractility, $\beta_2 \Rightarrow$ vasodilation (and bronchoconstriction and glucose release from liver). Also blocks fx of catecholamines, $\downarrow$s renin production, slows SAN/AVN conduction.

**Use:** HTN\(^1\) (for advice on stepped HTN Mx see p. 235), IHD (angina Rx\(^2\), MI Px\(^3\)), portal HTN\(^4\) (Px of variceal bleed; NB: may worsen liver function), essential tremor\(^5\), Px of migraine\(^6\), anxiety\(^7\), ↑T (symptom relief\(^8\), thyroid storm\(^9\)), arrhythmias\(^8\) (inc severe\(^9\)).

**CI:** asthma/Hx of bronchospasm, peripheral arterial disease (if severe), Prinzmetal’s angina, severe $\downarrow$HR or $\downarrow$BP, SSS, 2nd-/3rd-degree HB, cardiogenic shock, metabolic acidosis, phaeo (unless used specifically with α-blockers), H (if uncontrolled).

**Caution:** COPD, 1st-degree HB, DM*, MG, Hx of hypersensitivity (may $\uparrow$ to all allergens), L/R/P/B.

**SE:** $\downarrow$HR, $\downarrow$BP, HF, peripheral vasoconstriction ($\Rightarrow$ cold extremities, worsening of claudication/Raynaud’s), fatigue, depression, sleep disturbance (inc nightmares), hyperglycaemia (and $\downarrow$sympathetic response to hypoglycaemia\(^*\)), GI upset. Rarely, conduction/blood disorders.

**Interactions:** $\ddagger$ verapamil and diltiazem $\Rightarrow$ risk of HB and $\downarrow$HR $\ddagger$. Risk of $\downarrow$BP and HF with nifedipine. Risk of $\downarrow$BP with α-blockers. $\uparrow$s risk of bupiva-/lido-caine toxicity. $\uparrow$s risk of AV block, myocardial depression and $\downarrow$HR with amiodarone, flecainide. Levels of both drugs can $\uparrow$ with chlorpromazine. Risk of $\uparrow$BP with moxisylyte. Risk of $\uparrow$BP (and $\downarrow$HR) with dobutamine, adrenaline and noradrenaline. Risk of withdrawal $\uparrow$BP with clonidine (stop β-blocker before slowly $\downarrow$ing clonidine).
**Dose:** 80–160 mg bd po\(^1\); 40–120 mg bd po\(^2\); 40 mg qds for 2–3 days, then 80 mg bd po\(^3\) (start 5–21 days post-MI); 40 mg bd po\(^4\) (↑dose if necessary); 40 mg bd/tds po\(^5,6\); 40 mg od po\(^7\) (↑dose to tds if necessary); 10–40 mg tds/qds\(^8\); 1 mg iv over 1 min\(^9\) repeating every 2 min if required, to max total 10 mg (or 5 mg in anaesthesia).

**NB:** ↓po dose in LF and ↓initial dose in RF. Withdraw slowly (esp in angina); if not can ⇒ rebound ↑of symptoms.

**PROPYLTHIOURACIL**

Thionamide antithyroid (peroxidase inhibitor): ↓s I\(^-\)⇒ I\(_2\) ↓s and ↓. ↓T\(_{3/4}\) production, as carbimazole does, but also ↓s peripheral T\(_4\) to T\(_3\) conversion. Possible immunosuppressant fx.

**Use:** ↑T\(_4\) (2nd-line in the UK; if carbimazole not tolerated).

**Caution:** L/R, P/B (can cause fetal/neonatal goitre/↓T\(_4\) ↓. use min dose and monitor neonatal development closely; ‘block-and-replace’ regimen ↓. not suitable as high doses used for this).

**SE:** blood disorders (esp agranulocytosis stop drug if occurs), skin reactions (esp urticaria, rarely cutaneous vasculitis/lupus), fever. Rarely hepatotoxicity, nephritis.

**Warn:** patient to report symptoms of infection (esp sore throat) or of liver disease (e.g. anorexia, N&C, jaundice, pruritis), & signs of LF (explain symptoms).

**Monitor:** FBC, LFTs, clotting.

**Dose:** 200–400 mg po in divided doses until euthyroid, then ↓ to maintenance dose of 50–150 mg od. NB: ↓dose if LF or RF.

**PROSCAR** see Finasteride; antiandrogen for BPH (and baldness).

**PROTAMINE (SULPHATE)**

Protein (basic) that binds heparin (acidic).

**Use:** reversal of heparin (or LMWH) following over-Rx/OD or after temporary anticoagulation for extracorporeal circuits (e.g. cardiopulmonary bypass, haemodialysis).

**Caution:** ↑risk of hypersensitivity reaction if: (1) vasectomy, (2) infertile man, (3) allergy to fish.
**SE:** ↓BP, ↓HR, N&V, flushing, dyspnoea. Rarely pulmonary oedema, hypertension, hypersensitivity reactions.

**Dose:** 1 mg per 80–100 units of heparin to be reversed (max 50 mg) iv/ivi at rate ≤ 5 mg/min; exact regimen depends on whether reversing heparin or LMWH and whether given iv or scBNF/SPC. NB: $t_{1/2}$ of iv heparin is short; ↓doses of protamine if giving to reverse iv heparin >15 min after last dose – see SPC.

Max total dose 50 mg: ☠️ high doses can ⇒ anticoagulant fx! ☠️

**PROXYMETHACAINE**
Topical anaesthetics (lasts 20 min).

**Use:** eye examination (if painful eye or checking IOP).

**SE:** corneal epithelial shedding.

**Dose:** 1 drop prn (not for prolonged treatment).

**PROZAC** see Fluoxetine; SSRI antidepressant.

**PULMICORT** see Budesonide; inh steroid for asthma. 50, 100, 200 or 400 microgram/puff. ▼ Aerosol (not other preparations).

**PYRAZINAMIDE**
Antibiotic: ‘cidal’ only against intracellular and dividing mycobacteria (e.g. TB). Good CSF penetration*.

**Use:** TB Rx (for initial phase, see p. 267), TB meningitis*.

**CI:** acute porphyria, L (if severe, otherwise caution).

**Caution:** DM, gout (avoid in acute attacks), P.

**SE:** hepatic toxicity ***, ↑urate, GI upset (inc N&V), dysuria, interstitial nephritis, arthr-/my-algia, sideroblastic ↓Hb, ↓Pt, rash (and photosensitivity).

**Monitor:** LFTs**.

**Warn:** patients and carers to stop drug and seek urgent medical attention if signs of LF (explain symptoms).

**Dose:** up to 2 g daily usually given as part of combination product (500 mg tablets of just pyrazinamide available, but unlicensed)—exact dose varies according to Wt and whether Rx is ‘supervised’ or notSPC/BNF.
**PYRIDOSTIGMINE**

Anticholinesterase: inhibits cholinesterase at neuromuscular junction
\[ \uparrow \text{ACh} \Rightarrow \uparrow \text{neuromuscular transmission} \].

**Use:** myasthenia gravis.

**CI:** GI/urinary obstruction.

**Caution:** asthma, recent MI, ↓HR/BP, arrhythmias, vagotonia, ↑T, PU, epilepsy, Parkinsonism, R/P/B/E.

**SE:** cholinergic fx (see p. 276) – esp if xs Rx/OD, where ↓BP, bronchoconstriction and (confusingly) weakness can also occur (= cholinergic crisis*); ↑secretions (sweat/saliva/tears) and miosis are good clues** of xs ACh.

**Interactions:** fx ↓d by aminoglycosides (e.g. gentamicin), polymixins, clindamycin, lithium, quinidine, chloroquine, propranolol and procainamide. ↑s fx of suxamethonium.

**Dose:** 30–120 mg po up to qds (can ↑to max total 1.2 g/24 h; if possible give <450 mg/24 h to avoid receptor downregulation).

**NB:** ↓dose if RF.

![Image of a medical alert symbol with text: ing weakness can be due to cholinergic crisis* as well as MG exacerbation; if unsure which is responsible**, get senior help (esp if ↓respiratory function) before giving Rx, as the wrong choice can be fatal!](image)

**QUETIAPINE/SEROQUEL**

Atypical (2nd generation) antipsychotic.

**Use:** schizophrenia¹, mania², depression in bipolar disorder³. Off-licence use for psychosis/behavioural disorders (esp in dementias, but use of antipsychotics in dementia generally not recommended).

**CI:** B.

**Caution:** cardiovascular disease, Hx of epilepsy, drugs that ↑QTc, L/R/E/P.

**SE/Interactions/Warn/Monitor:** as olanzapine but therapeutic doses are initially sedating and ↓BP requiring ↓. start with ↓dose*. Also levels ↑by ery-/clari-thromycin.

**Dose:** Needs titration* (see SPC/BNF): initially 25 mg bd ↑ing daily to max 750 mg/day¹; initially 50 mg bd ↑ing daily to max
800 mg/day; initially 50 mg od ing daily to max 600 mg/day. If RF, LF or elderly start at 25 mg od ing less frequently. Available in MR form (Seroquel XL); initially 300 mg od then 600 mg od the next day, then adjust to response (if giving for depression or if RF, LF or elderly start at 50 mg od then cautiously).

**QUININE**
Antimalarial: kills bloodborne schizonts.
**Use:** malaria Rx (esp falciparum), nocturnal leg cramps.
**CI:** optic neuritis, tinnitus, haemoglobinuria, MG.
**Caution:** cardiac disease (inc conduction dfx, AF, HB), G6PD deficiency, H/P/E.
**SE:** visual Δs (inc temporary blindness, esp in OD), tinnitus (and vertigo/deafness), GI upset, headache, rash/flushing, hypersensitivity, confusion, hypoglycaemia*. Rarely blood disorders, AKI, cardiovascular fx (can ⇒ severe ↓BP in OD).
**Monitor:** blood glucose*, ECG (if elderly) and e’lytes (if given iv).
**Interactions:** ↑s levels of flecainide and digoxin. ↑s risk of arrhythmias with pimozide, moxifloxacin and amiodarone. ↑risk of seizures with mefloquine. Avoid artemether/lumefantrine.
**Dose:** 200–300 mg nocte po as quinine sulphate. For malaria Rx, see p. 267 (NB: ↓iv maintenance dose if RF).

**RABEPROLAZOLE/PARIET**
PPI; as omeprazole, but ↓interactionsBNF/SPC.
**Dose:** 20 mg od (↓to 10 mg od for maintenance). Max 120 mg/day (depending on indication).

**RAMIPRIL/TRITACE**
ACE-i; see Captopril.
**Use:** HTN (for advice on stepped HTN Mx see p. 235), HF, Px post-MI. Also Px of cardiovascular disease (if age >55 years and at risk).
**Cl/Caution/SE/Monitor/Interactions:** as captopril.

**Dose:** initially 1.25 mg od (↑ing slowly to max of 10 mg daily)\(^1,2\); initially 2.5 mg bd then ↑to 5.0 mg bd after 2 days\(^3\) (start 3–10 days post-MI) then maintenance 2.5–5 mg bd; initially 2.5 mg od (↑ing to 10 mg)\(^4\).

NB: ↓dose if RF.

---

**RANITIDINE/ZANTAC**

\(H_2\) antagonist ⇒ ↓parietal cell \(H^+\) secretion.

**Use:** PU (Px if on long-term high dose NSAIDs\(^1\), chronic Rx\(^2\), a cute Rx\(^3\)), reflux oesophagitis.

**Caution:** acute porphyria, L/R/P/B. ☸ May mask symptoms of gastric cancer ☸.

**SE:** *all rare:* GI upset (esp diarrhoea), dizziness, confusion, fatigue, blurred vision, headache, Δ LFTs (rarely hepatitis), rash. Very rarely arrhythmias (esp if given iv), hypersensitivity, blood disorders.

**Dose:** initially 150 mg bd po (or 300 mg nocte)\(^1,2\), ↑ing to 600 mg/day if necessary but try to ↓to 150 mg nocte for maintenance; 50 mg tds/qds iv\(^3\) (or im/ivi\(^{SPC/BNF}\))

NB: ↓dose if RF.

---

**REOPRO** see Abciximab; antiplatelet agent for MI/ACS.

**RETEPLASE (=r-PA).**

Recombinant plasminogen activator: thrombolytic.

**Use/Cl/Caution/SE:** see Alteplase and p. 231 but only for Rx of AMI (i.e. not approved for CVA/other use).

**Dose:** 10 units as slow iv injection over < 2 min, repeating after 30 min.

Concurrent unfractionated iv heparin needed for 48 h; see p. 232.

---

**RIFABUTIN**

Rifamycin antibiotic; see Rifampicin.

**Use:** TB: Rx of pulmonary TB\(^1\) and non-tuberculous mycobacterial disease\(^2\). Also Px of *Mycobacterium avium* \(^3\) (if HIV with ↓CD4).
**CI/Caution/SEWarn/Monitor/Interactions:** as rifampicin, plus levels ↑ by macrolides, triazoles, imidazoles and antivirals (⇒↑risk of uveitis; ↓rifabutin dose) and ↓s carbamazepine and phenytoin levels.

**Dose:** 150–450 mg od¹; 450–600 mg od²; 300 mg od³. NB: ↓dose if severe LF or RF.

---

**RIFAMPICIN**

Rifamycin antibiotic: ‘cidal’ ⇒ ↓RNA synthesis.

**Use:** TB Rx, *N. meningitidis* (meningococcal)/*H. influenzae* (type b) meningitis Px. Rarely for *Legionella/Brucella/Staphylococcus* infections.

**CI:** jaundice, are concurrently receiving saquinavir/ritonavir therapy, hypersensitivity to rifamycins or excipients.

**Caution:** acute porphyria, *L/R/P/B*.

**SE:** hepatotoxicity, GI upset (inc AAC), headache, fever, ’flu-like symptoms (esp if intermittent use), orange/red body secretions*, SOB, blood disorders, skin reactions, shock, AKI.

**Warn:** of symptoms/signs of liver disease; report jaundice/persistent N&V/malaise immediately. Warn about secretions*.

**Monitor:** LFTs, FBC (and U&Es if dose >600 mg/day).

**Interactions:** ↑ P450 . many; most importantly ↓s fx of OCP**, lamotrigine, phenytoin, sulphonylureas, tolbutamide, mefloquine, gefi-/nifo-tinib, digoxin, keto-/flu-/itra-/.posa-/vori-conazole, antivirals, telithromycin, nevirapine, ciclosporin, siro-/taco-limus, imatinib, corticosteroids, haloperidol, aripiprazole, disopyramide, mefloquine, bosentan, propafenone, eplerenone and Ca²⁺ antagonists. W–.

**Dose:** for TB Rx, see p. 267; for other indications see SPC/BNF. (NB: well absorbed po; give iv only if ↓swallow.) NB: ↓dose if LF or RF.

Other contraception** needed during Rx.

---

**RIFATER** Combination preparation of rifampicin, isoniazid and pyrazinamide for 1st 2 months of TB Rx (⇒↓bacterial load/infectiousness until sensitivities known); see p. 267.
RISEDRONATE
Bisphosphonate: ↓s osteoclastic bone resorption.
**Use:** osteoporosis (Px/Rx, esp if postmenopausal or steroid -induced), Paget’s disease³.
**CI:** ↓Ca⁺², R (if eGFR <30 ml/min), P/B.
**Caution:** delayed GI transit/emptying (esp oesophageal abnormalities). Correct Ca⁺² and other bone/mineral metabolism Δ (e.g. vit D and PTH function) before Rx, dental procedures in patients at risk of osteonecrosis of the jaw (e.g. chemotherapy).
**SE:** GI upset, bone/joint/muscle pain, headache, rash. Rarely iritis, dry eyes/corneal lesions, oesophageal stricture/inflammation/ulcer*, osteonecrosis of the jaw and atypical femoral fractures.
**Warn:** of symptoms of oesophageal irritation and if develop to stop tablets/seek medical attention. Must swallow tablets whole with full glass of water on an empty stomach ≥30 min before, and stay upright until breakfast*. Need to report thigh, hip or groin pain.
**Interactions:** Ca⁺²-containing products (inc milk) and antacids (⇒ ↓absorption) ⇒ separate doses as much as possible from risedronate. Also avoid iron and mineral suplements.
**Dose:** 5 mg od¹,² (or 1 × 35-mg tablet/week as Actonel Once a Week²); 30 mg daily for 2 months³.

▼ RISPERIDONE/RISPERDAL
‘Atypical’ antipsychotic: similar to olanzapine (⇒↓extrapyramidal fx cf ‘typical’ antipsychotics, esp tardive dyskinesia).
**Use:** psychosis/schizophrenia (acute and chronic)NICE, mania & short term Rx (<6 wks) of persistent aggression unresponsive to non-pharmacological Rx in Alzheimer’s.
**CI:** phenylketonuria (only if Quicklet form used).
**Caution/SE:** similar to olanzapine but ⇒↓sedation, ↑hypotension (esp initially: ↑dose slowly* (retitrate if many doses missed), ↓hyperglycaemia, ↑extrapyramidal fx; if ↑stroke risk.
**Interactions:** levels may be ↓by carbamazepine and ↑by ritonavir, fluoxetine and paroxetine. ↑risk of CNS toxicity with sibutramine. ↑mortality rate in elderly if taking furosemide. ↑risk of arrhythmias
with drugs that ↑QTc and atomoxetine. ↑risk of ↓BP with general anaesthetics. ↓s fx of anticonvulsants. Avoid paliperidone.

**Dose:** initially 2 mg od titrating up if necessary, generally to 4–6 mg od (if elderly initially 0.5 mg bd titrating up if required to max 2 mg bd po). Also available as liquid or quick dissolving 1, 2, 3, or 4 mg tablets (‘Quicklets’) and as long-acting im 2-wkly injections (‘Consta’ ▼) for ↑compliance.

**NB:** ↓dose if LF or RF.

**RITUXIMAB/MABTRAHA**
Monoclonal Ab against B lymphocytes (CD20+).

**Use:** Various B cell non-Hodgkin’s lymphoma¹ (many indications for Diffuse Large B cell Lymphoma and Follicular Lymphoma² NICE), RA² (in combination with methotrexate, in severe active cases with inadequate response to DMARDs, inc ≥1 TNF-α inhibitor² NICE), SLE, vasculitis, CLL NICE.

**CI:** active severe infections, hypersensitivity to active substances or excipients, B.

**Caution:** IHD, if already on other cardiotoxic/cytotoxic drugs, with active or chronic infections (e.g. hepatitis B), H (avoid if severe and giving for RA) P.

**SE:** ☑ infusion hypersensitivity/cytokine release syndrome* (mainly during 1st infusion: fever, chills, arrhythmias, ARDS and allergic reactions) ☑, tumour lysis syndrome, pancytopenia, ↓BP, ↑risk of PML, ↑infections.

**Warn:** withhold antihypertensive drugs 12 h prior to ivi. Remember to give patient alert card.

**Monitor:** BP, neurological function (PML), FBC.

**Dose:** seek expert advice and product literature for dose/rate¹, 1 g ivi initially and repeat once after 2 wks² (see SPC/BNF).

☑ Only give if full resuscitation facilities available. Interrupt ivi for severe reactions* and institute supportive care measures.

**RIVASTIGMINE/EXELON**
Acetylcholinesterase inhibitor that acts centrally (crosses BBB): replenishes ACh, which is ↓d in certain dementias.
Use: Alzheimer’s disease\textsuperscript{NICE} & Parkinson’s disease dementia.  
Cl: L (if severe, otherwise caution), B.  
Caution: conduction defects (esp SSS), PU susceptibility, Hx of COPD/asthma/seizures, bladder outflow obstruction, R/P.  
SE: cholinergic fx (see p. 276), GI upset (esp nausea initially), headache, dizziness, behavioural/Ψ reactions. Rarely GI haemorrhage, ↓HR, AV block, angina, seizures, rash.  
Monitor: weight  
Dose: 1.5 mg bd po initially (↑ing slowly to 3–6 mg bd: specialist review needed for clinical response and tolerance). Available as daily transdermal patch releasing 4.6 mg or 9.5 mg/24 h. Continue only if MMSE remains 10–20\textsuperscript{NICE}.  

NB: If > several days doses missed retitration of dose required.

**RIZATRIPTAN/\textsc{MAXALT}**  
\(5\text{HT}_{1B/1D}\) agonist for acute migraine.  
**Use/Cl/Caution/SE/Interactions:** see Sumatriptan.  
**Dose:** 10 mg po (can repeat after \(\geq 2\) h if responded then recurs). Max 20 mg/24 h. NB: give 5 mg doses if RF or LF (and avoid if either severe).

**ROCURONIUM**  
Aminosteroid neuromuscular blocker (see Vecuronium). Most rapid onset of the non-depolarising neuromuscular blockers (2 mins). Intermediate duration of action.  
**Use:** neuromuscular blockade for surgery\textsuperscript{1} or during intensive care\textsuperscript{2}.  
**Cl:** anaesthetist not confident of airway maintenance.  
**Caution:** neuromuscular disease (MG, Eaton-Lambert, old polio), hypothermia, obesity, burns. L/R/E.  
**SE:** ↑HR/BP (mild), prolonged paralysis and myopathy*.  
**Warn:** Don’t drive until 24h after full recovery. Injection painful.  
**Monitor:** Cardiac, respiratory & motor function.  
**Interactions:** fx ↑ by aminoglycosides, clindamycin and polymyxins. Only administer after full recovery from neuromuscular blockade of suxamethonium. Corticosteroids can ↑ myopathy risk*.
**Dose:** initially 600 micrograms/kg iv then maintenance 150 micrograms/kg iv or initially 300–600 micrograms/kg/hr ivi adjusting to response\(^1\); initially 600 micrograms/kg iv (optional) then 300–600 micrograms/kg/hr ivi for 1st hr, then adjusting to response\(^2\). *NB: if obese (weight 30% above ideal body weight (IBW; see p.296)) use IBW for dose calculation.* ↓ Dose if elderly, LF or RF\(^{SPC/BNF}\).

Specialist use only. Needs respiratory assistance / control until drug inactivated or antagonised. Needs anaesthetic / sedative to prevent awareness.

**ROPINIROLE/REQUIP\(^1\) or ADARTREL\(^2\)**
Dopamine agonist (non-ergot derived); use in early Parkinson’s⇒ ↓motor complications (e.g. dyskinesias) but ↓motor performance cf L-dopa. Also adjunctive use in Parkinson’s with motor fluctuations.

**Use:** Parkinson’s\(^1\), moderate-severe restless legs syndrome (RLS)\(^2\).

**CI:** P/B.

**Caution:** major psychotic disorders, severe cardiovascular disease L/R.

**SE:** GI upset, sleepiness (inc sudden onset sleep),↓BP (inc postural, esp initially), \(Ψ\) disorders (esp psychosis and impulse control disorders, e.g. gambling and ↑sexuality), confusion, leg oedema, paradoxical worsening of restless legs syndrome symptoms or early morning rebound (may need to withdraw or reduce dose).

**Warn:** sleepiness and↓BP may impair skilled tasks (inc driving).

Avoid abrupt withdrawal.

**Dose:** initially 250 microgram tds\(^1\) (or 250 microgram nocte for RLS\(^2\)) ↑ing if tolerated/required to max 8 mg tds\(^1\) (or 4 mg nocte for RLS\(^2\)). Available in MR preparation (Requip XL) 2–24 mg od\(^1\).

**ROSUVASTATIN/CRESTOR**
HMG-Co A reductase inhibitor; ‘statin’ to ↓cholesterol (and TG).

**Use/CI/Caution/SE:** as simvastatin, but safe in porphyria, can ⇒ DM and proteinuria (and rarely haematuria). Avoid if severe RF.
**Interactions:** ↑risk of myositis with fibrates and ciclosporin, daptomycin, protease inhibitors, fusidic and nicotinic acid. Levels ↓ by antacids. Mild W+.

**Dose:** initially 5–10 mg od. If necessary ↑ to 20 mg after ≥4 wks (if not of Asian origin or risk factors for myopathy/rhabdomyolysis, can ↑ to 40 mg after further 4 wks). NB:↓dose if RF, Asian origin or other ↑risk factor for myopathy.

**(r)tPA** (Recombinant) tissue-type plasminogen activator; see Alteplase.

**SALBUTAMOL**

β₂ Agonist, short-acting: dilates bronchial smooth muscle (and endometrium). Also inhibits mast-cell mediator release.

**Use:** chronic¹ and acute² asthma. Rarely↑K⁺(give nebs prn), premature labour (iv).

**Caution:** cardiovascular disease (esp arrhythmias*, susceptibility to ↑QTc, HTN), DM (can ⇒ DKA, esp if iv ⇒ monitor CBGs), ↑T₄, P/B.

**SE:** neurological: fine tremor, headache, nervousness, behavioural/sleep Δs (esp in children); CVS:↑HR, palpitations/arrhythmias (esp if iv), ↑QTc*; other: ↓K⁺, muscle cramps, lactic acidosis. Rarely hypersensitivity, paradoxical bronchospasm. Prolonged Rx ⇒ small↑risk of glaucoma.

**Monitor:** K⁺ and glucose (esp if ↑ or iv doses).

**Interactions:** iv salbutamol ⇒ ↑risk of ↓↓BP with methyldopa.

**Dose:** 100–200 microgram (aerosol) or 200–400 microgram (powder) inh prn up to qds¹; 2.5–5 mg qds 4-hrly neb². If life-threatening (see p. 242), can ↑nebs up to every 15 min or give as ivi (initially 5 microgram/min, then up to 20 microgram/min according to response).

**SALMETEROL/SEREVENT**

Bronchodilator: long-acting β₂ agonist(LABA).

**Use:** 1st choice add-on for asthma Rx (on top of short-acting β₂ agonist and inh steroids). Not for acute Rx!

**Caution/SE/Monitor:** as salbutamol.
**Dose:** 50–100 microgram bd inh.

**SALOFALK** see Mesalazine; ‘new’ aminosalicylate for UC (↓SEs).

**SANDOCAL** Calcium supplement; available in ‘400’ (400 mg calcium = 10 mmol Ca$^{2+}$) or ‘1000’ (1 g calcium = 25 mmol Ca$^{2+}$) effervescent tablets.

**SANDO-K**

Effervescent oral KCl (12 mmol K$^+$/tablet).

**Use:** ↓K$^+$.

**CI:** K$^+$ > 5.0 mmol/l, R (if severe, otherwise caution).

**Caution:** GI ulcer/stricture, hiatus hernia, taking other drugs that ↑K$^+$ and cardiac disease.

**SE:** N&V, GI ulceration, flatulence.

**Dose:** according to serum K$^+$: start with 2–4 tablets/day if diet normal. Take with food. NB: ↓dose in RF/elderly (↑ if established ↓K$^+$).

**SENNA/SENOKOT**

Stimulant laxative; takes 8–12 h to work.

**Use:** constipation.

**CI:** GI obstruction.

**Caution:** P (try bulk forming or osmotic laxative 1st).

**SE:** GI cramps. If chronic use atonic non-functioning colon, ↓K$^+$.

**Dose:** 2 tablets nocte (can ↑ to 4 tablets nocte). Available as syrup.

**SEPTRIN** see Co-trimoxazole (sulfamethoxazole + trimethoprim).

**SERC** see Betahistine; histamine analogue for vestibular disorders.

**SERETIDE** Combination asthma or COPD inhaler with possible synergistic action: long-acting β$_2$ agonist (LABA) salmeterol 50 microgram (Accuhaler) or 25 microgram (Evohaler) + fluticasone (steroid) in varying quantities (50, 100, 125, 250 or 500 microgram/puff). Note different devices have different licensed indications.

**SEROXAT** see Paroxetine; SSRI antidepressant.
**SERTRALINE/LUSTRAL**
SSRI antidepressant; also increases dopamine levels; see Fluoxetine.
**Use:** depression (also PTSD in women, OCD, social anxiety disorder & panic disorder). Relatively good safety record in pregnancy and breast-feeding.
**Cl/Caution/SE/Warn/Interactions:** as fluoxetine, but ↓ incidence of agitation/insomnia, doesn’t ↑carbamazepine/phenytoin levels, but does ↑pimozide levels.
**Dose:** initially 50 mg od, ↑ing in 50 mg increments over several weeks to max daily dose 200 mg (if >100 mg/day, must be divided into at least 2 doses) \(^1\). NB: ↓dose if LF.

**SEVELAMER HYDROCHLORIDE**
PO\(_4\) binding agent; contains no Al/Ca\(^{2+}\) : no risk of ↑ing Al/Ca\(^{2+}\) (which can occur with other drugs, esp if on dialysis). Also ↓s cholesterol.
**Use:** ↑PO\(_4\) (if on dialysis).
**Cl:** GI obstruction.
**Caution:** GI disorders, P/B.
**Se:** GI upset.
**Interactions:** can ↓ plasma levels of ciprofloxacin and immunosuppressants used in renal transplant patients.
**Dose:** initially 800–1600 mg tds po, then adjust to response \(^{SPC/BNF}\).

**SEVREDOL** Morphine (sulphate) tablets (10, 20 or 50 mg).
**Dose:** see Oramorph.

**SILDENAFIL/VIAGRA or REVATIO (▼)**
Phosphodiesterase type-5 inhibitor: ↑s local fx of NO (⇒ ↑smooth-muscle relaxation :. ↑blood flow into corpus cavernosum).
**Use:** erectile dysfunction, pulmonary artery hypertension (and digital ulceration under specialist supervision).
**Cl:** recent CVA/MI/ACS, ↓BP (systolic <90 mmHg), hereditary degenerative retinal disorders, Hx of non-arteritic anterior ischaemic
optic neuropathy and conditions where vasodilation/sexual activity
inadvisable. **L/H** (if either severe).

**Caution:** cardiovascular disease, LV outflow obstruction, bleeding disorders (inc active PU), anatomical deformation of penis, predisposition to prolonged erection (e.g. multiple myeloma/leukaemias/sickle cell disease), **R/P/B.**

**SE:** headache, flushing, GI upset, dizziness, visual disturbances, nasal congestion, hypersensitivity reactions. Rarely, serious cardiovascular events, priapism and painful red eyes.

**Interactions:** 💥 Nitrates (e.g.GTN/ISMN/ISDN) and nicorandil can ↓BP : never give together 💥. Antivirals (esp rito-/ataza-/indinavir) ↑its levels. ↑s hypotensive fx of α-blockers; avoid concomitant use. Levels ↑by keto-/itra-conazole

**Dose:** initially 50 mg approx 1 h before sexual activity¹, adjusting to response (1 dose per 24 h, max 100 mg per dose); 20 mg tds².

**NB:** ↓dose if RF or LF.

**SIMVASTATIN/ZOCOR**

HMG-CoA reductase inhibitor (‘statin’): ⇒ ↓cholesterol(↓s synthesis), ↓LDL (↑s uptake), mildly ↓s TG.

**Use:** ↑cholesterol, Px of atherosclerotic disease: IHD (inc 1° prevention), CVA, PVD.

**Cl:** acute porphyria, L (inc active liver disease or ΔLFTs), P (contraception required during, and for 1 month after, Rx), B.

**Caution:** ↓T₄, alcohol abuse, Hx of liver disease, R (if severe).

**SE:** hepatitis and myositis* (both rare but important), headache, GI upset, rash. Rarely pancreatitis, hypersensitivity.

**Monitor:** LFTs (and CK if symptoms develop*).

**Interactions:** ↑risk of myositis (± ↑levels) with 💥 fibrates 💥, clari-/ery-/teli-thromycin, itra-/keto-/mi-/posa-conazole, ciclosporin, protease inhibitors, nicotinic acid, fusidic acid, colchicine, danazol, amiodarone, verapamil, diltiazem, amlodipine, ranolazine and grapefruit juice. Mild **W +.**

**Dose:** 10–80 mg nocte (usually start at 10–20 mg**(SPC/BNF)** ↑ing at intervals ≥ 4 wks.↓max dose if significant drug interactions**(SPC/BNF).** NB:↓dose if RF or other ↑risk factor for myositis*. 
Myositis* can rarely ⇒ rhabdomyolysis; ↑risk if ↓T₄, RF or taking drugs that ↑levels/risk of myositis (see above).

**SINEMET** see Co-careldopa; L-dopa for Parkinson’s.

**SLOW-K**
Slow-release (non-effervescent) oral KCl (8 mmolK⁺/tablet).
**Use:** ↓K⁺ where liquid/effervescent tablets inappropriate.
**CI/Caution/SE:** as Sando-K, plus caution if ↓swallow.
**Dose:** according to serum K⁺: average 3–6 tablets/day. NB: ↓dose if RF (and caution if taking other drugs that ↑K⁺).

**SODIUM BICARBONATE iv**
Alkalising agent.
**Use:** TCA overdose with ECG Δs; cardiac arrest* (only if due to ↑K⁺ or TCAs), rarely for severe metabolic acidosis due to xs bicarbonate loss.
**SE:** paradoxical intracellular acidosis, negative inotrope, ↓s O₂ delivery (O₂ saturation curve shift to left), ↓K⁺, ↑Na⁺, ↑serum osmolality.
**Dose:** iv: available in 1.26%, 4.2% and 8.4% solutions; in cardiac arrest* give 50 mmol (50 ml of 8.4% solution) repeating if necessary. NB: *specialist use only* – strongly consider getting senior help before giving.

Inflammatory if extravasates when given iv (⇒ tissue necrosis).

**SODIUM VALPROATE** see Valproate; antiepileptic.

**SOTALOL**
β-Blocker (non-selective); class II (+III) antiarrhythmic.
**Use:** Px of SVT (esp of paroxysmal AF), Rx of VT (if life-threatening/symptomatic, esp non-sustained or spontaneous sustained dt IHD or cardiomyopathy).
**CI:** as propranolol, plus ↑QT syndromes, torsades de pointes, R (if severe, otherwise caution).
**Caution:** as propranolol, plus electrolyte Δs (⇒ ↑risk of arrhythmias, esp if ↓K⁺/↓ Mg²⁺; ∴ beware if severe diarrhoea).

**SE:** as propranolol, plus arrhythmias (can ⇒ ↑QT ± torsades de pointes*, esp in females).

**Interactions:** as propranolol (NB: Verapamil and diltiazem ⇒ risk of ↓HR and HB ☠) plus disopyramide, quinidine, procainamide, amiodarone, moxifloxacin, mizolastine, dolasetron, ivabradine, TCAs and antipsychotics ⇒ ↑risk arrhythmias*.

**Dose:** 40–160 mg bd po (⇑if life-threatening to max 640 mg/day); 20–120 mg iv over 10 min (repeat 6-hrly if necessary). NB: ↓dose if RF.

Give under specialist supervision and with ECG monitoring.

**SPIRIVA** see Tiotropium; new inhaled muscarinic antagonist.

**RESPIMAT** (non HandiHaler).

---

**SPIRONOLACTONE**

K⁺-sparing diuretic: aldosterone antagonist at distal tubule (also potentiates loop and thiazide diuretics).

**Use:** ascites (esp 2° to cirrhosis or malignancy), oedema, HF (adjunct to ACE-i and/or another diuretic), nephrotic syndrome, 1° aldosteronism.

**CI:** ↑K⁺, ↓Na⁺, Addison’s, P/B.

**Caution:** porphyria, L/R/E.

**SE:** ↑K⁺, gynaecomastia, GI upset (inc N&V), impotence, ↓BP, ↑Na⁺, rash, confusion, headache, hepatotoxicity, blood disorders.

**Monitor:** U&C.

**Interactions:** ↑s digoxin and lithium levels. ↑s risk of RF with NSAIDs (which also antagonise its diuretic fx).

**Dose:** 100–400 mg/day po (25 mg od if for HF).

bcd Beware if on other drugs that ↑K⁺, e.g. amiloride, triamterene, ACE-i, angiotensin II antagonists and ciclosporin. Do not give with oral K⁺ supplements inc dietary salt substitutes ☠.

**STEMETIL** see Prochlorperazine; DA antagonist antiemetic.
STREPTOKINASE
Thrombolytic agent: ↑s plasminogen conversion to plasmin
⇒↑fibrin breakdown.
Use: AMI, TE of arteries (inc PE, central retinal artery) or veins
(DVT, central retinal vein).
CI/Caution/SE: see p. 230.
Dose: AMI: 1.5 million units ivi over 60 min; other indications:
250,000 units ivi over 30 min, then 100,000 units ivi every hour for
up to 12–72 h (see SPC).

STREPTOMYCIN
Aminoglycoside antibiotic.
Use: TB (if isoniazid resistance established before Rx); see p. 267.
CI/Caution/SE/Interactions: see Gentamicin.

STRONTIUM RANELATE/PROTELOS
↑s bone formation and ↓s bone resorption.
Use: postmenopausal osteoporosis\textsuperscript{NICE} if bisphosphonates CI/not tolerated & aged >75 with previous fracture.
CI: VTE (inc Hx of), temporary or prolonged immobilisation,
phenylketonuria (contains aspartame), P/B.
Caution: ↑risk of VTE, Δs urinary and plasma Ca\textsuperscript{2+} measurements.
R (avoid if severe).
SE: severe allergic reactions* GI upset.
Warn: to report any skin rash* and immediately stop drug.
Interactions: absorption ↓ by concomitant ingestion of Ca\textsuperscript{2+} (e.g.
milk) and Mg\textsuperscript{2+}. ↓s absorption of quinolones and tetracycline.
Dose: 2 g (1 sachet in water) po od at bedtime\textsuperscript{SPC\textsuperscript{B}/BNF}. Avoid food/milk 2 h before and after taking.

SULFASALAZINE
Aminosalicylate: combination of the immune modulator 5-aminosalicylic
acid (5-ASA) and the antibacterial sulfapyridine (a sulphonamide).
Use: rheumatoid arthritis\(^1\). Also UC\(^2\) (inc maintenance of remission) and active Crohn’s disease\(^2\), but not 1st-line, as newer drugs (e.g. mesalazine) have ↓sulphonamide SEs; still used if well-controlled with this drug and with no SEs or if joint manifestations.

CI: sulphonamide or salicylate hypersensitivity, R (caution if mild).

Caution: slow acetylators, Hx of any allergy, porphyria, G6PD deficiency, L/P (give only under specialist care)/B.

SE: GI upset (esp ↓appetite/Wt), hepatotoxicity, blood disorders, hypersensitivity (inc severe skin reactions like Stevens–Johnson syndrome), seizures, lupus.

Monitor: LFTs, U&Es, FBC.

Warn: to report signs of blood disorders

Dose: 500 mg/day ↑ing to max 3 g/day\(^1\); 1–2 g qds po for acute attacks\(^2\), ↓ing to maintenance of 500 mg qds – can also give 0.5–1.0 g pr bd after motion (as supps) ± po Rx.

**SUMATRIPTAN/IMIGRAN**

5HT\(_{1B/1D}\) agonist.

Use: migraine (acute). Also cluster headache (sc route & unlicenced use intranasally).

CI: IHD, coronary vasospasm (inc Prinzmetal’s), PVD, HTN (moderate, severe or uncontrolled). Hx of MI, CVA or TIA.

Caution: predisposition to IHD (e.g. cardiac disease), L/H/P/B/E.

SE: sensory Δs (tingling, heat, pressure/tightness), dizziness, flushing, fatigue, N&V, seizures, visual Δs and drowsiness.

Interactions: ↑risk of CNS toxicity with SSRIs, MAOIs, moclobemide and St John’s wort. ↑risk of vasospasm with ergotamine and methysergide.

Dose: 50 mg po (can repeat after ≥2 h if responded then recurs and can ↑doses, if no LF, to 100 mg if required). Max 300 mg/24 h. Available sc or intranasally BNF/SPC.

NB: frequent use may ⇒ medication overuse headache.

**SUXAMETHONIUM**

Depolarising neuromuscular blocker. Nicotinic ACh antagonist at neuromuscular junction.
Use: Muscle relaxation in general anaesthesia (short duration)  
CI: anaesthetist not confident of airway maintenance, FHx of malignant hyperthermia, ↑K+, major trauma, severe burns, neurological disease with acute major muscle wasting, prolonged immobilisation (↑K+ risk), Hx or FHx congenital myotonic disease, Duchenne muscular dystrophy, ↓ plasma-cholinesterase activity (inc severe LF), conscious patient.  
Caution: action irreversible (cf non-depolarising agents- see page 185), recovery is spontaneous (assisted ventilation must continue until muscle function restored), MG and Eaton-Lambert syndrome (resistant to action), cardiac / respiratory / neuromuscular disease, ↑IOP, severe sepsis (↑K+ risk). L/P/B (resume once mother recovered from neuromuscular block)  
SE: ↑ gastric pressure, ↑K+, post-op muscle pain, myoglobinuria, myoglobinemia, ↑IOP, flushing, rash, arrhythmias, cardiac arrest, bronchospasm, apnoea, prolonged respiratory depression. Painful fasciculations prior to neuromuscular block ↓. give after induction.  
Monitor: cardiac and respiratory function.  
Interactions: anticholinesterases (e.g. neostigmine) ↑ neuromuscular block. fx ↑ by aminoglycosides, clindamycin, vancymycin & polymixins. Myocardial depression and ↓HR risk with propofol. Can’t be mixed with any other agent in same syringe.  
Dose: IV: 1-1.5mg/kg; IM: up to 2.5mg/kg (max 150mg)  

Specialist use only; requires respiration assistance / control until drug inactivated or antagonised and anaesthetic / sedative to prevent awareness.  

SYMBICORT Combination asthma inhaler: each puff contains x microgram budesonide (steroid) + y microgram formoterol (long-acting β2 agonist) in the following ‘x/y’ strengths; ‘100/6’, ‘200/6’ and ‘400/12’.  
SYNACTHEN SYNthetic ACTH (adreno cortico trophic hormone), also called tetracosactide.
**Use:** Dx of Addison’s disease: in ‘short’ syncathen test will find ↓plasma cortisol 0, 30 and 60 min after 250 microgram iv/im dose.

**Cl:** allergic disorders (esp asthma). NB: can ⇒ anaphylaxis.

**TACROLIMUS (= FK 506)**
Immunosuppressant (calcineurin inhibitor): ↓s IL-2-mediated LØ proliferation.

**Use:** Px of transplant rejection (esp renal). Also used topically as 0.1% or 0.03% ointment in moderate-severe atopic eczema unresponsive to conventional therapy (specialist use).

**Cl:** macrolide hypersensitivity, immunodeficiency, P (exclude before starting), B.

**Caution/SE:** as ciclosporin, but ⇒ ↑neuro-/nephro-toxicity (although ⇒ ↓hypertrichosis/hirsutism); also diabetogenic and rarely ⇒cardiomyopathy (monitor ECG for hypertrophic Δs).

**Interactions:** metab by P450. · many, but most importantly: ↑s levels of ☹ ciclosporin ☹. Levels ↑ by clari-/ery-/teli-thromycin, quinu-/dalfro-pristin, chloramphenicol, antifungals, ataza-/rito-/nelfi-/saqui-navir, nifedipine, diltiazem and grapefruit juice. Levels ↓ by rifampicin, phenobarbital, phenytoin and St John’s wort. Nephrotoxicity↑ by NSAIDs, aminoglycosides and amphotericin. Avoid with other drugs that ↑K⁺.

**Dose:** specialist use SPC/BNF. NB: may require ↓dose if LF.

◆ Interactions important: ↑levels ⇒ toxicity; ↓levels may ⇒ rejection. Available in immediate release & modified release preparations with different dosing; Adoport, Capexon, Modigraf, Prograf, Tacni & Vivadex (bd) and Advagraf (MR od preparation) ⊂: mustn’t confuse ☹.

**TADALAFIL/CIALIS/ADCIRCA (▼)**
Phosphodiesterase type-5 inhibitor; see Sildenafil.

**Cl/Use/Caution/SE/Interactions:** as sildenafil plus CI in moderate HF and uncontrolled HTN/arrhythmias.

**Dose** *(for erectile dysfunction):* initially 10 mg ≥30 min before sexual activity, adjusting to response (1 dose per 24 h, max 20 mg per dose, unless RF or LF when max 10 mg).
TAMOXIFEN
Oestrogen receptor antagonist.
**Use:** oestrogen receptor-positive Ca breast¹ (as adjuvant Rx: ⇒ ↑survival, delays metastasis), anovulatory infertility².
**CI:** P ** (exclude pregnancy before starting Rx).
**Caution:** ↑ risk of TE* (if taking cytotoxics), porphyria, B.
**SE:** hot flushes, GI upset, menstrual/endometrial Δs (� inc Ca: if Δ vaginal bleeding/discharge or pelvic pain/pressure ⇒ urgent Ix�).
Also fluid retention, exac of bony metastases pain. Many other gynaecological/blood/skin/metabolic Δs (esp lipids, LFTs).
**Warn:** of symptoms of endometrial cancer and TE* (and to report calf pain/sudden SOB). If appropriate, advise non-hormonal contraception**.
**Interactions:** W +.
**Dose:** 20 mg od po¹; for anovulatory infertility² see SPC/BNF.

TAMSULOSIN/FLOMAXTRA XL
α-Blocker ⇒ internal urethral sphincter relaxation (.: ⇒ ↑bladder outflow) and systemic vasodilation.
**Use:** BPH.
**CI/Caution/SE/Interactions:** as doxazosin plus L (if severe).
**Dose:** 400 microgram mane (after food).

TAZOCIN Combination of piperacillin (antipseudomonal penicillin) + tazobactam (β-lactamase inhibitor).
**Use:** severe infections/sepsis (mostly in ITU setting or if resistant to other antibiotics).
**CI/Caution/SE/Interactions:** as benzylpenicillin.
**Dose:** 2.25–4.5 g tds/qds iv. NB: ↓to bd/tds if RF.

TEGRETOL see Carbamazepine; antiepileptic.

TEICOPLANIN Glycopeptide antibiotic.
**Use:** serious Gram-positive infections (mostly reserved for MRSA).
**Caution:** vancomycin sensitivity, R/P/B/E.
**SE:** GI upset, hypersensitivity/skin reactions, blood disorders, nephrotoxicity, ototoxicity (but less than vancomycin), ΔLFTs, local reactions at injection site.

**Monitor:** U&Es, LFTs, FBC, auditory function (esp if chronic Rx or on other oto-/nephro-toxic drugs, e.g. gentamicin, amphotericin B, ciclosporin, cisplatin and furosemide). Drug levels may be monitored in some situations – consult local guidelines/experts.

**Dose:** if weight <70 kg, initially 400 mg iv/ivi every 12 hrs for 3 doses, then 400 mg od (subsequent doses can be given im).

If weight >70 kg, initially 6 mg/kg iv/ivi every 12 hrs for 3 doses, then 6 mg/kg od. **NB:** ↑dose if sepsis, septic arthritis, osteomyelitis, severe burns or endocarditis and ↓dose if RF; see SPC/BNF.

**TELmisartan/Micardis**
Angiotensin II antagonist; see Losartan.

**Use:** HTN; for advice on stepped HTN Mx see p. 235.

**CI:** biliary obstruction, **L** (if severe, otherwise caution), **P/B**.

**Caution/SE/Interactions:** as Losartan, plus ↑s digoxin levels.

**Dose:** 20–80 mg od (usually 40 mg od). **NB:** ↓dose if LF or RF.

**TEmazepam**
Benzodiazepine, short-acting.

**Use:** insomnia.

**CI/Se/Interactions:** see Diazepam.

**Dose:** 10 mg nocte (can ↑dose if tolerant to benzodiazepines, but beware respiratory depression). **Dependency common:** max 4-wk Rx. **NB:** ↓dose if LF, severe RF or elderly.

**TENECTeplase (= TNK-tPA)/MetalysE**
Recombinant thrombolytic; advantageous as given as single bolus.

**Use:** Acute myocardial infarction (i.e. not approved for CVA/other use).

**CI/Caution/SE:** see p. 231, plus **B**.

**Dose:** iv bolus over 10 sec according to weight: ≥90 kg, 50 mg; 80–89 kg, 45 mg; 70–79 kg, 40 mg; 60–69 kg, 35 mg; <60 kg, 30 mg.

Concurrent unfractionated iv heparin or enoxaparin is needed for 24–48 h; see p. 209.
TERAZOSIN/HYTRIN
α-Blocker ⇒ internal urethral sphincter relaxation (\(\Rightarrow\) bladder outflow) and systemic vasodilation.

**Use:** BPH\(^1\) (and rarely HTN\(^2\)).

**Caution:** Hx of micturition syncope or postural \(\downarrow\)BP, \(P/B/E\).

**SE/Interactions:** see Doxazosin. ‘1st-dose collapse’ common.

**Dose:** initially 1 mg nocte, ↑ing as necessary to max 10 mg/day\(^1\) (or 20 mg/day\(^2\)).

TERBINAFINE/LAMISIL
Antifungal: oral\(^1,2\) or topical cream\(^3\).

**Use:** ringworm\(^1\) (\(Tinea\) spp), dermatophyte nail infections\(^2\), fungal skin infections\(^3\). NB: ineffective in yeast infections.

**Caution:** psoriasis (may worsen), autoimmune disease (risk of lupus-like syndrome), \(L/R\) (neither apply if giving topically), \(P/B\).

**SE:** headache, GI upset, mild rash, joint/muscle pains. Rarely neuro-\(\Psi\) disturbances, blood disorders, hepatic dysfunction, serious skin reactions (stop drug if progressive rash).

**Dose:** 250 mg od po for 2–6 wks\(^1\) or 6 wks–3 months\(^2\); 1–2 topical applications/day for 1–2 wks\(^3\).

TERBUTALINE/BRICANYL
Inhaled \(\beta_2\) agonist similar to salbutamol.

**Dose:** 500 microgram od–qds inh (powder or aerosol); 5–10 mg up to qds neb. Can also give po/sc/im/iv \(^\text{SPC/BNF}\).

TETRACYCLINE
Tetracycline broad-spectrum antibiotic: inhibits ribosomal (30S subunit) protein synthesis.

**Use:** acne vulgaris\(^1\) (or rosacea), genital/tropical infections (NB: doxycycline often preferred).

**CI:** age <12 years (stains/deforms teeth), acute porphyria, \(R/P/B\).

**Caution:** may worsen MG or SLE, \(L\).

**SE:** GI upset (rarely AAC), oesophageal irritation, headache, dysphagia. Rarely hepatotoxicity, blood disorders, photosensitivity, hypersensitivity, visual \(\Delta s\) (rarely 2° to BIH; stop drug if suspected).
**THEOPHYLLINE**

Methylxanthine bronchodilator. *Theories of action:* (1) ↑s intracellular cAMP; (2) adenosine antagonist; (3) ↓s diaphragm fatigue. NB: additive fx with β2 agonists (but with ↑risk of SEs, esp ↓K⁺).

**Use:** severe asthma/COPD: acute (iv as aminophylline; see p. 243) or chronic (po).

**Cl:** hypersensitivity to any ‘xanthine’ (e.g. aminophylline/theophylline), acute porphyria.

**Caution:** cardiac disease (risk of arrhythmias*), epilepsy, ↑T₄, PU, HTN, fever, porphyria, acute febrile illness, L/P/B/E.

**Se:** (tachy)arrhythmias*, seizures (esp if given rapidly iv), GI upset (esp nausea), CNS stimulation (restlessness, insomnia), headache, ↓K⁺.

**Monitor:** K⁺, serum levels (4–6 h post dose) as narrow therapeutic window (10–20 mg/l = 55–110 micromol/l) but toxic fx can occur even in this range.

**Interactions:** metab by **P450** (⇒ very variable t₁/₂): levels ↑d in HF/LF*/viral infections/elderly, and if taking fluvoxamine/cimetidine/ciprofloxacin/norfloxacin/macrolides (ery-/clari-thromycin)/propranolol/’flu vaccines/fluconazole/ketoconazole/OCP/Ca²⁺ channel blockers. Levels ↓d in smokers/chronic alcohol abuse, and if taking phenytoin/carbamazepine/phenobarbital/ rifampicin/ritonavir/St John’s wort. ↑risk of convulsions with quinolones.

**Dose:** MR preparations preferred (↓SEs) and doses vary with brand⁹; range 200–500 mg bd. Available iv as aminophylline.

**NB:** ↓dose if LF*. Note: dose adjustment may be necessary if smoking started or stopped during chronic treatment.
THIAMINE (= vitamin B1).

**Use:** replacement for nutritional deficiencies (esp in alcoholism).

**Dose:** 100 mg bd/tds po in severe deficiency (25 mg od if mild/chronic).

For iv preparations, see **Pabrinex** and p. 272 for Mx of acute alcohol withdrawal.

THYROXINE (= LEVOTHYROXINE).

Synthetic T₄ (NB: thyroxine often now called ‘levothyroxine’).

**Use:** ↓T₄ Rx (for maintenance); NB: acutely, e.g. myxoedema coma, liothyronine (T₃) often needed – see p. 257.

**Cl:** ↑T₄.

**Caution:** panhypopituitarism/other predisposition to adrenal insufficiency (corticosteroids needed 1st), chronic ↓T₄, cardiovascular disorders (esp HTN/IHD; can worsen)*, DI, DM**, P/B/E.

**SE:** features of ↑T₄ (should be minimal unless xs Rx): D&V, tremors, restlessness, headache, flushing, sweating, heat intolerance, angina, arrhythmias, palpitations, ↑HR, muscle cramps/weakness, ↓Wt. Also osteoporosis (esp if xs dose given; use min dose necessary).

**Interactions:** can Δ digoxin and antidiabetic** requirements, ↑fx of TCAs and ↓levels of propranolol. W +.

**Monitor:** baseline ECG to help distinguish Δs due to ischaemia or ↓T₄.

**Dose:** 25–200 microgram mane (titrate up slowly, esp if >50 yrs old/△↓T₄/HTN/IHD*).

TIMOLOL EYE DROPS/TIMOPTOL

β-Blocker eye drops; ↓aqueous humour production.

**Use:** glaucoma (2nd line), ocular HTN (1st line); not useful if on systemic β-blocker.

**Cl:** asthma, ↓HR, HB, H (if uncontrolled).

**Caution/SE/Interactions:** as propranolol* plus can ⇒ local irritation.

**Dose:** 1 drop bd (0.25% or 0.5%). Also available in long-acting od preparations TIMOPTOL LA (0.25 and 0.5%) and NYOGEL /
**TIOPEX** (0.1%). Timolol 0.5% also available in combination with other classes of glaucoma medications; carbonic anhydrase inhibitors (dorzolamide **Cosopt**, brinzolamide ▼ **Azarga**), PG analogues (latanoprost **Xalacom**, travoprost **Duotrav**, bimatoprost **Ganfort**) α-agonists (brimonidine **Combigan**).

⚠️ Systemic absorption possible despite topical application* 🎧.

**TINZAPARIN/INNOHEP**
Low-molecular-weight heparin (LMWH).
**Use:** DVT/PE Rx¹ and Px² (inc pre-operative). Not licensed for MI/ unstable angina (unlike other LMWHs).
**Cl/Caution/SE/Monitor/Interactions:** as heparin, plus Ci if breast feeding (B) and caution in asthma (⇒ ↑hypersensitivity reactions).
**Dose:** (all sc) 175 units/kg od¹; 50 units/kg or 4500 units od² (3500 units od if low risk).

Consider monitoring anti-Xa (3–4 h post dose) ± dose adjustment if RF (i.e. creatinine >150), severe LF, pregnancy, Wt >100 kg or <45 kg; see p. 209.

**TIOTROPIUM/SPIRIVA**
Long-acting inh muscarinic antagonist for COPD/(unlicenced for asthma) similar to ipratropium, but only for chronic use and caution in RF.
**SE:** dry mouth, urinary retention, glaucoma.
**Dose:** 18 microgram dry powder inhaler or 5 microgram by soft mist inhaler (▼ **Respimat**) od inh.

**TIROFIBAN/AGGRANSTAT**
Antiplatelet agent: glycoprotein IIb/IIIa receptor inhibitor – stops binding of fibrinogen and inhibits platelet aggregation.
**Use:** Px of MI in unstable angina/NSTEMI *(if last episode of chest pain w/in 12 h)*, esp if high risk and awaiting PCI⁸**NICE** (see p. 233).
**Cl:** abnormal bleeding or CVA w/in 30 days, haemorrhagic diathesis, Hx of haemorrhagic CVA, intracranial disease (neoplasm/ aneurysm/AVM), severe HTN, ↓Pt, ↑INR/PT, B.
**Caution:** ↑risk of bleeding (e.g. drugs, recent bleeding/trauma/procedures; see SPC/BNF), L (avoid if severe), H (if severe), R/P.

**SE:** bleeding, nausea, fever, ↓Pt (reversible).

**Monitor:** FBC (baseline, 2–6 h after giving, then at least daily).

**Dose:** 400 nanograms/kg/min for 30 min, then 100 nanograms/kg/min for ≥48 h (continue for 12–24 h post-PCI), for max of 108 h. Needs concurrent heparin. NB: ↓dose if RF.

Specialist use only: get senior advice or contact on-call cardiology.

**TOLBUTAMIDE**

Oral antidiabetic (short-acting sulphonylurea).

**Use/CI/Caution/SE/Interactions:** as gliclazide. Can also ⇒ headache and tinnitus. fx ↑ by azapropazone.

**Dose:** 0.5–2.0 g daily in divided doses, with food. NB: ↓dose if RF or LF.

**TOLTERODINE/DETRUSITOL**

Antimuscarinic, antispasmodic.

**Use:** detrusor instability; urinary incontinence/frequency/urgency.

**CI/Caution/SE:** as oxybutynin (SEs mostly antimuscarinic fx; see p. 276) plus caution if Hx of, or taking drugs that, ↑QTc, P/B.

**Interactions:** ↑risk of ventricular arrhythmias with amiodarone, disopyramide, flecainide and sotalol.

**Dose:** 1–2 mg bd po. NB: ↓dose if RF or LF. (MR preparation available as 4 mg od po; not suitable if RF or LF.)

**tPA** (= tissue-type plasminogen activator) see Alteplase.

**TRAMADOL**

Opioid. Also ↓s pain by ↑ing 5HT/noradrenergic transmission.

**Use:** moderate/severe pain (esp musculoskeletal).

**CI/Caution:** as codeine, but also CI in uncontrolled epilepsy, P/B. Not suitable as substitute in opioid-dependent patients.

**SE:** as morphine, but ↓respiratory depression, ↓constipation, ↓addiction. ↑confusion (esp in elderly) compared to codeine.

**Interactions:** as codeine; also ↑risk convulsions with SSRIs/TCAs/antipsychotics, ↑risk serotonin syndrome with SSRIs. Carbamazepine and ondansetron ↓ its fx. W +.
**TRIAMTERENE**

**Dose:** 50–100 mg up to 4-hrly po/im/iv, max 400 mg/day. Post-op: initially 100 mg im/iv, then 50 mg every 10–20 min prn (max total dose of 250 mg in 1st hr), then 50–100 mg 4–6-hrly (max 600 mg/day). **NB:** ↓dose if RF, LF or elderly.

**TRANDOLAPRIL/GOPTEN**

ACE-i for HTN (for advice on stepped HTN Mx see p. 235), HF and LVF post-MI.

**CI/Caution/SE/Monitor/Interactions:** see Captopril.

**Dose:** initially 0.5 mg od, ↑ing at intervals of 2–4 wks if required to max 4 mg od (max 2 mg if RF). ↓doses if given with diuretic. If for LVF post-MI, start ≥3 days after MI.

**TRANEXAMIC ACID**

Antifibrinolytic: inhibits activation of plasminogen to plasmin.

**Use:** bleeding: acute bleeds\(^1\) (esp 2° to anticoagulants, thrombolytic/anti-Pt agents, epistaxis, haemophilia), menorrhagia\(^2\), hereditary angioedema\(^3\).

**CI:** TE disease, Hx of convulsions, R (if severe, otherwise caution).

**Caution:** gross haematuria (can clot and obstruct ureters), DIC, P.

**SE:** GI upset, colour vision Δs (stop drug), TE.

**Dose:** 15–25 mg/kg bd/tds po (if severe, 0.5–1 g tds iv); 1 g tds po for 4 days (max 4 g/day); 1–1.5 g bd/tds po\(^3\). **NB:** ↓dose if RF.

**TRAVOPROST EYE DROPS/TRAVATAN**

Topical PG analogue for glaucoma; see Latanoprost.

**Use/Ci/Caution/SE:** see Latanoprost.

**Dose:** 1 drop od, preferably in the evening.

**TRIAMTERENE**

K\(^+\)-sparing diuretic (weak); see Amiloride.

**Use/Ci/Caution/SE:** as amiloride, but ⇒ less ↓BP. not used for HTN (unless used with other drugs), plus L (avoid if severe).

**Warn:** urine may go blue.

**Interactions:** ↑s lithium and phenobarbital levels. NSAIDs ↑risk of RF and ↑K\(^+\).
**Dose:** almost exclusively used with stronger K\(^+\)-wasting diuretics in combination preparations (e.g. co-triamterzide). For use alone, initially give 150–250 mg daily, ↓ing to alternate days after 1wk.

⚠ Beware if on other drugs that ↑K\(^+\), e.g. amiloride, spironolactone, ACE-i, angiotensin II antagonists and ciclosporin. Do not give with oral K\(^+\) tablets or dietary salt substitutes ⚠.

**TRI-IODOTHYRONINE**
See Liothyronine; synthetic T\(_3\) mostly used in myxoedema coma.

**TRIMETHOPRIM**
Antifolate antibiotic: inhibits dihydrofolate reductase.

**Use:** UTIs (rarely other infections).

**Cl:** blood disorders (esp megaloblastic ↓Hb).

**Caution:** ↓folate (or predisposition to), porphyria, R/P/B/E.

**SE:** see Co-trimoxazole (Septrin), but much less frequent and severe (esp BM suppression, skin reactions). Also GI upset, rash, rarely other hypersensitivity.

**Warn:** those on long-term Rx to look for signs of blood disorder and to report fever, sore throat, rash, mouth ulcers, bruising or bleeding.

**Interactions:** ↑s phenytoin levels. ↑s risk of arrhythmias with amiodarone, antifolate fx with pyrimethamine and toxicity with ciclosporin, azathioprine, mercaptopurine and methotrexate. W +.

**Dose:** 200 mg bd po (100 mg nocte for chronic infections or as Px if at risk; NB: risk of ↓folate if long-term Rx). NB: ↓dose if RF.

**TROPICAMIDE EYE DROPS**
Antimuscarinic: mydriatic (lasts approx 4 hrs), weak cycloplegic.

**Use:** dilated retinal examination. See also ‘Dilating eye drops’.

**Cl:** untreated acute angle closure glaucoma.

**Caution:** ↑IOP\(^\ast\) (inc predisposition to), inflamed eye (↑risk of systemic absorption).

**SE:** transient stinging & blurred vision & ↓accommodation. Rarely precipitation of acute angle closure glaucoma (↑risk if >60 yrs, long sighted, family history).
Warn: unable to drive until can read car number plate at 20 metres (approx 4 hrs).

Dose: 1 drop 1.0% solution 15–20 min before examination. 0.5% in children <1 yr old. NB: Rare cause of acute angle closure glaucoma* (esp if >60 yrs or hypermetropic).

TURBOHALER Inh delivery device for asthma drugs.

(SODIUM) VALPROATE
Antiepileptic and mood stabiliser: potentiates and ↑s GABA levels.

Use: epilepsy¹, mania (and off-licence for other Ψ disorders).

CI: acute porphyria, personal or family Hx of severe liver dysfunction, L (inc active liver disease).

Caution: SLE, ↑bleeding risk*, R, P (⇒ neural-tube/craniofacial dfx, Px folate), B.

SE: sedation, cerebellar fx (see p. 278; esp tremor, ataxia), headache, GI upset, ↑Wt, SOA, alopecia, skin reactions, ↓cognitive/motor function, Ψ disorders, encephalopathy (2° to ↑ammonia). Rarely but seriously hepatotoxicity, blood disorders (esp ↓Pt*), pancreatitis (mostly in 1st 6 months of Rx).

Warn: of clinical features of pancreatitis and liver/blood disorders. Inform women of childbearing age of teratogenicity/need for contraception.

Monitor: LFTs, FBC ± serum levels pre-dose (therapeutic range 50–100 mg/l; useful for checking compliance but ↓use for efficacy).

Interactions: fx ↓d by antimalarials (esp mefloquine), antidepressants (inc St John’s wort), antipsychotics and some antiepileptics². Levels ↑by cimetidine & carbopenems. ↑s fx of aspirin and primidone. ↑risk of ↓NØ with olanzapine. Mild W +.

Dose: initially 300 mg bd, ↑ing to max of 2.5 g/day¹. NB: ↓dose if RF. Can give false-positive urine dipstick for ketones.

▼ VALSARTAN/DIOVAN
Angiotensin II antagonist; see Losartan.

Use: HTN¹ (for advice on stepped HTN Mx see p. 235), MI with LV failure/dysfunction², heart failure³.
**VANCOMYCIN**
Glycopeptide antibiotic. Poor po absorption (unless bowel inflammation*), but still effective against *C. difficile*** as acts 'topically' in GI tract.

**Use:** serious Gram-positive infections¹ (inc endocarditis Px and systemic MRSA), AAC² (give po)**.

**Caution:** Hx of deafness, IBD* (only if given po), avoid rapid infusions (risk of anaphylaxis), R/P/B/E.

**SE:** nephrotoxicity, ototoxicity (stop if tinnitus develops), blood disorders, rash, hypersensitivity (inc anaphylaxis, severe skin reactions), nausea, fever, phlebitis/irritation at injection site.

**Monitor:** serum levels: keep predose trough levels 10–15 mg/l; start monitoring after 3rd dose (1st dose if RF); NB: higher trough recommended in osteomyelitis, endocarditis. Also monitor U&Es, FBC, urinalysis (and auditory function if elderly/RF).

**Interactions:** ↑nephrotoxicity with ciclosporin. ↑ototoxicity with loop diuretics. ↑s fx of suxamethonium.

**Dose:** 1–1.5 g bd ivi at 10 mg/min¹; 125 mg qds po². NB: ↓dose if RF or elderly.

NB: if ivi given too quickly ⇒ ↑risk of anaphylactoid reactions (e.g. ↓BP, respiratory symptoms, skin reactions).
Dose: initially 10 mg approx 25–60 min before sexual activity, adjusting to response (1 dose per 24 h, max 20 mg per dose). NB: halve dose if LF, RF, elderly or taking α-blocker.

VECURONIUM (BROMIDE)
Use: neuromuscular blockade for surgery.
CI: anaesthetist not confident of airway maintenance.
Caution: hypersensitivity to other neuromuscular blockers (allergic cross-reactivity), MG and hypothermia prolong activity (use lower doses), fluid/e’lyte Δ (unpredictable response), burns (resistance can develop), cardiovascular disease (↓rate of administration); obesity (↑duration of action), L / R.
SE: ↓ or ↑ HR. Rarely acute myopathy*.
Monitor: Cardiac, respiratory and motor function.
Interactions: fx ↑by aminoglycosides, clindamycin & polymyxins. Corticosteroids can ↑ myopathy¹.
Dose: initially 80–100 micrograms/kg iv; then maintenance either 20–30 micrograms/kg iv (max. 100 micrograms/kg in caesarian section) or 0.8–1.4 micrograms/kg/min ivi, adjusting to response. NB: if obese (weight 30% above ideal body weight (IBW; see p.296)) use IBW for dose calculation.

Specialist use only; respiration needs assistance / control until drug inactivated or antagonised and anaesthetic / sedative to prevent awareness.

VENLAFAXINE/EFEXOR
Serotonin and Noradrenaline Reuptake Inhibitor (SNRI): antidepressant with ↓sedative/antimuscarinic fx cf TCAs. ↑danger in OD/heart disease than other antidepressants.
Use: depression¹, generalised anxiety disorder.
CI: very high risk of serious cardiac ventricular arrhythmia (e.g. significant LV dysfunction, NYHA class III/IV), uncontrolled HTN, P.
**Caution:** Hx of mania, seizures or glaucoma, L/R (avoid if either severe) H/B.

**SE:** GI upset, ↑BP (dose-related; monitor BP if dose >200 mg/day), withdrawal fx (see p. 277; common even if dose only a few hours late), rash (consider stopping drug, as can be 1st sign of severe reaction*), insomnia/agitation, dry mouth, sexual dysfunction, ↑weight, drowsiness, dizziness, SIADH and ↑QTc.

**Warn:** report rashes* and can ↓driving/skilled task ability. Don’t stop suddenly.

**Monitor:** BP if heart disease ± ECG.

**Interactions:** ✗ Never give with, or ≤2 wks after, MAOIs ✗. ↑s risk of bleeding with aspirin/NSAIDs and CNS toxicity with selegiline/sibutramine. Avoid artemether/lumefantrine. ↑s levels of clozapine. Mild W +.

**Dose:** 37.5–187.5 mg bd po¹; start low and ↑dose if required.

Efexor XL MR od preparation available (max 225 mg od). NB: halve dose if moderate LF (PT 14–18 s) or RF (GFR 10–30 ml/min).

VENTOLIN see Salbutamol; β-agonist bronchodilator.

**VERAPAMIL**

Ca²⁺ channel blocker (rate-limiting type): fx on heart ( ⇒ ↓HR, ↓contractility*) > vasculature (dilates peripheral/coronary arteries); i.e. reverse of the dihydropyridine type (e.g. nifedipine). Only Ca²⁺ channel blocker with useful antiarrhythmic properties (class IV).

**Use:** HTN¹ (for advice on stepped HTN Mx see p. 235), angina², narrow complex tachyarrhythmias (SVTs, esp instead of adenosine if asthma)³.

**Cl:** ↓BP, ↓HR (<50 bpm), 2nd-/3rd-degree HB, ↓LV function, SAN block, SSS, AF or atrial flutter ²° to WPW, acute porphyria. H * (inc Hx of).

**Caution:** AMI, 1st degree HB, L/P/B.

**SE:** constipation (rarely other GI upset), HF, ↓BP (dose-dependent), HB, headache, dizziness, fatigue, ankle oedema, hypersensitivity, skin reactions.

**Interactions:** ↑risk of AV block and HF with ✗ β-blockers ✗ disopyramide, flecainide, dronedarone and amiodarone. ↑s
hypotensive fx of antihypertensives (esp α-blockers) and anaesthetics. ↑s levels/fx of digoxin, theophyllines, carbamazepine, quinidine, ivabradine, dabigatran and ciclosporin. Levels/fx ↓ by rifampicin, barbiturates and primidone. ↑ risk of myopathy with simvastatin. Sirolimus ↑ s levels of both drugs. Levels may be ↑ by clari-/ery-thromycin and ritonavir. Risk of VF with iv dantrolene. 

Warn: fx ↑d by grapefruit juice (avoid).

Dose: 80–160 mg tds po¹; 80–120 mg tds po²; 40–120 mg tds po³; 5–10 mg iv (over 2 min (3 min in elderly) with ECG monitoring), followed by additional 5 mg iv if necessary after 5–10 min³. MR (od/bd) preparations availableBNF. NB: ↓ oral dose in LF.

VIAGRA see Sildenafil; phosphodiesterase inhibitor.

VITAMIN K see Phytomenadione.

VOLTAROL see Diclofenac; moderate-strength NSAID.

WARFARIN
Oral anticoagulant: blocks synthesis of vitamin-K-dependent factors (II, VII, IX, X) and proteins C and S.

Use: Rx/Px of TE; see p. 212.

CI: severe HTN, PU, severe bleeding, haemorrhagic CVA, P.

Caution: recent surgery, bacterial endocarditis, 48 hrs post-partum, L/R (avoid if creatinine clearance <10 ml/min)/B.


Warn: fx are ↑d by alcohol and cranberry juice (avoid).

Dose: see p. 214.

NB: W + and W– denote significant interactions throughout this book: take particular care with antibiotics and drugs that affect cytochrome P450 (see p. 279).

XALATAN see ▼ Latanoprost; topical PG analogue for glaucoma.

ZALEPLON
‘Non-benzodiazepine’ hypnotic; see Zopiclone.
**ZIDOVUDINE (AZT)**
Antiviral (nucleoside analogue): reverse-transcriptase inhibitor.

**Use:** HIV Rx (and Px, esp of vertical transmission).

**CI:** severe ↓NØ or ↓Hb (caution if other blood disorders), acute porphyria, **B.**

**Caution:** ↓B12, ↑risk of lactic acidosis, **L/R/P/E.**

**SE:** blood disorders (esp ↓Hb or ↓WCC; monitor FBC), GI upset, headache, fever, taste Δs, sleep disorders. Rarely hepatic/pancreatic dysfunction, myopathy, seizures, other neurological/Ψ disorders.

**Interactions:** levels ↑ by fluconazole. fx ↓ by ritonavir.
↑myelosuppression with ganciclovir. ↑risk of ↓Hb with ribavirin. ↓s fx of stavudine and tipranavir.

**Dose:** see SPC/BNF.

**ZIRTEK** see Cetirizine; non-sedating antihistamine for allergies.

**ZOLEDRONIC ACID/ZOMETA**
Bisphosphonate: ↓s osteoclastic bone resorption.

**Use:** Px of bone damage¹ in advanced bone malignancy, damage or Rx of ↑Ca²⁺ in malignancy², Rx of Paget’s disease of bone³, Rx of osteoporosis (postmenopausal or in men)⁴.

**CI:** **P/B.**

**Caution:** cardiac disease, dehydration*, ↓Ca²⁺/PO₄²⁻/Mg²⁺. **L** (if severe)/**R/H.**

**SE:** ’flu-like syndrome, fever, bone pain, fatigue, N&V. Also arthr-/my-algia, ↓Ca²⁺/PO₄²⁻/Mg²⁺, pruritus/rash, headache, conjunctivitis, RF, hypersensitivity, blood disorders (esp ↓Hb) and osteonecrosis (esp of jaw; consider dental examination or preventive Rx before starting drug).
Monitor: Ca$^{2+}$, PO$_4^{2-}$, Mg$^{2+}$, U&E. Ensure patient adequately hydrated predose* and advise good dental hygiene.

Dose: 4 mg ivi every 3–4 weeks$^1$; 4 mg ivi as single dose$^2$. Also available as once yearly preparation (▼ Aclasta) 5 mg ivi over ≥15 mins$^3$$^4$. NB: ↓dose in RF.

**ZOLMITRIPTAN/ZOMIG**
5HT$_{1B/1D}$ agonist for acute migraine.

Use/CI/Caution/SE/Interactions: as sumatriptan plus CI in WPW or arrhythmias assoc with accessory cardiac conduction p’way.

Dose: 2.5 mg po (can repeat after ≥2 h if responded then recurs and can ↑doses to 5 mg if required). Max 10 mg/24 h (5 mg/24 h if moderate-severe LF). Available intranasallyBNF/SPC.

**ZOLPIDEM**
‘Non-benzodiazepine’ hypnotic; see Zopiclone.

Use/CI/Caution/SE/Interactions: as Zopiclone but CI in psychotic illness, P.

Dose: 10 mg nocte. NB: halve dose if LF (avoid if severe), severe RF or elderly.

**ZOMORPH** Morphine sulphate capsules (10, 30, 60, 100 or 200 mg), equivalent in efficacy to Oramorph but SR: 12-hrly doses.

**ZOPICLONE**
Short-acting hypnotic (cyclopyrrolone): potentiates GABA pathways via same receptors as benzodiazepines (although isn’t a benzodiazepine!): can also ⇒ dependence* and tolerance.

Use: insomnia (not long-term*).

CI: respiratory failure, sleep apnoea (severe), marked neuromuscular respiratory weakness (inc unstable MG), L (if severe**), B.

Caution: Ψ disorders, Hx of drug abuse*, muscle weakness, MG, R/P/E.

SE: all rare: GI upset, taste Δs, behavioural/Ψ disturbances (inc psychosis, aggression), hypersensitivity.
**Interactions:** Levels ↑ by ritonavir, erythromycin and other enzyme inhibitors. Levels ↓ by rifampicin. Sedation ↑’d by other sedative medications and alcohol.

**Dose:** 7.5 mg nocte, ↑ ing to 15 mg if necessary. NB: halve dose if LF (avoid if severe**), severe RF or elderly.

ZOTON see Lansoprazole; PPI.

ZYBAN see Bupropion; adjunct to smoking cessation.
Drug selection

Analgesia in the ED 178
Antiemetics in the ED 179
Local anaesthesia 181
Procedural sedation and analgesia 182
Rapid sequence induction 184
Drug infusion guideline 186
ANALGESIA IN THE ED

Patients commonly present with pain to the emergency department (ED). All require prompt treatment whilst the underlying cause(s) are addressed.

Physical and psychological approaches such as splinting, elevation, ice or heat, with reassurance and explanation are as important (and usually much quicker) than relying on pharmacological agents.

When opiate analgesia is indicated for severe acute pain, give this iv titrated to effect.

GENERAL RULES

• Look for/treat the underlying cause(s) and reassess cause at each step.

- All opioids can ⇒ constipation, respiratory depression and ↓GCS (esp if elderly or RF – even low doses). Can also ⇒ coma if LF.
- All NSAIDs can ⇒ PU (related to strength of drug and length of Rx. Consider PPI or changing to COX2 inhibitor\textsuperscript{NICE}) Can also ⇒ AKI if fluid depleted (: rehydrate 1st or avoid).

- Simple analgesia: paracetamol 1 g qds usually 1st-line as few SEs.
  NSAIDs 2nd-line; 1st line if predominant inflammatory component, e.g.:
  – ibuprofen 200–400 mg tds po for mild pain.
  – diclofenac (\textit{Voltarol}) 50 mg tds im/po or 75 mg SR bd im/po or 100 mg pr (max 150 mg/day) for moderate pain.
- Consider specialist analgesia according to cause, e.g. buscopan for colic, colchicine for gout, antacids for reflux, GTN for angina. For neuropathic pain try amitriptyline, gabapentin or pregabalin.

- High dose weak opioid e.g.:
  – dihydrocodeine 30 mg qds
  – tramadol 50–100 mg qds (also has 5HT fx: ↓SEs for same analgesia)

- Strong opioid: iv if acute (e.g. morphine) po if chronic (e.g. oramorph)

Figure 2.1 Analgesia ladder. (Stepwise approach based on WHO pain relief ladder for cancer pain.)
• Regular Rx ↓s recurrences but always review to check whether still needed.
• If pain ↓s, ‘step down’ (see Figure 2.1) and ensure adequate prn analgesia in case ↑s again.
• Pain has many adverse medical fx and is rarely refractory unless incorrectly/under-treated.
• Pain out of proportion to that expected may indicate an unrecognised serious underlying cause such as compartment syndrome, vascular compromise, necrotising fasciitis etc.
• If pain persists, get senior or specialist help (e.g. anaesthetist or pain team).

**ANTIEMETICS IN THE ED**

Commonly used 1st-line/narrow-spectrum antiemetics. See Figure 2.2.

**Causes of nausea/vomiting:**

- **GI:** surgical (obstruction, peritonism, pancreatitis, biliary colic) and gen medical (oesophagitis, gastritis, PU).
- **Neurological:** migraine, ↑ICP (esp tumour), meningo-encephalitis, Menière’s, labyrinthitis.
- **Metabolic:** ↑Ca^{2+} (also ↓Na^+, ↑K^+), DKA, AKI, Addison’s.
- **Infection:** gastroenteritis, UTI (often presenting symptom in elderly), respiratory infection (coughing).
- **Drugs:** esp opiates, chemotherapy/cytotoxics, antibiotics (esp erythromycin, metronidazole). Also dopamine agonists, antidepressants (esp fluoxetine), theophyllines, colchicine, FeSO_4 and acutely amiodarone/digoxin.
- **Poisoning:** paracetamol; aspirin; agents above
- **Other:** pregnancy, MI (esp inferior, often with atypical pain if DM/elderly).
**General rules**
- Look for/treat reversible causes (see p. 179).
- Reassess causes at each step.
- Start iv/im/sc switching to po when able.
- Don’t stop Rx unless cause removed.
- Combine different antiemetics: aim to progressively block different receptors.

---

**Step 1**
- Start narrow-spectrum (1st line) drug: choose most appropriate agent from the table below.

**Step 2**
- Try alternative or add 2nd narrow-spectrum agent.
- Consider dexamethasone if cause is brain tumour (or other cause of ICP) or chemotherapy.

**Step 3**
- Try levomepromazine or a 5HT₃ antagonist (e.g. ondansetron).

**Step 4**
- Try metoclopramide (Gs causes ↑s Gl motility), migraine, drugs (esp opiates)
- ⇒ prolactin, extrapyramidal fx, Cl if Gl obstruction

---

**Figure 2.2 Antiemetic ladder – (designed for cancer patients;) step 4 is rarely needed in the ED.**

<table>
<thead>
<tr>
<th>Class</th>
<th>Example</th>
<th>Good for</th>
<th>Beware</th>
</tr>
</thead>
<tbody>
<tr>
<td>Butyrophenone</td>
<td>Haloperidol</td>
<td>Opiates, general anaesthetic, postoperative, chemo-/radio-therapy (if mild), 1st choice in LF</td>
<td>⇒ ↑ prolactin, extrapyramidal fx, ↓s seizure threshold, ↓BP</td>
</tr>
<tr>
<td>(D₂ antagonist)</td>
<td>0.5–1.5 mg sc/po</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenothiazine</td>
<td>Levomepromazine</td>
<td>Broad spectrum: useful when cause unclear/multifactorial</td>
<td>⇒ sedation, ↓BP ↓s seizure threshold</td>
</tr>
<tr>
<td>(D₂ antagonist)</td>
<td>6.25–25 mg od or bd po/sc/iv</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzamide (D₂ antagonist)</td>
<td>Metoclopramide</td>
<td>(Gl causes ↑s Gl motility), migraine, drugs (esp opiates)</td>
<td>⇒ ↑ prolactin, extrapyramidal fx, Cl if Gl obstruction</td>
</tr>
<tr>
<td></td>
<td>10 mg tds po/sc/im/iv(Maxolon)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Benzamine (D₂ antagonist)  | **Domperidone**  | Parkinson’s disease\(^b\), morning-after pill, chemotherapy  
| 10–20 mg tds po or 30–60 mg bd pr (not iv or im)  |  ⇒ ↑ prolactin, but minimal sedation and extrapyramidal fx\(^b\), QT-prolongation  

**Antihistamines**  | **Cyclizine** 50 mg tds po/sc/im/iv  | GI obstruction\(^a\)/postoperative N&V, vestibular/labyrinthine disorders. Antiemetic of choice in LF  
|  ⇒ Antimuscarinic fx (esp sedation). Avoid in IHD\(\downarrow\)s beneficial cardiodynamic fx of opiates  

**5HT\(^3\) antagonists**  | **Ondansetron** 4–8 mg bd po/im/iv (16 mg od pr) **Granisetron** **Tropisetron**  | Severe/resistant cases (esp chemo-/radiotherapy)  
| Minimal side effects: headache, constipation, dizziness  

\(^a\) Prokinetic fx of metoclopramide by anticholinergic drugs (see p. 276), esp cyclizine if also used in this setting.  
\(^b\) Extrapyramidal fx possible with all D₂ antagonists (see p. 278) but less so with domperidone.

**LOCAL ANAESTHESIA**

Used for wound exploration and repair; painful procedures such as chest drain placement, LP and large cannula insertion or ABG puncture; local blocks such as ring block or femoral nerve block, and regional blocks such as Bier’s.

**SAFE USAGE**

- Exclude allergy (ask), local infection (look), bleeding disorder (if nerve block planned).
- Know maximum safe doses (see Table 2.1).
Lay patient down and aspirate for blood prior to local anaesthetic infiltration (avoids inadvertent systemic delivery).

- Recognise features of systemic toxicity and call for senior help (see Table 2.2).

**PROCEDURAL SEDATION AND ANALGESIA**

Must *only* be performed when two doctors are available, in a suitable monitored resuscitation area, on a carefully selected patient, with experienced (ideally credentialed) staff and full documentation including informed consent.

**GENERAL PRINCIPLES**

- Consider for brief painful procedure such as fracture manipulation, dislocation reduction, cardioversion or abscess drainage.
- Patients should ideally be fasted, haemodynamically stable, and without pre-existing cardiorespiratory impairment.
- Capnography is recommended as well as pulse oximetry (essential).
- Agent(s) chosen are given at minimum dose to achieve adequate sedation and analgesia for the particular procedure (see Table 2.3).
- Make certain patient is fully recovered after a period of observation before discharging home. Certain criteria must be fulfilled before they are ready to go (see Table 2.4).

**Table 2.1 Maximum recommended safe dose and duration of action of common local anaesthetics**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose (mg/kg)</th>
<th>Duration (hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lignocaine</td>
<td>3</td>
<td>0.5–1</td>
</tr>
<tr>
<td>Lignocaine with adrenaline</td>
<td>7</td>
<td>2–5</td>
</tr>
<tr>
<td>Bupivacaine</td>
<td>2</td>
<td>2–4</td>
</tr>
<tr>
<td>Prilocaine</td>
<td>6</td>
<td>0.5–1.5</td>
</tr>
</tbody>
</table>

*a A 1% solution contains 10 mg/mL*
Table 2.2 Features of systemic local anaesthetic toxicity (in order of increasing plasma levels)

Circumoral tingling
Dizziness
Tinnitus
Visual disturbance
Muscular twitching
Confusion
Convulsions
Coma
Apnoea
Cardiovascular collapse (highest plasma levels)

Table 2.3 IV procedural sedation drug doses for 70 kg adult. Reduce doses in the elderly, or with small muscle bulk

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial IV bolus</th>
<th>Subsequent titrated IV boluses</th>
<th>Maximum cumulative dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>2.5 mg</td>
<td>2.5 mg</td>
<td>10–15 mg</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25–50 microgram</td>
<td>25 microgram</td>
<td>150–200 microgram</td>
</tr>
<tr>
<td>Midazolam</td>
<td>2 mg</td>
<td>1 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Diazepam</td>
<td>5 mg</td>
<td>2.5 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Propofol</td>
<td>40–50 mg</td>
<td>20 mg</td>
<td>150 mg</td>
</tr>
<tr>
<td>Ketamine</td>
<td>20–30 mg</td>
<td>10–20 mg</td>
<td>120 mg</td>
</tr>
<tr>
<td>Etomidate</td>
<td>5–7 mg</td>
<td>2 mg</td>
<td>20 mg</td>
</tr>
</tbody>
</table>
Rapid sequence induction (RSI) is the simultaneous administration of sedation and a short-acting muscle relaxant in predetermined doses to enable laryngoscopy and placement of an endotracheal tube (ETT). It is only performed by doctors trained in the technique including how to manage the difficult airway, in a suitable monitored resuscitation area, with experienced (ideally credentialed) staff, on a patient at risk of aspiration (full stomach, or critically ill or injured) to create, maintain and/or protect the airway, plus to facilitate ventilation.

**GENERAL PRINCIPLES**

- Drugs given fall into three groups: premedication agents (discretionary); induction agents to rapidly achieve anaesthesia; and muscle relaxants including rapid onset/short acting to place the ETT (suxamethonium or rocuronium) and then long acting for maintaining paralysis (see Table 2.5).
- Maintenance of oxygenation is paramount, including a period of pre-oxgenation, then throughout the procedure, and in any failed intubation drill including for the difficult airway.
- Confirm ETT placement using end-tidal CO₂ monitoring to avoid missing inadvertent oesophageal intubation.

### Table 2.4 Criteria for discharge following procedural sedation in adults

- Alert and oriented, or has returned to pre-procedure state
- Ambulates safely, or has returned to pre-procedure state
- Comfortable and has discharge analgesia arranged
- Discharged into care of a responsible adult
- No driving or similar for a minimum of 8 hours
- Avoid alcohol or other CNS depressants for 12–24 hours
- Warn about the potential for post-procedure pain, unsteadiness or dizziness. Seek medical attention if significant or disabling
### Table 2.5 Drugs for rapid sequence induction (RSI) intubation

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Action</th>
<th>Onset (min)</th>
<th>Duration (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Premedication agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine</td>
<td>0.02 mg/kg</td>
<td>Vagal blockade</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>1.5 mg/kg</td>
<td>Decreases ICP</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>1.5 microgram/kg</td>
<td>Analgesic</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>Morphine</td>
<td>0.15 mg/kg</td>
<td>Analgesic</td>
<td>4</td>
<td>120</td>
</tr>
<tr>
<td>Midazolam</td>
<td>0.05 mg/kg</td>
<td>Anxiolytic</td>
<td>2</td>
<td>30</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>0.01 mg/kg</td>
<td>Defasciculation</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td><strong>Induction agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiopentone</td>
<td>1–5 mg/kg</td>
<td>Rapid-onset sedation (+ decreases ICP)</td>
<td>0.5</td>
<td>10</td>
</tr>
<tr>
<td>Propofol</td>
<td>1–2 mg/kg</td>
<td>Sedation</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>10–20 microgram/kg</td>
<td>Sedation, analgesic</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>Midazolam</td>
<td>0.05–0.1 mg/kg</td>
<td>Rapid-onset sedation</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Diazepam</td>
<td>0.1 mg/kg</td>
<td>Rapid-onset sedation</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td>Ketamine</td>
<td>1 mg/kg</td>
<td>Dissociative state</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td><strong>Muscle relaxants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suxamethonium</td>
<td>1.5 mg/kg</td>
<td>Depolarizing MR³</td>
<td>0.5</td>
<td>5</td>
</tr>
<tr>
<td>Rocuronium</td>
<td>1.0 mg/kg</td>
<td>Non-depolarizing MR³</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Vecuronium</td>
<td>0.2 mg/kg</td>
<td>Non-depolarizing MR</td>
<td>2</td>
<td>40</td>
</tr>
</tbody>
</table>

*(Continued)*
Table 2.5 (Continued) Drugs for rapid sequence induction (RSI) intubation

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Action</th>
<th>Onset (min)</th>
<th>Duration (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atracurium</td>
<td>0.5 mg/kg</td>
<td>Non-depolarizing</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancuronium</td>
<td>0.1 mg/kg</td>
<td>Non-depolarizing</td>
<td>3</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ICP, intracranial pressure; MR, muscle relaxant.

*a Short acting.

**DRUG INFUSION GUIDELINE**

Drug infusions are common in critical care areas where monitoring and close supervision are standard. Each hospital/area will have their preferred dilutions and delivery systems.

**SAFE USAGE**

- Checking and re-checking drug doses added is essential, as is reviewing the clinical effects for improvement or complications.
- See Table 2.6 for drug and dose calculations in adults based on body weight of 70–80 kg.
### Table 2.6 Critical care area drug infusion guideline

<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Paediatric infusion range (&lt; 30 kg)</th>
<th>Dilution Infusion pump (IP)</th>
<th>Syringe driver</th>
<th>Concentration</th>
<th>Adult dose (70–80 kg)</th>
<th>Volume per hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenaline (epinephrine)</td>
<td>According to condition 1–100 micrograms/kg</td>
<td>0.05–1.0 micrograms/kg/min</td>
<td>6 mg in 100 mL DS</td>
<td>3 mg in 50 mL DS</td>
<td>60 micrograms/mL</td>
<td>2–20 micrograms/min</td>
<td>2–20 mL/h</td>
</tr>
<tr>
<td>Aminophylline b <strong>Standard</strong></td>
<td>5.0 mg/kg in 100 mL DS over 20 min by IP</td>
<td>0.5–0.9 mg/kg/h</td>
<td>1000 mg in 500 mL DS</td>
<td>—</td>
<td>2 mg/mL</td>
<td>0.5–0.9 mg/kg/h</td>
<td>17.5–30 mL/h</td>
</tr>
<tr>
<td>a <strong>Transport</strong></td>
<td>5.0 mg/kg in 100 mL DS over 20 min by IP</td>
<td>0.5–0.9 mg/kg/h</td>
<td>100 mL DS</td>
<td>250 mg in 50 mL DS</td>
<td>5 mg/mL</td>
<td>0.5–0.9 mg/kg/h</td>
<td>7–13 mL/h</td>
</tr>
<tr>
<td>Amiodarone b <strong>Standard</strong></td>
<td>2–5 mg/kg in 100 mL DW over 30 min by IP</td>
<td>5–15 micrograms/kg/min</td>
<td>600 mg in 500 mL DW glass bottle. Discard at 12 h</td>
<td>—</td>
<td>1.2 mg/mL</td>
<td>20–60 mg/h (max. 15 mg/kg/24h)</td>
<td>17–52 mL/h</td>
</tr>
<tr>
<td>a <strong>Transport</strong></td>
<td>2–5 mg/kg in 100 mL DW over 30 min by IP</td>
<td>5–15 micrograms/kg/min</td>
<td>300 mg in 100 mL DW</td>
<td>150 mg in 50 mL DW</td>
<td>3 mg/mL</td>
<td>20–60 mg/h (max. 15 mg/kg/24h)</td>
<td>7.5–22 mL/h</td>
</tr>
</tbody>
</table>

(Continued)
Table 2.6 (Continued) Critical care area drug infusion guideline

<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Paediatric infusion range (&lt; 30 kg)</th>
<th>Dilution</th>
<th>Adult dose (70–80 kg)</th>
<th>Volume per hour</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonazepam</td>
<td>1.0–2.0 mg</td>
<td>5–10 micrograms/kg/h</td>
<td>10 mg in</td>
<td>0.35–0.7 mg/h</td>
<td>3.5–7.0 mL/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 mL DS</td>
<td>5 mg in</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50 mL DS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dobutamine</td>
<td>—</td>
<td>2–30 micrograms/kg/min</td>
<td>250 mg in</td>
<td>2–30 micrograms/kg/min</td>
<td>2–30 mL/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>125 mg in</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50 mL DS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dopamine</td>
<td>—</td>
<td>Renal: 0.5–2.5 micrograms/kg/min</td>
<td>200 mg in</td>
<td>Renal: 0.5–2.5 micrograms/kg/min</td>
<td>1–5 mL/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inotrope: 5–20 micrograms/kg/min</td>
<td>100 mL DS</td>
<td>Inotrope: 5–20 micrograms/kg/min</td>
<td>10–40 mL/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 mL DS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50 mL DS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>1–5 micrograms/kg</td>
<td>1–10 micrograms/kg/h</td>
<td>1000 micrograms in 100 mL DS</td>
<td>50–200 micrograms/h</td>
<td>5–20 mL/h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>500 micrograms in 50 mL DS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10 micrograms/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glyceryl trinitrate (GTN)</td>
<td>1–10 micrograms/kg/min</td>
<td>200 mg in 500 mL DW. Use glass bottle/low-absorption set</td>
<td>400 micrograms/mL</td>
<td>0.4–8 mg/h</td>
<td>1–20 mL/h</td>
</tr>
<tr>
<td>Drug</td>
<td>Description</td>
<td>Dose Details</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fusion</strong></td>
<td>Transport</td>
<td>1–10 mg/kg/h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Insulin</strong> (short-acting)</td>
<td></td>
<td>2–20 units/ kg/h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Isoprenaline</strong></td>
<td>Low dose</td>
<td>50–100 micrograms/min</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>High dose</strong></td>
<td></td>
<td>0.05–1.0 micrograms/min</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ketamine</strong></td>
<td></td>
<td>IV: 1–2 mg/kg/ kg/h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lignocaine</strong> (lidocaine)</td>
<td>Standard</td>
<td>1–2 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Transport</strong></td>
<td></td>
<td>1–2 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table 2.6 (Continued) Critical care area drug infusion guideline

<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Paediatric infusion range (&lt; 30 kg)</th>
<th>Dilution</th>
<th>Adult dose (70–80 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Magnesium sulphate</strong></td>
<td>0.15–0.3 mmol/kg = 10–20 mmol</td>
<td>0.05–0.1 mmol/kg/h</td>
<td>40 mmol in 100 mL DS</td>
<td>20 mmol in 50 mL DS</td>
</tr>
<tr>
<td>49.3% solution in 5 mL = 10 mmol = 2.47 g</td>
<td>(adult) Dilute in 50 mL DS Infuse: 2 min (VT) to 20 min (pre-eclampsia)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methyl prednisolone</strong></td>
<td>30 mg/kg over 30 min by IP</td>
<td>5.4 mg/kg/h</td>
<td>4 g in 100 mL. Reconstitute in water BP Dilute in DS</td>
<td>2 g in 50 mL. Reconstitute in water BP Dilute in DS</td>
</tr>
<tr>
<td><em>Spinal injury</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Midazolam</strong></td>
<td>0.05–0.1 mg/kg in 1–2.5 mg increments</td>
<td>10–100 micrograms/kg/h</td>
<td>50 mg in 100 mL DS</td>
<td>25 mg in 50 mL DS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Morphine</strong></td>
<td>2.5–15 mg in 2.5 mg increments</td>
<td>10–50 micrograms/kg/h</td>
<td>100 mg in 100 mL DS</td>
<td>50 mg in 50 mL DS</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose/Concentration</td>
<td>Route</td>
<td>Volume</td>
<td>Concentration</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------</td>
<td>-------</td>
<td>--------</td>
<td>---------------</td>
</tr>
<tr>
<td>Naloxone</td>
<td>0.4–2.0 mg (max. 10 mg)</td>
<td>10 micrograms/kg/h</td>
<td>4 mg in 100 mL DS</td>
<td>2 mg in 50 mL DS</td>
</tr>
<tr>
<td>Nimodipine</td>
<td>—</td>
<td>6–30 micrograms/kg/h</td>
<td>10 mg in 50 mL dispensed</td>
<td>10 mg in 50 mL dispensed</td>
</tr>
<tr>
<td>Noradrenaline (norepinephrine)</td>
<td>—</td>
<td>0.05–1.0 micrograms/kg/min</td>
<td>6 mg in 100 mL DS</td>
<td>3 mg in 50 mL DS</td>
</tr>
<tr>
<td>Octreotide</td>
<td>50–200 micrograms</td>
<td>3–5 micrograms/kg/h</td>
<td>1000 micrograms in 100 mL DS</td>
<td>500 micrograms in 50 mL DS</td>
</tr>
<tr>
<td>Phenobarbitone (phenobarbital)</td>
<td>15–25 mg/kg in 100 mL DS over 20–30 min (max. 50 mg/min) by IP</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>15–18 mg/kg in 100 mL NS over 20–30 min (max. 50 mg/min) by IP</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*(Continued)*
<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Paediatric infusion range (&lt; 30 kg)</th>
<th>Dilution</th>
<th>Syringe driver</th>
<th>Concentration</th>
<th>Adult dose (70–80 kg)</th>
<th>Dose per hour</th>
<th>Volume per hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>10 mg/kg (max. 1000 mg) in 100 mL DW over 30 min by IP</td>
<td>20–80 micrograms/kg/min</td>
<td>1000 mg in 100 mL DW</td>
<td>500 mg in 50 mg DW</td>
<td>10 mg/mL</td>
<td>2–6 mg/min</td>
<td>12–36 mL/h</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>Sedation: 0.5–1.0 mg/kg Induction: 2–3 mg/kg</td>
<td>1–10 mg/kg/h</td>
<td>—</td>
<td>500 mg in 50 mL (dispensed as 20-mL and 50-mL amps, both with 10 mg/mL)</td>
<td>10 mg/mL</td>
<td>Sedation 1–2 mg/kg/h Anaesthesia 5–10 mg/kg/h</td>
<td>7–15 mL/h</td>
<td>35–70 mL/h</td>
</tr>
<tr>
<td>rt-PA (alteplase)</td>
<td>15-mg bolus (15 ml)</td>
<td>—</td>
<td>100 mg in 100 ml water BP</td>
<td>—</td>
<td>1 mg/ml</td>
<td>(a) 15-mg bolus (b) 0.75 mg/kg (max 50 mg) over 30 min (c) 0.5 mg/kg (max 35 mg) over 60 min</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose and Administration Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>---------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>r-PA (reteplase)</strong></td>
<td>10-U bolus in 2 min. After 30 min, second 10-U bolus in 2 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 vials/prefilled syringes/reconstitution devices and needles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Salbutamol (asthma)</strong></td>
<td>5–10 micrograms/kg in 100 ml DS over 10 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.0–5.0 micrograms/kg/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 mg in 100 ml DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 mg in 50 ml DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>60 micrograms/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5–50 micrograms/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5–50 ml/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Salbutamol (obstetric)</strong></td>
<td>5–10 micrograms/kg in 100 ml DS over 10 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.2–1.0 micrograms/kg/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 mg in 100 ml DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 mg in 50 ml DS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>60 micrograms/ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10–50 micrograms/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10–50 ml/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sodium nitroprusside</strong></td>
<td>—</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.05–10 micrograms/kg/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>100 mg in 500 mL DW in glass bottle</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Protect from light</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discard at 24 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Min 200 micrograms/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Max 800 micrograms/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(max. 1.5 mg/kg/24h)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.05–10 micrograms/kg/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1–210 mL/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>500 mL/24h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Streptokinase AMI</strong></td>
<td>1.5 million units in 100 mL NS over 45 min by IP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>—</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15 000 units/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5 mL/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>150 mL/h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*(Continued)*
<table>
<thead>
<tr>
<th>Drug</th>
<th>Loading dose</th>
<th>Paediatric infusion range (&lt; 30 kg)</th>
<th>Dilution</th>
<th>Adult dose (70–80 kg)</th>
<th>Volume per hour</th>
<th>Adult dose (70–80 kg)</th>
<th>Volume per hour</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>PE, DVT, etc.</em></td>
<td>250 000 units in 100 mL NS over 30 min by IP</td>
<td>1500–2000 units/kg/h</td>
<td>Infusion pump (IP) 500 000 units in 100 mL NS</td>
<td>—</td>
<td>100 000 units/h</td>
<td>5000 units/mL</td>
<td>20 mL/h</td>
</tr>
<tr>
<td><em>Thiopentone</em> (thiopental)</td>
<td>3–6 mg/kg (0.5 mg/kg in shock)</td>
<td>1–5 mg/kg/h</td>
<td>Syringe driver BP Protect from light</td>
<td>25 mg/mL</td>
<td>75–350 mg/h</td>
<td>1250 mg in 50 mL water BP Protect from light</td>
<td>3–15 mL/h</td>
</tr>
<tr>
<td><em>Vecuronium</em></td>
<td>0.1 mg/kg</td>
<td>0.05–0.1 mg/kg/h</td>
<td>Infusion pump (IP) 100 mg in 100 mL. Reconstitute in water BP Dilute in DS</td>
<td>50 mg in 50 mL. Reconstitute in water BP Dilute in DS</td>
<td>4–8 mg/h</td>
<td>100 mg in 100 mL</td>
<td>1.0 mg/mL</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarct; DS, dextrose saline, or any isotonic crystalloid; DVT, deep vein thrombosis; DW, 5% dextrose in water; IM, intramuscular; IP, infusion pump; IV, intravenous; MAP, mean arterial pressure; NS, normal saline; PE, pulmonary embolus; VT, ventricular tachycardia; water BP, water for injection.

*Standard: use in Emergency department.*

*Transport: use for retrievals/interhospital transfers.*

Reproduced by kind permission of Associate Professor CT Myers, Director and Head, Department of Emergency Medicine, The Prince Charles Hospital, Brisbane.
How to prescribe

- Intravenous fluids 196
- Insulin 204
- Anticoagulants 209
- Steroids 217
- Sedation in the ED 219
- Controlled drugs 221
INTRAVENTOUS FLUIDS

The same degree of care should be taken when ‘prescribing’ intravenous fluids in the emergency department (ED) on the fluid order form, as when writing up drugs on the medication chart. See Table 3.1 for the composition of the iv fluids most commonly used in the ED.

CRYSTALLOIDS

Isotonic: used for replacement and or maintenance regimens:

- **Normal (0.9%) saline**: 1 litre contains 154 mmol Na\(^+\). Use as replacement and maintenance fluid in all situations, unless local protocol dictates otherwise. Caution in ↑Na\(^+\) and liver dysfunction.
- **Hartmann’s solution**: compound sodium lactate, used instead of normal saline (note 1 litre contains 5 mmol K\(^+\)). Avoid if RF.
- **Glucose\(^*\) saline**: 1 litre contains mixture of NaCl (30 mmol Na\(^+\)) and glucose (4\% = 222 mmol). Although considered useful as contains correct proportions of constituents (excluding KCl, which can be added to each bag) for ‘average’ daily requirements (see below), it will soon lead to hyponatraemia longer term (days), and does not account for individual patient needs. Also used as ivi in insulin sliding scales (see p. 205).
- **5% glucose\(^*\)**: 1 litre contains 278 mmol (=50 g) glucose, which is rapidly taken up by cells and included only to make the fluid isotonic (calories are minimal, at 200 kcal). Used as method of giving pure H\(_2\)O and as ivi with insulin sliding scales (see p. 205).

NB: commonest cause of ↓Na\(^+\) in hospital is overuse of glucose saline or 5% glucose as fluid replacement (often post-op).
Table 3.1 Composition of commonly used fluids

<table>
<thead>
<tr>
<th></th>
<th>Na (mmol/L)</th>
<th>Cl (mmol/L)</th>
<th>K (mmol/L)</th>
<th>Ca (mmol/L)</th>
<th>Mg (mmol/L)</th>
<th>Other constituents (L)</th>
<th>Osmolarity mOsm/L (osmolality mOsm/kg)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CRYSTALLOIDS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.9% sodium chloride</td>
<td>154</td>
<td>154</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>308 (300)</td>
<td>4.0–7.0</td>
</tr>
<tr>
<td>(normal saline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.45% sodium chloride</td>
<td>77</td>
<td>77</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>154 (150)</td>
<td>4.0–7.0</td>
</tr>
<tr>
<td>(half normal saline)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hartmann’s solution</td>
<td>131</td>
<td>111</td>
<td>5</td>
<td>2</td>
<td>–</td>
<td>29 mmol lactate</td>
<td>280 (274)</td>
<td>5.0–7.0</td>
</tr>
<tr>
<td>(compound sodium lactate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Hartmann’s</td>
<td>131</td>
<td>135</td>
<td>29.5</td>
<td>2</td>
<td>–</td>
<td>29 mmol lactate</td>
<td>329 (324)</td>
<td></td>
</tr>
<tr>
<td>Ringer’s lactate</td>
<td>130</td>
<td>109</td>
<td>4</td>
<td>3</td>
<td>–</td>
<td>28 mmol lactate</td>
<td>272</td>
<td></td>
</tr>
<tr>
<td>5% dextrose</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>50 g dextrose</td>
<td>278 (252)</td>
<td>3.5–6.5</td>
</tr>
</tbody>
</table>

(Continued)
Table 3.1 (Continued) Composition of commonly used fluids

<table>
<thead>
<tr>
<th>Composition of commonly used intravenous fluids</th>
<th>Osmolarity mOsm/L (osmolality mOsm/kg)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na (mmol/L)</td>
<td>Cl (mmol/L)</td>
<td>K (mmol/L)</td>
</tr>
<tr>
<td>10% dextrose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50% dextrose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3% dextrose, 0.3% sodium chloride (3 and a 1/3)</td>
<td>51</td>
<td>51</td>
</tr>
<tr>
<td>4% dextrose, 0.18% sodium chloride (4 and a 1/5)</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>8.4% sodium bicarbonate</td>
<td>1000</td>
<td>−</td>
</tr>
<tr>
<td>Fluids</td>
<td>Na</td>
<td>K</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>-----</td>
<td>----</td>
</tr>
<tr>
<td>Plasma-Lyte</td>
<td>140</td>
<td>98</td>
</tr>
<tr>
<td>Plasma-Lyte—Replacement and Glucose 5%</td>
<td>140</td>
<td>98</td>
</tr>
<tr>
<td>Plasma-Lyte Maintenance and 5% Glucose</td>
<td>40</td>
<td>40</td>
</tr>
</tbody>
</table>

**COLLOIDS**

<table>
<thead>
<tr>
<th>Fluids</th>
<th>Na</th>
<th>K</th>
<th>Ca</th>
<th>Mg</th>
<th>CI</th>
<th>Other Ions</th>
<th>Volumes</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gelofusine</td>
<td>154</td>
<td>120</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>40 g succinylated gelatin</td>
<td>274</td>
<td>7.4+/−0.3</td>
</tr>
<tr>
<td>Albumin 4%</td>
<td>140</td>
<td>128</td>
<td>&lt;2</td>
<td>–</td>
<td>–</td>
<td>40 g albumin, 6.4 mmol octanoate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 3.1 (Continued) Composition of commonly used fluids

<table>
<thead>
<tr>
<th>Composition of commonly used intravenous fluids</th>
<th>Osmolarity mOsm/L (osmolality mOsm/kg)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na (mmol/L)</td>
<td>Cl (mmol/L)</td>
<td>K (mmol/L)</td>
</tr>
<tr>
<td>Haemaccel</td>
<td>145</td>
<td>145</td>
</tr>
<tr>
<td>Dextran 40 in 0.9% Saline</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Dextran 40 in 5% Dextrose</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dextran 70 in 0.9% Saline</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>Dextran 70 in 5% Dextrose</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Non-isotonic: only for specialist/emergency situations by those experienced in their use:

- **Hypertonic (5%) saline**: 1 litre contains 856 mmol Na⁺; given for severe symptomatic hyponatraemia, i.e. with seizures. Seek specialist help first.
- **Hypotonic (0.45%) saline**: for severe ↑Na⁺ (e.g. HHS).
- **10% and 20% glucose**: for mild/moderate hypoglycaemia.
- **50% glucose**: for severe hypoglycaemia (see p. 251), or if insulin being used to lower K⁺ (see p. 269).
- **Sodium bicarbonate (1.26% or move rarely 1.4%)**: useful replacement for 0.9% saline if ↓pH or ↑K⁺ which often coexist. Not isotonic so caution re: salt load and accompanying fluid retention. Seek specialist help from nephrologists/others accustomed to its use.

*NB: glucose = dextrose. Low-strength glucose solutions used to be called dextrose solutions; this is now being phased out.

**COLLOIDS**
Plasma expanders and substitutes helpful to ↑/maintain plasma oncotic pressure.

- **Gelifusine**: succinylated gelatin used in resuscitation of shock (non-cardiogenic). NB: electrolyte content is often overlooked: 1 litre Gelifusine has 154 mmol Na⁺.
- **Albumin**: prepared from whole blood and containing soluble proteins and electrolytes, but no clotting factors etc. May be fluid of choice in sepsis.
- **HAEMACCEL**: bovine-derived polygeline (derivative of gelatin), may cause anaphylaxis.

**DAILY FLUID AND ELECTROLYTE REQUIREMENTS (STANDARD)**
*Standard daily fluid and electrolyte requirement*: For a 70 kg adult male is approx 30–40 ml/kg H₂O (3 litres); 1.5–2.0 mmol/kg Na⁺ (100–150 mmol Na⁺); and 0.5–1.0 mmol/kg K⁺ (40–70 mmol K⁺).
When no expected oral intake (↓GCS, unsafe swallow, post-CVA, preoperative, etc), this may be provided as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Infusion Fluid</th>
<th>Volume</th>
<th>Additives If Any Drug and Dose</th>
<th>Rate of Admin</th>
<th>Duration</th>
<th>Dr’s Signature</th>
<th>Time Started</th>
<th>Time Completed</th>
<th>Set Up by Signature</th>
<th>Batch No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01</td>
<td>5% Glucose</td>
<td>1 litre</td>
<td>20 mmol KCl</td>
<td></td>
<td>8h</td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08/01</td>
<td>Normal saline</td>
<td>1 litre</td>
<td></td>
<td></td>
<td>8h</td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08/01</td>
<td>5% Glucose</td>
<td>1 litre</td>
<td>20 mmol KCl</td>
<td></td>
<td>8h</td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 3.1 Drug chart showing how to write up intravenous fluids.

This ‘1 sour (0.9% saline), 2 sweet (5% glucose)’ regimen may be used in fit pre-operative patients. Otherwise, if there are abnormal losses such as fever, vomiting, diarrhoea etc, use normal (0.9%) saline unless liver failure (see below) or if Na\(^+\) outside normal range (↓ or ↑).

Always get senior help if unsure, as incorrectly prescribed fluids can be as dangerous as any other incorrectly used drug.

Individual fluid and electrolyte requirements may differ substantially according to:

- Body habitus, age, residual oral intake, if on multiple iv drugs (which are sometimes given with significant amounts of fluid).
- Insensible losses (normally about 1 litre/day). ↑skin losses if fever or burns. ↑lung losses in hyperventilation or inhalation burns.
- GI losses (normally about 0.2 litre/day). Any vomiting (↑Cl\(^-\) content) or diarrhoea (↑K\(^+\) content) must be taken into account as well as less obvious causes, e.g. ileus, fistulae.
- Fluid compartment shifts, esp vasodilation with distributive shock if sepsis/anaphylaxis.

**K\(^+\) CONSIDERATIONS**

Do not give at >10 mmol/h iv unless K\(^+\) dangerously low, when it can be given quicker (see p. 270).

Post-op surgical patients often need less K\(^+\) in 1st 24 h, as K\(^+\) is released by cell necrosis (∴ proportional to extent of surgery).
HANDY HINTS

• Check the following before prescribing any iv fluid:
  — Clinical markers of hydration: temperature, skin turgor, mucous membranes, JVP, peripheral oedema, pulmonary oedema (basal crackles). Easy to overlook, yet simple and useful signs!
  — Recent input and output: if at all concerned, ask nurses to commence a strict fluid balance chart. Consider also starting a daily weight chart.
  — Recent U&Es, esp K⁺. Can use VBG to get an urgent result, before lab bloods are available.

• In general, encourage oral fluids (often overlooked in the ED): homeostasis (if normal) is safer, less expensive and less consuming of doctor/nurse time than iv fluids. Beware of shock, fever, vomiting, diarrhoea or ileus (iv fluid will be needed); ↓swallow; fluid overload (esp if HF or RF); ↓GCS; or if homeostasis disorders (esp SIADH).

• Take extreme care if major organ failure:
  — Heart failure: heart can quickly become ‘overloaded’ and ⇒ acute LVF. Even if not currently in HF, beware if predisposed (e.g. Hx of HF or IHD).
  — Renal failure: unless pre-renal cause (e.g. hypovolaemia), do not give more fluid than residual renal function can deal with. Seek help from senior doctor if at all concerned; good fluid Mx greatly influences outcomes in this group. Use saline unless specialist advice taken.
  — Liver failure: often preferable to use 5% glucose. Serum Na⁺ may be ↓d, but total body Na⁺ is often ↑d. Additional saline will end up in the wrong compartment (e.g. peritoneal fluid ⇒ ing ascites) but may be essential to ensure renal perfusion (RF often coexists).

• If in doubt, give ‘fluid challenges’: small volumes (normally 200–500 ml) of fluid over short periods of time, to see whether
clinical response to BP, urine output or left ventricular function is beneficial or detrimental before committing to longer-term fluid strategy.

It can be difficult to elicit all this information under time pressure. The trick is to know when to take extreme care. Be particularly careful if you do not know the patient, i.e. a handover, and be wary when asked to ‘just write up another bag’ without reviewing the patient. You may be asked to prescribe fluids when no longer necessary or even when they may be harmful. To save time for those on ward call (and to ↑ the chances of your patient getting appropriate fluids), leave clear instructions with the nurses and on the drug chart for as long as can be sensibly predicted (esp over weekends/long holidays).

INSULIN
See page 252 for DKA and HHS management.

TYPES
Many types of insulin exist, with differences in the timing of action onset O, peak P and duration D.
Acute use, e.g. sliding scales (see below), acute control:

- **Soluble** (aka normal/neutral) can be given iv (and sc as other types), e.g. Actrapid, Humulin S:
  - iv: O/P immediate, D 0.5 h.
  - sc: O 0.5–1 h, P 2–4 h, D 6–8 h.

Maintenance use, i.e. normal control (sc only):

- **Aspart** (NovoRapid), lispro (Humalog) or glulisine (▲ Apidra): recombinant human analogues. Rapid onset ⇒ ↑eating flexibility
(can give immediately before meals; other types of sc insulin must be given 30 min before), ↓duration ⇒ fewer hypos (esp before meals). □ 0.25 h, ▼ 1–3 h, ▲ 2–5 h. + usually given with intermediate- or long-acting insulin (‘basal/bolus’ regime).

- **Isophane**: intermediate-acting e.g. Humulin I, Insulatard or Insuman Basal, mostly given bd.
- **Glargine**: long-acting recombinant insulin with delayed and prolonged absorption from sc injection site ⇒ constant, more ‘physiological’ basal supply; mostly given od but can be split into bd dosing (e.g. Lantus).
- **Detemir**: long-acting analogue. Binds to albumin and has different action from that of glargine but similar advantages. Give od or bd (e.g. Levemir).

*Biphasic insulins*: contain mixtures of intermediate- or long-acting insulin (e.g. isophane) with short-acting soluble insulin (e.g. aspart or lispro); e.g. Humalog Mix 25, Humulin M3, Insuman Comb 15, Insuman Comb 25, Novomix 30. Usually given bd (sometimes od).

*Short-acting insulins*: can also be given by continuous sc infusion, using a portable pump, which gives basal insulin with patient-activated boluses.

**SLIDING SCALE INSULIN**

= Variable rate insulin ivi. Aim is for optimal blood glucose control in diabetics if (i) NBM/preoperative, (ii) MI*/ACS*, (iii) severe concurrent illness (e.g. sepsis), (iv) recovery after DKA/HHS.

See page 252 for DKA where a fixed rate ivi is recommended rather than sliding scale (not universal, so follow local protocols).
How to write an insulin sliding scale on a fluid chart

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Infusion Fluid</th>
<th>Volume</th>
<th>Additives If Any Drug and Dose</th>
<th>Rate of Admin</th>
<th>DURATION</th>
<th>Dr’s Signature</th>
<th>Time Started</th>
<th>Time Completed</th>
<th>Set Up by Signature</th>
<th>Batch No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01</td>
<td>Normal saline</td>
<td>50 ml</td>
<td>ACTRAPID 50 units</td>
<td>As below</td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08/01</td>
<td>Glucose saline</td>
<td>1 litre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CBG (= BM)</th>
<th>INSULIN ivi (ml/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–4</td>
<td>0.5 (call Dr if CBG &lt; 2.5)</td>
</tr>
<tr>
<td>4.1–7</td>
<td>1</td>
</tr>
<tr>
<td>7.1–9</td>
<td>2</td>
</tr>
<tr>
<td>9.1–11</td>
<td>3</td>
</tr>
<tr>
<td>11.1–13</td>
<td>4</td>
</tr>
<tr>
<td>≥13.1</td>
<td>6</td>
</tr>
</tbody>
</table>

Always run glucose saline (4% glucose + 0.18% saline) ivi at 125 ml per hour if CBG (BM) < 15.

Figure 3.2 Drug chart, showing slide scale.

*This is one approach* and : suggested only as an initial regimen: requirements will vary widely between individuals and within an individual over time (esp with intercurrent illness, e.g. infection). Regular review and adjustment is essential – see below. Use your hospital’s protocol where possible.

**Important points**

- Carefully consider need for starting a sliding scale, especially if patient eating/drinking normally and there is no other compelling indication.
- A poorly managed sliding scale ⇒ fluctuating glucose and ↑length of admission. prn insulin not recommended due to risk of hypoglycaemia.
- 💥 When prescribing any insulin, never abbreviate the word ‘units’ to ‘U’ (as ‘U’ can be mistaken for ‘O’ leading to ten-fold dosing error) 💥.
Check cannula patency before adjusting sliding scale (if not working could be why BG not improving).

Give 5% glucose or glucose saline (4% glucose with 0.18% saline, or 5% glucose with 0.45% saline and 0.15% KCl) ivi at 125 ml/h when CBG <15 mmol/l. If RF or mild HF give 5% glucose ivi at a slower rate. If severe HF give 10% glucose (preferably via central line) at 60–70 ml/h. KCl content should be adjusted according to individual needs.

Discuss clearly with nursing staff the frequency of CBG measurement required. Sicker patients need CBGs every 1 h, ideally with regular (2–4 hrly) laboratory BG readings (to confirm accuracy). If not that sick and CBGs stable, check 2–4 hrly.

Stop oral hypoglycaemics but remember to reintroduce them before ceasing sliding scale!

*NB: glucose = dextrose. Low-strength glucose solutions used to be called dextrose solutions; this is now being phased out.

**Initial insulin dose and adjustments**

Prescribe 50 units of soluble insulin (Actrapid or Humulin S) in 50 ml normal (0.9% NaCl) saline to run via a syringe driver according to one of the regimens (A, B, C, D) below.

Prime the line by flushing with 5 ml of the solution before attaching to the patient (as the plastic tubing adsorbs insulin) : remaining volume will be 45 ml.

1. Start with regimen A, unless known severe insulin resistance (i.e. normally takes ≥100 units sc insulin/day), in which case start with B.
2. If BG >10 (or >7 during acute MI, where target BG even lower) for 3 consecutive hourly tests and is ↑ing (or ↓ing by <25% in the past hour), step up to next sliding scale (i.e. if on A, step up to B; if on B, step up to C, etc).
3. If BG <3.5 mmol/l, step down to next scale (i.e. if on B, step down to A; if on C, step down to B, etc).
How to prescribe

Insulin ivi (units/h)

<table>
<thead>
<tr>
<th>CBG (=BM)</th>
<th>Regime A</th>
<th>Regime B</th>
<th>Regime C&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Regime D&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0–4.0&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>4.1–7.0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7.1–9.0</td>
<td>2</td>
<td>4</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>9.1–11.0</td>
<td>3</td>
<td>6</td>
<td>9</td>
<td>12</td>
</tr>
<tr>
<td>11.1–13.0</td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>&gt;13.0</td>
<td>6</td>
<td>12</td>
<td>18</td>
<td>24</td>
</tr>
</tbody>
</table>

<sup>a</sup> Stop ivi for 15 min if severe hypoglycaemia (CBG <2.5 or symptoms) and give Rx as on p. 251. Otherwise treat more gently with 5–10% glucose ivi and maintain insulin infusion (esp if DKA).

<sup>b</sup> Rarely needed; used mostly for patients with severe insulin resistance (i.e. on more than 100 units insulin/day before admission).

(Reproduced with permission from Professor S Kumar, Dr A Rahim and Dr P Dyer, Endocrinology Department, University of Warwick Medical School).

Coming off a sliding scale

Once eating/drinking normally and CBGs normal/stable, consider coming off sliding scale. This is rarely achieved within the ED (more commonly occurs on the ward):

- Post-DKA, change back only if blood free of ketones and pH back to normal.
- Avoid hypos by continuing ivi until 1st sc dose starts to work (usually 10–30 min). Always change from iv to sc before a meal.

How to start sc regimen (always consult senior doctor if unsure):

1. Calculate daily requirements by doubling the number of units used in the past 12 h from the sliding scale. Note what fluids were given during this period.

2. Start qds sc regimen. If patient is well and CBGs stable, this step can be omitted (i.e. go straight to a bd regimen). Give 1/3 of total daily dose at 10 pm (as intermediate, e.g. isophane, or long acting, e.g. glargine or determir, insulin) and give remaining 2/3
(as short-acting soluble insulin) divided equally between pre-breakfast, pre-lunch and pre-evening meal doses.

3 Or start a bd sc regimen: give 60% of daily dose pre-breakfast and the remaining 40% pre-evening meal, both doses as biphasic 30/70 insulin (e.g. Humulin M3).

**ANTICOAGULANTS**

**HEPARIN**
Immediate and short-term Rx/Px of TE. Two main types: low-molecular-weight heparins (LMWHs) and unfractionated heparin. Also used in ACS (see p. 226).

**LMWHs**
Give sc. ↑convenience (↓monitoring, can give to outpatients). ↓incidence of HIT* and osteoporosis cf unfractionated heparin, so now preferred for most indications (esp MI/ACS, DVT/PE Rx and pre-cardioversion of AF). Types include:

- Enoxaparin (*Clexane*), dalteparin (*Fragmin*), and tinzaparin (*Innohep*) are the most common. Each hospital tends to use one in particular; ask staff which one they stock or call pharmacy.
- Prophylaxis does not need monitoring but do not use for >7–10 days if creatinine >150.

**Monitoring of treatment with LMWH**
Via peak anti-Xa assay: usually necessary only if renal impairment (i.e. creatinine >150), pregnancy or at extremes of Wt (i.e. <45 kg or >100 kg). Take sample 3–4 h post dose, which is therefore usually done on the wards.

**HIT* = heparin-induced thrombocytopenia**
Much more common with unfractionated heparin but can occur with all heparins. Watch for ↓ing platelet count. Get senior help if concerned. Discuss investigation and Mx with haematologist.
If HIT confirmed, stop heparin immediately – danaparoid (Orgaran) or lepirudin (Refludan) may be substituted.

UNFRACTIONATED HEPARIN
Given iv*: rapidly reversible (immediately if protamine given; see p. 212), which is useful if patient at ↑risk of bleeding, or following use of extracorporeal circuits such as haemodialysis or cardiopulmonary bypass.

- Is also used with recombinant fibrinolytics in AMI, but due to difficulty keeping in therapeutic range, LMWH increasingly preferred where possible – discuss with senior.
- *Can be given sc (only for Px), but now largely replaced by LMWH.

Starting iv unfractionated heparin
1. Load with 5000** units as iv bolus: prescribe on the ‘once-only’ section of the drug chart (give 10 000** units in severe PE).
2. Set up ivi at 15–25 units/kg/h: usually = 1000–2000 units/h. A sensible starting rate is 1500 units/h, which can be achieved by adding 25 000 units of heparin to 48 ml of normal saline to make 50 ml of solution (500 units/ml), then run at 3 ml/h via a syringe driver.
3. This can be written up as follows:

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Infusion Fluid</th>
<th>Volume</th>
<th>Additives if Any Drug and Dose</th>
<th>Rate of Admin</th>
<th>Duration</th>
<th>Dr’s Signature</th>
<th>Time Started</th>
<th>Time Completed</th>
<th>Set Up by Signature</th>
<th>Batch No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01</td>
<td>Normal saline</td>
<td>50 ml</td>
<td>HEPARIN 25,000 units</td>
<td></td>
<td></td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 3.3 Drug chart showing how to write up intravenous heparin infusion.

NB
Dosing for co-therapy with fibrinolytics (according to ESC guidelines) is slightly different; see p. 231.
**Monitoring**

Via APTT ratio (= Activated Partial Thromboplastin Time of patient plasma divided by that of control plasma). Results can (rarely) be given as patient’s exact APTT: the normal range is 35–45 sec. You then need to calculate the ratio: take the middle of the normal range for your lab (e.g. 40 sec) for your calculations.

*Target ratio is commonly 1.5–2.5, but this can vary: check your hospital’s protocol and aim for the middle of range.*

NB: there is no national (let alone international) consensus on methods of measuring APTT, so results are not yet standardised!

*Don’t take sample from drip arm* (unless from site distal to ivi).

Although usually done on the inpatient ward, check APTT ratio after 6 h, then 6–10 h until stable, and then daily at a minimum, adjusting to the following regimen: (based on APTT ratio therapeutic range of 1.5–2.5).

<table>
<thead>
<tr>
<th>APTT ratio</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1.2</td>
<td>Give 5000-unit bolus iv and ↑ivi by 200–250 units/h</td>
</tr>
<tr>
<td>1.2–1.5</td>
<td>Give 2500-unit bolus iv and ↑ivi by 100–150 units/h</td>
</tr>
<tr>
<td>1.5–2.5</td>
<td>No change</td>
</tr>
<tr>
<td>2.5–3.0</td>
<td>↓ivi by 100–150 units/h</td>
</tr>
<tr>
<td>&gt;3.0</td>
<td>Stop ivi for 1h then restart ivi, ↓ing by 200–250 units/h</td>
</tr>
</tbody>
</table>

Adjustments are safest made by writing a fresh ivi prescription at a different strength, but the same effect can also be achieved by calculating the appropriate rate change to the original prescription.

*Variable rate of ivi:* using fixed prescription of 25 000 units heparin in 50 ml saline:

<table>
<thead>
<tr>
<th>Desired heparin ivi rate (units/h)</th>
<th>Rate of ivi (ml/h)</th>
<th>Desired heparin ivi rate (units/h)</th>
<th>Rate of ivi (ml/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000</td>
<td>2.0</td>
<td>1500</td>
<td>3.0</td>
</tr>
<tr>
<td>1050</td>
<td>2.1</td>
<td>1550</td>
<td>3.1</td>
</tr>
</tbody>
</table>
How to prescribe

<table>
<thead>
<tr>
<th>Desired heparin iv rate (units/h)</th>
<th>Rate of iv (ml/h)</th>
<th>Desired heparin iv rate (units/h)</th>
<th>Rate of iv (ml/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1100</td>
<td>2.2</td>
<td>1600</td>
<td>3.2</td>
</tr>
<tr>
<td>1150</td>
<td>2.3</td>
<td>1650</td>
<td>3.3</td>
</tr>
<tr>
<td>1200</td>
<td>2.4</td>
<td>1700</td>
<td>3.4</td>
</tr>
<tr>
<td>1250</td>
<td>2.5</td>
<td>1750</td>
<td>3.5</td>
</tr>
<tr>
<td>1300</td>
<td>2.6</td>
<td>1800</td>
<td>3.6</td>
</tr>
<tr>
<td>1350</td>
<td>2.7</td>
<td>1850</td>
<td>3.7</td>
</tr>
<tr>
<td>1400</td>
<td>2.8</td>
<td>1900</td>
<td>3.8</td>
</tr>
<tr>
<td>1450</td>
<td>2.9</td>
<td>1950</td>
<td>3.9</td>
</tr>
</tbody>
</table>

Overtreatment/overdose (all heparins)
If significant bleeding, stop heparin and observe: iv heparin has short $t_{1/2}$ (30 min–2 h), so fx wear off quickly.
If bleeding continues or is life-threatening, consider iv protamine (1 mg per 80–100 units of heparin to be neutralised as ivi over 10 min. ↓doses if giving >15 min after heparin stopped). Seek expert help from haematology on-call if in any doubt!
NB: protamine is less effective against LMWH, and repeat administration may be required.

▼ FONDAPARINUX
New parenteral anticoagulant (synthetic pentasaccharide). Licensed for use in Rx of VTE and MI/ACS and Px of VTE in medical patients and patients undergoing orthopaedic or abdominal surgery. Monitoring is not necessary.
Also useful for Px of VTE for patients with history of HIT* or allergy to heparin. See BNF/SPC for dosing. NB: Caution if RF or LF.

WARFARIN
Patients are rarely started on warfarin whilst in the ED, but may present awaiting an INR (see below) and need that day’s dose prescribed.

Basics
Oral anticoagulant for long-term Rx/Px of TE: loading (see below) usually takes several days and as it is initially prothrombotic,
heparin (LMWH), which is effective immediately, is used as short-term cover until therapeutic levels are achieved.

**Monitoring**

Use INR = ratio of patient’s PT (prothrombin time) to a control raised to the power of a variable dependent on exact reagents used in each lab.

A target INR is set at the start of Rx, according to indication (see below); variations of ±0.5 are acceptable.

**BCSH guidelines for target INRs.** Adapted with permission from *British Journal of Haematology* 2011; 154(3): 311–24.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Target INR (± 0.5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVT/PE&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.5</td>
</tr>
<tr>
<td>Thrombophilia (if symptomatic)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.5</td>
</tr>
<tr>
<td>Paroxysmal nocturnal haemoglobinuria (PNH)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>2.5</td>
</tr>
<tr>
<td>AF&lt;sup&gt;d&lt;/sup&gt; (or other causes of cardiac emboli&lt;sup&gt;e&lt;/sup&gt;)</td>
<td>2.5</td>
</tr>
<tr>
<td>Bioprosthetic heart valves&lt;sup&gt;f&lt;/sup&gt;</td>
<td>2.5</td>
</tr>
<tr>
<td>Mechanical heart valves&lt;sup&gt;g&lt;/sup&gt;</td>
<td>3.5</td>
</tr>
</tbody>
</table>

<sup>a</sup> Treat for = 6 weeks if calf vein thrombosis, for = 3 months if provoked proximal (peroneal or above) DVT/PE, for = 6 months or lifelong if idiopathic venous TE or permanent risk factors. If recurrent DVT/PE whilst on therapeutic Rx, target INR = 3.5. Discuss all other than 1st presentation with anticoagulant service.

<sup>b</sup> Arterial thrombosis in antiphospholipid syndrome is exception with target INR 3.5.

<sup>c</sup> Paroxysmal nocturnal haemoglobinuria (PNH); only under guidance of consultant haematologist.

<sup>d</sup> Maintain INR >2.0 for 3 weeks before and 4 weeks after elective DC cardioversion.

<sup>e</sup> Dilated cardiomyopathy, mural thrombus post-MI or rheumatic value disease.

<sup>f</sup> Only for first 3–6 months post valve insertion at discretion of each centre.

<sup>g</sup> New generation aortic values INR target 3.0.

Although not in the BCSH guidelines, a target INR of 2.5 is widely agreed for nephrotic syndrome (generally once albumin <20 g/l).
Starting warfarin Rx i.e. for acute thrombosis: (rarely done in the ED)

Check INR before 1st dose and every day for 4 days, then assess stability of INR and adjust accordingly. If on LMWH, do not stop until 2 days after therapeutic INR achieved.

For loading regimens, where possible use your hospital’s own guidelines, since these often vary. Otherwise, it is sensible to use the BCSH guidelines:


<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>INR</td>
<td>Dose (mg)</td>
<td>INR</td>
<td>Dose (mg)</td>
</tr>
<tr>
<td>&lt;1.4</td>
<td>10</td>
<td>&lt;1.8</td>
<td>10</td>
</tr>
<tr>
<td>1.8</td>
<td>1</td>
<td>2.0–2.1</td>
<td>5</td>
</tr>
<tr>
<td>&gt;1.8</td>
<td>0.5</td>
<td>2.2–2.3</td>
<td>4.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.4–2.5</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.6–2.7</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.8–2.9</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.0–3.1</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.2–3.3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.4</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.6–4.0</td>
<td>0.5</td>
</tr>
<tr>
<td>&gt;4.0</td>
<td>0</td>
<td>3.6–4.0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.1–4.5</td>
<td>Miss 1 day then 2 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;4.5</td>
<td>Miss 2 days then 1 mg</td>
</tr>
</tbody>
</table>

$^a$ Predicted maintenance dose.
Situations when dose (especially loading) may need review

↓dose: if age >80 yrs, LF, HF, post-op, poor nutrition, ↑baseline INR or taking drugs that potentiate warfarin, so check for W+ symbols in this book (includes almost all antibiotics).

↑dose: if taking drugs that inhibit warfarin, so check for W− symbols in this book.

Herbal remedies/non-prescription drugs: can have significant interactions – always ask patients if taking any, as they may not realise the importance (e.g. glucosamine can ↑INR). Check each one with your hospital’s drug information office for significance.

Alcohol and diet: can affect dosing, especially if intake varies – the goalposts will move for an individual’s therapeutic range. It is a common misconception that BMI influences response.

Slow loading: give 3–5 mg for 5–7 days which achieves therapeutic levels with less overshoot and may be preferable for outpatient initiation in atrial fibrillation. (BCSH guidelines 3rd edition 2005 update www.bcshguidelines.com)

Interrupting warfarin

If interrupting warfarin (e.g. before operation/procedure), assess thrombotic risk and use bridging anticoagulation with LMWH as necessary; do not reload post-op as above, but restart at usual dose +50% for 2 days, then return to usual dose if no contraindications (e.g. bleeding/taking W+ drugs).

Make small infrequent dose changes unless INR dangerously high or low. ‘Steering a supertanker’ is a good analogy; there is often significant delay between dose changes and their fx, so don’t fiddle!

Warfarin and pregnancy

Warfarin is contraindicated in early pregnancy (teratogenic during weeks 6–12). Women of childbearing age must be counselled by a specialist prior to planning pregnancy (inc informed to do pregnancy test whenever a period is >2 days late).
Any woman who is pregnant and on warfarin must be converted immediately to LMWH under specialist guidance.

**Overtreatment/overdose**

Seek expert help from senior doctor or haematology on-call as xs vitamin K will make re-anticoagulation difficult. The fx can last for weeks ⇒ ↑risk of recurrence of condition that warfarin was started for.

---

**Recommendations for Mx of excess warfarin (BCSH guidelines).** Adapted with permission from *British Journal of Haematology* 2011; 154(3): 311–24.

<table>
<thead>
<tr>
<th>INR</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.0–6.0 if target 2.5 (4.0–6.0 if target 3.5)</td>
<td>↓dose or stop warfarin; restart when INR &lt;5.0</td>
</tr>
<tr>
<td>6.0–8.0 and no/minor bleeding</td>
<td>Stop warfarin; restart when INR &lt;5.0</td>
</tr>
<tr>
<td>&gt;8.0 and no/minor bleeding</td>
<td>Stop warfarin; restart when INR &lt;5.0</td>
</tr>
<tr>
<td>If other bleeding risks (e.g. age &gt; 70 yrs, Hx of bleeding complications or liver disease)</td>
<td>give phytomenadione (vit K₁) 0.5mg³ iv or 5mg po</td>
</tr>
</tbody>
</table>

| Major bleeding, e.g. ↓ing Hb or cardiodynamic instability | Stop warfarin |
| | Phytomenadione (vit K₁) 5 or 10 mg iv, repeating 24 h later if necessary |
| | Prothrombin complex concentrate 30–50 units/kg not exceeding 3000 units (if unavailable give FFP³ 15ml/kg) |

---

³Since publication of BCSH guidelines some advise larger doses of iv vit K, e.g. 2 mg

³Although not stated in BCSH guidelines, note that FFP is not fully effective in warfarin reversal.

**DABIGATRAN**

Dabigatran etexilate (Pradaxa, an oral direct thrombin inhibitor, is a new oral anticoagulant licensed for once-daily administration for extended thromboprophylaxis after elective total knee or hip replacement*. (*)
Although it does not require monitoring of anticoagulant fx, and has fewer drug–food interactions than warfarin, it can pose a challenge in a patient with an acute problem such as an intracranial bleed, as it is not reversible (unlike warfarin).

NB: Caution if LF or RF. Note may also be associated with an increased risk of MI or ACS.

### CORTICOSTEROIDS

Commonly used systemic drugs include:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Equivalent dose</th>
<th>Main uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone</td>
<td>5 mg</td>
<td>Acute asthma/COPD, rheumatoid arthritis (po)</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>4 mg</td>
<td>Acute flares rheumatoid arthritis/MS (iv)</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>750 microgram</td>
<td>(\uparrow)ICP, CAH, Dx Cushing’s (iv/po)</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>20 mg</td>
<td>Acute asthma/COPD (iv)</td>
</tr>
</tbody>
</table>

**Therapeutic effects**

Glucocorticoid fx predominate; mineralocorticoid fx for all these are mild apart from hydrocortisone (has moderate fx) and dexamethasone (has minimal fx . used when \(\text{H}_2\text{O}\) and \(\text{Na}^+\) retention are particularly undesirable, e.g. \(\uparrow\)ICP).

**Side effects: (i.e. Cushing’s syndrome!)**

- **Metabolic:** \(\text{Na}^+\)/fluid retention*, hyperlipoproteinaemia, leukocytosis, negative \(\text{K}^+\)/\(\text{Ca}^{2+}\)/nitrogen balance, generalised fluid/electrolyte abnormalities.
- **Endocrine:** hyperglycaemia/\(\downarrow\)GTT (can \(\Rightarrow\) DM), adrenal suppression.
  - **Fat*:** truncal obesity, moon face, interscapular (‘buffalo hump’) and suprascapular fat pads.
— **Skin**: hirsutism, bruising/purpura, acne, striae, ↓healing, telangiectasia, thinning.
— **Other**: impotence, menstrual irregularities/amenorrhoea, ↓growth (children), ↑appetite*.

- **GI**: pancreatitis, peptic/oesophageal ulcers: give PPI if on ↑doses.
- **Cardiac**: HTN, CCF, myocardial rupture post-MI, TE.
- **Musculoskeletal**: proximal myopathy, osteoporosis, fractures (can ⇒ avascular necrosis).
- **Neurological**: ↑epilepsy, ↑ICP/papilloedema (esp children on withdrawal of corticosteroids).
- **Ψ**: mood Δs (↑ or ↓), psychosis (esp at ↑doses), dependence.
- **Ocular**: cataracts, glaucoma, corneal/scleral thinning.
- **Infections**: ↑susceptibility, ↑rapidity (↑severity at presentation), TB reactivation, ↑risk of chickenpox/shingles/measles.

**SEs are dose-dependent**
If patient is on a high dose, make sure this is intentional: it is possible in fluctuating (e.g. inflammatory) illnesses for a patient to be left on high doses by mistake. Seek specialist advice if unsure.
If on long term Rx consider giving Ca/vit D supplements/ bisphosphonate to ↓risk of osteoporosis, and PPI to ↓risk of GI ulceration.

**Cautions**
These can mostly be worked out from the SEs. Take care if patient already has any condition that is a potential SE.
Systemic corticosteroids are CI in systemic infections (w/o antibiotic cover).
NB: avoid live vaccines. If never had chickenpox, avoid exposure.

**Interactions**
Apply to all systemic Rx. fx can be ↓d by rifampicin, carbamazepine, phenytoin and phenobarbital. fx can be ↑d by erythromycin, ketoconazole, itraconazole and ciclosporin (whose own fx are ↑d by methylprednisolone).
↑risk of ↓K⁺ with amphotericin and digoxin.

**Withdrawal effects**
Sudden withdrawal can precipitate acute adrenal insufficiency (= Addisonian crisis; ☠ can be fatal ☠ see p. 256): ↓BP, ↑HR, postural hypotension, weakness, myalgia, abdominal pain, vomiting, ↓Wt, confusion leading to coma, and characteristic e’lyte changes with ↓BG, ↓Na⁺, ↑K⁺, ↑urea, ↑Ca. Note intercurrent infection/AMI/trauma may also precipitate an Addisonian crisis.

∴ must withdraw corticosteroids slowly if patient has had >3 wks Rx (or a shorter course w/in 1 year of stopping long-term Rx), other causes of adrenal suppression, received high doses (>40 mg od prednisolone or equivalent), or repeat doses in evening, or repeat course.

Thus intercurrent illness, trauma, surgery also need ↑doses to avoid precipitating relative withdrawal.

Steroid Rx card should be carried by all patients on prolonged Rx.

**MINERALOCORTICOIDs, e.g. fludrocortisone**
Used for Addison’s disease and acute adrenocortical deficiency (but rarely needed for hypopituitarism).

Are also used for orthostatic/postural hypotension. Main SEs are H₂O/Na⁺ retention.

**SEDATION IN THE ED**

**ACUTE SEDATION**
Consider for the acutely agitated, disturbed or violent patient in the ED.

Note: procedural sedation and analgesia before a brief painful procedure is described on page 182.

**Important points**

**Delirium (acute confusional state)**
- Delirium is the abrupt onset of clouding of consciousness that may fluctuate, disorientation in time and place, impaired memory, visual, olfactory or tactile hallucinations, and illusions.
There is restlessness, irritability, emotional lability and poor comprehension.

- Look for and treat hypoxia, drug intoxication or withdrawal (esp alcohol/opiates), sepsis including meningitis, cerebral event inc trauma, endocrine and metabolic causes (esp hypoglycaemia).

**Violent or disturbed patient**

- Most commonly the result of alcohol intoxication, or other recreational drugs such as cocaine, amphetamines or phencyclidine. Other causes inc mental illness such as mania or paranoid schizophrenia, as well as acute delirium as above (always check a CBG, and vital signs when able).
- A well-lit calm room and verbal reassurance may be all that is required. Call for senior help early. Follow with a ‘show of force’, with physical restraint as a last resort.
- Oral medications should be tried if possible, before parenteral.

There are two main choices – benzodiazepines and antipsychotics: ☺ good for/reasons to choose; ☹ bad for/reasons to not give.

**Benzodiazepines**

- ☺ Alcohol withdrawal, anxiety.
- ☹ Respiratory disease (⇒ respiratory depression; care if COPD/asthma), elderly (⇒ falls and rarely paradoxical agitation/aggression but can use with caution/↓ doses).
- *Lorazepam* 0.5–1 mg po/im/iv (maximum 4 mg/24 h). Shorter-acting than diazepam .: better if hepatic impairment.
- *Diazepam* 2–5 mg po/iv (if iv preferably as *Diazemuls*) or 10–20 mg pr. Can ↑ doses SPC/BNF esp if tolerance/much previous exposure to benzodiazepines.
- *Midazolam* 1.0–7.5 mg iv: titrate up slowly, according to response. Wears off relatively quicker.

**Antipsychotics**

- ☺ Taking benzodiazepines, elderly (use with caution, esp if ↑ risk of CVA), delirium (non-alcohol withdrawal), psychosis (e.g. hallucinations/delusions/schizophrenia).
• Antipsychotic-naive, alcohol withdrawal, cardiac disease, movement disorders (esp Parkinson’s; de novo extrapyramidal fx are also common – see p. 278).
• Haloperidol 0.5–5 mg po (or im/iv if necessary). 1–2 mg is sensible starting dose for delirium in elderly. 5 mg is safe for acute psychosis in young adults. Maximum 18 mg im or 30 mg po in 24 h.
• If suspect acute schizophrenia use atypical antipsychotic as 1st-line\textsuperscript{NICE}, e.g. olanzapine 10 mg po (⇒ ↓SEs) – now also available im.

**CONTROLLED DRUGS**

These drugs are rarely if ever prescribed to take home from the ED, except for severe acute pain or palliative care. NB: Chronic users of controlled drugs should only receive new supplies from authorised/licensed medical practitioners.

Note: special ‘Prescription requirements’ apply in the UK to ‘schedule’ 1, 2 or 3 drugs only, the most likely of which might be prescribed by a junior doctor are morphine, diamorphine, fentanyl, methadone, oxycodone (and less commonly buprenorphine or pethidine). The following must be written ‘so as to be indelible, e.g. written by hand, typed or computer generated’ (NB: this is a recent change from previously having to be written by hand – only the signature now needs to be handwritten):

- Date
- The patient’s full name and address and, where appropriate, age
- Drug name plus its form\textsuperscript{*} (and, where appropriate, strength)
- Dosing regimen (NB: the directions ‘take one as directed’ constitutes a dose but ‘as directed’ does not)
- Total amount of drug to be dispensed in words and figures (e.g. for morphine 5 mg qds for one week (5 mg×4 times a day×7 days = 140) write: ‘140 milligrams = one hundred and forty milligrams’)
- Prescriber’s address must be specified (should already be on prescription form, e.g. hospital address).
*Omitting the form (e.g. tablet/liquid/patch) is a common reason for an invalid prescription. It is often assumed to be obvious from the prescription (e.g. fentanyl as a patch or Oramorph as a liquid), but it still has to be written even if only one form exists.

These requirements *do not* apply to temazepam (despite being schedule 3), schedule 4 drugs (e.g. benzodiazepines) and schedule 5 drugs (such as codeine, dihydrocodeine/DF118 and tramadol). For full details on controlled drug guidance in the UK see www.dh.gov.uk/controlleddrugs.
## Medical emergencies

<table>
<thead>
<tr>
<th>Condition</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiopulmonary resuscitation (CPR)</td>
<td>225</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>225</td>
</tr>
<tr>
<td>Acute coronary syndrome (ACS)</td>
<td>226</td>
</tr>
<tr>
<td>Acute LVF</td>
<td>234</td>
</tr>
<tr>
<td>Hypertension and accelerated hypertension</td>
<td>235</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>240</td>
</tr>
<tr>
<td>Acute severe asthma</td>
<td>242</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>244</td>
</tr>
<tr>
<td>COPD exacerbation</td>
<td>247</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>248</td>
</tr>
<tr>
<td>Acute upper GI haemorrhage</td>
<td>249</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>251</td>
</tr>
<tr>
<td>DKA</td>
<td>252</td>
</tr>
<tr>
<td>HHS (HONK)</td>
<td>255</td>
</tr>
<tr>
<td>Addisonian crisis</td>
<td>256</td>
</tr>
<tr>
<td>Myxoedema coma/crisis</td>
<td>257</td>
</tr>
<tr>
<td>Thyrotoxic crisis/thyroid storm</td>
<td>257</td>
</tr>
<tr>
<td>Meningitis</td>
<td>258</td>
</tr>
</tbody>
</table>
Seizures 260
TIA and stroke 261
Severe sepsis or septic shock 264
Febrile neutropenia 265
Urinary tract infections 265
GI infections 266
TB pneumonia 267
Malaria 267
Electrolyte disturbances 269
Alcohol withdrawal 271
Acute poisoning 274
CARDIOPULMONARY RESUSCITATION (CPR)

See algorithms for adult BLS and adult ALS inside front cover. CPR is required if a collapsed person is unconscious or unresponsive, not breathing, and has no pulse in a large artery such as the carotid or femoral. The following may also be seen: occasional/ineffectual (agonal) gasps, pallor or cyanosis, dilated pupils, or a brief tonic grand mal seizure.

WHEN TO STOP
Survival from out-of-hospital cardiac arrest is greatest when:

- Event is witnessed.
- Bystander starts resuscitation, even if only chest compressions (doubles or triples survival rate).
- Heart arrests in VF or VT (22% survival).
- Defibrillation is carried out at an early stage, with successful cardioversion achieved within 3–5 min (49–75% survival), and not more than 8 min.
  - each minute of delay before defibrillation reduces survival to discharge by 10–12%
  - survival after more than 12 min of VF in adults is less than 5%.

ANAPHYLAXIS

See anaphylaxis algorithm inside front cover.

*Anaphylaxis*: is an allergic/immunological, IgE-mediated, multi-system reaction that may rapidly follow drug ingestion, particularly parenteral penicillin, a bee or wasp sting, or food such as nuts and seafood.

*Non-IgE-mediated, non-allergic anaphylaxis*: (previously termed an anaphylactoid reaction) is a clinically identical reaction most commonly following radio-contrast media, or aspirin/NSAID exposure, but which is not triggered by IgE antibodies.
These are both treated the *same* way, with first line drugs including adrenaline, oxygen, and fluids (if shock).

**ACUTE CORONARY SYNDROME (ACS)**

ACS encompasses the following:

1. **STEMI**: ST elevation myocardial infarction (see p. 230).
2. **NSTEMI**: Non-ST elevation MI; troponin (T or I) +ve.
3. **UA(P)**: Unstable angina (pectoris); troponin (T or I) –ve. Angina at rest, increasing in frequency or duration, or abnormality found on provocation testing such as EST.

**Clues**: Hx of IHD or angina, N&V, sweating, LVF (see p. 234), arrhythmia. Remember atypical pain/silent infarct in DM, elderly or if ↓GCS.

**Differential diagnosis of chest pain**: see table 4.1 for other causes of chest pain. Suspect and rule out ACS if no alternate diagnosis is made.

**ALL ACS**

- **O₂**: Do *not* administer routinely, but give supplemental oxygen only if oxygen saturation <93%, or evidence of shock.
- **Aspirin**: 300 mg po stat (chew/dispersible form) unless CI. Check has not already been given by paramedics or GP.
- **Clopidogrel**: 300 mg po (some give 600 mg, esp if immediate PCI planned). Prasugrel (60 mg po loading dose) and ticagrelor (reversible) are alternative ADP-receptor blocking antiplatelet agents used in combination with aspirin – check local guidelines for which to use.
- **Opiate**: most UK centres give diamorphine 2.5–5 mg iv + antiemetic (e.g. metoclopramide 10 mg iv), repeated according to response. Use morphine as an alternative, initially 3–5 mg iv, repeated every few minutes until pain free.
- **GTN**: 1–2 sprays or sl tablets (max 1.2 mg). If pain resistant or if LVF develops, set up ivi titrated to BP and pain. NB: As can
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Classic history</th>
<th>Physical examination</th>
<th>Diagnostic testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute coronary syndrome</td>
<td>Band-like, tight, or pressure pain with radiation to neck and arms, sweating, dyspnoea, cardiac risk factors</td>
<td>May be normal, or may have evidence of heart failure, hypotension</td>
<td>Cardiac biomarkers, ECG, possibly stress testing</td>
</tr>
<tr>
<td>Pulmonary embolus (see p. 248)</td>
<td>Sudden onset, pleuritic pain, dyspnoea, risks for venous thrombo-embolism</td>
<td>Tachycardia, tachypnoea, pleural rub, low-grade fever</td>
<td>CXR, V/Q scan, CTPA</td>
</tr>
<tr>
<td>Aortic dissection</td>
<td>Sudden, sharp, tearing pain radiating to back, neurologic symptoms</td>
<td>Unequal pulses or BP, new murmur, bruits</td>
<td>CXR, echocardiogram, CT angiogram</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>Pleuritic, positional ache, worse lying down</td>
<td>Fever, pericardial rub, tachycardia</td>
<td>ECG, CXR, echocardiogram</td>
</tr>
<tr>
<td>Pneumonia (see p. 244)</td>
<td>Cough, fever, dyspnoea, pleuritic pain, malaise</td>
<td>Fever, hypoxia, tachypnoea, tachycardia, abnormal breath sounds</td>
<td>CXR, WCC</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>Pleuritic pain, dyspnoea</td>
<td>Reduced breath sounds over hemithorax</td>
<td>CXR</td>
</tr>
</tbody>
</table>

(Continued)
Table 4.1 (Continued) Causes of chest pain in the ED

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Classic history</th>
<th>Physical examination</th>
<th>Diagnostic testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oesophageal rupture (Boerhaave’s syndrome)</td>
<td>Constant, severe retrosternal pain, dysphagia</td>
<td>Subcutaneous emphysema</td>
<td>CXR, CT chest</td>
</tr>
<tr>
<td>Gastrointestinal causes</td>
<td>Burning, nocturnal pain, gastrointestinal symptoms</td>
<td>Abdominal tenderness, rebound or guarding</td>
<td>Lipase, AXR, ultrasound</td>
</tr>
<tr>
<td>Musculoskeletal causes</td>
<td>Pain increased with movement or muscular activity</td>
<td>Chest-wall tenderness to palpation (may occur in ACS!)</td>
<td>Normal</td>
</tr>
</tbody>
</table>

ACS, acute coronary syndrome; AXR, abdominal X-ray; BP, blood pressure; CT, computerized tomography; CTPA, computerized tomography pulmonary angiogram; CXR, chest X-ray; ECG, electrocardiograph; V/Q, ventilation perfusion; WCC, white cell count.
↓BP, do not give if systolic \( \leq 100 \) mmHg (esp if combined with an antihypertensive), or inferior infarct is suspected (i.e. RV involvement).

<table>
<thead>
<tr>
<th>Date/Time</th>
<th>Infusion Fluid</th>
<th>Volume</th>
<th>Additives If Any</th>
<th>Drug and Dose</th>
<th>Rate of Admin</th>
<th>Duration</th>
<th>Dr's Signature</th>
<th>Time Started</th>
<th>Time Completed</th>
<th>Set Up by Signature</th>
<th>Batch No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>25/12</td>
<td>N. Saline</td>
<td>50 ml</td>
<td></td>
<td>50 mg GTN</td>
<td>0–10 ml/hr*</td>
<td>TN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*TITRATE TO PAIN: Stop if systolic BP < 100 mmHg

Figure 4.1 Drug chart showing how to write up GTN iv.

Consider:
- **β-blocker**: unless CI (see propranolol p. 139), esp beware 🕉asthma, acute LVF 🕉, ↓BP (systolic <100 mmHg), ↓HR (<60/min), 2nd-/3rd-degree HB; get senior help if in doubt.
  - *Can be given po or iv*: often recommended to give iv for STEMI, and po for NSTEMI and UAP. In acute settings, metoprolol is a drug of choice as short \( t_{1/2} \) means it wears off quickly if acute LVF develops (in chronic LVF use bisoprolol). Consult local protocol or get senior advice if unsure.
  - **iv**: metoprolol 1–5 mg iv, giving 1–2 mg aliquots at a time while monitoring BP and HR. Repeat to max 15 mg, stopping when BP \( \leq 100 \) mmHg or HR \( \leq 60 \). Then decide on starting metoprolol po.
  - **po**: metoprolol 25–50 mg bd. If haemodynamically stable 24 h later, change to long-acting β-blocker, e.g. bisoprolol 5–10 mg od.
  - If already on β-blocker, ensure dose is adequate to control HR.
  - If β-blocker CI and ↑HR consider Ca\(^{2+}\) blocker (e.g. diltiazem SR 60–120 mg bd) and get senior ± cardiology advice.
- **iv fluid**: cautious bolus if RV infarct. **Clues**: ↓BP with no pulmonary oedema, ↑JVP, and inferior or posterior ECG Δs (esp ST elevation \( \geq 1 \) mm in aVF). If suspect, do right-sided ECG and look for ↑ST in V4 i.e. –V4R lead. Then avoid vasodilating drugs (esp nitrates and ACE-i), and care with β-blockers (can ⇒HB).
• **Insulin:** for type I DM and type II DM, or non-diabetics with CBG >11 on admission. Aim to keep CBG in normal range using conventional sliding scale, although this and GIK ivi remain contentious. Contact CCU for advice.

**STEMI**

• **Reperfusion therapy:** primary PCI is the preferred option, but if unavailable within 90 min or CI consider thrombolysis. NB: starting either ASAP is paramount (‘time is muscle’) :: if appropriate, initiate/organise during above steps. See below for thrombolysis indications, CIs and choice of agent.

• **Heparin:** iv heparin is given with recombinant thrombolytics for 24–48 h to avoid the rebound hypercoagulable states they can cause, but is not needed with streptokinase.

• If ongoing chest pain or unresolving ECG Δs, get senior advice on further anticoagulation and arrange rescue PCI.

• Consider (consult cardiology on-call/local protocol when unsure):
  – **Glycoprotein IIb/IIIa inhibitor:** esp if not thrombolysed (CI or presentation too late), or PCI planned and still unstable. Use with caution (esp <48 h post-thrombolysis).
  – Rescue PCI: esp if thrombolysis given and doesn’t ↓ pain (e.g. within 90 min) or non-resolving (e.g ≤50% reduction in) ST elevation on ECG.

**Thrombolysis:**

**Indications** (from Resuscitation Council (UK) guidelines 2010):

• Onset of (cardiac) chest pain <12 h + Hx compatible with MI + one of:
  – ST elevation ≥2 mV (= 2 small squares) in ≥2 adjacent chest leads
  – ST elevation >1 mV (= 1 small square) in >2 limb leads
  – new LBBB: must assume it is new if cannot prove is old

• Onset of chest pain 12–24 h ago, but evidence of an evolving infarct, e.g. ongoing chest pain or worsening ECG changes. Get cardiology advice first.
Note:

- Primary PCI is still 1st line treatment for all patients presenting with acute MI if available.
- Posterior infarct is also widely considered to be an indication for primary PCI or thrombolysis. Diagnosis can be hard (look for ST depression + dominant R wave in V1–3); get cardiology advice if suspicious.
- Treatment needs to be started ASAP as ‘door to needle time’ should be <30 min.

**Contraindications**

From ESC guidelines 2012 (with permission from *European Heart Journal* 2012; 33: 2569–2619). As local guidelines/checklists often exist use these if available: consult cardiology ± haematology on-call if in any doubt.

**Absolute**

- Intracranial haemorrhage or stroke of unknown origin at any time
- Ischaemic stroke in preceding 6 months
- CNS damage, atrioventricular malformation or neoplasm
- Major trauma/surgery/head injury in preceding 3 weeks
- GI bleeding within the last month
- Known bleeding disorder (excluding menses)
- Aortic dissection
- Non-compressible punctures in last 24 h (e.g. liver biopsy, lumbar puncture).

**Relative**

- TIA in past 6 months
- Refractory hypertension (systolic >180 mmHg and/or diastolic >110 mmHg)
- Oral anticoagulant therapy
- Pregnancy or within 1-wk post partum
- Prolonged or traumatic resuscitation
- Advanced liver disease
- Infective endocarditis
- Active peptic ulcer.
Choice of agent

Use your hospital’s protocol when one exists – contact CCU or look on your hospital intranet for details.

Choose between a recombinant thrombolytic such as alteplase, reteplase or tenecteplase and streptokinase. Each hospital tends to stock one in particular; see individual drug entries in common drugs section for dosing regimen.

NICE guidance recommends that, in hospitals, the choice of agent should take account of:

- ‘The likely balance of benefit and harm (e.g. stroke) to which each of the thrombolytic agents would expose the individual patient.’ Recombinant forms (compared with streptokinase) are probably more efficacious and have ↓ incidence of allergic reactions, CCF and bleeding other than stroke. However they have ↑ incidence of haemorrhagic stroke.
- ‘Current UK clinical practice, in which it is accepted that patients who have previously received streptokinase should not be treated with it again.’ Streptokinase is less effective and more likely to cause allergic reaction after first administration (due to Ab production). Do not give if patient has been given it in the past.
- ‘The hospital’s arrangements for reducing delays in the administration of thrombolysis.’ Some agents are quicker to set up and administer and this can reduce ‘door to needle’ time.

Heparin co-therapy

Recombinant forms always need concurrent iv heparin for 24–48 h (this does not apply for streptokinase). Use your hospital’s CCU protocol if one exists.

Otherwise use ESC guideline: 60 units/kg (max 4000 units) iv bolus, then ivi at 12 units/kg/h for 24–48 h (max 1000 units/h). Monitor APTT at 3, 6, 12, 24 and 48 h, with target APTT (≠ APTT ↑ ratio!) of 50–70 sec. NB: this is different from ‘standard’ iv heparin regimens (see p. 210).
NSTEMI or UAP

- **Heparin:** LMWH, e.g. enoxaparin 1 mg/kg bd sc or fondaparinux 2.5 mg od sc esp if PCI planned in 1st 24–36 h after symptom onset.
- Consider (consult local protocol/cardiology on-call if unsure):
  - **Glycoprotein IIb/IIIa inhibitor:** if high risk* (defined by ACC/ESC as: haemodynamic or rhythm instability, persistent pain, acute or dynamic ECG Δs, TIMI risk score >3 (see below), ↓left ventricular function, ↑troponin) and/or ongoing chest pain/ECG Δs.

**TIMI risk score for NSTEMI/UA. (Source: Antman E, et al. JAMA 2000; 284: 835–842).**

1 point for presence of each of the following:

- Age ≥65 yrs
- ≥3 of following risk factors for IHD: FHx of IHD, ↑BP, ↑cholesterol, DM, current smoker
- Prior coronary stenosis (≥50% occlusion)
- Aspirin use in past 7 days
- Severe angina (≥2 episodes w/in 24 h)
- ST segment deviations (↑ or ↓) at presentation
- +ve serum cardiac markers (troponin).

Score >3 indicates ↑risk (20% or more) of developing cardiac events and death.

**SECONDARY PREVENTION**

In all ACS unless CI or already started – will be commenced on CCU / medical ward:

- **Next day:** aspirin 75 mg od, ‘statin’ (e.g. simvastatin 40 mg od) and clopidogrel 75 mg od (for 1 yr**NICE**). If prasugrel used (instead of clopidogrel) 10 mg od unless >75 yrs or <60 kg in which case use 5 mg od.
- **When stable:** β-blocker (e.g. bisoprolol 1.25 mg od once any LVF clears; see above for CI) and ACE-i (e.g. ramipril 2.5 mg
bd po started 2–10 days after MI, then 5 mg bd after 2 days if tolerated). Consider addition of aldosterone antagonist eplerenone in established LVF (EF <40 %) and signs of HF after 3 days (closely monitor U&Es).

- Diet/lifestyle Δs (↓Wt, diet Δs, ↑exercise, ↓smoking, etc).

### ACUTE LVF

**Clues:** SOB, S₃ or S₄ gallop, pulmonary oedema with widespread rales (can ⇒ pink frothy sputum if severe), ↓BP, Hx of IHD, ↑JVP and peripheral oedema (if also RVF, i.e. CCF).

- **O₂**: 60–100% to maintain SaO₂ >95% (care if COPD) and keep patient upright.
- **Furosemide**: 20–40 mg iv initially (max 100 mg in 1st 6 h); consider repeat doses or ivi (5–40 mg/h) later. If not ‘in extremis’, ↓doses (40 or 60 mg) od and monitor urine output.
- **GTN ivi**: see p. 229.
- **Diamorphine**: 0.5–1 mg iv (at 0.5 mg/min) or morphine 1–2.5 mg iv (1 mg/min) + metoclopramide 10 mg iv. Beware resp depression, esp if need to use NIV.

Not responding/worsens. Get senior help and consider:

- **Non-invasive ventilation** (NIV) as continuous positive airways pressure (CPAP). Staff must be familiar with its use.
- **Inotropes**: e.g. dobutamine (2–20 microgram/kg/min) if ↓BP, via central line. If patient is this sick, will also be needed for CVP measurement and CCU care (± intra-aortic balloon pump). Get cardiology involved.
- **Underlying cause**: AMI, arrhythmia (esp AF), valve rupture (try to listen for new murmur), ↑↑BP; or non-cardiogenic i.e. sepsis, ARDS, ICH, AKI with volume overload, hypoalbuminaemia, smoke inhalation, and poisons/OD (e.g. aspirin).

ACE-i: once stable and if no CI, e.g. enalapril 2.5 mg od (↑later).
HYPERTENSION AND ACCELERATED HYPERTENSION

HYPERTENSION
Adapted with permission from NICE www.nice.org.uk/guidance/CG127 (2011 revision).

When to treat
Most hypertensive patients in the ED do not require treatment, as they are usually asymptomatic. Never treat a single high BP unless there are assoc symptoms or signs.

A decision to treat is thus best made by the GP, in the medical clinic or on the ward, and will depend on severity and other factors:

<table>
<thead>
<tr>
<th>Severity</th>
<th>Clinic BP(^a)</th>
<th>ABPM(^b) or HBPM(^c)</th>
<th>Drug therapy(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normotensive</td>
<td>&lt;140/90 OR &lt;135/85</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Stage 1</td>
<td>≥140/90 AND ≥135/85</td>
<td>Yes</td>
<td>Consider(^e)</td>
</tr>
<tr>
<td>Stage 2</td>
<td>≥160/100 AND ≥150/95</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>SBP ≥180 OR DBP ≥110</td>
<td>Yes, immediate</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) All measurements are in mmHg. If 1st clinic BP ≥140/90, repeat. If 2nd measurement much lower than 1st take 3rd reading; lowest of 2nd & 3rd is taken as clinic BP. Clinic BP persistently ≥140/90 should be confirmed by ABPM/HBPM unless ≥180 OR 110.

\(^b\) Ambulatory BP monitoring (ABPM); average of ≥14 daytime readings.

\(^c\) Home BP monitoring (HBPM); average of ≥4 days a.m. & evening readings, excluding 1st days readings.

\(^d\) Encourage lifestyle modifications for all ↑BP: ↓salt, ↓Wt, ↓alcohol, stop smoking, ↑exercise, ↑fresh fruit/vegetables, ↓intake of total and unsaturated fat. For Stage 1 without CVD or target organ damage*, these measures can be tried before drug therapy.

\(^e\) Indicated in those <80 years old if established CVD or DM, or evidence of target organ damage*, or 10-yr CVD risk ≥20% (see risk charts at back of BNF or at http://www.bhsoc.org/Cardiovascular_Risk_Charts_and_Calculators.stm).

*HF, established IHD, CVA/TIA, chronic kidney disease (CKD, ↓GFR, ↑creatinine or proteinuria/microalbuminuria), hypertensive/diabetic retinopathy or LVH.
**Aim for:** Clinic BP ≤140/90 mmHg if <80 y.o.; <150/90 if ≥80 y.o. If CKD ≤140/90 mmHg. If DM or CKD and >1g/24h proteinuria (urinary albumin:creatinine ratio >70 mg/mmol or protein:creatinine ratio >100 mg/mmol) ≤130/80 mmHg. Consider ABPM/HBPM in those with white coat effect. If target not achieved with Step 1, progress to Step 2 etc.

**Primary causes:** look for and exclude (esp if treatable), e.g. RAS, Conn’s (1° hyperaldosteronism), ↑Ca²⁺, Cushing’s, phaeo (esp if variable BP, headaches, sweats, palpitations), oestrogen-containing contraceptive pills and recreational drugs (e.g. alcohol, cocaine, amphetamines).

---

**Practice points**

- It is rare to ever need to start new antihypertensive treatment in the ED. Leave this to the medical clinic/ward.
- If you do start treatment make a written Rx plan for (other) doctors, nurses and patient. Include target BP and how Rx should change if it is not achieved.
- Age/ethnic origin influence response to drugs (see table below).
- A single agent is rarely successful at achieving target BP. Rather than ↑ing doses, add 2nd and 3rd agents, which often work in an additive or complementary fashion, esp if table below used.
- Exclude/minimise dietary salt and NSAID (inc unrecognised ‘over-the-counter’) use, as reason for poor treatment response.
Choice of drug: rational combination therapy\textsuperscript{NICE/2011}

<table>
<thead>
<tr>
<th>Step</th>
<th>Younger (&lt;55 yrs) and non-black</th>
<th>Older (≥55 yrs) or black\textsuperscript{a}</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(A)\textsuperscript{b}</td>
<td>(C)\textsuperscript{c}</td>
</tr>
<tr>
<td>2</td>
<td>(A + C)\textsuperscript{c}</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>(A + C + D)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Resistant hypertension\textsuperscript{d}</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a} Black = African (not Asian) origin.
\textsuperscript{b} \(\beta\)-Blockers are an alternative to ACE-i/ARBS but see notes below.
\textsuperscript{c} If C not suitable (e.g. presence or risk of LVF, intolerance, oedema) offer D [thiazide-like diuretic].
\textsuperscript{d} Ensure on optimal/best tolerated doses of A+C+D. Check adherence to lifestyle advice. If \(K^+\) ≤4.5 mmol/L, add spironolactone (e.g. 25 mg od). \(X\) CKD, due to risk of \(\uparrow K^+\). If \(K^+\) >4.5 mmol/L consider higher dose thiazide diuretic (e.g. chlorthalidone 50--200 mg od), \(\alpha\)-blocker or \(\beta\)-blocker. Consider missed 1° cause ± specialist referral.

\(\bigcirc\) good for, \(\bigotimes\) avoid/caution, \(\bigotimes\) beware!

- \(A\) = ACE-i, e.g. ramipril initially 2.5 mg od (1.25 mg if elderly or CKD). \(\bigcirc\) CKD (but with caution!), HF, DM, IHD. \(\bigcirc\) PVD (as assoc with RAS\textsuperscript{*}). \(\bigotimes\) Pregnancy, bilateral RAS\textsuperscript{*}. \textit{(Must monitor U&Es 2 wks after starting, then regularly, esp if vasculopathy or CKD)}.

Angiotensin II receptor blockers (ARBs) preferred to ACE-I in black person of African or Caribbean origin, or if ACE-i not tolerated (esp dt dry cough). Use low cost ARBs. Monitor as for ACE-i. Do not combine ACE-i + ARB.

- \(B\) = \(\beta\)-blocker, e.g. atenolol 50 mg od. \(\bigcirc\) younger patients with \(\uparrow\)sympathetic drive or childbearing potential, IHD (post-MI/angina), chronic stable LVF, intolerance to ACE-i or ARB. If used for Step 1, add C for Step 2 (in preference to D) to \(\downarrow\) risk of DM. \(\bigotimes\) dyslipidaemia, PVD, DM (unless also IHD), if on diltiazem. \(\bigotimes\) asthma/COPD, HB, acute LVF, if on verapamil.
• **C = Ca\(^{2+}\) channel blocker**: dihydropyridines such as amlodipine 5 mg or nifedipine LA (e.g. **Adalat LA** 20–30 mg od) usually 1st-line. 😊 oedema, polyuria. 😖 aortic stenosis, recent ACS.

  If IHD ‘rate-limiting’ types (verapamil, diltiazem) often preferred. 😖 HF, HB, if on other rate-limiting drugs (esp β-blockers).

• **D = thiazide-like diuretic**, e.g. indapamide SR 1.5 mg od or chlorthalidone 25 mg od. 😊 oedema/HF. 😖 dyslipidaemia. 😖 gout. If patient on conventional thiazide diuretic (e.g. bendroflumethiazide) and BP controlled, continue this.

NB: starting doses only are given; see main drugs section or SPCs/BNF for doses thereafter.

**ACCELERATED HYPERTENSION**

Various terms are used sometimes interchangeably such as severe hypertension, hypertensive urgency, hypertensive emergency, hypertensive crisis and malignant hypertension.

The key is whether there is acute end-organ damage or dysfunction. Get senior help before embarking on any treatment – it may be unnecessary!

**Practice points**

• Accelerated hypertension Dx: diastolic >120 mmHg (or systolic >220 mmHg) plus grade III (haemorrhages/exudates) or IV (papilloedema) hypertensive retinopathy.

• 😖 Do not drop BP too quickly as can ⇒ MI, CVA or AKI 😖.

• Patients are often salt and water depleted (look for postural drop of >20 mmHg) so may require fluid replacement as well as antihypertensives.

**Life-threatening target organ damage**

• Encephalopathy, intracranial haemorrhage, aortic dissection, unstable angina, acute MI, acute LVF/pulmonary oedema or pre-eclampsia/eclampsia.

• Get senior help immediately and aim to ↓ diastolic to 110–115 mmHg over 1–2 h (systolic to <110 mmHg in aortic dissection)
and then more slowly thereafter (e.g. ↓diastolic to 100 mmHg after 48 h).

- This should always be done in the ITU/HDU/CCU setting and generally (but not always) involves an iv antihypertensive and intra-arterial invasive BP monitoring.
- Choose from nitroprusside (most commonly used but can ⇒ cyanide poisoning, esp if used in ↓GFR + may not ↓cerebral vascular resistance as well as labetalol), hydralazine (commonly used in pregnancy), labetalol (in pregnancy but can ⇒ severe ↓BP), phentolamine (esp if phaeo known/suspected), or GTN/ISDN (if pulmonary oedema).

**No life-threatening target organ damage**

- Uncomplicated acute kidney injury, mild LVF, etc: aim to ↓diastolic BP to 110–115 mmHg over 24–48 h using oral medication.
- Choose from nifedipine (e.g. Adalat Retard) 10 mg po. Monitor and reassess; consider repeat doses (e.g. after 2 h) and if required/tolerated aim to get patient on to higher doses (e.g. 20 mg tds). Tablets to be swallowed (not chewed) and avoid quick release or sr preparations. Convert to amlodipine once stable.
- If IHD consider adding β-blocker* later (e.g. atenolol 25–50 mg od).
- When nifedipine CI, consider diltiazem (e.g. 60 mg SR bd initially) or β-blocker instead*: metoprolol (e.g. 12.5–25 mg initially then tds regimen) or labetalol (e.g. 50–800 mg bd/tds) are good choices as short acting and needs no dose adjustment with ↓GFR. When BP controlled withdraw β-blocker except in IHD (risk of new-onset DM). In IHD consider converting to atenolol (e.g. 50 mg po) once stable.
- Other possibilities include ACE-i** (can ⇒ severe ↓BP; if so give iv saline) and diuretics (if patient fluid overloaded).

*If underlying cause is a phaeo (suspect when BP very variable, headaches, sweats or palpitations; get senior help): will need α-blocker (phenoxybenzamine) and may need salt supplements. If
tachycardia a problem, must not give β-blocker until several days after α-blocker started.

**If cause is renal artery stenosis (suspect when other clinical vascular disease/multiple CVD risk factors/↓GFR): try to avoid renin system blockade (i.e. ACE-i/ARB/direct renin inhibitor) as risk of severe ↓BP) and monitor U&Es (risk of RF including delayed onset after 3–4 weeks); if used, starting dose must be low (e.g. enalapril 2.5 mg od).

Atrial Fibrillation

See ALS tachycardia algorithm on inside back cover.

**Clues:** Irregularly irregular ↑HR ± SOB, angina or heart failure. Confirm diagnosis with 12 lead ECGs; narrow QRS, absent P waves (esp V1), (irregularly) irregular R-R interval.

**Practice point**
Treatment (rate or rhythm control) depends on: presence of haemodynamic instability (systolic BP <90 mmHg), acuteness of onset (<48 h) and presence of structural heart disease (e.g. LVH: clinically/ECG/echo) or heart failure (clinically/CXR/echo).

**Haemodynamically unstable patient:**
- DC cardioversion; ideally after initiating anticoagulation* but this should not delay emergency interventionNICE. Procedural sedation will be required (see p. 182).

**Haemodynamically stable patient**

**Acute onset (<48 h)**
+ No evidence of structural heart disease: flecainide 100 mg bd po or 2 mg/kg iv over 30 min (max 150 mg) with appropriate antithrombotic cover (e.g. enoxaparin 1.5 mg/kg daily); seek cardiology advice if unsuccessful and consider DC cardioversion.
+ Evidence of structural heart disease (or any doubt): amiodarone 300 mg ivi over 20–60 min followed by 900 mg ivi over next 24 h and then 1.2–1.8 g/day (po or iv) until 10 g total. Then minimum
maintenance dose (100–400 mg/day) to control sinus rhythm. If unsuccessful consider DC cardioversion.

**Onset >48 h (or unknown)**

+ **No evidence of heart failure:** β-blocker po (e.g. metoprolol 25–50 mg bd). If β-blocker CI (e.g. COPD/asthma) use Ca²⁺ channel blocker (e.g. diltiazem MR 120 mg bd).

+ **Evidence of heart failure:** digoxin 250–500 microgram iv/po loading dose and two repeat half doses at 6–12 h intervals followed by appropriate maintenance dose (62.5–250 microgram). Use half the dose if elderly or RF. Monitor levels and e’lytes on the ward to avoid toxicity.

- All inpatients initially need anticoagulation (e.g. LMWH); for paroxysmal, persistent and permanent AF use risk stratification for benefit vs haemorrhagic risk to guide thromboprophylaxis:
  - High stroke risk\(^{\text{NICE}}\): use warfarin (post stroke/TIA/TE; age \(\geq 75\) with HTN, diabetes or vascular disease; structural heart disease or LVF; CHADS\(_2\)\(^* >3\)).
  - Moderate risk\(^{\text{NICE}}\): use warfarin or aspirin (age \(\geq 65\) + no risk factors; age <75 and HTN, diabetes or vascular disease).
  - Low risk\(^{\text{NICE}}\): use aspirin.

- When non-acute (planned) cardioversion anticoagulate \(\geq 3\) wks before (and after) cardioversion\(^{\text{NICE}}\).

**CHADS\(_2\) score for risk of stroke in (non-rheumatic) AF:** JAMA 2001; 285: 2864–2870.

- Congestive heart failure Hx = 1 point
- Hypertension Hx = 1 point
- Age \(\geq 75\) = 1 point
- DM Hx = 1 point
- Stroke symptoms or TIA = 2 points
ACUTE SEVERE ASTHMA

Clues: SOB with wheeze and cannot complete sentences in 1 breath, HR ≥110/min, RR ≥25/min, SaO₂ ≥92%, PEF <50% of best*:

- Attach sats monitor.
- 40–60% O₂ through high-flow mask, e.g. Hudson mask.
- Salbutamol 5 mg neb in O₂: repeat up to every 15 min if persisting.
- Ipratropium 0.5 mg neb in O₂: repeat up to every 4–6 h if persisting or fails to respond to salbutamol.
- Prednisolone 40–50 mg po od for at least 5 days.
  Hydrocortisone 100 mg qds iv can be given if unable to swallow or retain tablets. Both hydrocortisone and prednisolone can be given if seriously ill.

Life-threatening features (critical asthma)

- PEF <33% of best*
- O₂ sats <92%
- PaO₂ <8.0kPa, PaCO₂ >4.6kPa or pH <7.35
- Silent chest, cyanosis or ↓respiratory effort
- ↓HR, ↓BP or dysrhythmia
- Exhaustion, confusion or coma

*or predicted best (see Figure 4.2).

LIFE-THREATENING/Critical Asthma

NB: patient may not always appear that distressed, esp if silent chest 😞, get senior help and consider the following.

- MgSO₄ iv: 1.2–2 g over 20 min (8 mmol=2 g=4 ml of 50% solution) unlicensed indication.
- Salbutamol iv: 5 microgram/kg over 10 min initially (then up to 20 microgram/min ivi according to response): back-to-back or continuous nebs now often preferred.
• Call anaesthetist for consideration of ITU admission and/or intubation. Initiate these during the above steps if deteriorating.

• **Aminophylline iv**: give loading dose providing are **not** on maintenance po aminophylline/theophylline (omit if they are) 5 mg/kg iv over 20 min, then iv at 0.5–0.7 mg/kg/h (0.3 mg/kg/h if

---

**Figure 4.2** Peak expiratory flow (PEF) predictor for normal adults using European standard ‘EU’ (EN 13826) scale. (Adapted with permission of BMJ group from Gregg I, Nunn AJ. *BMJ* 1989; 298: 1098, corrected to the EN 13826: 2003 scale values by Clement Clarke International Ltd.)
elderly). Risk of serious arrhythmias, hypotension, vomiting and seizures.

PNEUMONIA

COMMUNITY-ACQUIRED PNEUMONIA (CAP)

Severity assessment of community acquired pneumonia in hospital
‘CURB 65’ score – 1 point each for:

• Confusion; MTS ≤8/10 or new disorientation in time, place or person
• Urea >7 mmol/l
• Respiratory rate ≥30/min
• BP↓: systolic <90 mmHg or diastolic ≤60 mmHg
• 65: age ≥65 yrs

<2: Non-severe*: likely to be suitable for home treatment.
  2: Moderate** with increased risk of death: consider admission (or hospital supervised outpatient care) using clinical judgement.
>2: Severe** with high risk of death: admit and consider HDU/ITU (esp if ≥4).

1Use ‘CRB 65’ for assessment in the community, as does not need blood test: 0 = likely to be suitable for home treatment; 1–2 = consider hospital referral; 3–4 = urgent hospital admission.
2MTS = (Abbreviated) Mental Test Score; see p. 293 for details.

Adapted with permission of BMJ Publishing Group from BTS guidelines. Thorax 2001; 56 (suppl IV) and 2004 update.

Treatment
Non-severe*: amoxicillin 500 mg–1 g tds po ± clarithromycin*** 500 mg bd po (if admitted for clinical reasons).
Severe**: co-amoxiclav 1.2 g tds iv + clarithromycin*** 500 mg bd iv. ± flucloxacillin 1 g qds iv if S. aureus (Hx or epidemic of ’flu). ± rifampicin 600 mg bd po/iv if Legionella (do urinary Ag test).
• No improvement, consider changing co-amoxiclav to **tazocin** (piperacillin + tazobactam).
• If risk factors, consider Rx for aspiration (see below) or TB (see p. 267).
• Use clarithromycin*** only if penicillin hypersensitivity.
• ***Clarithromycin is better tolerated than erythromycin (⇒ ↓GI upset); consult local protocol to check preference.

**Causes of community-acquired pneumonia (UK adults)**

- **48%** *Streptococcus pneumoniae*: esp in winter or shelters/prison.
- **23%** viruses: influenza (A >> B), RSV, rhinoviruses, adenoviruses.
- **15%** *Chlamydia psittaci*: esp from animals, and only 20% from birds (less commonly *Chlamydia pneumoniae*, esp if long-term Hx and headache).
- **7%** *Haemophilus influenzae*.
- **3%** *Mycoplasma pneumoniae*: ↑s during 4-yrly epidemics.
- **3%** *Legionella pneumophila*: ↑d if recent travel (esp Turkey, Spain).
- **2%** *Moraxella catarrhalis*: ↑d in elderly.
- **1.5%** *Staphylococcus aureus*: mostly post-influenza ↑s in winter.
- **1.4%** Gram-negative infection: *Escherichia coli, Pseudomonas, Klebsiella, Proteus, Serratia*.
- **1.1%** Anaerobes: e.g. *Bacteroides, Fusobacterium*.
- **0.7%** *Coxiella burnetii*: ↑s in April–June and in sheep farmers.

NB: As 25% are mixed aetiology this accounts for total >100%. However, in ≥20% of cases, a causative pathogen is not identified. Adapted with permission of BMJ Publishing Group from Lim WS, et al. Thorax 2001; 56: 296–301.

The term ‘atypical pathogen’ or ‘atypical pneumonia’ is no longer considered useful by the BTS (referring to *Mycoplasma, Legionella,*
Chlamydia, Coxiella), as there is no clinical presentation characteristic of the pneumonias they cause.

HOSPITAL-ACQUIRED PNEUMONIA
See below for typical causes.

Non-severe: co-amoxiclav 625 mg tds po.
Severe: co-amoxiclav 1.2 g tds iv; or tazocin (piperacillin + tazobactam) 4.5 g tds iv if Pseudomonas suspected; or meropenem 1 g tds if penicillin allergy.

DO NOT prescribe meropenem if history of anaphylactic or accelerated allergic reaction – discuss alternatives with microbiologist.
+ gentamicin if septic shock or failure to improve.
+ metronidazole 500 mg tds ivi if aspiration suspected (controversial).

MRSA: teicoplanin/vancomycin if confirmed colonisation/infection.

Causes of hospital-acquired pneumonia

- **Simple**: (w/in 7 days of admission): H. influenzae, S. pneumoniae, S. aureus, Gram-negative organisms.
- **Complicated***: Gram-negative organisms (esp P. aeruginosa), Acinetobacter, MRSA.
- **Anaerobic**: Bacteroides, Fusobacterium.
- **Special situations**:
  1. Head trauma, coma, DM, RF: consider S. aureus.

* > 7 days after admission, recent multiple antibiotics or complex medical Hx (e.g. recent ITU/recurrent admissions or severe comorbidity).

**esp if risk of aspiration, recent abdominal surgery, bronchial obstruction/poor dentition.

Aspiration pneumonia
Treat as for community- or hospital-acquired pneumonia, + metronidazole 500 mg tds iv or 400 mg tds po.

Cavitating pneumonia
Co-amoxiclav 1.2 g tds iv (or flucloxacillin 1 g qds iv).
- Exclude TB with sputum microscopy and Ziehl–Neelsen staining, culture and PCR/Heaf test ± pleural Bx.
- Consider septic emboli as a cause, e.g. from right-sided endocarditis.
- If MRSA suspected/confirmed use vancomycin iv plus rifampicin po.


COPD EXACERBATION

Clues: Sudden worsening of SOB, productive cough, wheeze, RR >25/min, HR >110 in a patient with emphysema, chronic bronchitis ± asthma.

Treatment
- Attach sats monitor and do baseline ABGs.
- 28% O₂ via Venturi mask, which should be prescribed on drug chart. ↑dose cautiously if hypoxia continues, but repeat ABGs to ensure CO₂ not ↑ing and (more importantly) pH not ↓ing.
- Salbutamol 5 mg neb in O₂: repeat up to every 15 min if ill (seldom necessary to give >hourly).
- Ipratropium 0.5 mg neb in O₂: repeat up to every 4–6 h if ill.
- Prednisolone 30 mg po then od for ≤2 wks (usually 7–10 days). Can give 1st dose as hydrocortisone 200 mg iv – rarely used now unless unable to swallow.
- **Doxycycline 200 mg od po** (1st-line), or **amoxicillin/co-amoxiclav** (2nd-line), if 2 out of 3 of Hx of ↑ing SOB, ↑ing volume or ↑ing purulence of sputum.

Not improving, consider
- **Aminophylline ivi**: see Mx of asthma (p. 243) for details.
- **Assisted non-invasive ventilation**: CPAP if just ↓PaO\(_2\) or NIV (BIPAP) if also ↑PaCO\(_2\)
- **Doxapram** if NIV not available. Get senior advice and or ITU involved.
- **Intubation**: discuss with ITU/anaesthetist.

**PULMONARY EMBOLISM**

**Practice points**
- Important symptoms are dyspnoea (73%), chest pain (66% – not always pleuritic), cough (37%), apprehension, sweating, haemoptysis and syncope.
- Important signs are tachypnoea > 20/min (70%), crepitations (51%), tachycardia (30%), low grade fever.
- Important laboratory findings are atelectasis or parenchymal abnormality on CXR, PaO\(_2\) under 80 mmHg in absence of lung disease.
- ECG: sinus tachycardia common; AF, RAD, RBBB. Note S\(_1\)Q\(_3\)T\(_3\) is neither sensitive nor specific.
- Hospital mortality is 5% or less.

NB: Absence of dyspnoea plus tachypnoea > 20 / min has a negative predictive value (NPV) for PE of 90%; absence of these and pleuritic pain has NPV of 97%; with absence of CXR changes or a low PaO\(_2\) as well virtually excluding a PE.

**Treatment**
- 60–100% O\(_2\) if hypoxic. Care if COPD (difficult to know when to suspect PE).
Anticoagulation: LMWH, e.g. enoxaparin or dalteparin. Once PE confirmed, load with warfarin, usually on medical ward (see p. 212). Consider iv heparin if surgery being contemplated, or rapid reversal may be required*.

Analgesia: if xs pain or distress, try paracetamol/ibuprofen 1st; consider opiates if severe or no response ( ✔️ can ⇒ respiratory depression 🛑).

Massive PE: with worsening hypoxia or cardiovascular instability (↓BP, RV strain/failure) has mortality 30–50%. Seek senior help and consider:

- Fluids ± inotropes: if systolic BP <90 mmHg
- Thrombolysis (e.g. alteplase): if ↓BP ± collapse
- Vena cava filter: introduced at bedside under ultrasound guidance
- Embolectomy*: seek urgent cardiothoracic opinion.

ACUTE UPPER GI HAEMORRHAGE

Clues: Haematemesis (fresh red or coffee grounds), and/or melaena/haematochezia; also consider as differential in unexplained sudden collapse/hypovolaemic shock – at least do a PR.

ASSESS SEVERITY OF BLEEDING

- Pulse >100 or ↑ of >20 bpm
- Systolic BP <100 mmHg (or postural drop >10 mmHg)
- Urine output <0.5 ml/kg/h (30 ml/h)
- Cold, clammy peripheries
- Age over 65 yrs
- Suspected varices – previous variceal bleed, cirrhosis with portal hypertension e.g. alcoholic/hepatitis C, B and D/autoimmune (primary biliary or chronic active hepatitis).
MANAGEMENT

• **Resuscitate:**
  - Give high-flow O₂
  - Insert 2 wide bore intravenous cannulae (14-/16-gauge), and take blood for FBC, INR, U&É, LFT + group and save or cross match 2–6 units depending on severity of bleed.
  - Fluid iv (crystalloid/colloid then blood) to maintain systolic BP >100, but *avoid* over-transfusion in elderly/heart or renal disease. Consider CVP line.
  - Correct clotting with iv fresh frozen plasma if INR >1.5 (NB: although vit K reverses warfarin, it does not alone improve clotting problems due to liver cell failure).

• **Monitor:**
  - Pulse, BP, urine output (consider catheter)
  - Intra-arterial line (suspected varices).

• **Drugs:**
  - Significant non-variceal bleed, give omeprazole 80 mg iv over 40–60 min, then ivi 8 mg/hr for 72 hrs (unlicensed indication, usually following endoscopic treatment)
  - Give 2 mg terlipressin iv ‘stat’ if variceal bleed suspected (and continue qds – NB: caution in IHD)
  - Suspected variceal bleeds should also receive a short course of prophylactic antibiotics active against Gram negative bacteria to reduce risk spontaneous bacterial peritonitis e.g ceftriaxone 1 g iv, or ciprofloxacin/norfloxacin
  - Stop antihypertensives, diuretics, NSAIDs, anticoagulants.

• **Endoscopy** – Arrange urgently if:
  - Variceal bleed suspected
  - Continued bleeding requiring >4 units blood to maintain systolic BP >100 mmHg
  - Re-bleed after resuscitation
  - Pre-OGD Rockall score ≥2 (see below).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-OGD Score</strong></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0</td>
</tr>
<tr>
<td>&lt;60</td>
<td>0</td>
</tr>
<tr>
<td>60–79</td>
<td></td>
</tr>
<tr>
<td>&gt;80</td>
<td></td>
</tr>
<tr>
<td>Shock</td>
<td>sBP&gt;100; HR&lt;100</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>nil major</td>
</tr>
<tr>
<td><strong>Post-OGD Score</strong></td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Mallory-Weiss, no lesion, no SRH</td>
</tr>
<tr>
<td>Major SRH</td>
<td>None or dark spot only</td>
</tr>
</tbody>
</table>

OGD = Oesophago gastro duodenoscopy; sBP = systolic blood pressure; SRH = stigmata of recent haemorrhage.

Pre-OGD score 0 or 1 assoc with <2.5% mortality. Can usually be safely endoscoped on the next available list (but w/in 24 hours).

Pre-OGD score >2 assoc with >5% mortality. May require urgent endoscopy.

**HYPOGLYCAEMIA**

Treat if <3 mmol/l or symptoms: ↑sympathetic drive (↑HR, sweating, aggression/behavioural Δs), seizures or confusion/↓GCS.
• **Glucose orally:** esp sugary drink, mouth gel (e.g. hypostop/glucogel) or dextrose tablets. Omit this step if confusion/\(\downarrow\)GCS, but useful if given at first sign symptoms.

• **Glucose 20–50 ml of 50% iv stat via large iv cannula.** Then flush with saline as 50% glucose is viscous and hypertonic. Repeat if necessary. Can give 5–10% glucose ivi if only mild symptoms or until 50% glucose found, but beware of fluid overload in HF.

• **Glucagon 1 mg** im/iv stat: if symptomatic low glucose or no iv access. Give oral carbohydrate within 10–30 min to prevent recurrence.

NB: look for and correct underlying causes, esp DM Rx (missed meal/undue exertion/excessive insulin), alcohol withdrawal, liver failure, aspirin/sulphonylurea poisoning, and rarely Addison’s disease or pituitary insufficiency. If dt sulphonylureas, relapse is common and will need admission.

**DKA**

**Practice points**

• **Diagnostic criteria:** include triad of hyperglycaemia, acidaemia and ketonaemia: BG >11.1 mmol/l; pH <7.3 and/or HCO\(_3\) <15 mmol/l; +ve ketones with serum ≥3 mmol/l or urine dipstick ≥2+. (NB: urinalysis may miss 3-β hydroxybutyrate early).

• **Precipitating causes:** new diagnosis of diabetes (10–27%), infection (35%), inadequate insulin (30%), surgery, trauma, alcohol, cocaine, other drugs such as steroids/thiazides/pentamidine. NB: no cause in 19–38%, but poor compliance/economic reasons frequent.

**Clues:** Kussmaul’s (deep/rapid) breathing, ketotic breath; thirst, polydipsia/polyuria then nausea, vomiting and abdominal pain; dehydration with tachycardia ± hypotension; confusion/\(\downarrow\)GCS.
‘Joint British Diabetes Societies Inpatient Care Group’ published UK guidelines for the Mx of DKA in adults in March 2010 (http://www.diabetes.org.uk/Documents/) or (http://eng.mapofmedicine.com/evidence/map/diabetes4.html). These recommend a fixed rate insulin ivi rather than sliding scale; blood ketone measurement to guide treatment; bedside glucose and ketone meters when available; and use of venous rather than arterial blood gases. These are increasingly being incorporated into local guidelines, and the treatment below reflects this. However follow your local diabetes team protocol(s) where applicable.

Management

- **Initial measures**: O₂ if hypoxic, weigh patient (if possible), 2 wide bore iv cannulae. Consider NGT (if coma), and central line (esp if ↓↓pH or Hx of HF), but urinary catheter usually sufficient.
- **Initial Ix**: CBG then venous BG, U&Es, venous blood gases (ABG if hypoxic), blood ketones, FBC, blood cultures (infection suspected), ECG, CXR, urinalysis and culture.
- **Ongoing biochemical monitoring**: hourly CBG and ketones (bedside if available), venous blood gas (for pH, bicarbonate and K⁺) hourly for 1st 2 h, then 2-hourly.
- **Iv fluids and K⁺**: initially 0.9% saline guided by pulse, BP, urine output ± CVP. Typical deficits include 100 ml/kg H₂O, 7–10 mmol/kg Na⁺ and 3–5 mmol/kg K⁺. Thus the following is a guide:
  - **Systolic BP <90 mmHg**: 500 ml 0.9% saline over 15 min. If BP remains <90 mmHg repeat this but call for senior help.
  - **Otherwise** give 0.9% saline more slowly, e.g. 1 litre over 1 h, then 2 litres over 4 h, then 2 litres over 8 h.
  - Add KCl once K⁺ <5.5 mmol/l, as will ↓ rapidly dt insulin (but do not give KCl in 1st litre unless K⁺ <3.5 mmol/l).
  - About 40 mmol/l K⁺ is needed during rehydration: adjust K⁺ to individual response with regular checks – best done with...
blood gas machine that gives K+ levels. Use venous samples as long as put in ABG or other heparinised syringe.

- **Insulin**: as soluble insulin ivi (e.g. Actrapid). Use a fixed rate ivi 0.1 units/kg/h (estimate Wt if necessary). Aim for:
  - ↓BG (by 3 mmol/l/h), ↓ketogenesis (↓blood ketones 0.5 mmol/l/h; if no ketone measurement: ↑bicarbonate 3 mmol/l/h), ↓K+ (keep between 4 and 5 mmol/l).
  - If delay in ivi availability, give 0.1 units/kg im stat (↓dose if BG <20 mmol/l).
  - If patient takes long-acting insulin sc (Lantus or Levemir) continue this at usual dose/time.
  - If blood ketones not ↓ing to target, ↑insulin ivi rate by 1 unit/h.
  - Once BG <14 add 10% glucose 125 ml/h alongside 0.9% saline. If BG <7 do not stop insulin but ↑rate of glucose ivi.
  - Continue insulin ivi until blood ketones are cleared, pH normal and eating/drinking; then switch to sc regimen (see p. 205).

- **Heparin**: give LMWH until mobile (follow local guidelines – essential with HHS. See below).

**Consider also**

- **Antibiotics**: search for and treat infection, but note vomiting and acidosis will ↑WCC in absence of infection.
- **Pregnancy test**: for presentation of gestational diabetes.
- **HDU/ITU**: for one-to-one nursing ± ventilation (if coma–think cerebral oedema esp child/or for pulmonary oedema–rare).
- **Diabetes specialist team**: involve ASAP.
- **Bicarbonate**: very rarely needed and potentially dangerous. Get senior help if concerned about pH <7.
- **Complications**: Watch for e’lyte Δs (esp ↓K+, ↓Na+, ↓Mg2+, ↓PO4), TE (esp DVT/PE), cerebral oedema (↓GCS, papilloedema, false-localising cranial nerve palsies), ARDS, infection (esp aspiration pneumonia if ↓GCS).
HHS (HONK)

Hyperosmolar, hyperlycaemic state (HHS) – was formerly known as HONK. Usually seen in older age group than DKA, and is managed similarly but with lower rate of insulin ivi + a slower rate of rehydration.

Practice points
- Key features are severe hyperglycaemia and hyperosmolality (usually >340 mOsmol/l; calculate using \(2(K^+ + Na^+) + \text{urea} + \text{BG}\), all in mmol/l).
- Generally \(\uparrow\) age of patient and \(\uparrow\) length of Hx of decline/insidious onset (NB: may be 1st presentation and no past Hx).
- Or may be precipitated by intercurrent illness or drugs (e.g. steroids, thiazides).

Clues: as for DKA, but no ketones, normal pH, \(\uparrow\) glucose, \(\uparrow\) dehydration and \(\uparrow\) confusion.

Management
- **Initial measures**: as for DKA; see above.
- **iv fluids**: as for DKA, but correct dehydration *more slowly* over 2–3 days, as will have occurred more gradually, and also \(\downarrow\)s risk of e’lyte abnormalities.
  - A rough guide is 1 litre of 0.9% saline over 1 h, then 1 litre over 2 h, then 1 litre over 4 h, then over 6–8 hrs.
  - Less KCl will be needed, as less insulin will be used.
  - Can remain in circulatory collapse despite clinically adequate fluid replacement; if so, give 500 ml colloid and monitor CVP.
  - Consider 0.45% saline if \(Na^+ >155\) mmol/l but get senior (ideally specialist) help first as rapid \(\downarrow\)osmolality can \(\Rightarrow\) cerebral oedema
- **Insulin**: commence insulin ivi but start at lower dose than DKA, e.g. 2 or 3 units/h.
  - Aim to \(\downarrow\text{BG}\) by 3–6 mmol/l/h and continue ivi for \(>24\) h (adding glucose if necessary to keep BG normal).
— Seek early senior help and follow local protocols. Sliding scale insulin may be required. Discuss with diabetes team, including need for subsequent sc insulin.

• **Heparin:** usually LMWH (see p. 209). Always give, as ↑↑osmolality ⇒ ↑risk of TE (and consider TEDS).

**Consider also**

• **Antibiotics:** search for and treat infection, as above.

• **Complications:** watch esp for TE (CVA, IHD), AKI, cerebral oedema.

### ADDISONIAN CRISIS

**Clues:** ↓BP, ↑HR, ↓glucose, ↓Na+/↑K+, ↑urea/↑ CA²⁺, Hx of chronic high-dose steroid Rx with missed doses or intercurrent illness*.

• **O₂** if hypoxic.

• **Fluids iv:** 0.9% saline ± central line if ↓↓BP.

• **Glucose iv:** if hypoglycaemic; see p. 251.

• **Steroids:** usually hydrocortisone 100 mg iv stat then qds (ensure to take a blood sample for cortisol and ACTH before first dose if Dx is not certain).
  — Otherwise give 1st dose as dexamethasone 8 mg iv if a Synacthen test is planned (hydrocortisone will affect test result).
  — Consider fludrocortisone once stable and on the medical ward.

• **Antibiotics:** look for and treat infection*: dipstick urine, MSU, CXR and blood cultures. If in doubt, start empiric Rx.

NB: Other pituitary hormones will need to be checked in case of other pituitary dysfunction.
MYXOEDEMA COMA/CRISIS

Clues: ‘myxoedema facies’ (periorbital puffiness/scanty eyebrows/facial pallor/large tongue/lemon-yellow skin tint–carotenaemia), goitre, thyroidectomy scar, ↓temperature, ↓HR, ↓reflexes, ↓glucose, slow mentation, delirium/seizures, coma. NB: Ψ features common.

- **O₂**: if hypoxic; protect airway.
- **Monitor**: pulse, BP to watch for ↓HR, ↓BP, HF.
- **Glucose iv**: if hypoglycaemic (often coexists); see p. 251.
- **0.9% saline ivi**: slowly as per individual needs (care if HF).
- **Liothyronine** (T₃ / tri-iodothyronine): 5–20 microgram ivi bd for >2 days, then gradually ↑dose with endocrinologist’s advice before converting to thyroxine po.
  - Liothyronine can precipitate angina; ↓rate ivi if occurs.
  - Thyroxine can be given 1st line instead
- **Hydrocortisone**: 100 mg iv tds, until hypopituitarism excluded (↑likelihood when no goitre or past Hx of Rx for ↑T₄).

Consider also

- **Rewarming measures**: e.g. Bair-Hugger (forced-air warming blanket), warm iv fluids / warmed humidified O₂.
- **Antibiotics**: infections are common and may have precipitated decline, so have low threshold for empirical Rx.
- **ITU/Ventilation**: condition has high mortality (25–50%).

THYROTOXIC CRISIS/THYROID STORM

Clues: ↑HR/AF, tremor, agitation, fever, abdominal pain, D&V, confusion, coma. Look for Graves’ eye disease, goitre, Hx of ↓compliance with antithyroid Rx. May be precipitated in a thyrotoxic patient by intercurrent illness/trauma/surgery.

- **O₂**: if hypoxic.
- **0.9% saline ivi**: slowly as per individual needs (care if HF).
• **Hydrocortisone**: 100 mg qds iv (or dexamethasone 4 mg qds po). $\downarrow$s T$_4$ $\Rightarrow$ T$_3$ conversion.

• **Propranolol 40 mg tds po**: aim for HR <100 and titrate up dose as necessary. If $\uparrow\uparrow$HR, give propranolol iv 1 mg over 1 min, repeating if necessary every 2 min to max total of 10 mg. When $\beta$-blocker Cl, give diltiazem 60–120 mg qds po.

• **Carbimazole**: 15–30 mg qds po (↓later on ward under specialist advice).

• **Lugol’s solution (iodine)**: 0.1–0.3 ml tds po (normally for 1 wk). Start 4 h after carbimazole. Blocks T$_4$ release from gland.

**Consider also**

• **Treat heart failure** (common if fast AF), e.g. furosemide.

• **Digoxin /LMWH** (if AF): DC shock rarely works until euthyroid.

• **Antibiotics**: if evidence/suspicion of infection.

• **Cooling measures**: paracetamol, sponging. NB: avoid aspirin as may displace thyroxine from TBG.

If vomiting, insert NGT for drug administration and to avoid aspiration.

**MENINGITIS**

**TREATMENT**

**Empirical**: (until results of LP known – esp Gram stain).

• **Cefotaxime** 2 g qds iv: Rx of choice for *N. meningitidis* (meningococcus; commonest cause in UK adults).
  - If Hx of severe hypersensitivity (e.g. anaphylaxis) to cephalosporins (or penicillin, as up to 10% also sensitive to cephalosporins) consider chloramphenicol 1 g tds/qds iv (can $\uparrow$ to 100 mg/kg/day$^{SPC/BNF}$).
  - If allergy (but not anaphylaxis) use meropenem 2 g tds iv.
Consider also
• *Ampicillin* 2 g 4-hrly ivi + gentamicin iv if *Listeria* suspected, e.g. immunosuppression/elderly or indicative CSF with Gram-positive rods.
• *Aciclovir* 10 mg/kg over 1 h tds ivi if HSV encephalitis suspected, e.g. more prominent confusion, behavioural Δs and seizures.
• *TB Rx* (as for pneumonia): if risk factors (HIV/immunocompromise, born or lived in high prevalence country, recent pulm TB contact); or suggestive CSF findings (↑ LØ, ↑ protein, ↓ glucose).
  — NB: negative CSF stains for acid-fast bacilli do NOT exclude the diagnosis of TB; if clinical suspicion is high, do not delay Rx while awaiting microbiological confirmation. Discuss with Infectious Diseases/Microbiology early.

**Causes of meningitis in the UK**

Common:
• *N. meningitidis*, serotype B: majority (70–80%) of cases.
• *N. meningitidis*, serotype C: ↓ ing secondary to vaccine.
• *N. meningitidis*, serotype A: ↓ ing again (had been ↓ ing).
• *S. pneumoniae*: stable incidence.

Rarer:
• *Listeria monocytogenes*: esp age >60 yr, ↓ immunity, neonates.
• *H. influenzae*, type b: ↓ ing secondary to Hib vaccine.
• Gram-negative bacilli (esp in neonates).

Don’t forget:
• **Viral**: HSV/HZV, EBV, HIV, mumps: esp if encephalitic (↓ GCS). Less commonly entero/echo/Coxsackie/polio viruses.
• **TB**, other bacteria, e.g. *Borrelia*: esp if ↓ immunity/HIV.
• **Fungi**: *Cryptococcus, Candida*: esp if ↓ immunity/HIV.
• **Group B Streptococcus**: predominantly in neonates.
• **S. aureus**: if neurosurgery, trauma or ventricular shunt.
SEIZURES

Practice points

- **Status epilepticus** = grand mal seizure lasting >30 min or multiple seizures lasting >30 min without full recovery between episodes. However, >5 min is suggested as a more practical definition to initiate treatment.
  - Mortality: 4% if last < 30 min; 35% if seizures last > 1 hr.
- **Non-convulsive status epilepticus**: consists of two categories (with vastly different aetiology according to age, and prognosis):
  - Absence seizures (petit mal): brief, sudden lapses of consciousness—‘staring’, that can become multiple and lead to lethargy and confusion. Are easily missed.
  - Complex partial status: prolonged or repetitive complex partial seizures (with a presumed focal onset, often temporal) that produce an ‘epileptic twilight state’, with fluctuating lack of responsiveness, automatisms, and confusion.
  - NB: complex partial status may also occur in post-ictal phase of multiple grand mal seizures, causing a prolonged confusional state.
  - Differentiate this from subtle status epilepticus, that occurs in the late stages of multiple grand mal seizures, as they ‘burn out’ and diminish (but continue).

Treatment:

- **Monitor**: attach O\textsubscript{2} sats, ECG and BP monitors and place in recovery position.
- **O\textsubscript{2}**: give high-flow O\textsubscript{2} via Hudson mask.
- **Exclude/treat**: reversible causes esp ↓glucose (give thiamine if treating ↓glucose in alcoholic or malnourished patient), ↓O\textsubscript{2}.
- **Terminate seizure**: lorazepam 4 mg iv over 2 min (terminates 60–90% of status epilepticus). If not available use diazepam 10 mg iv over 2 min. If no iv access consider midazolam 5–10 mg im, or buccal.
- **0.9% saline ivi**: maintain or ↑mean arterial BP to provide appropriate cerebral perfusion pressure.
• **Protect airway**: with tracheal intubation if seizures continue: call anaesthetist early if concerned.

### Seizures continue

- Get senior help
- Repeat lorazepam 4 mg iv over 2 min (or alternatives as above). If no response after 5 min, call anaesthetist and give:
- Phenytoin iv to total dose 18 mg/kg in normal saline (not compatible with glucose) at 25–50 mg/min then adjust (see p. 132).
  - Fosphenytoin iv is an alternative: see p. 77 for dose, as is different to phenytoin.
  - Monitor BP and HR (both can drop) and ECG (esp QRS, as arrhythmias may occur). Phenytoin will abort 60% of status epilepticus not terminated by lorazepam.
  - Make sure have looked for underlying cause such as head injury or ICH (need CT brain); infection (esp meningitis); alcohol toxicity or withdrawal; other drug poisoning (theophylline, isoniazid). Remember eclampsia.
- If seizures persist, consider phenobarbital iv 15 mg/kg at 100 mg/min. Can consider giving phenobarbital before phenytoin iv, if already taking phenytoin po (and plasma levels assumed adequate).
- Seizures still continue = refractory status epilepticus. Requires general anaesthesia with thiopental, or propofol (unlicensed indication) in ICU ideally with EEG monitoring.

### TIA AND STROKE

See algorithms for TIA and for stroke on inside back cover.

### Practice points

- TIA with stroke symptoms and signs (numbness, weakness or paralysis, slurred speech, blurred vision, confusion) that resolve within 24 hours (usually within 10 min) has forward risk of stroke of 3.9% at 2 days, 5.5% at 7 days and 9.2% at 90 days.
• Risk stratify using ABCD² score (see TIA algorithm inside back cover): admit those with score > 4 points.
  – Arrange specialist investigation within one week for those with score ≤4 points and start aspirin po.

STROKE: 80–85% infarction (thrombotic or embolic). May be eligible for time-critical thrombolysis (see below).
  – Rest 15–20% are haemorrhagic (inc SAH), with overall > 50% one month mortality. Treatment is supportive.

Management
• Determine exact time of onset of 1st symptoms. If not clear, the last time patient was known to be normal should be used.
• Ensure glucose normal (e.g. check CBG).
• Perform CT brain imaging immediately if any of the following apply:\textsuperscript{NICE}:
  – Indications for thrombolysis (see below) or early anticoagulation treatment.
  – Known bleeding tendency.
  – GCS (<13).
  – Unexplained progressive or fluctuating symptoms.
  – Papilloedema, neck stiffness or fever.
  – Severe headache at onset of stroke symptoms.
• Consider thrombolysis for an acute ischaemic stroke: Must be a senior doctor decision with experience in its use, ideally within a specialist stroke centre.
  – Currently only alteplase is licensed for this indication and only if given ≤3 h from symptom onset (although ECASS-III trial shows evidence of benefit ≤4.5 h).
  – Act quickly: 5% ↓ in efficacy per 5 min delay. Aim for ‘door to needle’ time of 30 min.
  – Indications and contraindications vary according to centre (see below). Research into risk/benefit is ongoing; always ensure you check your local protocol.
Consent (where possible) using latest evidence: e.g. 1:8 chance of improvement and 1:30 chance of symptomatic bleed.

- Give alteplase iv: total dose = 0.9 mg/kg (maximum 90 mg).
  - 10% given as iv bolus over 2 min, remaining 90% given over 60 min via iv pump. Dissolve in water for injection to a concentration of 1 mg/ml or 2 mg/ml.

### Indications stroke lysis

<table>
<thead>
<tr>
<th>Indications stroke lysis</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical signs of acute stroke</td>
<td>Rapidly improving or minor symptoms</td>
</tr>
<tr>
<td>Clear time of onset</td>
<td>Stroke or serious head injury in last 3 months</td>
</tr>
<tr>
<td>Treatment within 4.5 h of onset</td>
<td>Past history of intracranial haemorrhage</td>
</tr>
<tr>
<td>Haemorrhage excluded on brain imaging</td>
<td>Recent major surgery, GI bleed, etc. BP &gt; 185/110mmHg&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Age 18–80 yrs&lt;sup&gt;b&lt;/sup&gt;</td>
<td>INR &gt; 1.6 or other clotting disorder</td>
</tr>
<tr>
<td>Some centres use NIHSS to define suitable severity (e.g. score of 5–25, but can vary)</td>
<td>Infarction of &gt;1/3 MCA territory seen on CT</td>
</tr>
<tr>
<td></td>
<td>Seizure at onset</td>
</tr>
</tbody>
</table>

<sup>a</sup> If ↑BP is a contraindication can ↓BP with labetalol or GTN; get senior advice.

<sup>b</sup> Often given to older patients. MCA = middle cerebral artery

### Post-thrombolysis management

- Observations: every 15 min for 2 h, every 30 min for 6 h, then hrly
- Treat ↓O₂/↓glucose if present
- Treat hyperglycaemia BG if >8 mmol/l
- Bed rest for 24 h (flat bed recommended initially)
- No antiplatelet therapy for 24 h. Avoid cannulas, NGTs and ivis
- If BP >180/105 mmHg, consider labetalol 10 mg iv over 1–2 min, then infusion at 2–8 mg/min. Get senior advice.
- If intracranial haemorrhage occurs (CT diagnosis), arrange 5–10 units cryoprecipitate (± platelets ± FFP) and seek neurosurgical opinion.
SEVERE SEPSIS OR SEPTIC SHOCK

Practice points
• **Severe sepsis** = known or suspected infection plus either organ dysfunction, or with features of hypotension or hypoperfusion (e.g. confusion/oliguria/raised lactate).
• **Septic shock** = a subset of severe sepsis with sepsis-induced hypotension (SBP < 90 mmHg), or hypoperfusion abnormality such as lactate ≥ 4 mmol/L persisting despite adequate fluid resuscitation (20–30 mL/kg)

**Clues:** evidence of infection + ↓BP (MAP <65 mmHg); serum lactate >4 mmol/l; or ↓urine output.

Management
• Get senior help urgently!
• **Oxygen:** 100% via non-rebreather mask (caution if COPD).
• **Fluids:** 1 litre of crystalloid or 300–500ml of colloid (albumin) bolus over 30 min; if still ↓BP measure CVP and consider further iv fluids (20 ml/kg) to achieve CVP >8 mmHg and urine output >0.5 ml/kg/h (caution if LVF).
• **Inotropes:** if systolic BP <90 mmHg after fluid resuscitation start noradrenaline (1–10 microgram/min) to maintain MAP >65 mmHg.
  – Measure mixed venous O₂ saturation and if <65–70% need further fluid/packed RBCs to achieve haematocrit >30% (check your local recommended ‘sepsis bundle’ management).
• **Antibiotics:** Give empiric targeted antibiotics ASAP (w/in 1 h), ensuring all cultures taken 1st (unless significantly delays antibiotics). Note mortality ↑7% per hr delay.
• **Steroids:** consider iv hydrocortisone (200–300 mg/day) when ↓BP responds poorly to adequate fluid resuscitation and vasopressors, especially if begun within 8 hours shock onset.
• **Blood glucose:** aim for <8.3 mmol/l using insulin sliding scale, but avoid hypoglycaemia.
- Deep vein thrombosis prophylaxis: low-dose LMWH (e.g. enoxaparin 40 mg sc od) unless CI.
- Stress ulcer prophylaxis: PPI or H₂ antagonist.
- Blood products: the aim is now for a lower target such as transfuse to Hb 7–9 g/dl, compared to previously i.e. Hb >10 g/dl.
- Activated protein C: No longer recommended and may increase risk of bleeding.


FEBRILE NEUTROPENIA

Clues: If temperature 38°C for ≥2 h (or ≥38.5°C for ≥1 h) and no clues as to the fever’s aetiology, give:

- 1st/2nd episodes: gentamicin 5 mg/kg od iv + Tazocin 4.5 g tds iv (use ceftazidime 2 g tds iv if penicillin allergy).
- Persistent or recurrent fever at any later stage: call haematologist/oncologist ± microbiologist on call for advice.

NB: Always do full septic screen before giving antibiotics inc blood, urine and any other appropriate cultures (e.g. sputum, stool, central/other lines) ± CXR, providing this does not delay them.

URINARY TRACT INFECTIONS

Management

- Dipstick urine and obtain microscopy to confirm presence of infection. Request urine culture on clean-catch MSU.
- **Simple UTI**: trimethoprim 200 mg bd po. Another option is nitrofurantoin 50–100 mg qds po (not suitable if RF).
- **Pyelonephritis**: cefotaxime 1 g tds iv. If no response within 24 h (and still no culture results), try co-amoxiclav 1.2 g tds iv + gentamicin.

Causes of UTIs

- Most are caused by *E. coli* (70–80%).
- Remainder caused by Enterococci, or other Gram-negatives – e.g. *Proteus* (assoc. with stones), *Klebsiella, Serratia* or *Pseudomonas*.
- *Staph saprophyticus* seen in young women.
- Multi-resistant organisms more likely in catheterised or hospitalised patients.

GI INFECTIONS

Gastroenteritis

- **Simple infections**: Many causes inc traveller’s diarrhoea (enterotoxigenic *E. coli*), toxin related (*Staphylococcus/ Bacillus cereus*), viral (rota/Norwalk-like), *Salmonella/Shigella, Campylobacter, Giardia*. These rarely need Rx; take a travel history, focus on rehydration, and contact microbiology department if in doubt.
- **AAC (Clostridium difficile)**: Ask about any antibiotic use in previous 8 weeks, and send stool for *C. difficile* toxin. Give metronidazole 400 mg tds po and stop other antibiotics if possible. If no response after 4 days, change to vancomycin 125 mg qds po for 10–14 days.
TB PNEUMONIA

This may well be suspected in the ED, but it is rare to ever commence therapy. Should normally be managed by a respiratory or infectious disease physician with expertise in this area.

NB: isolate a potentially infectious patient, and send multiple sputum samples for Ziehl–Neelsen staining / PCR, followed by culture.

NB: notify proven case to public health authorities (usually once on the medical ward).

Treatment

- **Initial phase**: 1st 2 months: ↓s bacterial load and covers all strains: Rifater* (Rifampicin + Isoniazid + Pyrazinamide) + Ethambutol** = ‘RIPE’.
- **Continuation phase**: next 4 months (or longer if CNS involvement): Rifinah* (rifampicin + isoniazid) = ‘RI’. If resistance to rifampicin/isoniazid known (or suspected), continue pyrazinamide = ‘RIP’.
  - Consider pyridoxine 10 mg od po: ↓s isoniazid neuropathy BNF.
  - Combined tablets* ⇒ ↑compliance and ease of prescribing.
  - Doses are by weight; see BNF for details.
  - All drugs are hepatotoxic: check LFTs before and during Rx.
- **Ethambutol**: is nephrotoxic and can ⇒ optic neuritis: check U&Es and visual acuity before and during Rx. Alternative is streptomycin (also nephrotoxic), or both can be omitted if ↓risk of isoniazid resistance.
- **Corticosteroids**: usually added to this regimen from the start, if meningeal or pericardial TB.

MALARIA

Practice points

- *Falciparum malaria ‘malignant tertian’*: severe cases present with altered conscious level ± convulsions (‘cerebral malaria’),
jaundice, oliguria or haemoglobinuria (‘blackwater fever’),
anaemia (Hb < 5 g/dl), hypoglycaemia, metabolic acidosis (HCO₃
<15 mmol/l), ↓BP or resp distress; or have > 5–10% red cells
parasitized. Admit to ITU.

• Consider in any returning traveller with fever, rigors, headache,
N&V, diarrhoea ± hepatosplenomegaly. Always consult
infectious diseases ± microbiology team if malaria suspected/
confirmed.

**Clues:** travel (even >1 year previously—not with falciparum) + fevers
(±3-day cycles ± rigors), jaundice, ↑spleen/liver, ↓Pt, ↓Hb.

**Treatment**

**Confirmed non-falciparum (‘benign’)**

- **Chloroquine** (as base; see below) dose 620 mg po, then 310 mg
6–8 h later, then 310 mg od 24 h later for 2 days (all doses of
chloroquine as base).

- **Primaquine:** follow, unless pregnant, with 14 days primaquine if
*P. ovale* (15 mg od) or *P. vivax* (30 mg od) to kill parasites in the
liver and prevent relapses (‘radical cure’).

**Falciparum (‘malignant’); or species mixed/unknown.**

**Seriously ill:**

- **Quinine** (as salt; see below): load with 20 mg/kg ivi (max 1.4
g) over 4 h (NB: omit loading dose if quinine, quinidine or
mefloquine given in past 12 h.) Then, 8 h after the start of the
loading dose, give 10 mg/kg (max 700 mg) ivi over 4 h every 8
h for up to 7 days (↓doses to 5–7 mg/kg if RF or >48 h if iv Rx
needed), changing to oral quinine (600 mg tds of salt) once able
to swallow and retain tablets to complete a 7-day course.
— Always consult infectious diseases ± microbiology team.

- **Doxycycline** 200 mg od po (clindamycin 450 mg tds po if
pregnant) with or following quinine course for 7 days.

- **Artesunate or artemether:** consider if patient has been to quinine-
resistant areas of SE Asia: get specialist advice.
Stable, normal GCS, able to swallow and retain tablets:
• **Quinine**: 600 mg tds po for 7 days followed by *doxycycline* or *clindamycin*.
• **Proguanil + atovaquone (Malarone), artemether + lumefantrine (Riamet)** are alternatives (Rx for 3 days only) to quinine, which only need to be taken for 3 days and do not need any subsequent drugs.

Quinine doses here are as ‘salt’ (quinine hydrochloride, dihydrochloride or sulphate). Choloroquine doses are as ‘base’ (i.e. the chloroquine component of the total drug compound). Specify salt or base on the prescription–don’t confuse salt or base doses as they are not equivalent.

**ELECTROLYTE DISTURBANCES**

**HYPERKALAEMIA (↑K⁺)**

**Practice points**
• **Haemolysis**: if this is possible (poor venesection technique – usually ‘difficult vein’), ring lab ± repeat the sample.
• **K⁺ >6 mmol/l considered dangerous, with risk of cardiac arrhythmia ± arrest.**
• **K⁺ >6.5 mmol/l or ECG Δs (tall ‘tented’ T waves, QRS >0.12 sec (>3 small squares), loss of P waves or sinusoidal pattern) needs immediate treatment plus cardiac monitoring:**

**Treatment**
• **10% Ca²⁺ gluconate**: 10–20 ml iv over 3 min as ‘cardioprotection’; or 10 ml of 10% CaCl iv at ≤1ml/min. NB: does not alter serum K⁺ level.
• **Insulin**: (soluble e.g. Actrapid) 10 units iv + 50 ml 50% glucose ivi over 5–15 min. Stimulates cellular uptake of K⁺: aim for drop of 1–2 mmol/l over 30–60 min.
• **Salbutamol**: 5–20 mg nebs. Utilises K⁺-lowering fx (unlicensed indication).
- **8.4% Sodium bicarbonate**: 25–50 ml only if acidotic and not volume overloaded (beware dialysis pt).

**Consider also**
- *Look for and treat cause*: esp AKI (may need urgent dialysis) and drugs; e.g. iv KCl, oral K+ supplements, ACE-i, ARBs, K+-sparing diuretics, NSAIDs. Also ciclosporin (do not adjust without specialist advice).

NB: Contrary to popular opinion, *Calcium Resonium* is not useful in the ED.

**HYPOKALAEMIA (↓K+)**
K+ <2.5 mmol/l ⇒ risk of arrhythmias: attach cardiac monitor.

**Treatment**
- *Normal saline (0.9%) 1 litre + 40 mmol KCl*: over 4 h via infusion device.
  - If unstable or arrhythmias develop, seek senior help as KCl can be given quicker. Consider possibility of assoc Mg2+ deficiency and replace Mg2+ as well.
  - Patient may not tolerate faster peripheral ivi due to pain (consider central line).
- *Oral K+ replacement*: should also be commenced (e.g. Sando-K, Slow-K 2 tablets tds, or as much as can be tolerated – unpleasant taste!).
  - Oral therapy is often sufficient if K+ >2.5 mmol/l and no clinical features (fatigue, weakness, leg cramps) or ECG Δs (small T waves or large U waves).

**HYPERCALCAEMIA (↑Ca2+)**
Ca2+ >2.65 mmol/l is abnormal. Symptoms usually start once Ca2+ >2.9 mmol/l.

*Clues*: ‘stones, bones, groans and psychic moans’! Coming from renal colic ± AKI; bone pain (consider metastases); abdominal pain, constipation ± vomiting, polyuria and thirst; confusion, psychosis.
**Treatment**

- $\text{Ca}^{2+} > 3.5 \text{ mmol/l}$ or severe symptoms:
- *Normal saline (0.9%) ivi*: average requirements 4–6 litres over 24 h (↓ if elderly/HF). Monitor fluid balance carefully and correct electrolytes.

**No improvement in $\text{Ca}^{2+}$ levels yet rehydrated**

- *Loop diuretic*: (e.g. furosemide). *Never* use a thiazide (worsens $\text{Ca}^{2+}$).
- *Bisphosphonate*: (e.g. pamidronate) esp if ↑PTH or malignancy.
- *Calcitonin*: if no response to bisphosphonate.
- *Steroids*: if sarcoid, lymphoma, myeloma or vitamin D toxicity.
- *Dialysis*: if AKI or life-threatening symptoms (coma).

**ALCOHOL WITHDRAWAL**

**Practice point**

Patients dependent on alcohol are common in the ED. Use a simple screening questionnaire CAGE to help identify those at risk (see Table 4.2).

**Table 4.2 CAGE screening questionnaire for alcohol abuse.**

<table>
<thead>
<tr>
<th>C</th>
<th>Have you ever felt you should Cut down on your drinking?</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Have people Annoyed you by criticising your drinking?</td>
</tr>
<tr>
<td>G</td>
<td>Have you ever felt bad or Guilty about your drinking?</td>
</tr>
<tr>
<td>E</td>
<td>Have you ever had a drink as an Eye-opener first thing in the morning to steady your nerves or help get rid of a hangover?</td>
</tr>
</tbody>
</table>

‘Yes’ to two or more indicates probable chronic alcohol abuse or dependence

**PREVENTION OF AGITATION, SEIZURES AND DELIRIUM TREMENS**

Start a long-acting benzodiazepine in a tapered regimen as follows (will need medical admission):
Alcohol withdrawal regimen. Courtesy of Professor H. Ghodse, St George’s Hospital.

<table>
<thead>
<tr>
<th>Day</th>
<th>Chlordiazepoxide</th>
<th>OR</th>
<th>Diazepam</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30 mg qds</td>
<td></td>
<td>15 mg qds</td>
</tr>
<tr>
<td>2</td>
<td>30 mg tds</td>
<td></td>
<td>10 mg qds</td>
</tr>
<tr>
<td>3</td>
<td>20 mg tds</td>
<td></td>
<td>10 mg tds</td>
</tr>
<tr>
<td>4</td>
<td>20 mg bd</td>
<td></td>
<td>5 mg tds</td>
</tr>
<tr>
<td>5</td>
<td>10 mg bd</td>
<td></td>
<td>5 mg tds</td>
</tr>
<tr>
<td>6</td>
<td>10 mg od</td>
<td></td>
<td>5 mg bd</td>
</tr>
<tr>
<td>7</td>
<td>10 mg prn</td>
<td></td>
<td>5 mg od</td>
</tr>
</tbody>
</table>

This is only a suggested initial average regimen

Ideal regimens involve an initial 24-h assessment of prn doses, but require adequate training and staff time to monitor closely and ensure no under- (or over-) treatment occurs. Start with dose of 20–40 mg chlordiazepoxide or 10–20 mg diazepam and add up doses used in 1st 24 h, then reduce by 1/5th (–1/7th) per day for 5(–7) days.

- Chlordiazepoxide usually 1st line, but diazepam preferred if Hx of seizures (esp if occurred in context of alcohol withdrawal).
- Significant liver failure (e.g. ↑AST or ALT): consider shorter-acting benzodiazepines such as oxazepam or lorazepam at equivalent doses; avoids xs metabolite build up and sedation (but marginal ↑seizure risk).
- Only start once acute alcohol intoxication has resolved.

THIAMINE (VIT B₁) AND OTHER SUPPLEMENTS

Give thiamine (vit B₁) for Px or Rx of suspected Wernicke’s encephalopathy (WE) with one or more of: ophthalmoplegia, ataxia, acute confusion, memory disturbance, unexplained hypotension, hypothermia or coma.
Thiamine must be given before patient receives any carbohydrate load po or iv (which can precipitate WE).

慎重著：Take particular care if hypoglycaemic and iv glucose needed! 慎重著

- **Parenteral thiamine (iv or im):** e.g. Pabrinex (contains other B and C vits); prescribe as ‘1 pair Pabrinex vials’ or ‘Pabrinex 1 and 2’. British Association for Psychopharmacology substance abuse guidelines 2004/2012 update (Journal of Psychopharmacology 2012) recommends:
  - **WE suspected** (see below) or established: 2 pairs tds iv (or im) for 3–5 days, then 1 pair od for a further 3–5 days.
  - **High risk** of WE (malnourished/chronic severe abuse): 1 pair od iv or im for 3–5 days.
  - **Low risk** of WE: no parenteral treatment needed, but give oral thiamine.

Pabrinex can ⇒ anaphylaxis

慎重著：have resus facilities at hand. NB: ↑risk if given iv too quickly; ensure mixture of both vials either given as injection over ≥10 min or as infusion (with 50–100 ml saline) over ≥30min 慎重著。

- Oral vitamins and supplements:
  - Thiamine 100 mg bd/tds po; should be given for 1 month if no parenteral treatment required.
  - Multivitamins 1 tablet/day long-term; cheap and potentially important if future diet likely to be poor.

**Wernicke’s encephalopathy**

Caused by thiamine deficiency and often missed; only 10% have classical triad of confusion, ataxia and eye signs (ophthalmoplegia or nystagmus; seen in only 30% of cases). Suspect diagnosis if any evidence of chronic alcohol misuse and any one of: acute confusion, ataxia, ophthalmoplegia, ↓BP + ↓temp, ↓GCS or ↓memory.
If unsure whether intoxication or WE is causing any of these, always assume it is WE and give treatment. Rarely WE is caused by other malnutrition, e.g. malabsorption, eating disorders, protracted vomiting, CRF, AIDS and other drug misuse.

\[ \text{NB: Mg}^{2+} \text{ can } \Rightarrow \text{ Rx refractory WE : check } \pm \text{ correct Mg}^{2+} \text{ too.} \]

**MAINTENANCE OF ABSTINENCE**

It is essential to:

- Encourage abstinence and refer to local alcohol liaison practitioner (if available) ± addiction services.
- Arrange adequate social support, and look for and treat assoc depression.
- The following are used as aids:
  - *Acamprosate*: modulates alcohol withdrawal fx & limits −ve reinforcement of drinking cessation ⇒ ↓ cravings and ↓ relapse rate.
  - *Disulfiram*: ⇒ unpleasant symptoms if alcohol consumed.
  - *Naltrexone*: ↓s pleasurable fx of alcohol and ↓s craving and relapse rate. Specialist use only (unlicensed in UK for this indication).

**ACUTE POISONING**

Deliberate self-harm is a common problem seen in the ED. Methods inc cutting or self-mutilation, or more commonly ingestion of drugs (inc over-the-counter/herbal remedies), chemicals (industrial or household), plants and biologicals.

The following sources should always be consulted:

- *TOXBASE* ([www.toxbase.org](http://www.toxbase.org)): authoritative and updated regularly. Should be used in the 1st instance to check clinical features and Mx of the poison(s) in question.
- You need to sign in under your departmental account username and password.

- **UK National Poisons Information Service (NPIS):** if in UK phone 0844 892 0111 (if in Ireland 01 809 2566) for specialist advice if unsure of TOXBASE instructions, and for rarer/complex poisonings.

**GENERAL MEASURES**

- **Activated charcoal:** if w/in 1 h of significant ingestion, but CI if ↓GCS (unless ET tube *in situ*), if bowel sounds absent or if corrosive substance/petroleum ingested.
  - Repeated doses and administration later than 1 h suggested for certain drugs (e.g. quinine, carbamazepine, theophylline, or sustained release preparations).
  - Charcoal *not* effective for lithium, iron, organophosphates, ethylene glycol, ethanol, methanol.
  - See TOXBASE for dosing guide for activated charcoal. NB: ‘routine’ GI decontamination is no longer recommended.

- **Gastric lavage:** Rarely ever used now. Only consider if w/in 1 h of life-threatening ingestion that cannot be removed effectively (e.g. iron). *Must* protect the airway, esp if ↓GCS. CI if corrosive/petroleum distillate ingested.

- Check a paracetamol level in any patient who is unable/unwilling to give an accurate Hx of the exact poisons ingested, and perform an ECG. Send a salicylate level if pt symptomatic ‘salicylism’, or comatose / unexplained metabolic acidosis.

- Other drug levels will depend on suspected ingestion, but note the majority of poisonings are managed supportively, and only a few have a specific antidote.

**SIDE EFFECT PROFILES**

Knowledge of side effect profiles (SEs) together with a drug’s mechanism(s), allow anticipation of that drug’s SEs or toxic effect (toxidrome).
**CHOLINOCEPTORS**

ACh stimulates muscarinic and nicotinic receptors.

**Anticholinesterases** ⇒ ↑ACh and ↓: stimulate both receptor types and have ‘cholinergic fx’.

↓**cholinoreceptor** action drugs do this mostly via muscarinic receptors (antinicotinics used only in anaesthesia) and are ↓: more accurately referred to as ‘antimuscarinics’ rather than ‘anticholinergics’.

<table>
<thead>
<tr>
<th>Cholinergic fx</th>
<th>Antimuscarinic fx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generally ↑secretions</td>
<td>Generally ↓secretions</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Constipation</td>
</tr>
<tr>
<td>Urination</td>
<td>Urinary retention</td>
</tr>
<tr>
<td>Miosis (constriction)</td>
<td>Mydriasis↓accommodation(^a)</td>
</tr>
<tr>
<td>Bronchospasm/bradycardia(^b)</td>
<td>Bronchodilation/tachycardia</td>
</tr>
<tr>
<td>Excitation of CNS (and muscle)</td>
<td>Drowsiness, Dry eyes, Dry skin</td>
</tr>
<tr>
<td>Lacrimation↑</td>
<td></td>
</tr>
<tr>
<td>Saliva/sweat↑</td>
<td></td>
</tr>
</tbody>
</table>

**Commonly caused by:**

- **Anticholinesterases:** Atropine, ipratropium (Atrovent)
- MG Rx, e.g. pyridostigmine
- Dementia Rx, e.g. rivastigmine, donepezil
- Antihistamines (inc cyclizine)
- Antidepressants (esp TCAs)
- Antipsychotics (esp ‘typicals’)
- Hyoscine, la antiarrhythmics

\(^a\)↑blurred vision and ↑IOP. \(^b\)Together with vasodilation ⇒ ↓BP.

**ADRENOCEPTORS**

α generally excites sympathetic system (except\(^*\)):

- α1 ⇒ GI smooth-muscle relaxation\(^*\), otherwise contracts smooth muscle: vasoconstriction, GI/bladder sphincter constriction (uterus, seminal tract, iris (radial muscle)). Also ↑salivary secretion, ↓glycogenolysis (in liver).
• $\alpha_2 \Rightarrow$ inhibition of neurotransmitters (esp NA and ACh for feedback control), Pt aggregation, contraction of vascular smooth muscle, inhibition of insulin release. Also prominent adrenoceptor of CNS (inhibits sympathetic outflow).

$\beta$ generally inhibits sympathetic system (except*):

• $\beta_1 \Rightarrow \uparrow HR^*, \uparrow$ contractility* (and $\uparrow$s salivary amylase secretion).
• $\beta_2 \Rightarrow$ vasodilation, bronchodilation, muscle tremor, glycogenolysis (in hepatic and skeletal muscle). Inhibits further mediator release from mast cells via $\uparrow$intracellular cAMP (important in anaphylaxis). Also $\uparrow$s renin secretion, relaxes ciliary muscle and visceral smooth muscles (GI sphincter, bladder detrusor, uterus if not pregnant).
• $\beta_3 \Rightarrow$ lipolysis, thermogenesis (of little pharmacological relevance).

SEROTONIN (5HT)

'Serotonin syndrome' $\Rightarrow$ relative excess: occurs with antidepressants at $\uparrow$ doses, or if swapped without an adequate ‘tapering’ or ‘washout period’. Causes restlessness, sweating and tremor, progressing to shivering, myoclonus and confusion, and, if severe enough, convulsions/death.

‘Antidepressant withdrawal/discontinuation syndrome’ $\Rightarrow$ relative deficit: occurs when antidepressants stopped too quickly; likelihood depends on $t_{1/2}$ of drug. Causes ’flu-like symptoms (chills/sweating, myalgia, headache and nausea), and dizziness, tinnitus, anxiety, irritability, insomnia, vivid dreams. Rarely $\Rightarrow$ movement disorders and $\downarrow$ memory/concentration.

DOPAMINE (DA)

Relative excess: causes behaviour Δ, confusion and psychosis (esp if predisposed, e.g. schizophrenia). Seen with L-dopa and DA agonists used in Parkinson’s (and some endocrine disorders, e.g. bromocriptine).

Relative deficit: causes extrapyramidal fx (see below), $\uparrow$ prolactin (sexual dysfunction, female infertility, gynaecomastia), neuroleptic
malignant syndrome. Occurs with DA antagonists, esp antipsychotics and certain antiemetics such as metoclopramide, prochlorperazine and levomepromazine.

**EXTRAPYRAMIDAL EFFECTS**
Abnormalities of movement control arising from dysfunction of basal ganglia.

- *Parkinsonism*: rigidity and bradykinesia ± tremor.
- *Dyskinesias* (= abnormal involuntary movements):
  - *Dystonia* (= abnormal posture): dynamic (e.g. oculogyric crisis) or static (e.g. torticollis).
  - *Tardive (delayed onset) dyskinesia*: esp orofacial movements.
  - *Others*: tremor, chorea, athetosis, hemiballismus, myoclonus, tics.
- *Akathisia* (= intolerable sense of inner restlessness): seen with antipsychotic or neuroleptic drugs, but also with antiemetics (e.g. metoclopramide, prochlorperazine).

All the above are more commonly caused by antipsychotics (esp older ‘typical’ drugs) but are a rare complication of antiemetics (e.g. metoclopramide, prochlorperazine – esp in young women). Dyskinesias and dystonias are common with antiparkinsonian drugs (esp peaks of L-dopa doses).

Most respond to stopping (or ↓dose of) the drug – if not possible, fails or immediate Rx needed add an antimuscarinic drug (e.g. procyclidine) – this does not work for akathisia (try β-blocker, or benzodiazepine) + can worsen tardive dyskinesia: seek neurology ± psychiatry opinion if in doubt.

**CEREBELLAR EFFECTS**
Esp antiepileptics (e.g. phenytoin) and alcohol.

- Dysdiadokokinesis, dysmetria (= past-pointing) and rebound
- Ataxia of gait (wide-based, irregular step length) ± trunk
- Nystagmus: towards side of lesion; mostly coarse and horizontal
- Intention tremor (also titubation = nodding-head tremor)
• Speech: scanning dysarthria – slow, slurred or jerky
• Hypotonia (less commonly hyporeflexia or pendular reflexes).

CYTOCHROME P450 (CYP)
Substrates of P450 that often result in significant interactions (these drugs can \( \uparrow \) severe problems if rendered ineffective or toxic by interactions \( \vdash \). always check for interactions when prescribing):

• Inhibitors and inducers can affect warfarin, phenytoin, carbamazepine, ciclosporin and theophyllines. Interactions can \( \vdash \) toxicity or treatment failure.
• Inducers also affect OCP so can \( \uparrow \) failure as contraceptive \( \vdash \). recommend alternate barrier method.

NB
CYP system is complex and mediated by many isoenzymes (> 60 key forms with hundreds of genetic variations); predicting significant interactions requires understanding which drugs are metabolised by which isoenzymes as well as which, and to what degree, other drugs affect these isoenzymes.

Look for P450 symbols in this book as a rough guide; check SPCs if concerned (available online at www.medicines.org.uk/emc/), and for a full overview of the CYP system see www.edhayes.com/startp450.html.

PARACETAMOL
Significant poisoning is >75 mg/kg in any 24 h period (serious toxicity may occur if >150 mg/kg, toxicity uncommon if 75–150 mg/kg).

Initial management
Dependent on time since ingestion.
0–8 h post-ingestion:

• Activated charcoal: if w/in 1 h of significant poisoning.
• Acetylcysteine: wait until 4 h post-ingestion then take urgent sample for paracetamol level (result is meaningless before 4 h post). If presents at 4–8 h post-ingestion, take immediate sample.
Level above the treatment line (see nomogram): use the following acetylcysteine regimen:
- 150 mg/kg in 200 ml 5% glucose ivi over 1 hr.
- 50 mg/kg in 500 ml 5% glucose ivi over 4 h.
- 100 mg/kg in 1000 ml 5% glucose ivi over 16 h.
NB: if patient weighs >110 kg, use 110 kg (rather than their actual weight) for these calculations.

Do not delay acetylcysteine beyond 8 h post-ingestion if waiting for a paracetamol level after a significant ingestion (beyond 8 h, efficacy drops substantially) – ivi can always be stopped if the level comes back below treatment line and timing of ingestion is certain, and INR, ALT and creatinine normal.

8–15 h post-ingestion:
- Acetylcysteine: give above regimen ASAP if significant ingestion. Do not wait for urgent paracetamol level result. Acetylcysteine can be stopped later (see note).

15–24 h post-ingestion:
- Acetylcysteine: give above regimen ASAP unless certain that significant ingestion has not taken place–do not wait for paracetamol level result. Presenting this late ⇒ severe risk, and treatment lines are unreliable: always finish the course of acetylcysteine.
- Be aware that paracetamol level might be over treatment line but reported as undetectable (e.g. a level of 16 mg/L may be reported as <20 mg/L); if in doubt, TREAT.

>24 h post-ingestion:
- Acetylcysteine is controversial when presenting this late. Check creatinine, LFTs, INR, glucose, and paracetamol concentration, and consult TOXBASE or NPIS.
Figure 4.3 Treatment lines for acetylcysteine treatment of paracetamol overdose. (Reproduced courtesy of Medicines and Healthcare products Regulatory Agency (UK).)
Important points regarding acetylcysteine

- Have lower threshold for initiating Rx if doubts over timing of ingestion, if it was staggered, if present 24–36 h post-ingestion, or if evidence of LF/severe toxicity regardless of time since ingestion. Contact NPIS if unsure.

- Anaphylactoid reactions common esp at initial faster rates. Reduce infusion rate or stop temporarily until reaction settles. Give antihistamine (e.g. chlorphenamine 10–20 mg iv over 1 min) if required. Give salbutamol nebs if significant bronchospasm. Once reaction settles restart acetylcysteine, and consider giving the second bag at half normal rate (i.e. 50 mg/kg over 8 h). A past Hx of such a reaction is not an absolute CI to future treatment. Pretreatment with chlorphenamine 10 mg iv or administration of 1st ivi at slower rate may reduce risk of reaction.

- Acetylcysteine ⇒ mildly ↑INR itself; so if after treatment ALT is normal but INR is ≤1.3 no further monitoring or treatment is needed. But if ALT is ↑ continue acetylcysteine ivi at rate of 150 mg/kg given over 24 h (unless substantial pause in ivi further loading dose not needed), and seek immediate TOXBASE/liver unit advice.

Subsequent management

Patients may be medically fit for discharge once acetylcysteine ivi is completed, and INR, ALT, creatinine and HCO₃⁻ (±pH) are normal (or recovering in two successive checks if additional acetylcysteine has been administered).

Psychiatric evaluation must still be undertaken for all patients who have taken tablets deliberately.

A patient with laboratory abnormalities despite acetylcysteine, seek immediate TOXBASE/liver unit advice.
SALICYLATE/ASPIRIN

Much less commonly seen now. A complex poisoning to manage.

Initial management:

- **Activated charcoal** and consider *gastric lavage* (if airway protected): if w/in 1 h of ingestion of >125 mg/kg. As aspirin delays gastric emptying (esp if enteric-coated tablets), both may be considered >1 h after ingestion. Can repeat activated charcoal every 4 h, if salicylate level continues to rise despite measures below. Consult TOXBASE.

- **Measure/monitor** U&Es, glucose, clotting, ABGs (or venous pH and HCO$_3^-$) and fluid balance (often need large volumes of iv fluid). Send a salicylate level if ingested >120 mg/kg; take sample at least 2 h post-ingestion if symptomatic or 4 h post-ingestion if not. Repeat in both cases 2 h later if severe toxicity suspected (hyperthermia, dehydration, agitation, confusion, seizures, ↓GCS, metabolic acidosis) in case absorption was delayed (repeating until levels↓). Note that peak concentrations are often delayed after large ingestions.
  - If significant biochemical abnormalities, get senior help and contact ITU for advice, then consider the following.

- **Sodium bicarbonate ivi**: give 1.5 litres 1.26% over 2 h (or 225 ml of 8.4%) if metabolic acidosis and salicylate levels >500 mg/l (3.6 mmol/l) – will minimise movement of salicylate into tissues, and enhance renal elimination. Beware risk of tissue necrosis if extravasation. Bicarbonate administration may cause hypokalaemia: watch K$^+$ closely, and hypoglycaemia. Monitor arterial blood gases to ensure correction of acid–base disturbance.

- **Haemodialysis**: salicylate levels >700 mg/l (5.1 mmol/l) or unresponsive to the above measures. Also consider if AKI, CCF, non-cardiac pulmonary oedema, severe metabolic acidosis, convulsions or any CNS fx that are not resolved by correction of pH, and in patients aged >70 yrs due to increased risk of toxicity.
OPIATES
Clues: pinpoint pupils, ↓respiratory rate, ↓GCS, drug chart and Hx/signs of opiate abuse (e.g. collapsed vein ‘track marks’).

- O₂ + maintain airway ± ventilatory support.
- Naloxone 0.4–2 mg iv (or im) stat initially, repeating after 2 min if no response (check pupils). Note that large doses (>2 mg) may be required in some patients.
  - Start with a smaller dose naloxone 0.1 mg if chronic user and build up, to avoid precipitating acute withdrawal.

BENZODIAZEPINES

- O₂ + maintain airway with positioning ± ventilatory support.

⚠️ Flumazenil is not to be used as a diagnostic test, and must not be given routinely ⚠️. Risk of inducing seizures (esp if epileptic or habituated to benzodiazepines) and arrhythmias (esp if co-ingested TCA or amphetamine-like drug).
Surgical emergencies

Acute abdomen  286
Orthopaedic infections  287
ENT infections  288
Eye infections  288
ACUTE ABDOMEN

The aims are to resuscitate critically ill patients; differentiate those requiring referral to a surgical, gynaecological, urological or medical team; and to determine who can be allowed home.

MANAGEMENT IF SERIOUSLY ILL

• Resuscitate:
  — Give high-flow O₂.
  — Insert 1 or 2 large bore intravenous cannulae (14-/16-gauge), and take blood for FBC, U&E, BG, LFT, amylase/lipase, lactate + group and save or cross match blood, if haemorrhage suspected (ruptured AAA, ectopic pregnancy–check pregnancy test).
  — Fluid iv: crystalloid/colloid (blood if haemorrhage) to maintain systolic BP >100 mmHg, but avoid over-transfusion in elderly/heart or renal disease + if ongoing bleeding (need operation!). Consider CVP line.

• Investigate:
  — Bloods as above, urinalysis, preg test, ECG (abdo pain in the elderly); CXR (perforation, basal pneumonia).
  — USS to look for ruptured AAA, free fluid from ectopic.
  — CT scan once resuscitated and stabilised.

• Treat:
  — Analgesia: morphine titrated to effect ± antiemetic. Morphine does not mask intra-peritoneal signs, and it is inappropriate and inhumane to withhold it.
  — Antibiotics: cefuroxime 1.5 g iv or gentamicin 5 mg/kg, and metronidazole 500 mg iv for generalized peritonitis.
  — NGT: bowel obstruction, ileus or peritonitis.

• Refer:
  — Involve the surgical team early.
ORTHOPAEDIC INFECTIONS

BONE AND JOINT INFECTIONS

Septic arthritis
Suspect if severe pain, redness and swelling, with decreased movement (active and passive). Perform joint aspiration and refer to orthopaedic team for admission.

- Treat as for osteomyelitis (see below), but consider changing after urgent Gram stain, e.g. to iv 3rd-generation cephalosporin (cefotaxime, ceftriaxone) if *H. influenzae* suspected (Gram-negative bacilli, esp in non-immunised child).
- Suspect Salmonella in sickle cell disease; or TB/fungi if immunocompromised.

Osteomyelitis
Suspect in any deep DM ulcer, or postoperative joint pain/redness. *Staph aureus* is usual cause, but in spinal infection consider also Gram-negatives (discuss with Microbiology).

- **Flucloxacillin** 1–2 g qds iv + **fusidic acid** 500 mg tds po (can give iv in severe cases, but is poorly tolerated and often not required).
- MRSA suspected: consult local guidelines ± microbiologist.
- **Co-amoxiclav** 1.2 g tds iv instead of flucloxacillin, if associated with chronic ulceration.
- **Clindamycin** 600 mg qds iv, if penicillin allergy.

Cellulitis

- **Mild**: co-amoxiclav 625 mg tds po or flucloxacillin 500 mg qds po.
- **Severe** (systemically unwell): benzylpenicillin 1.2 g iv 4–6-hrly + flucloxacillin 1 g qds iv.
  - Add metronidazole 500 mg tds ivi if suspect anaerobes, e.g. abdominal wound (admit surgical).
  - Consider vancomycin 1 g bd ivi if confirmed MRSA colonisation/infection.
ENT INFECTIONS

Acute epiglottitis

- Becoming uncommon since Hib vaccination. Call senior help immediately before doing anything else!
- **Cefotaxime** 1 g tds iv + **metronidazole** 500 mg tds ivi (or Tazocin (piperacillin + tazobactam) 4.5 g tds iv).

Pharyngitis/tonsillitis

- **Penicillin V** (phenoxydimethylpenicillin) 500 mg qds po for ‘Strep’ throat only when recent Hx of otitis media, confirmed group A Strep infection, or 3 of the following 4 clues that infection is bacterial (rather than viral)–tender cervical lymphadenopathy, purulent tonsils, Hx of fever or absence of cough.

Sinusitis/otitis media

- **Amoxicillin** 500 mg tds po if systemically unwell with fever and vomiting, or when does not resolve in 2–3 days (as would be expected if viral). Also regular analgesia such as paracetamol.

Otitis externa

- **Topical steroid + antibiotic combination**: Sofradex or Otomize.
- Less commonly fungal (look for black spores); give topical Otosporin or Neo-cortef.
- If does not resolve or evidence of perichondritis (inflamed pinna), cellulitis, boil/local abscess, refer to ENT for advice and systemic Rx (e.g. amoxicillin, co-amoxiclav, flucloxacillin) with local aural toilet (esp if fungal).

EYE INFECTIONS

Orbital cellulitis

- **Co-amoxiclav** po if preseptal ‘peri orbital’ (lids only, related to local infection) ⇒ can be managed as outpatient with close observation.
• **Ceftriaxone** 2 g iv + **flucloxacillin** 2 g iv if postseptal (true ‘orbital’, usually arising from paranasal sinuses or occ orbital trauma) ⇒ admit.

**Corneal ulcer**

• **Ofloxacin** 0.3% 1 drop hrly (day and night) for 48 h, then hrly daytime. Urgent ophthalmology referral.
  – Suspect in contact lens wearer with painful red eye
  – Give antibiotic drops once scrape taken for Gram stain/culture.
  – Do not allow patient to self-administer topical anaesthetic for analgesia as ⇒ epithelium to slough 🙁.

**Conjunctivitis**

• **Chloramphenicol** 0.5% 1 drop qds. Only if mucopurulent/prolonged.

**Blepharitis**

• Lid margin/eyelash: scrubs/hygiene only.
• If severe or lid hygiene alone insufficient ⇒ Maxitrol ointment (dexamethasone 0.1% & neomycin 0.35%) to eyelashes bd for 1 month + lid hygiene. Hypromellose artificial tears help reduce symptoms.

**Stye (external hordeolum)**

• Regular warm compresses to release cyst (antibiotics usually not required).
• If concern early cellulitis ⇒ co-amoxiclav po may be given.

**Meibomian abscess (internal hordeolum)**

• Infected Meibomian gland within tarsal plate, which does not discharge as readily as an external stye. May leave a residual Meibomian lipogranulomatous cyst (chalazion).
• Give co-amoxiclav po. Warm compresses do not help.
GLASGOW COMA SCALE

A standardised assessment tool to describe the level of consciousness originally introduced in 1974 for head injured patients, now used universally. GCS score 8 or less usually means ‘unconscious’. See Table 6.1

NB: ‘Medical’ causes of a low GCS score may be rapidly reversible such as dt hypoglycaemia, whereas in head trauma the GCS can be used as a guide to severity:

- GCS 13–15 = minor
- GCS 9–12 = moderate
- GCS <9 = severe injury

Table 6.1 The Glasgow Coma Scale (GCS) score

<table>
<thead>
<tr>
<th>Score</th>
<th>Eye opening</th>
<th>Verbal response</th>
<th>Motor response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Spontaneously</td>
<td>Oriented</td>
<td>Obey commands</td>
</tr>
<tr>
<td></td>
<td>To speech</td>
<td>Confused</td>
<td>Localizes pain</td>
</tr>
<tr>
<td></td>
<td>To pain</td>
<td>Inappropriate</td>
<td>Withdraws (pain)</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>Incomprehensible</td>
<td>Flexion (pain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
<td>Extension (pain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

The maximum score is 15. Any reduction in score indicates deterioration in the level of consciousness.
MENTAL STATE EXAMINATION

Abbreviated Mental Test Score (AMTS)
Most basic assessment of cognitive impairment; popular due to its brevity (esp for use in the elderly).

Score: <8/10 is abnormal and suggests delirium / dementia (look for these).

W World War II: what year did it end?¹
H Hospital (what is name of building you are in?).
A Address: 42 West St (ask to remember and repeat at end of test*).
T Time: to the nearest hour.
Y Year.
E Elizabeth II (who is current monarch/prime minister etc ?)¹.
A Age (of patient).
R Recognition of 2 persons: e.g. Dr and other².
B Birthday (patient’s date of birth).
C Count backwards from 20 to 1.
? ? Can you repeat that address?*

¹If culturally inappropriate change to relevant question or omit.
²If alone with patient omit.

When a question is omitted, record why and reduce denominator of score.

Mini Mental State Examination (MMSE)
Best validated 30-point, basic cognitive assessment that includes orientation, attention and calculation, immediate and short-term recall, language and ability to follow simple verbal and written commands.

Score: ≥25 is effectively normal; 21–24 is mild cognitive impairment; and ≤20 indicates moderate to severe cognitive impairment suggesting delirium/dementia (look for these).
(Questions to ask are in bold):

Orientation:
Time – (1–3) Date? 1 point each for day, month and year.
(4) Season? (5) Day of week?
Place – (1) Country? (2) County/state (or large city)?
(3) Town (or city area)? (4) Building? (5) Floor?
Registration: Say ball, flag, tree. Repeat until success or 5 attempts.
Attention/concentration: Spell ‘WORLD’ backwards.
Recall: Can you remember those 3 items? (ball, flag, tree).
3-stage command: Take paper in R hand, fold in half and put on floor.
Language: What is this? Point to pen and then wristwatch.
Repeat exactly after me: ‘No ifs, ands or buts.’
Reading/comprehension: Do what the sentence below instructs.
Praxis: Write a sentence of your choice. Provide dotted line.
Copy this shape as best you can alongside it.

1 Precede with ‘I will mention 3 objects to you. Please repeat them to me once I have finished all 3.’ Allow 1 s between objects. At end say ‘I will ask you to remember these later’ which is tested in Recall in next, but one section – should be done after 1 min.
2 ‘Serial 7s’ can also be used which obviously tests calculation too so remember to take into account premorbid numeracy skills.
3 Write out in large, clear capital letters ‘CLOSE YOUR EYES’.
4 Only correct if makes 4-sided shape formed by 2 intersecting pentagons.

• Allow 1 min for tasks, except 30 s for 3-stage command and writing of sentence.
• Frontal lobe tests are not covered; useful to add these e.g. abstract thinking, verbal fluency etc.

ACID-BASE NOMOGRAM
Plot the arterial blood gas results on the acid-base nomogram (Flenley) below and read off the interpretation. See Figure 6.1.
Alternatively, to determine the likely acid-base disorder from the pH, PaCO₂ and HCO₃⁻ see Table 6.2.

**USEFUL FORMULAE**

A-a gradient = P_AO₂ - P_aO₂, where P_AO₂ = (F_iO₂ × (760 - 47)) - (P_aCO₂ / 0.8).
Normal is <10 torr (mmHg), or roughly < (Age/4) + 4 in yrs.

Serum osmolality = 1.86 (K⁺ + Na⁺)+urea+glucose
NB: all units are in mmol/l and this calculation is an estimate (actual osmolality usually differs by ±13 mosm/kg).
Table 6.2 Determining the likely acid-base disorder from the pH, PaCO₂ and HCO₃

<table>
<thead>
<tr>
<th>pH</th>
<th>PaCO₂</th>
<th>HCO₃</th>
<th>Acid-base disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓</td>
<td>N</td>
<td>↓</td>
<td>Primary metabolic acidosis</td>
</tr>
<tr>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>Metabolic acidosis with respiratory compensation</td>
</tr>
<tr>
<td>↓</td>
<td>↑</td>
<td>N</td>
<td>Primary respiratory acidosis</td>
</tr>
<tr>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>Respiratory acidosis with renal compensation</td>
</tr>
<tr>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>Mixed metabolic and respiratory acidosis</td>
</tr>
<tr>
<td>↑</td>
<td>↓</td>
<td>N</td>
<td>Primary respiratory alkalosis</td>
</tr>
<tr>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>Respiratory alkalosis with renal compensation</td>
</tr>
<tr>
<td>↑</td>
<td>N</td>
<td>↑</td>
<td>Primary metabolic alkalosis</td>
</tr>
<tr>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Metabolic alkalosis with respiratory compensation</td>
</tr>
<tr>
<td>↑</td>
<td>↓</td>
<td>↑</td>
<td>Mixed metabolic and respiratory alkalosis</td>
</tr>
</tbody>
</table>

Note: respiratory compensation occurs rapidly by changes in PaCO₂. Renal compensation occurs more slowly by changes in HCO₃. N, normal.

Anion gap = (Na⁺ + K⁺) – (Cl⁻ + HCO₃⁻)
Normal range 8–16 mEq/l
>16 = loss of HCO₃⁻ w/o concurrent increase in Cl⁻.

Creatinine clearance = [Urine creatinine] × urine flow rate/[Plasma creatinine]

Body mass index = Weight (kg)/height (m)²
‘Normal’ (target) = 18.5–25

Ideal body weight (kg) Men = [(height (cm) – 154) × 0.9] + 50
Women = [(height (cm) – 154) × 0.9] + 45.5

Metric conversions:

Weight 1 kg = 1000 g; 1 g = 1000 mg; 1 mg = 1000 micrograms;
1 microgram = 1000 nanograms
1 stone = 6.35 kg; 1 kg = 2.2 lb
Temp. Fahrenheit to Celsius: \((^\circ F - 32) \times \frac{5}{9} = ^\circ C\)

Celsius to Fahrenheit: \(^\circ C \times \frac{9}{5} + 32 = ^\circ F\)

Pressure 1 kPa = 7.5 mmHg

Length 1 foot = 0.3048 metres; 1 inch = 25.4 mm
1 metre = 3 feet 3.4 in; 1 cm = 0.394 in

Volume 1 tablespoon = 15 ml (approx.); 1 teaspoon = 5 ml
1 litre = 1.76 pints (UK imperial) = 2.11 pints (USA liquid)

**COMMON LABORATORY REFERENCE VALUES**

NB: normal ranges often vary between laboratories. The ranges given here are deliberately narrow to minimise missing an abnormal result, but this means that your result may be normal for your laboratory’s range, which should always be checked if possible.

**Biochemistry**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na(^+)</td>
<td>135–145 mmol/l</td>
</tr>
<tr>
<td>K(^+)</td>
<td>3.5–5.0 mmol/l</td>
</tr>
<tr>
<td>Urea</td>
<td>2.5–6.5 mmol/l</td>
</tr>
<tr>
<td>Creatinine</td>
<td>70–110 (\mu)mol/l</td>
</tr>
<tr>
<td>Ca(^{2+})</td>
<td>2.15–2.65 mmol/l</td>
</tr>
<tr>
<td>PO(_4)</td>
<td>0.8–1.4 mmol/l</td>
</tr>
<tr>
<td>Albumin</td>
<td>35–50 g/l</td>
</tr>
<tr>
<td>Protein</td>
<td>60–80 g/l</td>
</tr>
<tr>
<td>Mg(^{2+})</td>
<td>0.75–1.0 mmol/l</td>
</tr>
<tr>
<td>Cl(^-)</td>
<td>95–105 mmol/l</td>
</tr>
<tr>
<td>Glucose (fasting)</td>
<td>3.5–5.5 mmol/l</td>
</tr>
<tr>
<td>LDH</td>
<td>70–250 iu/l</td>
</tr>
<tr>
<td>CK</td>
<td>25–195(^a) u/l (↑ in blacks)</td>
</tr>
</tbody>
</table>

*(Continued)*
### Biochemistry (Continued)

<table>
<thead>
<tr>
<th>Test</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trop l</td>
<td>&lt;0.4 ng/ml (=microgram/l)</td>
</tr>
<tr>
<td>Trop T</td>
<td>&lt;0.1 ng/ml (=microgram/l)</td>
</tr>
<tr>
<td>D-dimers</td>
<td>&lt;0.5 mg/l</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>3–17 µmol/l</td>
</tr>
<tr>
<td>ALP</td>
<td>30–130 iu/l</td>
</tr>
<tr>
<td>AST</td>
<td>3–31 iu/l</td>
</tr>
<tr>
<td>ALT</td>
<td>3–35 iu/l</td>
</tr>
<tr>
<td>GGT</td>
<td>7–50&lt;sup&gt;a&lt;/sup&gt; iu/l</td>
</tr>
<tr>
<td>Amylase</td>
<td>0–180 u/dl</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>3.9–5.2 mmol/l</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>0.5–1.9 mmol/l</td>
</tr>
<tr>
<td>LDL</td>
<td>&lt;2.0 mmol/l</td>
</tr>
<tr>
<td>HDL</td>
<td>0.9–1.9 mmol/l</td>
</tr>
<tr>
<td>Urate</td>
<td>0.2–0.45 mmol/l</td>
</tr>
<tr>
<td>CRP</td>
<td>0–10 mg/l</td>
</tr>
</tbody>
</table>

<sup>a</sup> Sex differences exist: females occupy the lower end of the range.

<sup>b</sup> D-dimer normal range can vary with different test protocols: check with your lab.

### Haematology

<table>
<thead>
<tr>
<th>Test</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb male</td>
<td>13.5–17.5 g/dl</td>
</tr>
<tr>
<td>Hb female</td>
<td>11.5–15.5 g/dl</td>
</tr>
<tr>
<td>Pt</td>
<td>150–400 × 10⁹/l</td>
</tr>
<tr>
<td>WCC</td>
<td>4–11 × 10⁹/l</td>
</tr>
<tr>
<td>NØ</td>
<td>2.0–7.5 × 10⁹/l (40–75%)</td>
</tr>
<tr>
<td>LØ</td>
<td>1.3–3.5 × 10⁹/l (20–45%)</td>
</tr>
<tr>
<td>EØ</td>
<td>0.04–0.44 × 10⁹/l (1–6%)</td>
</tr>
<tr>
<td>PCV (Hct)</td>
<td>0.37–0.54&lt;sup&gt;a&lt;/sup&gt; l/l</td>
</tr>
<tr>
<td>MCV</td>
<td>76–96 fl</td>
</tr>
</tbody>
</table>
### Haematology (Continued)

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR</td>
<td>&lt;age in years (+10 in women)/2</td>
</tr>
<tr>
<td>HbA1c</td>
<td>2.3–6.5%</td>
</tr>
</tbody>
</table>

*Sex differences exist: females occupy the lower end of the range.

#### Clotting

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>APTT</td>
<td>35–45 s</td>
</tr>
<tr>
<td>APTT ratio</td>
<td>0.8–1.2</td>
</tr>
<tr>
<td>INR</td>
<td>0.8–1.2</td>
</tr>
</tbody>
</table>

#### Haematinics

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron</td>
<td>11–30 μmol/l</td>
</tr>
<tr>
<td>Transferrin</td>
<td>2–4 g/l</td>
</tr>
<tr>
<td>TIBC</td>
<td>45–72 μmol/l</td>
</tr>
<tr>
<td>Serum folate</td>
<td>1.8–11 microgram/l</td>
</tr>
<tr>
<td>B12</td>
<td>200–760 pg/ml (5 ng/l)</td>
</tr>
</tbody>
</table>

#### Arterial blood gases

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO₂</td>
<td>&gt;10.6 kPa</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>4.7–6.0 kPa</td>
</tr>
<tr>
<td>pH</td>
<td>7.35–7.45</td>
</tr>
<tr>
<td>HCO₃⁻</td>
<td>24–30 mmol/l</td>
</tr>
<tr>
<td>Lactate</td>
<td>0.5–2.2 mmol/l</td>
</tr>
<tr>
<td>Base xs</td>
<td>±2 mmol/l</td>
</tr>
</tbody>
</table>

#### Thyroid function

<table>
<thead>
<tr>
<th>Test</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroxine (total T₄)</td>
<td>70–140 nmol/l</td>
</tr>
<tr>
<td>Thyroxine (free T₄)</td>
<td>9–22 pmol/l</td>
</tr>
<tr>
<td>TSH</td>
<td>0.5–5 mU/l</td>
</tr>
</tbody>
</table>
Adult tachycardia (with pulse) algorithm

European Resuscitation Council Guidelines 2010

Synchronised DC Shock*
Up to 3 attempts
*Attempted electrical cardioversion is always undertaken under sedation or general anaesthesia

Yes/unstable

Adverse features?
1. Shock
2. Syncope
3. Myocardial ischaemia
4. Heart failure

No/stable

Broad QRS

Irregular
Seek expert help

Regular

Is QRS narrow (< 0.12 sec)?

Narrow

If Ventricular Tachycardia (or uncertain rhythm):
• Amiodarone 300 mg iv over 20–60 min; then 900 mg over 24 h
If previously confirmed SVT with bundle branch block:
• Give adenosine as for regular narrow complex tachycardia

Irregular Narrow Complex Tachycardia
Probable atrial fibrillation
Control rate with:
• β-Blocker or diltiazem
• Consider digoxin or amiodarone if evidence of heart failure
Anticoagulate if duration > 48 h

Regular

Irregular

Narrow QRS
Is rhythm regular?

Normal sinus rhythm restored?

YES

Probable re-entry Paroxysmal SVT:
• Record 12-lead ECG in sinus rhythm
• If recurs, give adenosine again & consider choice of anti-arrhythmic prophylaxis

NO
Seek expert help

Possible atrial flutter
• Control rate (e.g. β-blocker)

Probabilities include:
• AF with bundle branch block treat as for narrow complex
• Pre-excited AF consider amiodarone
• Polymorphic VT (e.g. torsades de pointes — give magnesium 2 g over 10 min)

• Amiodarone 300 mg iv over 10–20 min and repeat shock; followed by:
• Amiodarone 900 mg over 24 h

• Assess using the ABCDE approach
• Give oxygen if appropriate and obtain IV access
• Monitor ECG, BP, SpO₂, record 12 lead ECG
• Identify and treat reversible causes (e.g. electrolyte abnormalities)

Seek expert help

Wide QRS

Is QRS regular?

Regular

Irregular

Possibilities include:
• AF with bundle branch block treat as for narrow complex
• Pre-excited AF consider amiodarone
• Polymorphic VT (e.g. torsades de pointes — give magnesium 2 g over 10 min)

• Amiodarone 300 mg iv over 10–20 min and repeat shock; followed by:
• Amiodarone 900 mg over 24 h

• Assess using the ABCDE approach
• Give oxygen if appropriate and obtain IV access
• Monitor ECG, BP, SpO₂, record 12 lead ECG
• Identify and treat reversible causes (e.g. electrolyte abnormalities)
**Adult bradycardia algorithm**

**European Resuscitation Council UK Guidelines 2010**

- Assess using the ABCDE approach
- Give oxygen if appropriate and obtain IV access
- Monitor ECG, BP, SpO₂, record 12 lead ECG
- Identify and treat reversible causes (e.g. electrolyte abnormalities)

**Adverse features?**
1. Shock
2. Syncope
3. Myocardial ischaemia
4. Heart failure

**Atropine 500 µg iv**

**Satisfactory response?**
- YES
- NO

**Risk of asystole?**
- Recent asystole
- Mobitz type II AV block
- Complete heart block with broad QRS
- Ventricular pause > 3s

**Interim measures:**
- **Atropine** 500 µg iv: repeat to max of 3 mg
- **Isoprenaline** 5 µg/min iv
- **Epinephrine** (adrenaline) 2–10 µg/min iv
- **Alternative drugs**
  - **Transcutaneous (external) pacing**

**NO**
- Seek expert help
- Arrange transvenous pacing

**YES**
- **Observe**

*Alternatives include: Aminophylline, Dopamine, Glucagon (if β-blocker or Ca⁺⁺ channel blocker overdose) or Glycopyrrolate (can be used instead of atropine)*
**Pocket Prescriber Emergency Medicine**

“This excellent book will prove itself an invaluable prescribing guide for all frontline clinical staff who work in an emergency department, whether they are permanent or in-training members of the team.”

—Associate Professor Geoff Hughes, MBBS, FRCP, FCEM, FACEM, DRCOG, Editor-in-Chief, *Emergency Medicine Journal*, from the foreword

Drug-prescribing errors are a common cause of hospital admission, and adverse reactions can have devastating effects, none more fatal. *Pocket Prescriber Emergency Medicine* is a concise, up-to-date prescribing guide containing all the "must have" information on a vast range of drugs that staff from junior doctors to emergency nurses, nurse prescribers, paramedics and other pre-hospital providers may encounter in the emergency setting.

**Key Features**

- A list of over 500 of the most commonly prescribed drugs with each entry containing the key prescribing information
- Safety considerations, drug actions and adverse effects
- Practical guidance on drug selection, plus protocols and resuscitation guidelines
- Advice and reference information for complicated prescriptions
- Clinical management summaries for common medical and surgical emergencies
- Essential data for pain relief—from acute pain management to procedural sedation
- Concise lists of key facts from basic pharmacology to acute poisoning syndromes

*Pocket Prescriber Emergency Medicine* supplies all your information needs concerning commonly prescribed drugs at a glance, enabling on-the-spot decision-making to provide the highest standard of care whilst mitigating prescribing errors.